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According to the Center for Disease Control (CDC) in 2018, there were 
599,274 cancer deaths in the USA; 283,721 were among females and 315,553 
were among males (out of an estimated total US population of 328 million in 
2018) [1]. Worldwide in 2020 there were an estimated 10.1 million new cases 
of cancer in males and 5.5 million cancer-related deaths; in females estimated 
new cases were 9.2 million and 4.4. million deaths [2]. Lung cancer is cur-
rently the leading cause of all cancer deaths (25.1% of all cases), but for 
females breast cancer is currently the leading cause of cancer deaths (15.5%) 
[2]. According to an April 4th, 2020 report of the International Agency for 
Research on Cancer (IARC), cancer is now the most common form of death 
worldwide ahead of heart disease. The report suggests that many cancers can 
be prevented, and better diagnoses and treatment could improve outcomes 
[3]. The World Health Organization (WHO) warns that if current trends con-
tinue, the world will see a greater than 100% increase in annual cancer deaths 
over the next 40 years – from about 9–10 million deaths in 2020 to about 19 
million deaths in 2060 [4]. The greatest increase (81%) in new cases will 
occur in low- and middle-income countries, where survival rates are currently 
lowest. This is double (40%) the new cancer cases that are expected in high-
income countries [4]. The report outlines several steps to save millions of 
lives worldwide, including (1) controlling tobacco use (currently responsible 
for 25% of all cancer deaths), (2) vaccinating against hepatitis B to prevent 
liver cancer, (3) eliminating cervical cancer by vaccinating against HPV, (4) 
improving screening and treatment, and (5) implementing high-impact can-
cer management interventions that bring value for money, and ensure access 
to palliative care, including pain relief. The report notes that in highincome 
countries there has been a marked decline (by approximately 20%) in prema-
ture deaths due to cancer between the years 2000 and 2015. This is presum-
ably due to outstanding research into cancer causes and the development of 
improved treatments. On the other hand, the report notes that the situation is 
much less promising in low-income countries where the reduction in cancer 
mortality during this period was only 5%. Much of this discrepancy is due to 
inadequate methods for diagnosis and treatment in lowincome countries ver-
sus high-income countries [4].
What can be done to improve the diagnoses of cancer and the survival rate, 
especially in low-income countries? Obviously, early diagnosis and improved 
diagnostic accuracy are vitally important and I will return to this point later. 
President Richard Nixon in his January 1971 State of the Union Address to 
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the Nation declared war on  cancer signing the National Cancer Act into law. 
This act gave the National Cancer Institute (NCI) unique autonomy within 
the National Institutes of Health (NIH) with special budgetary authority in 
the fight against cancer [5]. Many years later, President Barack Obama, hav-
ing lost his mother to ovarian cancer, picked up the cause and called for an 
aggressive war on the disease. In his final State of the Union message in 2016 
President Obama tasked his vice president—Joe Biden—to spearhead an ini-
tiative to cure cancer: “Last year, Vice President Biden said that with a new 
moonshot, America can cure cancer,” Obama said, noting that Biden had 
worked with Congress to add resources for the NIH. Obama stated in part 
“For the loved ones we’ve all lost, for the family, we can still save, let’s make 
America the country that cures cancer once and for all” [6]. There is no ques-
tion of the enormous contributions of the NIH (and many other government- 
sponsored and private funding agencies in the USA and worldwide) that have 
helped biomedical researchers understand how cancers arise and how to 
develop appropriate treatments. The physics of what was required to land a 
man on the moon was well understood in 1969 (the year of the first successful 
moon landing). However, no such unique understanding pertains to cancer. 
We now know that every type of cancer is different and can arise from a mul-
titude of disparate inherited or acquired mutations, and that even within a 
single type of cancer, individual cancer cells may have varying mutational 
and phenotypic profiles. These considerations pose enormous challenges for 
the early diagnosis of many cancers and for appropriate interventions to pre-
vent cancer metastases.
What options are available to minimize the risk of cancer? Obvious life-
style changes that can help minimize the risk of cancer include eschewing 
smoking, maintaining a healthy diet, maintaining a recommended body-mass 
index, exercising regularly, avoiding excessive sunlight, acquiring appropri-
ate vaccinations, and avoiding risky lifestyles [7]. Regular health checkups, 
including screening for colon, breast, and skin cancers, can help detect can-
cers at an early enough stage to improve treatment outcomes, especially 
among those with increased risk. But what sorts of treatments are available 
once a patient has been diagnosed with cancer? The American Cancer Society 
lists seven possible treatment options, namely, surgery, chemotherapy, radia-
tion therapy, targeted therapy, immunotherapy, stem cell or bone marrow 
transplant, and hormone therapy [8]. The NCI provides a similar list of treat-
ment options, but also includes a category entitled precision medicine [9]. 
Targeted therapy and precision medicine are relatively new concepts regard-
ing cancer treatment options. Targeted therapy is aimed at the changes in 
cancer cells that help them grow, divide, and spread [9]. On the other hand, 
precision medicine helps doctors select treatments that are most likely to help 
patients based on genetic or other characteristics of their disease [9]. Some 
authors have suggested that a distinction between precision medicine and 
personalized medicine is useful and not just semantics. Nevertheless, accord-
ing to the National Research Council, “personalized medicine” is an older 
term with a meaning similar to “precision medicine.” There was concern that 
the word “personalized” could be misinterpreted to imply that treatments and 
preventions are being developed uniquely for each individual; in precision 
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medicine, the focus is on identifying which approaches will be effective for 
which patients based on genetic, environmental, and lifestyle factors. The 
Council therefore preferred the term “precision medicine” to “personalized 
medicine” [10]. Accordingly, I will use the term precision medicine here. Dr. 
Anne Le in her capacity as Editor of “Heterogeneity of Cancer Metabolism” 
and contributor to each chapter in this book makes the convincing case that 
one way to treat cancers is to understand the varied metabolic “tricks” that 
enable cancers not only to survive in an often hostile environment but to 
thrive and multiply. Once these metabolic tricks are uncovered, physicians 
should be able to use this knowledge to “tailor” interventions to precisely 
target the unique metabolic profiles of each type of cancer. Dr. Le has done an 
admirable job of “knitting” together the various ways by which cancers use 
metabolic pathways to thrive, and she suggests ways in which this knowledge 
can be used for the design of treatment options.
To understand how precision therapy is intertwined with the theme of the 
current book it is worth stepping back more than ninety years when the 
acclaimed German Scientist Otto Warburg noticed that many cancer cells 
exhibit a unique metabolism, which has since become known as the “Warburg 
effect.” Warburg noted that cancer cells “ferment” glucose to lactate even in 
the presence of adequate oxygen rather than fully oxidize it to CO2 [e.g., 11]. 
The energy available from glycolytic conversion of one equivalent of glucose 
to two equivalents of lactate is much less than that available via complete 
oxidation of one equivalent of glucose to CO2 via the mitochondrial tricar-
boxylic acid (TCA) cycle. Nevertheless, cancer cells can afford such waste-
fulness because they can obtain ample glucose from the circulation—in a 
sense parasitizing the body. Warburg believed that the mitochondria and the 
TCA cycle in cancer cells are somewhat defective [12]. However, the forma-
tion of two equivalents of lactate (empirical formula C3H6O3) from glucose 
(empirical formula C6H12O6) and no change in NAD+ and NADH status will 
result in no net biomass formation [13]. Thus, in order to support growth and 
proliferation (i.e., increase biomass) the TCA cycle in cancer cells remains 
intact but has been preempted to serve the cancer cell’s unique properties. It 
appears that the TCA cycle in cancer cells is “rewired” to provide an effective 
“anaplerosis machine” that can provide building blocks for cancer cell growth 
and proliferation, and thereby contribute to the increase in biomass [e.g., 13]. 
The Warburg effect, although not entirely forgotten since its discovery, was 
mentioned only cursorily in Biochemistry texts for many years. However, 
interest in the Warburg effect in cancers has burgeoned in recent decades as 
evidenced by the thousands of articles a year published on the subject since 
the year 2000 [13]. An excellent background to the Warburg effect is provided 
in Chap. 1.
It is now recognized that the amino acid glutamine has a special role in can-
cer metabolism and that many cancer cells exhibit “glutamine addiction” mak-
ing use of a process known as glutaminolysis. Glutamine is the most abundant 
amino acid in the body [14] and is readily converted to α-ketoglutarate by glu-
taminolysis, while at the same time contributing nitrogen for DNA and poly-
amine syntheses. This α-ketoglutarate can enter the TCA cycle for the 
anaplerotic production of energy and/or for the provision of carbon for the 
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construction of important small-molecular-weight biomolecules and more 
complex biomolecules. Several excellent reviews of glutamine addiction in 
cancers have been published [e.g., 15, 16] including one written by Dr. Le [17]. 
Glutaminolysis in cancer cells is described in Chap. 2.
Given the importance of glutamine addiction to the survival of many can-
cers it is not surprising that several clinical trials are ongoing targeting the 
glutaminolysis pathway. The advantages and disadvantages of current strate-
gies that are designed to inhibit glutaminolysis either directly (e.g., by inhib-
iting glutaminase, an important enzyme contributing to glutaminolysis) or 
indirectly (e.g., by inhibiting glutamate dehydrogenase or aspartate amino-
transferase) as cancer therapies are well documented in Chap. 2. Three gluta-
minase 1 inhibitors are currently under investigation as possible anticancer 
agents, namely CB-839 (Talglenasat; a potent inhibitor of glutaminase C 
splice variant), BPTES (bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)
ethyl sulfide; an allosteric inhibitor of glutaminase 1) and 968 (an allosteric 
inhibitor of glutaminase C splice variant). In fact, CB-839 is in current clini-
cal trials (see chapter 2; Glutamine metabolism in cancer). Li et al. suggest 
methods by which the effectiveness of glutaminase inhibitors as anticancer 
agents may be improved, perhaps in combination with other drugs (e.g., 
metformin).
Another aspect of glutamine addiction relates to fatty acid/lipid synthesis 
and metabolism. As noted by Cheng et al “Reprogramming of lipid metabo-
lism is a newly recognized hallmark of [cancer] malignancy” [18]. It is well 
known that glucose is a major source of acetyl carbon for the synthesis of 
fatty acids and cholesterol. Cholesterol and fatty acids are important compo-
nents of cell membranes, and fatty acids (but not cholesterol) are also an 
important energy source. Cholesterol and fatty acids must either be taken up 
from the circulation or synthesized de novo in rapidly dividing cancer cells. 
Pyruvate carbon obtained through glycolysis enters the TCA cycle as acetyl 
units via the pyruvate dehydrogenase complex (PDHC) reaction. During de 
novo fatty acid synthesis, the acetyl units derived from pyruvate are incorpo-
rated into citrate via the TCA cycle in mitochondria. This citrate then exits the 
mitochondria to the cytosol where it acts as a precursor for acetyl-CoA and 
hence for both fatty acids and cholesterol synthesis. However, during “times 
of plenty” (e.g., after a fat-laden meal) fatty acids can be taken up from the 
circulation by cancer cells and stored, later to be oxidized to produce energy 
as needed. Thus, cancer cells can “fine-tune” their needs to synthesize and 
store fatty acids or to metabolize them as an effective energy source as dic-
tated by the needs of the cell. But as mentioned above, lactate is a preferred 
end product of glycolysis (rather than pyruvate) in many cancer cells. As a 
result, pyruvate carbon entry into the TCA cycle may become limiting in 
cancer cells. Thus, glutamine “steps in” once again. Glutaminolysis provides 
anaplerotic α-ketoglutarate to the TCA cycle which in turn can be used for the 
synthesis of fatty acids. As noted throughout the book, many cancers upregu-
late the glutaminase pathway and also the transporter principally involved in 
glutamine uptake (SLC1A5/ ASCT2). Thus, as discussed by Dr. Le and asso-
ciates, an inhibitor of the glutaminolysis pathway(s) or transporter would not 
only interfere with energy production in cancer cells but also interfere with 
lipid and cholesterol synthesis.
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Dr. Le and her associates have emphasized the importance of metabolic 
reservoirs that help cancers survive during “lean times.” One such reservoir is 
glycogen that can be a source of glucose when necessary. Not surprisingly, 
inhibitors of glycogen synthesis or breakdown are being considered as anti-
cancer agents. N-Acetyl-aspartyl-glutamate (NAAG) is a well-documented 
neurotransmitter, but Dr. Le and her associates have found that it also has an 
unexpected role in cancer cell metabolism, namely as a metabolic reservoir of 
aspartate and glutamate. These amino acids can then be readily converted to 
the TCA cycle components oxaloacetate and α-ketoglutarate, respectively. As 
noted above, cancers generate large amounts of lactate through glycolysis as 
an, albeit inefficient, source of ATP. Thus, not surprisingly, selective inhibi-
tors of lactate dehydrogenase are also being considered as potential antican-
cer agents. However, Dr. Le has suggested that the generated lactate may not 
be just a waste product of inefficient glycolysis but may have a role as a meta-
bolic reservoir of pyruvate, the carbon of which can then enter the TCA cycle 
via the PDHC. The concept of metabolic reservoir cycles, their importance to 
cancer cells, and potential for disruption by anticancer agents is exceptionally 
well covered in this book.
An important factor in a cancer cell’s survival is its microenvironment. 
Recently there has been considerable interest and research into the role of 
cancer-associated fibroblasts (CAF) as cancer promoters (pCAF) [e.g., 19]. 
CAF may also act to restrain cancer growth (rCAF). As noted by Miyai et al. 
[20] in a recent review “CAF promote cancer progression through pleiotropic 
mechanisms, including the secretion of soluble factors and extracellular 
matrix, physical interactions with cancer cells, and the regulation of angiogen-
esis, immunity and metabolism.” The authors provide a review of rCAF and 
discuss how the findings with these cells “can be exploited to develop novel 
anticancer therapies in the future.” An interesting property of CAF is their 
ability to shed exosomes to the microenvironment containing macromolecules 
that can aid in cancer survival and promote metastasis and chemoresistance 
[e.g., 21]. Dr. Le and her associates discuss CAF from a number of perspec-
tives, including their role in immunosuppression, but in the current treatise 
emphasize the role of CAF in providing metabolic support for their associated 
cancers. They also provide an excellent overview of how CAF may be an 
“indirect” target for cancer therapy, in particular targeting glutaminolysis in 
the CAF cells that contributes to the survival of the associated cancer.
Finally, Dr. Le and her associates discuss cancer in relation to, e.g., diabe-
tes, neurological diseases, and heart disease. She and her associates posit that, 
although there are very obvious differences between these diseases and can-
cer, there are similarities in their observed metabolic derangements. Thus, 
lessons learned from treatments of these noncancerous diseases may provide 
clues as to better treatment of cancers and vice versa. One final point I wish 
to make is that although contributions of metabolic processes such as gluta-
minolysis are beginning to be understood in terms of cancer survival in broad 
outlines, as emphasized throughout the current book each cancer exhibits a 
unique metabolic profile and even within a given cancer the metabolic profile 
may vary with time and position within the cancer. It is anticipated that 




In summary, I hope that I have convinced the interested reader that under-
standing how cancer cells adapt metabolically to their often hostile environ-
ment will provide new insights for designing cancer treatments, perhaps in 
conjunction with existing conventional therapies. Dr. Le is to be commended 
not only for her obvious enthusiasm for the topic but also for her work as a 
leading expert in the field of cancer metabolism. In returning full circle to my 
introductory statements, I anticipate that her work will contribute, through 
evermore increasingly sophisticated and sensitive metabolomic analyses 
methods, to realizing the goal of precision medicine. This will help not only 
in the invention of treatments designed for the early detection of cancer but 
also for effective treatments for cancers that have already been diagnosed, 
especially for the more devastating cancers such as pancreatic cancer. Finally, 
it is hoped that these considerations will eventually lead to a relatively inex-
pensive methodology that will lessen the cancer burden, not only in the more 
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Genetic alterations in cancer, in addition to being the fundamental drivers of 
tumorigenesis, can give rise to a variety of metabolic adaptations that allow 
cancer cells to survive and proliferate in diverse tumor microenvironments. 
This metabolic flexibility is different from normal cellular metabolic pro-
cesses and leads to heterogeneity in cancer metabolism within the same can-
cer type or even within the same tumor. In this book, the authors delve into 
the complexity and diversity of cancer metabolism and highlight how under-
standing the heterogeneity of cancer metabolism is fundamental to the devel-
opment of effective metabolism-based therapeutic strategies for cancer 
treatment. Deciphering how cancer cells utilize various nutrient resources 
will enable researchers and clinicians to pair specific chemotherapeutic 
agents with patients who are most likely to respond with positive outcomes, 
allowing for more cost-effective and personalized cancer treatment.
This book is the second edition and contains all the contents from the first 
edition with the addition of new information with unique features that make 
the book distinctive. This book has four major parts:
Part I: Basic Metabolism of Cancer Cells
Part II: Heterogeneity of Cancer Metabolism
Part III: Relationship Between Cancer Cells and Cancer-Associated 
Fibroblasts
Part IV: The Metabolic Interplay Between Cancer and Other Diseases.
This book is designed for cancer metabolism researchers, cancer biolo-
gists, any other researchers, physicians, epidemiologists, health care profes-
sionals of various disciplines, policymakers, marketing and economic 
strategists, etc. It is also designed for teaching undergraduate and graduate 
students.
The metabolic pathways and their regulations mentioned in this book 
serve as examples to illustrate the heterogeneity of cancer metabolism and are 
non-inclusive.
Baltimore, MD Anne Le 
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• Tumor cells exhibit an upregulation in glycol-
ysis, glycogen metabolism, and gluconeogen-
esis as opposed to normal cells.
• Several oncogenes and tumor suppressors 
drive the metabolic reprogramming underly-
ing the Warburg effect and other changes in 
glucose metabolism.
• There is heterogeneity in glucose metabolism 
across tumor types as well as within the tumor 
microenvironment.
• Numerous therapies targeting glucose 
 metabolism have been developed but have yet 
to show success in clinical trials.
1  Introduction
Otto Warburg observed a peculiar phenomenon 
in 1924, unknowingly laying the foundation for 
the field of cancer metabolism. While his con-
temporaries hypothesized that tumor cells derived 
the energy required for uncontrolled replication 
from proteolysis and lipolysis, Warburg instead 
found them to rapidly consume glucose, convert-
ing it to lactate even in the presence of oxygen 
[1]. The significance of this finding, later termed 
the Warburg effect, went unnoticed by the broader 
scientific community at that time. The field of 
cancer metabolism lay dormant for almost a cen-
tury awaiting advances in molecular biology and 
genetics, which would later open the doors to 
new cancer therapies [2, 3].
2  The Warburg Effect
2.1  Otto Warburg’s Early Studies 
of Normal Cellular Respiration
Warburg began his forays into research studying 
the oxygen consumption of sea urchin eggs, find-
ing that the rate of respiration increased several-
fold after fertilization. He went on to further 
describe two processes that were crucial to 
cellular glucose metabolism: respiration and fer-
mentation [4].
Most differentiated cells metabolize glucose 
through the tricarboxylic acid (TCA) cycle under 
aerobic conditions. They then undergo oxidative 
phosphorylation to generate ATP (between 32 
and 34 ATP molecules per glucose molecule) [5] 
(Fig. 1). While glycolysis produces two net mol-
ecules of ATP per one molecule of glucose, the 
majority of ATP production occurs during the 
TCA cycle and oxidative phosphorylation. 
During these latter steps of respiration, the pyru-
vate molecule produced in glycolysis undergoes 
a series of reactions in the presence of oxygen. 
Without the presence of oxygen, cells undergo 
fermentation or anaerobic glycolysis, shunting 
the resultant pyruvate molecules to lactate 
production.
2.2  The Warburg Effect Is 
a Prominent Feature of Cancer 
Cell Metabolism
In 1927, Warburg studied the processes of respi-
ration and fermentation in tumor cells. According 
to normal cellular respiration, glucose is con-
verted to pyruvate, which then enters the TCA 
cycle to undergo oxidative phosphorylation in 
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the presence of oxygen, and there should be min-
imal lactate production. However, in his in vivo 
and ex  vivo studies, Warburg observed an 
increased glucose uptake and increased lactic 
acid production in tumor cells as compared to 
normal cells, even in the presence of oxygen [6]. 
This phenomenon, the metabolism of glucose to 
lactate despite the presence of adequate oxygen, 
is called the Warburg effect or aerobic glycolysis 
(Fig. 1).
For Warburg, several questions remained 
unanswered, including why cancer cells would 
inefficiently shunt glucose-derived pyruvate to 
lactate production instead of to the TCA cycle, 
which would result in significantly higher ATP 
production. Warburg hypothesized that the lac-
tate production in cancer cells was due to the 
impairment of oxidative phosphorylation caused 
by mitochondrial damage [7].
There was a debate surrounding this theory 
with disagreement arising particularly from 
Sidney Weinhouse, one of Warburg’s contempo-
raries. Using isotope tracing [8], Weinhouse’s 
experiments showed that the rates of oxidative 
phosphorylation in both normal cells and tumor 
cells are similar, suggesting that the mitochon-
dria of tumor cells are intact [9]. Rather, tumor 
cells in oxygen-rich environments utilize both 
aerobic glycolysis and oxidative phosphorylation 
to sustain their rapid rates of proliferation. Only 
in hypoxic environments, such as the tumor core, 
do the rates of lactic acid production by anaero-
bic glycolysis overtake oxidative phosphoryla-
tion as the primary source of energy [10].
Fig. 1 Respiration in normal differentiated tissue (left) in contrast with the Warburg effect in proliferating tissue (right)
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2.3  The Biochemical Nature 
and Clinical Significance 
of the Warburg Effect
Examination of the underlying biochemical pro-
cesses elucidated possible reasons for why cancer 
cells paradoxically undergo aerobic glycolysis, a 
process yielding less ATP than oxidative phos-
phorylation per cycle. For example, given the inef-
ficiency of ATP production in the Warburg effect, 
there are likely differences in the kinetics of aero-
bic glycolysis and oxidative phosphorylation, 
which have led to cancer cells promoting aerobic 
glycolysis. Demetrios et  al. found that, in the 
Warburg effect, the flux of glucose to lactate is up 
to 100 times faster than through the TCA cycle 
resulting in similar amounts of ATP production 
over the same time [11]. Even when oxidative 
phosphorylation is actively continuing, aerobic 
glycolysis will see much higher glucose flux [12].
To further understand a cancer cell’s depen-
dence on aerobic glycolysis, it is necessary to 
revisit one of the hallmarks of cancer—rapid pro-
liferation supported by strong anabolism. Tumor 
cells need not only ATP but also anabolic metab-
olism to accumulate a large amount of biomass to 
sustain their growth. The Warburg effect via mul-
tiple glycolytic intermediates provides a carbon 
source which contributes to the nucleotide, fatty 
acid, and amino acid synthesis pathways [13]. 
For example, glucose-6-phosphate (G6P) 
becomes partially oxidized via the pentose phos-
phate pathway (PPP) to generate NADPH and 
nucleotide components. In addition to the PPP, 
NADPH is also generated with the shunting of 
3-phosphoglycerate out of the glycolytic path-
way and into the serine and glycine biosynthesis 
pathway [14]. NADPH is a reducing equivalent, 
which is then further used for lipid biosynthesis 
[15, 16]. In addition, phospholipid biosynthesis 
is enabled by the conversion of dihydroxyacetone 
phosphate (DHAP) to glycerol-3-phosphate [17], 
and fructose-6-phosphate (F6P) enters the hexos-
amine pathway to support protein posttransla-
tional modification [18].
Two other clinically significant hallmarks of 
cancer, the evasion of apoptotic cell death and the 
ability to metastasize, may provide additional 
reasons behind the upregulation of aerobic gly-
colysis in cancer. Anoikis is a type of apoptosis 
that is a consequence of reactive oxygen species 
(ROS) accumulation in the setting of the detach-
ment of a cell from the extracellular matrix [19]. 
When this detachment happens for a cancer cell, 
however, anoikis is inhibited because the Warburg 
effect reduces mitochondrial ROS production by 
decreasing the flow of pyruvate into oxidative 
phosphorylation [20]. Resistance to apoptosis in 
the setting of matrix detachment is essential to 
the metastatic spread of tumor cells.
The Warburg effect has clinical utility as 
well. One ubiquitous application is the use of 
positron-emission tomography (PET) imaging 
in oncology, which has become indispensable in 
the detection of tumors and the monitoring of 
the response of existing cancer to therapeutic 
intervention. PET is an exploitation of the high 
rate of glycolysis in cancer cells as it uses a 
radiolabeled glucose analog, [18F]fluoro-2-
deoxy-d-glucose (FDG), which accumulates in 
tumor cells due to their rapid uptake of glucose. 
Another developing application of the Warburg 
effect is the use of gene expression profiles 
linked to glycolysis to determine prognosis. 
Tools in both lung adenocarcinoma and triple-
negative breast cancer have shown that 
 glycolytic phenotypes are generally associated 
with worse patient survival [21–23].
2.4  Metabolic and Genetic 
Reprogramming Underlying 
the Warburg Effect
With current advances in genetics and molecular 
biology, much of the past several decades of can-
cer research have been consumed by character-
izing the genetic alterations, which lead to the 
development of cancers. However, cancer cells 
need not only a genetic switch but also metabolic 
building blocks and energy sources to undergo 
rapid proliferation. The recognition of the impor-
tance of energy sources allowed for the resur-
gence of cancer metabolism as a field that is 
closely related to tumor genetics. It is now 
understood that the metabolic reprogramming 
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 underlying the Warburg effect is driven by sev-
eral oncogenes and tumor suppressors.
Some of the identified oncogenes, namely 
protein kinase B (PKB/AKT), phosphoinositide 
3-kinase (PI3K), Ras, and Von Hippel-Lindau 
(VHL), act via the protein hypoxia-inducible fac-
tor 1α (HIF-1α), resulting in the non-hypoxic 
expression of HIF-1α. In normal cells, HIF-1α 
becomes stabilized in a hypoxic environment to 
form a transcription factor involved in promoting 
glycolysis and suppressing oxidative phosphory-
lation [24]. HIF-1α, when present, upregulates 
glucose transporter 1 (GLUT1) to promote the 
retention of glucose inside cells in addition to 
upregulating hexokinase 2 (HK2), the enzyme 
which catalyzes the first committed step of gly-
colysis [25]. Typically, when oxygen is present, 
HIF-1α degrades in a concentration-dependent 
manner. In tumor cells, however, even in the pres-
ence of oxygen, high AKT and mechanistic target 
of rapamycin (mTOR) oncogenic activity pro-
mote HIF-1α expression, leading to persistent 
transcription of the enzymes driving glycolysis 
and lactate production.
Other oncogenic pathways have been found to 
work independently of HIF-1α to promote aero-
bic glycolysis as well, namely the activation of 
oncogenes such as MYC, Ras, and AKT and the 
deactivation of tumor suppressors such as TP53. 
Like HIF-1α, MYC directly upregulates GLUT 
and HK2. The loss of TP53 function also upregu-
lates GLUT expression. Additionally, TP53 deac-
tivation indirectly leads to increased glycolysis. 
Without TP53 expression, TP53-induced glycol-
ysis and apoptosis regulator (TIGAR), a protein, 
which causes shunting of glucose to the PPP, is 
no longer upregulated, resulting in a greater flux 
of glucose through the glycolytic pathway [26].
3  Heterogeneity in Glucose 
Metabolism
Aerobic glycolysis is not consistent across tumor 
types or even within a single tumor’s microenvi-
ronment (Fig. 2). Examination of different tumor 
types revealed that the balance between aerobic 
glycolysis and oxidative phosphorylation could 
be very different. In a study evaluating the vari-
ability of metabolic gene expression across mul-
tiple different tumor types, it was found that there 
was an upregulation of genes related to oxidative 
phosphorylation in ovarian, lymphoma [27], leu-
kemia, and lung cancers, whereas the opposite 
was true in thyroid, colon, pancreatic [28], and 
renal cancers [29, 30]. It is thought that the vari-
able activation of different oncogenes such as 
RAS, AKT, and c-MYC is the driver behind these 
differences [31–35].
These differences in metabolism can be seen 
even in cells within the same tumor [36, 37]. 
Sometimes, these differences result from varia-
tions in the tumor microenvironment leading to 
metabolic flexibility, the ability of cancer cells 
to change their bioenergetic pathways according 
to available nutrients [38, 39]. One important 
resource is oxygen, which can vary significantly 
with the aberrant vascularization of tumors. As 
demonstrated in HeLa cells in hypoxia, there 
was an observed decrease in ATP derived from 
oxidative phosphorylation to just 29% com-
pared to 79% in normoxia [40]. However, in a 
study by Le et al., it was shown that a subpopu-
lation of cancer cells under hypoxia still exhib-
ited expressions of genes related to mitochondrial 
function and maintained their oxidative phos-
phorylation and tumorigenicity [37]. These 
results suggest that respiration, even when there 
is an oxygen shortage, may be necessary for 
tumorigenicity, which does not depend on the 
Warburg effect alone and is not reduced as a 
result of the maintenance of respiration under 
hypoxic conditions. There may also be differ-
ences rooted in the type of tumor cells within 
the microenvironment—cancer stem-cell-like 
cells (CSCs) versus more differentiated tumor 
cells. A recent study found that 80% showed 
high levels of glucose uptake, and 20% showed 
low levels of glucose uptake [41]. This may 
have been due to the presence of both CSCs and 
differentiated cells within the studied popula-
tion. Similarly, studies of small-cell lung cancer 
(SCLC) cells showed that the CSC subpopula-
tion was metabolically less active and preferred 
oxidative phosphorylation rather than glycoly-
sis to fulfill energy requirements [42].
Glucose Metabolism in Cancer: The Warburg Effect and Beyond
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4.1  Glycogen Metabolism Is 
Upregulated in Several 
Cancers
Glycolysis is not the only component of glucose 
metabolism, which plays a significant role in 
tumor growth. Glycogenolysis, the process by 
which glycogen is converted to glucose-1-phos-
phate (G1P) and then to G6P to enter the glyco-
lytic pathway, provides another energy source for 
tumors in the face of nutrient stress (Fig.  2). 
Glycogen metabolism, although studied far less 
than glycolysis by cancer researchers, is upregu-
lated in many cancer types, including renal, 
breast, bladder, uterine, ovarian, skin, and brain 
cancers. However, the glycogen content of cancer 
cells was found to be not associated with the rate 
of replication [43]. Renal cell carcinoma, which 
classically has clear cells on histology, appears 
this way due to high glycogen content.
Advances in tumor genetics have allowed for 
the characterization of tumor-suppressor genes 
and oncogenes, which have driven these changes 
in glycogen metabolism in tumor cells. The over-
expression of the oncogene Rab25 has been dem-
onstrated as a driver in increasing cellular 
glycogen stores via the AKT pathway [44]. In 




















Fig. 2 Heterogeneity in cancer glucose metabolism with respect to tumor type, tumor microenvironment, and 
differentiation
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AGL has been identified as a tumor suppressor. 
Additionally, deactivation of AGL leads to the 
accumulation of abnormal glycogen stores and 
promotes tumorigenesis in xenograft models [45]. 
Given this, Guo-Min Shen and colleagues studied 
glycogen metabolism in the setting of hypoxia. It 
was noted that glycogen accumulated in breast 
cancer cells after 24 and 48 h under hypoxia due 
to HIF-1α induction of protein phosphatase 1 reg-
ulatory subunit 3C (PPP1R3C), a glycogen syn-
thase [46]. Later studies demonstrated that 
glycogen synthesis promotes cancer cell survival 
in the setting of hypoxic conditions [47]. Both 
glycogenolysis and glycogen synthesis enzymes 
appear to be upregulated by tumor cells with 
HIF-1α dependence, including UTP:glucose-1-P 
uridylyltransferase 2 (UGP2), phosphoglucomu-
tase (PGM), 1,4-alpha-glucan branching enzyme 
(GBE), glycogen synthase 1 (GYS1), and 
PPP1R3C [48]. In vivo studies of suppression of 
glycogen synthase kinase 2 (GSK2) activity dem-
onstrated a reduction in prostate tumor growth 
[49]. Glycogen metabolism is an important target 
of therapy given that cancer cells can utilize gly-
cogen as an energy source even during nutrient 
deficiency due to poor angiogenesis [50, 51].
4.2  Upregulation 
of Gluconeogenic Enzymes 
in Cancer
Gluconeogenesis is the process of generating 
glucose from carbon substrates that are not car-
bohydrates. There are two gluconeogenic 
enzymes that play important roles in cancer 
metabolism: phosphoenolpyruvate carboxyki-
nase 1 (PCK1) and phosphoenolpyruvate car-
boxykinase 2 (PCK2). It has been demonstrated 
that TP53 inhibits both enzymes, meaning that 
the loss of TP53 upregulates these enzymes and 
gluconeogenesis [52]. It was also observed that 
the inhibition of mTOR in hepatocellular carci-
noma and renal cell carcinoma cells directs the 
glycolytic flux towards lactate and gluconeogen-
esis with resultant tumor cell death via the down-
regulation of PCK1 [53].




5.1  Therapies Targeting Glycolysis 
and the Warburg Effect
As discussed previously, over the latter half of 
the twentieth century, advances in molecular 
biology and the identification of oncogenes and 
tumor suppressors drew the attention of much of 
the anticancer therapeutic efforts. It is true that 
genetic alterations drive uncontrolled replication 
in cancer cells, but it is also important to recog-
nize that a cancer cell is still dependent on nutri-
ent availability. In the past two decades, there has 
been an upsurge in efforts to exploit the addiction 
of cancer cells to glucose and the Warburg effect 
for cancer treatment [54]. Several enzymes in the 
glycolytic pathway have been targeted, some 
showing tumoricidal effects in vitro and in vivo 
(Fig. 3). Unfortunately, there has been little clini-
cal success given that glycolysis is crucial to the 
glucose metabolism of normal cells as well. 
Thus, the focus should be on targeting those ele-
ments of aerobic glycolysis, which are more 
upregulated in cancer.
Glucose transporters (GLUT1–4) are upregu-
lated in tumor cells by MYC and HIF-1α. 
Previous attempts with small-molecule inhibitors 
of GLUT1 have seen in vitro tumoricidal effects 
in a renal cell carcinoma cell line [55] and hepa-
tocellular carcinoma cell line [56]. However, 
GLUT1 is a prevalent glucose transporter in nor-
mal cells as well, which would likely preclude 
clinical success. Homozygous Glut1 deletion is 
embryonically lethal in mice, and heterozygous 
deletion causes impaired motor activity and sei-
zures [57]. A GLUT1 inhibitor called silibinin 
failed to demonstrate any reduction in prostate-
specific antigen, a well-known biomarker for 
prostate cancer, in a phase I clinical trial and was 
associated with significant side effects [58].
Hexokinase phosphorylates glucose to glu-
cose-6-phosphate in the first committed step 
of glycolysis. Hexokinase 2 (HK2) is mostly 
Glucose Metabolism in Cancer: The Warburg Effect and Beyond
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expressed in cancer cells and is the primary 
hexokinase to function in tumors, so it is 
another potential therapeutic target. 
Experiments in which HK2 was systemically 
deleted have shown to be well tolerated in 
mice [59]. A glucose analog that competitively 
inhibits G6P isomerase in order to inhibit the 
phosphorylation of glucose, 2-deoxyglucose, 
has been studied in a phase I clinical trial in 
combination with radiation therapy with good 
toleration in glioblastoma multiforme [60, 
61]. However, a HK inhibitor called lonidam-
ine failed to show any benefit in two phase III 
randomized clinical trials [58].
Phosphofructokinase (PFK) is the enzyme 
which catalyzes the second committed step in 
glycolysis, the conversion of fructose-6-phos-
phate to fructose-1,6-bisphosphate (F1,6-BP). 
Although inhibiting PFK directly is not possible 
since it is crucial to glycolysis in normal cells, it 
may be feasible to target it indirectly. PFK is 
strongly allosterically activated by fructose-
2,6-bisphosphate (F2,6-BP). F2,6-BP is activated 
by another protein, 6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase 3 (PFKFB3), a target 
of HIF-1α. Attenuation of glycolysis was 
achieved in in  vitro and in  vivo studies with a 
small-molecule PFKFB3 inhibitor called 
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one 
(3PO) [62]. PFKFB3 inhibitors were also shown 
to reduce tumor angiogenesis [63].
Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) converts glyceraldehyde 3-phosphate 
to glycerate 1,3-bisphosphate with the produc-
tion of NADH and is a promising target for anti-
glycolytic therapy given the role of NADH in 
biosynthesis. The small-molecule pyruvate ana-
log, 3-bromopyruvate, is a nonselective inhibitor 
of GAPDH and has been shown to inhibit tumor 
oxidative phosphorylation and glycolysis with 
good preclinical efficacy [64, 65]. However, there 
is concern for toxicities such as burning sensation 
Fig. 3 Current targets of cancer therapies directed at glucose metabolism
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with intravenous infusion and there are no ongo-
ing clinical trials with this compound [66].
In seeking a target that was more unique to 
cancer cell metabolism and central to the Warburg 
effect, Le et al. focused on lactate dehydrogenase 
A (LDHA) which reciprocally mediates the 
redox-coupled conversion between lactate with 
NAD+ and pyruvate with NADH [67, 68]. 
Elevated expression level of LDHA is a hallmark 
of many types of tumors, including squamous 
head and neck cancer, colorectal cancer, and non-
small cell lung cancer [69–71]. By perturbing the 
NADH/NAD+ ratio, a small-molecular inhibitor 
of LDHA called FX-11 was shown to increase 
reactive oxygen species in tumor cells with sub-
sequent cell death in not only in vitro studies but 
also pancreatic and lymphoma xenografts 
[72–74].
Several other LDHA inhibitors, such as gos-
sypol, galloflavin, and N-hydroxyindole-based 
inhibitors, were tested in preclinical settings 
[72, 75–78]. Among them, gossypol (AT-101), 
a nonselective inhibitor of LDH, was tested in 
phase I and phase II clinical trials targeting 
glioblastoma (NCT00390403, NCT00540722), 
small-cell lung cancer, and prostate cancer [79, 
80]. Despite active investigations for develop-
ing LDH inhibitors, there is still a clinical need 
for highly selective and efficient LDH inhibi-
tors, as gossypol shows off-target effects such 
as the inhibition of NADH-dependent enzymes 
(e.g., GAPDH) [77]. Although compounds tar-
geting lactate metabolism have not yet been 
approved, it is clear that LDH-targeting strate-
gies are promising approaches for cancer 
therapy.
On a macro level, dietary changes to limit glu-
cose availability to tumor cells have also been 
studied. For example, ketogenic therapy, a diet 
with severe carbohydrate restriction, has been 
shown to sensitize gliomas and glioblastoma to 
chemoradiation therapy, reduce oxidative stress, 
and downregulate angiogenic proteins [81]. The 
success of this therapy may lie in the relative 
metabolic inflexibility of neuronal cells and their 
addiction to glucose.
5.2  Therapies Targeting 
Glycogenolysis and Glycogen 
Synthesis Have Shown 
Promising Results
Significantly fewer therapies targeting glycogen 
metabolism have been developed (Fig.  3). Lee 
et al. inhibited glycogen phosphorylase in a pan-
creatic cell line with a compound called 
CP-320626, leading to tumor cell death with no 
effect on normal human fibroblasts [82]. 
Flavopiridol, another glycogen phosphorylase 
inhibitor, had safe and modest efficacy in clinical 
trials with prostate cancer, renal cell carcinoma, 
and colorectal carcinoma [83–85]. However, fla-
vopiridol is also a cyclin-dependent kinase inhib-
itor [86], so it is uncertain whether the antitumor 
effects were purely from glycogen phosphorylase 
inhibition. More recently, inhibition of glycogen 
synthase kinase (GSK)3β by AR-A014418 and 
SB-216763 in an esophageal squamous cell car-
cinoma cell line has resulted in attenuated tumor 
growth and induced apoptosis; thus GSK3β has 
emerged as a potential target [87]. Similar results 
were shown in sarcoma cell lines [88]. Given 
these promising results, further investigation of 
glycogenolysis and glycogen synthesis-targeting 
agents is warranted.
6  Conclusion
Currently, there are several challenges to meta-
bolic cancer therapies. First, an understanding of 
the heterogeneity of metabolic phenotypes is only 
beginning to be established. Metabolic pheno-
types likely vary based on tissue of origin, tumor 
microenvironment, primary versus metastatic 
tumors, and mutational differences. Second, there 
are limitations in translating in vivo mouse studies 
to clinical trials, as is evidenced by the lack of 
success in advancing metabolic inhibitors through 
clinical trials up until this point. Third, there is the 
potential for metabolic inhibitors to be overcome 
by the adaptation of tumors to new energy sources 
as well as their inherent metabolic flexibility. 
Glucose Metabolism in Cancer: The Warburg Effect and Beyond
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With renewed interest in cancer metabolism, the 
development of metabolic  inhibitors will continue 
to grow, and it may be most effective to combine 
these therapies with other modalities of therapy in 
order to increase efficacy.
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• Glutamine addiction and dysregulation of the 
TCA cycle are characteristic features of gluta-
mine metabolism in cancers.
• Glutamine metabolism can be targeted by 
inhibiting glutaminolysis, employing 
 combination therapies, suppressing c-MYC 
expression, inhibiting GDH, depleting the 
glutamine supply, inhibiting glutamine uptake, 
and exploiting glutamine analogs.
• Transaminase upregulation and targeting of 
amino acid synthesis have the potential for 
cancer therapy.
• The metabolic reprogramming of cancers 
provides them with alternative sources of 
glutamate: via N-acetyl-aspartyl-glutamate 
(NAAG) and via glutaminase II pathway.
• Glutamine metabolism in the tumor microen-
vironment can impact the development of 
cancers.
1  Introduction
Metabolism is a fundamental process for all cel-
lular functions. For decades, there has been grow-
ing evidence of a relationship between 
metabolism and malignant cell proliferation. 
Unlike normal differentiated cells, cancer cells 
have reprogrammed metabolism in order to fulfill 
their energy requirements. These cells display 
crucial modifications in many metabolic path-
ways, such as glycolysis and glutaminolysis, 
which include the tricarboxylic acid (TCA) cycle, 
the electron transport chain (ETC), and the pen-
tose phosphate pathway (PPP) [1]. Since the 
discovery of the Warburg effect, it has been 
shown that the metabolism of cancer cells plays a 
critical role in cancer survival and growth. More 
recent research suggests that the involvement of 
glutamine in cancer metabolism is more signifi-
cant than previously thought. Glutamine, a non-
essential amino acid with both amine and amide 
functional groups, is the most abundant amino 
acid circulating in the bloodstream [2]. This 
chapter discusses the characteristic features of 
glutamine metabolism in cancers and the thera-
peutic options to target glutamine metabolism for 
cancer treatment.
2  Characteristic Features 
of Glutamine Metabolism 
in Cancer
2.1  Dysregulation of the TCA 
Cycle
This section focuses on abnormalities within the 
TCA cycle, also known as the citric acid cycle or 
Krebs cycle (Fig. 1), that alter cancer cell metab-
olism. The TCA cycle is the central metabolic 
hub of the cell; it acts as a common pathway for 
the catabolism of many different sugars, fatty 
acids, and amino acids [3]. It also generates elec-
trons that fuel oxidative phosphorylation, a pro-
cess that produces a majority of the energy used 
by normoxic cells [3].
Under aerobic conditions, pyruvate formed as 
a product of glycolysis goes through oxidative 
decarboxylation, a process that removes a car-
boxyl group as CO2 to form acetyl coenzyme A 
(acetyl-CoA), the typical starting molecule of the 
TCA cycle [4]. The TCA cycle takes place within 
the mitochondrial matrix [5]. The steps of the 
TCA cycle are as follows: (1) citrate synthase 
facilitates the condensation of oxaloacetate and 
acetyl-CoA to form citrate, (2) the enzyme aconi-
tase then converts citrate to isocitrate, (3) isoci-
trate is further oxidatively decarboxylated by 
isocitrate dehydrogenase (IDH), (4) the resulting 
compound α-ketoglutarate (α-KG) is transformed 
into succinyl-CoA, (5) succinyl-CoA is then fur-
ther converted to succinate by succinyl-CoA syn-
thetase, (6) the succinate dehydrogenase (SDH) 
complex catalyzes the oxidation of succinate to 
fumarate, (7) fumarate is hydrated to malate by 
fumarate hydratase (FH), and finally (8) malate is 
then oxidized to oxaloacetate by malate dehydro-
genase—initiating the cycle once again [6] 
(Fig. 1).
Mutations of TCA cycle genes have been 
linked to familial cancer types [6]. Recent 
research has found that mutations in the TCA 
cycle enzymes SDH, FH, and IDH resulted in a 

























































































































































































































































































































































































































































































dysfunction of the TCA cycle and defects in 
mitochondrial metabolism in a wide range of 
human cancers [7, 8]. The SDH complex (also 
known as mitochondrial complex II) is the only 
membrane-bound enzyme of the TCA cycle and 
consists of four subunits: SDHA, SDHB, SDHC, 
and SDHD.  SDHA and SDHB are catalytic 
 subunits that protrude into the mitochondrial 
matrix, while SDHC and SDHD are anchored to 
the inner membrane [9]. The SDH enzyme plays 
an essential role in tumor suppression. 
Heterozygous mutations in SDH genes cause 
complete inactivation of the protein function and 
are associated with hereditary paragangliomas 
and pheochromocytomas [10–12]. Tumors exhib-
iting SDH mutations are more aggressive and 
usually proliferate at a much faster rate than nor-
mal cells [9]. In addition to these cancers, several 
other neoplasms have been associated with muta-
tions in SDH subunits, including renal cell carci-
noma (RCC), neuroblastoma, gastrointestinal 
stromal tumors, thyroid cancer, and testicular 
seminoma [13–15].
Similar to SDH, FH mutations occur through-
out the genome. Research has indicated an asso-
ciation between heterozygous FH mutations and 
uterine fibroids, hereditary leiomyomatosis, and 
papillary renal cell cancer [16]. Additionally, loss 
of the wild-type allele in these cancers resulted in 
the absence of FH enzymatic activity. FH acts as a 
tumor suppressor in these cancers, and its reduced 
expression leads to the accumulation of the tran-
scription factor hypoxia-inducible factor-1α 
(HIF-1α) [1, 17]. High levels of fumarate accu-
mulate and act as oncometabolites, which often 
result in dysregulation of cellular functions in 
SDH- or FH-deficient cells [1]. Both accumulated 
succinate and fumarate are potent inhibitors of 
prolyl 4-hydroxylases (PHDs). PHDs are negative 
regulators of HIF-1α, a transcriptional factor that 
is upregulated under hypoxic conditions when 
tumor cells are deprived of adequate oxygen sup-
plies. Impaired PHD activity leads to HIF-1α acti-
vation under normoxia, a condition known as 
pseudohypoxia [6]. Pseudohypoxia, in turn, facil-
itates tumor cell growth.
Similar to the metabolic consequences of 
SDH and FH mutations, mutations in the IDH 
enzyme also result in dysfunction of the TCA 
cycle. There are three isoforms of the enzyme 
IDH. IDH1 is found in the cytoplasm and per-
oxisomes; IDH2 and IDH3 are localized in the 
mitochondrial matrix. IDH3 is the primary 
form of IDH in the TCA cycle, whose function 
is to convert isocitrate to α-KG. Genomic anal-
ysis has identified mutations in either IDH1 or 
IDH2  in the vast majority of grade II and III 
gliomas as well as glioblastoma multiforme 
(GBM) patient samples [18]. The abnormal 
expression and activity of IDHs result in the 
loss of the enzyme’s ability to catalyze the con-
version of isocitrate to α-KG; instead, it gains 
a new ability to facilitate the NADPH-
dependent reduction of α-KG to D-2-
hydroxyglutaric acid (D-2HG), an 
oncometabolite. Subsequently, excess accumu-
lation of 2HG contributes to the formation of 
malignant gliomas [19]. The discovery that 
IDH1 and IDH2 mutations are nearly all mis-
sense mutations localized to residues R132 and 
R172, respectively,  provides a promising bio-
marker for cancer diagnosis and possibly gene 
therapy [20, 21]. It was found that cells harbor-
ing IDH1-R132 and IDH2-R172 mutations in 
patients with acute myeloid leukemia gained 
the ability to convert α-KG to D-2HG [22].
2.2  Glutamine Addiction
In addition to glucose, proliferating cancer cells 
also rely on glutamine as a major source of 
energy and building blocks, with glutamine 
feeding into the TCA cycle. This condition is 
known as glutamine addiction. Glutamine is 
one of the most abundant nonessential amino 
acids in the bloodstream (produced by the 
human body and thus not an essential part of 
the diet) and contributes to virtually every bio-
synthetic pathway in proliferating cells. 
Moreover, it acts as a nitrogen donor in purine 
and pyrimidine synthesis as well as a precursor 
for protein and glutathione biosynthesis [23]. 
Many tumor cells are reliant on exogenous glu-
tamine and have been reported to die in its 
absence [24].
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Since glutamine-derived α-KG fuels the TCA 
cycle, cancer cells can employ glutaminolysis to 
sustain the biosynthesis of many essential 
 molecules. In RCCs that were either ETC or TCA 
cycle deficient, it was found that cancer cells 
relied on the reductive carboxylation of gluta-
mine-derived citrate to produce acetyl-CoA and 
other precursors to TCA cycle metabolites. 
Acetyl-CoA is a necessary intermediate for the 
synthesis of lipids, and without it, cancer cells are 
not viable. Furthermore, TCA cycle intermedi-
ates are needed to synthesize other essential cel-
lular building blocks. Thus, cells can become 
utterly dependent upon glutaminolysis as a result 
of genetic alterations affecting oxidative mito-
chondrial function [25]. A study by Gameiro 
et  al. found that the transcription factor HIF 
expression maintained a low level of intracellular 
citrate to maintain adequate lipogenesis. 
Therefore, the von Hippel-Lindau (VHL)-
deficient RCC cells that constitutively express 
HIF-1α and/or HIF-2α become heavily depen-
dent on glutamine for proliferation [26, 27].
Glutamine addiction was also found to occur 
in glioma cells that possess a recurrent mutation 
of IDH1. As mentioned in the section above, 
IDH1 catalyzes typically the conversion of isoci-
trate to α-KG, but the mutant isoform converts 
α-KG into D-2HG instead, which has been shown 
to inhibit cellular differentiation through epigen-
etic alterations [19]. Due to the mutant IDH1 
function, glioma cells become increasingly 
dependent upon glutamine-derived α-KG pro-
duction. Thereby cancer cells exhibiting gluta-
mine addiction rely on glutaminase (GLS), an 
enzyme that converts glutamine to glutamate, 
which in turn is converted to α-KG for survival. 
The inhibition of GLS suppresses the growth of 
glioma cells with IDH1 mutations by decreasing 
the availability of glutamine-derived α-KG [28].
Further evidence suggests that the dependence 
of specific cancer cells on glutamine may be 
more profound than previously thought. 
Fluorodeoxyglucose-positron-emission tomogra-
phy (FDG-PET) scanning, a clinical imaging tech-
nique, can detect cancers based on areas of 
increased glucose uptake. Specifically, 18F-FDG-
PET imaging exploits increased glucose transport 
and hexokinase II activities in proliferating tumor 
tissues to locate high levels of 18F-FDG, which can 
be visualized by PET images. However, some can-
cers are invisible to PET scans and are deemed 
PET negative. These PET-negative cancers must 
rely on alternative metabolic substrates for their 
primary source of energy, namely glutamine [29]. 
Researchers have used 5-11C-(2S)-glutamine and 
18F-(2S,4R)4-fluoroglutamine as glutamine-based 
PET imaging agents, where 18F is preferred 
because it has 5.5 times the half-life of 11C [30, 
31]. Both tracers are useful tools for probing 
in vivo metabolism of glutamine and monitoring 
radiation effects in cancer patients.
Cancer cells use precursors derived from the 
TCA cycle intermediates to synthesize proteins, 
lipids, and nucleic acids. In order to maintain 
mitochondrial activity, these cells must compen-
sate for lost TCA cycle intermediates caused by 
their metabolic diversions [32]. This process of 
replenishing metabolic intermediates is known as 
anaplerosis [33]. Glutamine provides mitochon-
drial anaplerosis because of its role as a nitrogen 
and carbon donor to the cells [32]. It traverses the 
cell membrane through amino acid transporters, 
ASCT2 (alanine, serine, cysteine transporter 2), 
and system N transporter SN2 [34]. Once it enters 
the cytoplasm, glutamine is hydrolyzed to gluta-
mate and ammonia (NH3) via GLS (Fig. 2) [24].
Glutamate can be further catabolized through 
the TCA cycle (via conversion to α KG) or serve 
as a substrate for glutathione synthesis. α-KG for-
mation can be catalyzed by either glutamate dehy-
drogenase (GDH) or aminotransferases. 
Alternatively, glutamate can be further converted 
to glutathione by glutathione cysteine ligase and 
glutathione synthetase. Glutathione is an antioxi-
dant vital to a cell’s immune defense, nutrient 
metabolism, and cellular functions [35]. It also 
plays an important role in the neutralization of 
mitochondrial reactive oxygen species (ROS). 
ROS are by-products of oxygen metabolism, the 
concentration of which plays a vital role in tumor 
proliferation, growth, apoptosis, and metastasis. 
Studies have found that ROS acts as a “double-
edged sword” in some cancers; moderately ele-
vated levels of ROS facilitate carcinogenesis while 
excessive levels can trigger apoptosis by causing 
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damage to DNA and other macromolecules [36]. 
The dual role of ROS is also evident in the early 
and late stages of cancer. At precancerous and neo-
plastic stages, ROS tends to promote proliferation 
by inducing oxidative damage and base-pair muta-
tions. In the late stages, however, increased energy 
need is correlated with an increase in ROS produc-
tion [37]. Therefore, for a ROS-mediated thera-
peutic approach to be effective, this therapy must 
limit ROS production when ROS would induce 
proliferation, and it must promote ROS production 
when ROS would induce apoptosis.
The inhibition of glutamine metabolism has 
been linked to ROS overproduction, which can 
devastate cancer cells [38, 39]. Mitochondrial 
glutamine metabolism is a significant anaple-
rotic step in tumorigenesis. It is often enhanced 
in cancer cells with increased levels of TCA 
cycle metabolites [32]. Therefore, inhibiting 
GLS could effectively starve cancer cells of the 
glutamine essential to their survival and pre-
vent further glutathione synthesis, thus increas-














































Fig. 2 Glutamate can be catalyzed via three different pathways by the aminotransferases GPT, GOT, and PSAT1, all of 
which yield α-ketoglutarate (α-KG) and a different amino acid, alanine, aspartate, and phosphoserine, respectively. These 
enzymes are upregulated in cancer, which results in increased α-KG production. Inhibition of the enzymes results in 
reduced cancer cell proliferation or tumor growth. Phosphoserine can enter serine and glycine metabolism, where the 
enzyme SHMT is also upregulated in cancer. This results in increased production of glycine, which supports protein and 
purine synthesis and oxidative phosphorylation, thus leading to tumor growth. Elevated level of glycine further leads to 
increased level of glutathione, which mediates oxidative stress and also leads to tumor growth. Tryptophan metabolism is 
linked to the regulation of antitumor immune responses, where the enzymes IDO and TDO can lead to immunosuppres-
sion. Inhibition of IDO or TDO leads to reduced tumor growth. Some cancers have reduced ASS1 which leads to decreased 
arginine level, causing these cancers to rely on exogenous arginine supply. GPT glutamic-pyruvate transaminase, GOT 
glutamic-oxaloacetic transaminase, PSAT1 phosphoserine aminotransferase 1, ASS1 argininosuccinate synthetase 1, IDO 
indoleamine-2,3-dioxygenase, TDO tryptophan-2,3-dioxygenase, SHMT serine hydroxymethyltransferase
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and via the Glutaminase II 
Pathway
Two recent studies have uncovered alternative 
sources of glutamate in cancer. The first study 
identified N-acetyl-aspartyl-glutamate (NAAG), 
which can be hydrolyzed to glutamate when 
needed by the oncogenic cells via glutamate car-
boxypeptidase II (GCP II) [41, 42], suggesting 
that GCPII is a viable target for cancer therapy, 
either alone or in combination with glutaminase 
inhibition. The second study demonstrated that 
upon the inhibition of glutaminase I pathway (the 
conversion of glutamine to glutamate by GLS), 
pancreatic cancer cells utilized the glutaminase II 
pathway to generate glutamate via glutamine 
transaminase K (GTK) [43]. Knocking down the 
expression of GTK inhibited the growth of pan-
creatic cancer cells in  vitro and tumorigenesis 
in vivo. The uncovering of the alternative sources 
of glutamate in cancer opens up new strategic 
approaches. Specifically, these studies suggest a 
combination therapy of GLS1 and GCPII and/or 
GTK inhibition for pancreatic cancer therapy.
3  Targeting Glutamine 
Metabolism for Cancer 
Therapy
Due to its central role in many cancers, glutami-
nolysis is becoming an increasingly prominent 
target for cancer therapy. Mammalian cells 
express two isoforms of GLS: kidney-type GLS1 
and liver-type GLS2. GLS1 is more broadly 
expressed in normal tissue, while GLS2 is mainly 
present in the liver, brain, pituitary gland, and 
pancreas [44]. Both encode a mitochondrial GLS, 
which catalyzes the hydrolysis of glutamine to 
glutamate [45, 46]. Studies have shown that 
c-MYC, a multifaceted transcriptional factor, 
upregulates glutamine importers and GLS1 
expression and that p53, a tumor-suppressor 
gene/protein, upregulates GLS2 expression 
[46–48].
Using stable isotope-resolved metabolomics 
(SIRM) studies [49], Le et  al. also reported the 
persistence of glutamine oxidation via the TCA 
cycle under hypoxia. SIRM studies track meta-
bolic transformations using stable isotope labeling 
and analyze the metabolic products using nuclear 
magnetic resonance (NMR) and mass spectrome-
try (MS) at different time points. Using a human 
Burkitt lymphoma model P493 cell line carrying 
an inducible MYC vector, the group showed the 
coexistence of oxidative and aerobic glycolysis. 
Thus, inhibition of GLS induced oxidative stress 
and diminished ATP levels in hypoxic cells [39]. It 
was also found that glutamine metabolism sup-
ports cellular bioenergetics and redox homeostasis 
for proliferation under both aerobic and hypoxic 
conditions. P493 cells exhibited low glutathione 
levels and high ROS production under inhibition 
of GLS and hypoxia. Furthermore, glutamine-
derived glutathione production was sustained 
under hypoxia as a coping method under high 
ROS levels [39]. These results again suggest that 
glutamine metabolism, specifically through GLS 
enzyme, is a promising target for cancer therapy.
The TP53 gene codes for a tumor-suppressor 
protein known to trigger cell cycle arrest, apopto-
sis, or senescence in response to a variety of cel-
lular dysfunctions, including DNA damage, 
oncogene activation, and hypoxia [50]. It is one 
of the most frequently mutated genes among all 
cancers. However, recent studies have discovered 
TP53’s additional roles in regulating energy 
metabolism and antioxidant defense mechanisms 
[51, 52]. GLS2 is a p53 target gene that plays an 
important role in mediating the tumor-suppres-
sant properties of p53. GLS2 increases intracel-
lular levels of glutamate and α-KG, thus leading 
to enhanced mitochondrial respiration and ATP 
production. It also leads to increased cellular glu-
tathione levels and thus decreased ROS levels 
[46]. Hu et  al. demonstrated that p53 increased 
GLS2 expression under both stressed and non-
stressed conditions—enhancing glutamate levels, 
mitochondrial respiration rates, and glutathione 
levels while decreasing ROS levels. Furthermore, 
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the GLS2 gene promoter contains a p53 consen-
sus DNA-binding element whose expression was 
induced in response to oxidative stress [1, 46]. 
Hu’s findings suggest that GLS2 may be a media-
tor to p53’s role in energy metabolism and anti-
oxidant defense, ultimately contributing to its 
tumor suppression abilities.
Due to its crucial role in energy regulation and 
biosynthesis, targeting glutamine metabolism has 
the potential to affect a broad spectrum of can-
cers. In addition to GLS inhibition, the role of 
oncogenes and tumor suppressors in regulating 
glutamine metabolism makes it a promising ven-
ture for therapeutic strategies. However, while 
many drugs have been synthesized to target glu-
tamine metabolism from its initial transport into 
the cell to its conversion to α-KG, most are still in 
preclinical stages (Table 1) [44].
3.1  Inhibition of Glutaminolysis 
by GLS Inhibitors
The most straightforward approach for targeting 
glutaminolysis is the inhibition of GLS, which cata-
lyzes the hydrolysis of glutamine to glutamate. The 
kidney isoform, GLS1 (or GLS), is found in many 
primary tumors, while the liver isoform, GLS2, is 
less often expressed in cancers [53]. Inhibiting GLS 
can starve cancer cells by blocking the synthesis of 
glutamate and thus prevent α-KG from feeding the 
TCA cycle. After nuclear factor kappa B (NF-kB) 
activates glutaminase C isoform (GAC), an alterna-
tively spliced isoform of GLS1, via phosphoryla-
tion, NF-kB itself is activated by Rho GTPases. 
Alteration of Rho GTPases by small-molecule 
inhibitors showed a significant decrease in GAC 
activity in human breast cancer cells [54]. The 
decrease in GAC activity caused breast cancer cells 
to stop proliferating and reduced their ability to 
invade surrounding cells [54]. Potent therapeutic 
GLS inhibitors, such as bis-2-(5-phenylacet-
amido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) 
and its analogs such as CB-839, are being actively 
investigated in GLS-targeting studies [38, 54–58].
BPTES allosterically inhibits GLS1 by alter-
ing the conformation of the enzyme and has been 
proven in many studies to inhibit cancer cell 
growth in  vitro and slow tumor growth in  vivo 
[39, 56, 59]. While BPTES produces formidable 
results in vitro, higher concentrations are needed 
to achieve the same effect in vivo. Due to its low 
solubility, BPTES tends to precipitate at high 
concentrations, posing a challenge to the physio-
logical delivery of the drug in clinical trials [60]. 
A solution was proposed by Elgogary et al. with 
an emulsification method that encapsulated 
BPTES into biodegradable nanoparticles coated 
with poly(ethylene glycol) (PEG) and poly(lactic-
coglycolic acid) (PLGA) to improve nanoparticle 
circulation time in the blood. This process 
enhanced the efficacy of BPTES in  vivo by 
improving its solubility and increasing tumor 
drug exposure [38].
The only GLS inhibitor to have entered clinical 
trials is commonly referred to as CB-839 or com-
mercially as Telaglenastat. CB-839 is a highly 
potent allosteric inhibitor that completed phase I 
clinical trials in March 2019  in patients with 
advanced RCC (NCT02071862) and has in 2020 
moved to phase II clinical trials in patients with 
non-small cell lung cancer (NCT04265534). Phase 
I trials have been completed for hematological 
tumors (NCT02071888) and leukemias 
(NCT02071927), although no clinical data is pub-
Table 1 Current therapeutic strategies and their mecha-
nism of action in targeting glutamine metabolism
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licized. CB-839 has shown efficacy in the treat-
ment of triple-negative breast cancer (TNBC), 
showing a marked decrease in glutamine consump-
tion, glutamate production, and levels of glutathi-
one and other TCA cycle intermediates [55]. 
Elevated GLS expression is also associated with 
different cancer types, including glioblastoma and 
pancreatic cancers, thereby encouraging investiga-
tion of more targets should current clinical trials 
prove successful [28, 61].
Taken together, glutamine dependency may be 
a particular metabolic vulnerability of cancer 
cells, and glutaminolysis-targeting strategies 
could be promising approaches for glutamine-
addicted cancer therapy.
3.2  Combination Therapy
The heterogeneity of cancer metabolism, even 
within the same tumor [62], poses many chal-
lenges for potential drug therapies. Hence, the 
use of combination therapies to target multiple 
metabolic pathways to suppress tumor growth 
may be most effective, especially in identifying 
cases that induce synthetic lethality, where two 
drugs induce cell death in combination, but not 
individually. Glutamine’s role in cellular func-
tions makes GLS inhibition an ideal candidate for 
combination therapy. In their study, Elgogary 
et al. found that combination therapy of BPTES 
and metformin produced better results in pancre-
atic tumors than monotherapy of either drug 
alone. Metformin is an FDA-approved drug for 
the treatment of type 2 diabetes that inhibits gly-
colysis and glycogen synthesis. In this case, 
BPTES targets glutamine metabolism, and met-
formin targets glucose metabolism, resulting in 
an optimal reduction of tumor development [38]. 
Other treatments that are synthetically lethal with 
the inhibition of GLS include GLUT2q1 inhibi-
tion, mTOR inhibition, and ATF4 activation [44].
In recent years, researchers have increasingly 
leveraged combination therapies for the treat-
ment of a variety of cancers (Table  2) [63]. 
Parlati et al. combined CB-839 with pomalido-
mide to target myeloma models [64]. Momcilovic 
et  al. treated lung cancer with the synergistic 
combination of CB-839 and erlotinib, demon-
strating significant reductions in glucose and 
glutamine uptake [68]. Emberley et al. explored 
the various combinations of CB-839 with 
CDK4/6 and PARP inhibitors in colorectal carci-
noma (CRC), TNBC, ovarian cancer, and non-
small cell lung carcinoma [67].
3.3  Knockdown of c-MYC
In a study by Wise et al., c-MYC expression was 
found to activate the transcription of key regula-
tory genes required for glutamine uptake and 
metabolism by selectively binding to the pro-
moter regions of glutamine transporters ASCT2 
and SN2. As a result, c-MYC induced reprogram-
ming of mitochondrial metabolism by diverting 
glucose away from the TCA cycle and leaving 
Table 2 Current combination therapeutic strategies 
employing CB-839 and BPTES on various cancer types 
and their results, non-exhaustive [63]
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BPTES + metformin *65% [38]
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cells susceptible to glutamine addiction to sustain 
anaplerosis. Moreover, c-MYC-transformed cells 
were found to be sensitive to GDH inhibitors. 
These results suggest that glutamine addiction 
may be a direct consequence of c-MYC activation 
[48]. Gao et  al. found that c-MYC expression 
induced the expression of mitochondrial GLS in 
human P493 lymphoma B cells and PC3 prostate 
cancer cells by suppressing microRNAs miR-23a 
and miR-23b, which target the GLS 3′ untrans-
lated region (UTR) seed sequence [1, 47]. Liu 
et al. established a direct link between glutamine 
and proline via MYC-induced proline biosynthe-
sis from glutamine, suggesting novel therapeutic 
strategies [69]. Overall, these results may be 
exploited for cancer therapy using inhibitors of 
enzymes involved in glutamine metabolism or 
therapeutics that inhibit the transcriptional prop-
erties of c-MYC.
The transcriptional factor MYC is an essential 
growth regulator that is overexpressed in most 
cancers, and hence is a highly sought-after target 
for cancer therapies [70, 71]. Niu et al. found that 
suppressing c-MYC expression resulted in 
reduced cell growth, colony formation, and tumor 
formation in nasopharyngeal carcinoma cell lines 
both in vitro and in vivo [72]. Using RNA inter-
ference (RNAi)-mediated silencing of the c-MYC 
gene, Zhang et al. showed that the downregula-
tion of c-MYC induced apoptosis in  vitro and 
suppressed the growth of colon cancer cells 
in vivo [73].
Other attempts at directly or indirectly target-
ing MYC have included knockdown, protein/pro-
tein and DNA interaction inhibitors, and 
translation and expression regulation [74]. Direct 
inhibition of MYC expression can be achieved by 
using G-quadruplex stabilizers that prevent MYC 
transcription or antisense oligonucleotides and 
siRNAs that prevent MYC translation [75–78]. 
Small-molecule protein/protein interaction inhib-
itors have also been used to interfere with MYC 
transcriptional activation [79, 80]. Indirect inhi-
bition methods encompass blocking transcrip-
tion, hindering mRNA translation, and targeting 
regulators of MYC protein stability [81, 82]. 
The most advanced methods currently in clinical 
trials or commercially approved employ indirect 
targeting by immunotherapies, which focus on 
immune components required for MYC-driven 
tumors or checkpoints that are altered in MYC-
driven tumors [83, 84].
3.4  Inhibition of Glutamate 
Dehydrogenase (GDH)
Inhibiting the oxidative deamination of gluta-
mate to α-KG has devastating effects on cancer 
cells comparable to inhibiting glutaminolysis 
[61, 85]. This process is catalyzed by GDH, 
which can be inhibited by the preclinical com-
pounds R162, epigallocatechin gallate (EGCG), 
and epicatechin gallate (ECG) [44, 86]. Using 
perifusion assays, Li et  al. showed that EGCG 
and ECG blocked GDH activity by binding to the 
allosteric regulator ADP’s binding site [87].
Furthermore, it was demonstrated that poly-
phenols such as hexachlorophene and bithionol 
might inhibit GDH function. These inhibitors 
work by restricting enzyme movement, either 
by forming ring barriers around the enzyme or 
by wedging between the enzyme’s subunits. 
Currently, polyphenols have been shown to 
inhibit lung, colon, and prostate adenocarci-
noma growth in xenograft models [88]. These 
compounds also had significant effects on glio-
blastoma, colon, lung, and prostate adenocarci-
noma cell proliferation [89]. Additionally, it was 
found that GDH inhibition through siRNA 
resulted in a marked decrease in the prolifera-
tion of glioblastoma cells that were glutamine 
dependent [18, 90].




One of the earlier means of suppressing glutamine 
metabolism arose from reducing the amount of 
available glutamine itself. Ollenschläger et  al. 
found that the abundance of glutamine in the body 
dropped precipitously by giving L-asparaginase 
to patients with acute myeloid leukemia. 
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Asparaginase catalyzes the removal of the amide 
nitrogen from asparagine to form aspartic acid. 
The administration of asparaginase also depleted 
stored levels of glutamine [91]. When applied in 
cell culture, asparaginase inhibited cell growth 
and induced cell death in pancreatic  cancer cells. 
The effect of asparaginase can largely be reversed 
through the reintroduction of small amounts of 
glutamine [92].
Studies of acute lymphoblastic leukemia 
indicated that asparaginase activity correlated 
with glutamine depletion in the bloodstream and 
improved treatment outcomes [93, 94]. 
Furthermore, cancer cells, with a deficiency of 
asparagine synthase (ASNS), an enzyme that 
generates asparagine, such as acute lymphoblas-
tic leukemia (ALL), must use asparagine from 
the blood [95]. In 1979, Ertel et al. treated ALL 
patients with asparaginase, which exhausted the 
asparagine supply in the blood. This treatment 
re-induced remission in up to 60% of cases [96]. 
ALL can upregulate ASNS to restore intracel-
lular asparagine levels and satisfy their aspara-
gine demand [97]. However, some studies show 
that ASNS levels may not impact the sensitivity 
of ALL to asparaginase treatments in all cases 
[98]. The diverse metabolic phenotypes of 
malignant cells create many challenges for ther-
apeutic strategies. It seems that a combination 
of drug therapy targeting both asparagine and 
glutamine metabolism could be a promising 
treatment.
Tempol (4-hydroxy-2,2,6,6-tetramethylpiper-
idine-1-oxyl), a drug previously known to inhibit 
cancer cell proliferation and increase vulnerabil-
ity to other cytotoxic agents, has been shown to 
interfere with glutamine metabolism through 
inhibition of IDH1/2 and slowing of the TCA 
cycle [99]. This effect was found both in  vitro 
and in vivo and showed that Tempol might be a 
powerful therapeutic in combination with other 
cancer drugs.
Another possible therapeutic in development is 
phenylbutyrate, a drug that lowers glutamine con-
centrations in the plasma. It is currently approved 
by the FDA and has shown clinical improvement 
in patients with hormone-refractory prostatic 
 carcinoma and GBM [94, 100, 101].
3.6  Inhibiting Glutamine Uptake
The c-MYC-activated amino acid transporter 
ASCT2 (or SLC1A5) is upregulated in many can-
cers and is involved in controlling glutamine 
uptake [48, 94]. High levels of ASCT2 are corre-
lated with aggressive tumor growth and short sur-
vival time. ASCT2 inhibitors include benzylserine, 
l-γ-glutamyl-p-nitroanilide (GPNA), and V-9302 
[44, 102, 103]. Additionally, Colas et  al. found 
that ASCT2 ligands chloroalanine, aminooxetane-
3-carboxylate (AOC), and γ-FBP also inhibit 
ASCT2-mediated glutamine uptake in human 
melanoma cells [104]. Research shows that the 
inhibition of glutamine importers significantly 
slowed growth in human colon and lung cancer 
cells [105, 106].
Benzylserine and GPNA are amino acid ana-
logs; however, while they reduce glutamine 
uptake, they do not exclusively inhibit the ASCT2 
function [107]. Their low affinity and specificity 
make them unsuitable for clinical trials that spe-
cifically target glutamine addiction via ASCT2. 
V-9302 is a more contemporary inhibitor; how-
ever, research has indicated that its efficacy was 
likely unrelated to ASCT2 inhibition, yielding 
again to the problem of non-specificity [108].
The development of blocking antibodies and 
antibody-drug conjugates presents an alternative, 
perhaps a more viable approach to inhibiting glu-
tamine uptake by regulating the ASCT2 trans-
porter [109]. MEDI7247 is the only ASCT2 
antibody-drug conjugate currently in phase I 
clinical trials (NCT03811652, NCT03106428).
3.7  Using Glutamine Mimetics
Another means of decreasing the availability of 
glutamine is the creation of glutamine analogs. 
Analogs such as 6-diazo-5-oxo-l-norleucine 
(DON) and acivicin did show cytotoxic effects 
against several tumor types, including leukemia 
and colorectal cancers; however, these analogs 
are no longer clinically available due to patient 
toxicity [110]. DON prodrugs have shown 
enhanced cerebrospinal fluid delivery, although 
toxicity was still observed [111].
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A few glutamine analogs, namely acivicin, 
azaserine, and DON, have been extensively 
researched in an effort to inhibit glutamine 
metabolism. DON is a substrate analog of gluta-
mine that binds to the active site of human kidney 
GLS to serve as an inhibition mechanism [112]. 
However, DON has had difficulty progressing 
into clinical trials due to concerns regarding its 
lack of selectivity to GLS and toxicity [110, 113, 
114]. Clinical studies of DON co-administered 
with PEGylated glutaminase (PEG-PGA) sug-
gested improved efficacy and it holds promise 
[115]. Similar to DON, acivicin and azaserine are 
also glutamine analogs that interrupt nucleotide 
synthesis by inhibiting amidotransferases [110, 
116]. All three analogs exhibit excessive side 
effects and toxicity that have prevented them 
from reaching or advancing in clinical trials.
4  Transaminase Upregulation 
and Targeting Amino Acid 
Synthesis for Cancer Therapy
Another means of inhibiting glutaminolysis 
is  to  target alanine transaminase through 
L-cycloserine or aspartate transaminase through 
the inhibitor amino oxyacetate, which could 
almost completely halt the growth of breast can-
cer in xenograft mice [117, 118]. What is truly 
promising is that there appears to be little to no 
toxicity in non-neoplastic cells. The effective-
ness of the inhibitor, combined with the lack of 
toxicity, makes inhibition of aspartate amino-
transferase a potentially successful chemothera-
peutic target.
Transaminases, also known as aminotransfer-
ases, are enzymes that catalyze reactions between 
amino acids and α-keto acids. Specifically, amino-
transferases can convert glutamate to α-KG with-
out producing ammonia. Glutamate acts as a 
nitrogen donor in these transaminations. Alanine 
aminotransferase, also known as glutamic-pyru-
vate transaminase (GPT), and aspartate amino-
transferase, also known as glutamic-oxaloacetic 
transaminase (GOT), are abundantly present in the 
liver and often serve as markers for liver toxicity. 
There are three aminotransferase pathways through 
which glutamate can be transformed to 
α-KG. These key enzymes in these pathways are 
GPT, GOT, and phosphoserine aminotransferase 1 
(PSAT1)—each of which produces a different 
amino acid by-product in addition to α-KG.  As 
illustrated in Fig. 2, GPT transfers nitrogen from 
glutamate to pyruvate to produce alanine and 
α-KG. GOT transfers nitrogen from glutamate to 
oxaloacetate to produce aspartate and α-KG. PSAT1 
transfers nitrogen from glutamate to 3-phosphohy-
droxypyruvate to produce phosphoserine and 
α-KG [44]. PSAT1 is also involved in the serine 
synthesis pathway, which is essential for many 
breast cancers [119]. Serine is essential for the syn-
thesis of proteins necessary for cell proliferation. 
PSAT1 expression has recently been demonstrated 
to be upregulated in cancers in many studies [44]. 
Possemato et al. found that serine pathway flux is 
augmented in some breast cancer cell lines and that 
suppression of PSAT1 inhibited proliferation of 
these cells in addition to causing a significant 
reduction of α-KG [120]. In a study by Son et al., 
aspartate aminotransferases were demonstrated to 
be vital in maintaining redox homeostasis in pan-
creatic ductal adenocarcinoma (PDAC) cells. 
Furthermore, oncogenic mutant KRAS activity was 
found to upregulate the expression of aminotrans-
ferases, hence yielding high ROS levels and slow-
ing tumor growth in  vivo [85, 116, 121]. Taken 
together, these works suggest that targeting the 
amino acid synthesis pathway may be another 
effective strategy for cancer therapy.
Apart from glutamine, many other amino acids 
play important roles in tumorigenesis, namely 
arginine, tryptophan, serine, and glycine. Arginine 
is a precursor for the synthesis of proteins, urea, 
and various signaling molecules [122]. Although 
arginine is considered a nonessential amino acid, 
many cancer cells are dependent upon arginine 
for proliferation. Argininosuccinate synthetase 1 
(ASS1) catalyzes the conversion of citrulline into 
argininosuccinate in the arginine synthesis path-
way. Loss or suppression of ASS1  in osteosar-
coma cells resulted in the depletion of arginine. 
Studies have shown that ASS1 acts as a tumor 
suppressor because cells with low ASS1 expres-
sion could not grow in an environment without 
arginine [123, 124].
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Tryptophan is linked to the regulation of antitu-
mor immune responses [125]. Figure 2 shows that 
it can be degraded to kynurenine via two enzymes: 
indoleamine-2,3-dioxygenase (IDO) and trypto-
phan-2,3-dioxygenase (TDO). IDO activity com-
monly leads to the suppression of the immune 
system [126]. Dendritic cells (immune system 
cells that present antigens to T cells) expressing 
IDO can limit tryptophan supply to T cells in the 
extracellular matrix, thus limiting T-cell response 
to tumor growth [127]. Studies have shown that 
mice transfected with IDO-induced cells devel-
oped large tumors and exhibited poor survival, 
while mice transfected with IDO-negative cells 
showed no signs of tumor development [128]. To 
further support this finding, immunohistochemical 
staining for IDO expression revealed a correlation 
between high IDO expression and low levels of 
immune cells CD3+, CD8+, and CD57+ [129]. 
This, in turn, can be correlated with aggressive 
tumor progression and poor survival in cancer 
patients with high IDO expression [129].
There are currently four IDO inhibitors under 
clinical development and more in preclinical 
testing [130]. In 2013, Beatty et al. studied the 
effects of the small-molecule IDO inhibitor 
INCB024360 treatment in 52 cancer patients. 
The drug was well tolerated by patients and suc-
cessfully inhibited more than 90% of IDO activ-
ity when administered twice a day. Results 
showed stable disease conditions in 30% of 
patients [131]. Because INCB024360 was well 
tolerated, it has the potential to be potent as 
either a monotherapy or part of combination 
therapy. Phase II clinical trials of this inhibitor 
have been completed for patients with ovarian 
cancer and myelodysplastic syndrome 
(NCT01822691, NCT01685255). Combinatorial 
therapies with IDO inhibitors and cancer vac-
cines have also shown progress. A phase I study 
of indoximod, another IDO inhibitor, in combi-
nation with docetaxel, an antimitotic chemother-
apy drug, showed stable or partially stable 
disease conditions in more than 50% of patients 
[132]. Other combinatorial therapies being 
tested in the clinic include INCB024360 and 
MK3475, an immune checkpoint inhibitor [130].
Other than IDO, cancer cells can also use 
TDO, an immunosuppressive enzyme, to avoid 
immune destruction. TDO is abundantly present 
in melanomas, bladder carcinomas, and hepato-
carcinomas. Similar to IDO, the use of TDO 
inhibitors prevents the growth of TDO-expressing 
tumor cells [133]. There are several other 
enzymes that cancer cells exploit for immune tol-
erance; hence, targeting tryptophan metabolism 
with combinatorial approaches may yield opti-
mal therapies [123].
The serine and glycine biosynthesis path-
ways are interconnected. They both provide 
methyl groups for the one-carbon pool that sup-
ports purine and pyrimidine synthesis in prolif-
erating cancer cells [134]. Research has shown 
that phosphoglycerate dehydrogenase 
(PHGDH), the enzyme that catalyzes the first 
reaction in the serine synthesis pathway, was 
highly upregulated in metastatic breast cancer 
and was correlated to short patient survival 
times [135, 136]. The gene encoding PHGDH is 
also amplified in melanoma and breast cancer 
types [120]. In addition to PHGDH, serine 
hydroxymethyltransferase (SHMT) is also 
implicated in tumorigenesis. SHMT catalyzes 
the conversion of serine to glycine and is regu-
lated by c-MYC, an oncogene that controls the 
transcription of 15% of human genes [123, 137, 
138]. Glycine is a component of glutathione and 
is required for regulating cellular redox balance. 
It also fuels nucleotide biosynthesis and sus-
tains oxidative phosphorylation in mitochon-
dria. Thus, glycine metabolism has been shown 
to promote rapid tumor proliferation [134, 139, 
140]. In an attempt to block glycine biosynthe-
sis, researchers are using antimetabolites (drugs 
that interfere with the effects of metabolites), 
methotrexate, and pemetrexed to inhibit SHMT 
[134, 141]. Since serine and glycine are consid-
ered nonessential, their depletion can be toler-
ated in  vivo. Maddocks et  al. found that mice 
fed diets lacking serine and glycine showed a 
reduction in tumor sizes and survived longer 
than those fed diets containing the amino acids, 
indicating that diet regulation may be a potential 
therapy for investigation [142].
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Many cancers become dependent on exoge-
nous amino acid supplies to increase de novo 
synthesis of other amino acids. This characteris-
tic can be exploited for cancer therapy by deplet-
ing amino acid supplies, blocking uptake by 
transporters, and inhibiting biosynthetic enzymes. 
The identification of novel therapeutic strategies 
targeting amino acid pathways could allow for 
the emergence of new drugs and enhance the cur-
rent therapeutic efficacy.
5  Glutamine Metabolism 
in the Tumor 
Microenvironment
In addition to its effects on metabolism in can-
cer cells, glutamine can have relevant effects on 
the metabolic, and subsequently functional, 
profiles of cells in a tumor microenvironment 
[143]. Immune cells are present throughout the 
tumor microenvironment, and they can heavily 
influence tumor progression [144]. Natural 
killer (NK) cells and T cells are regularly 
involved in early detection, control, and clear-
ance of tumors [144, 145]. Macrophages, on the 
other hand, can contribute to a microenviron-
ment conducive to tumor growth, invasion into 
nearby tissues, and metastasis [146, 147]. In 
addition, other cell types, such as fibroblasts, 
play important roles in promoting tumor growth 
and metastasis,  providing growth factors and 
contributing to  extracellular matrix remodeling 
with matrix metalloproteinases [148, 149]. 
These cell types elicit unique responses to dif-
ferent metabolites, each of which could enhance 
or impede a cancer therapy’s effectiveness in 
clearing cancers.
The responses to glutamine that these cell 
types exhibit add to the vast heterogeneity of 
possible metabolic schemes that cancers can 
adopt. Studying these metabolic processes builds 
upon a well-mapped understanding of cancer 
metabolism, which, in concert with existing and 
newly developed therapies, can make an 
immense difference in a cancer patient’s course 
of treatment.
5.1  The Role of Glutamine 
Metabolism in T Cells and NK 
Cells
T cells and NK cells are the cytotoxic effector 
cells of productive immune response to cancer, 
but they can be as influenced by a metabolic land-
scape as cancer cells are. Presnell et al. showed 
that human CD8+ cytotoxic T cells, when stimu-
lated in  vitro, produce significantly less 
interferon-γ and tumor necrosis factor-α (TNFα) 
in a glutamine-deprived environment, compared 
to a baseline glutamine-supplemented environ-
ment [150]. This decrease in cytokine production 
correlates with a decrease in CD8+ T-cell effector 
function when in a low-glutamine environment. 
Thioredoxin-interacting protein (TXNIP), a sup-
pressor of glucose uptake known to be active in 
low-glutamine conditions as a glycolytic sensor, 
was found to be strongly expressed in the gluta-
mine-deprived setting in activated CD8+ T cells 
[151]. These findings were corroborated in the 
work presented by Song et al., who showed that 
ovarian cancer could induce endoplasmic reticu-
lum stress in cytotoxic T cells, which depleted 
glutamine transporters in these cells and subse-
quently led to T-cell dysfunction [152]. This phe-
notype was rescued by repairing glutamine 
uptake in these T cells, further suggesting that 
glutamine deprivation in the tumor microenvi-
ronment serves as a powerful tool for tumor 
immune evasion.
However, Presnell et al. also showed that NK 
cells are more resilient against glutamine deple-
tion and still produced interferon-γ in a gluta-
mine-limited setting [150]. Additionally, 
activated NK cells did not show upregulation of 
TXNIP expression in a low-glutamine environ-
ment. This was investigated further, and, when 
faced with a low-glucose/low-glutamine environ-
ment, these cells were shown to rely on fatty acid 
oxidation or acetate for energy to mount a cyto-
kine response, further highlighting the metabolic 
resilience of NK cells.
Considering these findings in the greater 
scheme of cancer treatments and given the explo-
sive development of cancer immunotherapy tech-
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nologies to kick-start T-cell activity, it will be 
important for clinicians to consider the metabolic 
implications that different combinations of drugs 
can have.
5.2  The Role of Glutamine 
Metabolism in Tumor-
Associated Macrophages
Macrophages in the tumor microenvironment can 
define the immune landscape of a tumor, depend-
ing on the cytokines that they produce. 
Macrophages polarize to either M1 macrophages 
or M2 macrophages, and these phenotypes are 
dependent on the broader environment that the 
cells are in [146]. In a cancer setting, M1 macro-
phages generally promote inflammation and 
active antitumor immune responses. In contrast, 
M2 macrophages produce cytokine signals like 
IL-6 and IL-10 that help cancer cells evade 
immune surveillance, recruit endothelial cells for 
angiogenesis, and avoid apoptosis, thus allowing 
them to proliferate more freely [146, 153].
Fu et al. showed that, in a microenvironment 
deprived of glutamine, due to glutamine addiction 
in clear cell renal cell carcinoma (ccRCC), tumor-
associated macrophages (TAMs) promote an 
immunosuppressive microenvironment [154]. 
Glutamine-addicted ccRCC tumors deprive the 
tumor microenvironment of glutamine. This study 
showed that, in glutamine-deprived microenvi-
ronments, TAMs began producing interleukin-23 
(IL-23) via HIF1α activation. IL-23 subsequently 
activated the immune-suppressive regulatory T 
cells (Treg) in the tumor microenvironment. 
Through the production of IL-10 and transform-
ing growth factor-beta (TGF-β), Tregs suppressed 
nearby cytotoxic cells, leading to immune evasion 
for the tumor [155, 156]. This phenotype was 
explored in both mouse models and in vitro with 
an anti-IL-23 antibody to block IL-23 signaling 
where mice experienced prolonged survival and 
decreased tumor burden, and CD8+ cells in mice 
and in vitro showed enhanced cytotoxicity in the 
IL-23-depleted state [154] (Fig. 3).
This example highlights a direct link between 
glutamine addiction and immune function in the 
tumor microenvironment. These findings show 
that an understanding of cancer metabolism can 
be used to not only shape metabolically targeted 
therapies but also hint at therapies against other 
factors impacting the landscape of the cancer 
treatment.
5.3  The Role of Glutamine 
Metabolism in Cancer-
Associated Fibroblasts
Fibroblasts play a key role in solid tumors, fulfill-
ing important functions like secreting growth fac-
tors, remodeling the extracellular matrix, and 
promoting metastasis [148]. They may also influ-
ence the metabolic behaviors of cancer cells. 
Zhao et al. reported that cancer-associated fibro-
blasts (CAFs) secreted exosomes that contain 
metabolites, which are taken up by cancer cells 
and can alter the metabolic patterns within those 
cancer cells [157, 158]. Using an in vitro system 
of prostate cancer cell lines and patient-derived 
CAFs, this study visualized exosome uptake and 
noted that the uptake of these exosomes was fol-
lowed by a decrease in cancer cell mitochondrial 
oxidative phosphorylation, concomitantly lead-
ing to an increase in glycolysis. Through 13C5-
glutamine labeling experiments, they found that 
these prostate cancer cells also exhibited a greater 
reliance on glutamine following exosome uptake, 
with increased levels of 13C-labeled m + 5 α-KG 
and m + 5 glutamate indicative of reductive glu-
tamine metabolism for anaplerosis into the TCA 
cycle. This data suggests that CAFs are capable 
of shifting the metabolism of cancer cells from 
mitochondrial dependent to glycolytic dependent 
and upregulating their glutamine metabolism. 
These findings open the opportunities for therapy 
targeting metabolic cross talk between cancer 
cells and cancer-associated fibroblasts [159].
6  Conclusion
Glutaminolysis is a metabolic process that has 
been shown to play a critical part in a wide variety 
of cancers. As a result, glutamine metabolism is 
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an important potential target for cancer therapy. 
Cancer metabolism is heterogeneous. Just as only 
some cancers are dependent upon glucose for the 
TCA cycle, only some cancers will exhibit aber-
rant glutaminolysis. Even within a single patient, 
the cancer cells may exhibit vast differences in 
their dependence on metabolic fuel supplies. This 
implies that not all cancers will respond in the 
same manner, or to the same extent, to the inhibi-
tion of glutaminolysis. It is important to note that 
inhibiting glutaminolysis will be more effective 
on cancers that display glutamine addiction. That 
being said, there is a huge potential for inhibition 
of glutaminolysis in cancers [160, 161]. As stated 
before, genetic alterations, as well as the tumor 
microenvironment, can influence cancer cells’ use 
of glutaminolysis. Developing and exploring glu-
taminolysis inhibitors present a strategic course of 
action toward the goal of finding an effective 
treatment for the many glutamine-dependent can-
cers. Inhibitors of GLS, GDH, GCPII, GTK, or 
other key enzymes could be used in combination 
with standard chemotherapy treatments to 
increase their overall effectiveness (Fig. 3).
Currently, the use of SIRM with NMR has 
been very useful in tracking and examining 
metabolite usage within certain cancer lines [56]. 
Increased efforts should be made in the future to 


































Fig. 3 Cancer cells with glutamine addiction result in a glutamine-deprived tumor microenvironment. Decreased glu-
tamine level results in decreased interferon-γ and TNF-α production in T cells leading to tumor immune evasion. 
However, NK cells are not affected by decreased glutamine level. Decreased glutamine level also results in HIF-1α 
activation in tumor-associated macrophages which leads to immunosuppression through IL-23 signaling. Inhibition of 
IL-23 results in prolonged survival and reduced tumor growth. Cancer-associated fibroblasts in the tumor microenviron-
ment can release exosomes containing metabolites, which when absorbed by the cancer cells can promote glycolysis 
and glutamine metabolism
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Key Points
• Fatty acid synthesis is upregulated in cancer.
• The mitochondrial citrate transporter protein 
(CTP) protects mitochondrial function in 
cancer.
• ATP citrate lyase (ACLY) is upregulated in 
cancer.
• Inhibiting acetyl-CoA carboxylase (ACC) has 
multifaceted effects on cancer.
• The first fatty acid synthase (FAS) inhibitor, 
TVB-2640, is in clinical trials for cancer.
• Markers such as cell type, oncogene muta-
tions, expression/activity of lipid synthesis 
enzymes, and metabolic profiles can be used 
to predict cancer cell sensitivity to lipid syn-
thesis inhibition.
• The tumor microenvironment influences the 
sensitivity of cancer cells to lipid synthesis 
inhibitors.
• The efficacy of inhibiting cholesterol synthe-
sis with adjuvant statins is variable.
• Fatty acid uptake is associated with 
metastasis.
• Targeting fatty acid oxidation (FAO) for can-
cer therapy may be achieved by inhibiting car-
nitine palmitoyltransferase 1.
• Carnitine palmitoyltransferase 1 (CPT1) 
inhibitors are now in clinical trials for cancer 
treatment.
• FAO occurs at peroxisomes, where peroxi-
some proliferator-activated receptors (PPARs) 
act as ligand-activated transcription factors.
1  Introduction
The study of cancer cell metabolism has tradition-
ally focused on glycolysis and glutaminolysis. 
However, lipidomic technologies have matured 
considerably over the last decade and broadened 
our understanding of how lipid metabolism is rel-
evant to cancer biology [1–3]. Studies now sug-
gest that the reprogramming of cellular lipid 
metabolism contributes directly to malignant 
transformation and progression [4, 5]. For exam-
ple, de novo lipid synthesis can supply proliferat-
ing tumor cells with phospholipid components 
that comprise the plasma and organelle mem-
branes of new daughter cells [6, 7]. Moreover, the 
upregulation of mitochondrial β-oxidation can 
support tumor cell energetics and redox homeo-
stasis [8], while lipid-derived messengers can 
regulate major signaling pathways or coordinate 
immunosuppressive mechanisms [9–11]. Lipid 
metabolism has, therefore, become implicated in 
a variety of oncogenic processes, including meta-
static colonization, drug resistance, and cell dif-
ferentiation [10, 12–16]. However, whether we 
can safely and effectively modulate the underly-
ing mechanisms of lipid metabolism for cancer 
therapy is still an open question.
As discussed in previous chapters, inter- and 
intra-tumoral heterogeneities are major causes of 
treatment failure in clinical oncology because 
tumor subclones with either intrinsic or acquired 
resistance to therapy can be selected by Darwinian 
mechanisms and allowed to drive disease relapse 
[17–20]. An alarming number of parameters seem 
to be capable of inducing this diversity, including 
(epi)genetic lesions, microenvironmental con-
straints, stromal interactions, and treatment effects 
[21–23]. Perhaps unsurprisingly then, transla-
tional strategies targeting lipid metabolism have 
reported mixed or even diverging responses in 
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preclinical models of cancer. These results hint at 
differential tumor cell dependencies on lipids, but 
we are far from understanding the extent to which 
this heterogeneity arises. Moreover, how this 
 nonuniformity of lipid metabolism undermines 
patient treatment is unclear. To better understand 
the clinical potential of this emerging discipline, 
we will have to address both the spatial and 
 temporal heterogeneities of cellular lipid 
metabolism.
Here, we provide a brief synopsis of novel 
findings on the lipid metabolism of cancer cells, 
with an emphasis on heterogeneity across and/or 
within tumors. Given the rapid pace of this field, 
we focus on central pathways involving fatty acid 
synthesis, uptake, and oxidation.
2  Fatty Acid Synthesis Is 
Upregulated in Cancer
Endogenous fatty acid synthesis is frequently 
upregulated in cancer because fatty acids can 
serve as substrates to produce lipid signaling 
molecules, modify protein functions through lipi-
dation, synthesize phospholipids for cell mem-
branes, or store energy as triglycerides. The 
primary source of carbons for fatty acid synthesis 
in cancer cells comes from glucose. Glucose car-
bon is incorporated into acetyl-CoA, which then 
forms citrate in the mitochondria. The mitochon-
drial citrate transporter protein (CTP) carries 
citrate from the mitochondria to the cytosol. ATP 
citrate lyase (ACLY), a key enzyme of de novo 
fatty acid synthesis (DNLS), cleaves cytosolic 
citrate into acetyl-CoA and oxaloacetate. 
Cytosolic acetyl- CoA is used to form fatty acids. 
Hence, the localization of acetyl-CoA within a 
cell can determine its metabolic fate.
2.1  The Mitochondrial Citrate 
Transporter Protein (CTP) 
Protects Mitochondrial 
Function in Cancer
The Avantaggiati research group has extensively 
studied the mitochondrial citrate transporter 
protein (CTP) and demonstrated that CTP plays 
an important role in preventing mitochondrial 
damage and preserving its function, such as in 
cellular bioenergetics [24]. The inhibition of 
CTP resulted in anti-tumorigenesis in  vivo. 
Although the authors observed a decrease in 
fatty acid synthesis from glucose due to the sup-
pression of CTP-dependent transport of citrate 
by a benzene- tricarboxylate analog (BTA), they 
believe that this effect only played a partial role 
in tumor reduction because the total FA levels 
were not drastically affected. Moreover, CTP 
levels were associated with cancer aggressive-
ness [24].
2.2  ATP Citrate Lyase (ACLY) Is 
Upregulated in Cancer
ATP citrate lyase (ACLY) is found to be elevated 
in many types of cancers, including breast [25], 
lung [26], liver [27], and bladder cancers [28]. 
Migita et al. found that ACLY expression is sig-
nificantly higher in human lung adenocarcinoma 
samples as compared to normal lung tissue. It 
also correlated with stage, differentiation grade, 
and a poorer prognosis. ACLY inhibition arrested 
lung cancer cell growth in  vitro and in  vivo. 
ACLY knockdown compromised de novo lipo-
genesis, but intracellular lipids were increased, 
suggesting alternative mechanisms of lipid accu-
mulation [26]. A study by Schlichtholz et al. sim-
ilarly demonstrated upregulations of ACLY, 
glucose 6-phosphate dehydrogenase, 6-phospho-
gluconate dehydrogenase, and citrate synthase, 
which are enzymes involved in fatty acid synthe-
sis, in bladder cancer [28].
2.3  Multifaceted Effects 
of Inhibiting Acetyl-CoA 
Carboxylase (ACC) in Cancer
After ACLY produces cytosolic acetyl-CoA, the 
enzyme acetyl-CoA carboxylase (ACC) irrevers-
ibly converts acetyl-CoA into malonyl- CoA. 
Malonyl-CoA is required for fatty acid synthesis 
and elongation and negatively regulates 
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β-oxidation of long-chain fatty acids by inhibit-
ing the enzyme carnitine palmitoyltransferase 1 
(CPT1) [29]. ACC exists as two isozymes 
(ACC1/2, genes ACACA/B) [30]. ACC1 is prefer-
entially expressed in lipogenic cells, such as adi-
pocytes [30]. The two ACC isozymes catalyze 
the same reaction, and one can compensate for 
the loss of function of another as malonyl-CoA 
levels only decrease in hepatocytes if both ACC1 
and ACC2 are inhibited [31]. This demonstrates 
that inhibiting both ACC1 and ACC2 isozymes 
may be more efficacious than inhibiting either 
isozyme alone for the treatment of cancer. ACC is 
now receiving greater attention as a therapeutic 
target against cancer because the formation of 
malonyl-CoA catalyzed by ACC is the rate- 
limiting step of fatty acid synthesis.
The expression of ACC1 is highly enriched in 
breast [32], prostate [33], liver [34], and renal 
cancers [35]. The expression of ACC1 also 
increases with tumor grade in liver cancer, and its 
overexpression increases liver cancer cell viabil-
ity while decreasing apoptosis [34, 36]. ACC1 
expression is also prognostic for some cancers. 
High expression of ACC1 is correlated with 
worse survival in renal cancer [35]. Inhibition of 
ACC1 with siRNA reduced cell viability in breast 
[37] and liver cancers [36]. Furthermore, simulta-
neous inhibition of both ACC1 and ACC2 with a 
small chemical molecule or siRNA reduced 
tumor growth in the prostate [38], brain [39], and 
pancreatic cancers [40].
While ACC inhibition appears to arrest the 
growth of certain cancer types, it has paradoxi-
cally been shown to promote breast cancer 
invasion and metastasis by promoting epithe-
lial-to-mesenchymal transition (EMT) [41]. 
ACC-deficient hepatocytes are also more sus-
ceptible to diethylnitrosamine-induced hepato-
cellular carcinoma. ACC-deficient mice 
exhibited a reduction in hepatic lipogenesis, a 
decrease in glutathione, and an increase in 
NADPH [34]. Collectively, these preclinical 
studies demonstrate the duality of ACC inhibi-
tion: it could attenuate tumor growth in some 
cancer types, but it could also contribute to car-
cinogenesis or promote metastasis in others.
Long-term regulation of ACC occurs at the 
level of transcription, while short-term regulation 
of ACC occurs through allosteric binding and 
reversible phosphorylation. Short-term regula-
tion allows ACC activity to rapidly adapt to the 
microenvironment. For instance, AMP-activated 
protein kinase (AMPK) can inactivate ACC via 
phosphorylation (p-ACC). Metformin is a widely 
prescribed first-line treatment for type 2 diabetes 
that activates AMPK. Preclinical studies in mice 
have demonstrated that metformin can reduce 
cancer growth, in part by increasing p-ACC lev-
els [42, 43]. There are currently hundreds of clin-
ical trials investigating whether metformin can be 
repurposed to treat cancer as an adjuvant mono-
therapy or in combination with other drugs. 
However, a potential adverse effect of metformin 
may be an increase in the metastasis of certain 
cancer types, given that both metastatic breast 
and lung tumors have increased levels of p-ACC1 
[41]. Protein phosphatase 2A (PP2A) can reacti-
vate p-ACC by dephosphorylation. The tumor 
suppressor known as breast cancer susceptibility 
gene 1 (BRCA1), which is deactivated primarily 
in breast and ovarian cancers, prevents dephos-
phorylation of p-ACC [44]. Cancers with loss-of- 
function mutations in BRCA1 have increased 
ACC activity due to less phosphorylation of ACC 
and thus may be more susceptible to ACC inhibi-
tion [44, 45].
2.4  The First Fatty Acid Synthase 
(FAS) Inhibitor TVB-2640 Is 
in Clinical Trials for Cancer
A large number of studies have now documented 
an increase in the expressions of lipogenic 
enzymes across several cancers. For instance, 
Szutowicz et  al. revealed that the activity of 
citrate lyase, an important enzyme in lipogenesis, 
is elevated in breast carcinoma and fibrocystic 
disease compared to healthy breast tissue [25]. 
As such, it is reasonable that key enzymes 
involved in de novo fatty acid synthesis could be 
potential targets for cancer therapy. One such 
enzyme is fatty acid synthase (FAS) encoded by 
the FASN gene [46].
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FAS is a multienzyme protein complex that 
catalyzes the final reactions converting malonyl- 
CoA and acetyl-CoA into a saturated long-chain 
fatty acid composed of 16 carbons known as pal-
mitic acid. Palmitic acid can be used as a precur-
sor to produce lipid signaling molecules, modify 
protein functions through palmitoylation, store 
energy as triglycerides, or form structural lipids 
for cell membranes. NADPH is the reducing 
agent for fatty acid synthesis, and 14 molecules of 
NADPH are used to synthesize each molecule of 
palmitic acid starting with acetyl-CoA. The pen-
tose phosphate pathway (PPP) generates NADPH 
through the oxidation of glucose into pentose 
sugars and ribulose- 5- phosphate. Overexpression 
of FASN is usually accompanied by the overex-
pression of enzymes in the PPP to supply NADPH 
for fatty acid synthesis. Increased expression of 
FAS and PPP enzymes is associated with worse 
survival in renal and breast cancers [35, 47]. 
Increased FAS expression is also associated with 
tumor grade in prostate cancer [48]. Inhibition of 
FAS reduces cell proliferation and increases cell 
death in human breast [37, 43], prostate [49], and 
colon cancers [50]. FAS inhibitors can also be 
used in combination with chemotherapy taxane to 
improve anticancer efficacy [51]. Colorectal can-
cer metastasis is also mitigated by FAS inhibition 
in mice [50]. While inhibition of FAS reduces 
tumor growth and metastasis in most cancers, it 
has also been demonstrated to reduce survival 
rates in mice with lung cancer by increasing 
metastasis [52], demonstrating how FAS inhibi-
tion can sometimes worsen cancer outcomes as 
seen with ACC inhibition.
The FAS inhibitor TVB-2640 has been tested 
on cancer patients in clinical trials (Clinical Trial 
ID: NCT02223247). Inhibiting FAS did not result 
in severe side effects, and all of the mild side 
effects were reversible after discontinuation [53]. 
Moreover, side effects were not worsened by its 
combined application with the chemotherapy 
drug paclitaxel [53]. Monotherapy with TVB- 
2640 stabilized cancer progression in three out of 
six patients with KRAS-driven non-small cell 
lung cancer (NSCLC) [53]. There are now two 
clinical trials (phase II) testing the efficacy of 
TVB-2640  in combination with additional che-
motherapy drugs for HER2+ breast cancer 
(Clinical Trial ID: NCT03179904) and astrocy-
toma (Clinical Trial ID: NCT03032484). The 
third clinical trial is a phase I study investigating 
the pharmacodynamic effects of TVB-2640  in 
patients who require surgery for colon cancer 
(Clinical Trial ID: NCT02980029).
2.5  Which Markers Can Predict 
Cancer Cell Sensitivity to Lipid 
Synthesis Inhibition?
Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) 
is produced by phosphoinositide 3-kinase (PI3K) 
activation, which is mutated in many types of 
cancers [54–56]. PI3K, which is a key regulator 
of phosphoinositide metabolisms, is considered a 
potential target in preclinical and clinical settings 
to suppress advanced solid tumors, including 
malignant glioma, NSCLC, and breast cancer 
[57] (NCT00485719, NCT00777699, 
NCT00704080, NCT00907205, NCT00600275, 
NCT00876109, and NCT00726583).
Two highly studied intracellular signaling 
pathways that oncogenes activate to drive tumori-
genesis and increase expression of lipid synthesis 
enzymes are the PI3K/Akt/mammalian target of 
rapamycin (mTOR) pathway and the 
RAS/mitogen-activated protein kinase (MAPK) 
pathway [58, 59]. Constitutive activation of the 
PI3K/Akt/mTOR pathway results from activation 
of receptor tyrosine kinases (RTKs), loss-of- 
function mutations in the tumor suppressors phos-
phatase and tensin homolog (PTEN) and tuberous 
sclerosis protein (TSC), or gain-of-function muta-
tions in phosphatidylinositol-4,5- bisphosphate 
3-kinase catalytic subunit alpha (PIK3CA) and 
AKT1 [60]. The RAS oncogene family including 
HRAS, KRAS, and NRAS can also activate the 
PI3K/Akt/mTOR pathway [61]. Cancer cells that 
are driven by the overactivation of the PI3K or 
RAS pathways are more susceptible to inhibitors 
that target lipid synthesis than cancers that are 
driven by pathways not associated with lipid syn-
thesis regulation [62, 63]. Inhibitors of ACLY, 
ACC, and FAS have been shown to be efficacious 
in cancers with PI3K and RAS pathways [64–67]. 
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Cancer cells that overactivate RTKs, such as epi-
dermal growth factor receptor (EGFR, also known 
as HER) family members 1–4 and c-MET [68–
70], are also sensitive to lipid synthesis inhibition 
because these RTKs activate PI3K and RAS path-
ways. ACLY and ACC inhibitions are efficacious 
in HER1- and HER2-driven cancers [39, 66, 71–
73], and FAS inhibition is efficacious in HER1-, 
HER2-, and c-MET-driven cancers [68, 74, 75]. 
Additional oncogenic signaling pathways that 
may be susceptible to FAS inhibition are MYC, 
beta-catenin, and steroid-responsive tumors 
because FAS inhibition downregulates these path-
ways [64, 76, 77]. Cancers with a loss of function 
in BRCA1 and p53 are also sensitive to FAS and 
ACC inhibition [45, 67, 78]. Preclinical studies 
testing ACLY, ACC, and FAS inhibitors may 
reveal the oncogenes and RTKs that confer sus-
ceptibility to DNLS inhibition and guide the 
design of future clinical trials. To date, several 
mTOR/PI3K inhibitors, such as idelalisib, copan-
lisib, rapamycin, temsirolimus, everolimus, and 
ridaforolimus, have been approved by the FDA.
Nevertheless, not all cancers with oncogene- 
mediated overactivation of RAS and PI3K path-
ways appear to be susceptible to lipid synthesis 
inhibition. For instance, KRAS mutations corre-
lated with FAS inhibition sensitivity in lung can-
cer cell lines but not in colon cancer cell lines 
[64], which demonstrates that cancer cell sus-
ceptibility to lipid synthesis inhibition is not 
always driven by oncogenes. In other studies, 
oncogenes conferred resistance to FAS inhibi-
tion. Hepatocytes that are transformed into 
malignant cancer cells by the overactivation of 
c-MET and Akt are susceptible to FAS inhibi-
tion, but hepatocytes that are transformed by the 
overactivation of c-MET and Wnt/beta-catenin 
signaling are unresponsive to FAS inhibition 
[63]. The c-MET/beta-catenin-driven cancer 
cells may be unresponsive because beta-catenin 
activation in hepatocytes reduces FAS expres-
sion and lipid synthesis [63, 79, 80]. Interestingly, 
while beta- catenin decreases lipid synthesis in 
hepatocytes, beta-catenin signaling can increase 
lipid synthesis in B-cell lymphoma. Beta-
catenin-driven B-cell lymphoma is susceptible 
to FAS inhibition [81]. This demonstrates that 
cancer cell type is relevant to determining sus-
ceptibility to FAS inhibition since oncogenic 
signaling pathways can result in different pheno-
types depending on the cell type. In order for 
oncogenes to be reliable markers of lipid synthe-
sis inhibition sensitivity, it will be important to 
consider the cell type of the cancer being 
discussed.
Of note, protein expression or enzyme activity 
may be better predictors of susceptibility to lipid 
synthesis inhibitors than genetic markers. For 
example, mRNA expression of ACLY, ACC, and 
FAS may not correlate with protein expression 
and activity [64, 82]. Increased expression of 
FAS and ACC at the protein level can occur with-
out an increase in mRNA expression by increased 
translation of FAS and ACC mRNA via mTOR 
signaling [82].
Metabolic profiling may be a valuable method 
for determining susceptibility to FAS inhibition. 
One study examined 38 pancreatic cancer cell 
lines and classified them as lipogenic or glyco-
lytic depending on their metabolic profile, which 
was determined by the amount of lipogenic or 
glycolytic metabolites [83]. Glycolytic cancer 
cells were significantly more susceptible to gly-
colytic inhibitors than those that were lipogenic. 
However, lipogenic cancer cells were not signifi-
cantly more susceptible to lipogenic inhibitors, 
such as FAS inhibitors, than glycolytic cancer 
cells [83]. Only half of the lipogenic cancer cell 
lines were sensitive to FAS inhibition, suggesting 
that broad lipogenic profiling is not an accurate 
predictor of susceptibility to FAS inhibition. 
While no single marker is able to definitively pre-
dict which cancers are susceptible to lipid syn-
thesis inhibition, using a combination of markers, 
such as cell type, oncogene mutations, expres-
sion/activity of lipid synthesis enzymes, and met-
abolic profiles, may provide a reliable means to 
identify cancers that are sensitive to lipid synthe-
sis inhibitors.
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2.6  Tumor Microenvironment 
Influences the Sensitivity 
of Cancer Cells to Lipid 
Synthesis Inhibitors
As mentioned in the chapter “Different Tumor 
Microenvironments Lead to Different Metabolic 
Phenotypes,” TCA cycle activity is reduced under 
hypoxic conditions, which results in reduced 
citrate and acetyl-CoA production. However, 
cancer cells manage to generate acetyl-CoA for 
fatty acid synthesis by different mechanisms, 
including reliance on glutamine for citrate syn-
thesis and acetate for acetyl-CoA via acetyl-CoA 
synthetase (ACSS2). Evidence suggests that 
ACSS2 expression can be increased to maintain 
growth under microenvironmental stress, such as 
hypoxia [84].
Bensaad et  al. showed that while DNLS is 
repressed in hypoxia, lipid droplet accumulation 
and expression of fatty acid uptake proteins, such 
as fatty acid-binding protein 3 and 7 (FABP3 and 
FABP7), are induced by hypoxia-inducible factor 
1-alpha (HIF-1α). Lipid synthesis was restored in 
cancer cells after reoxygenation or the removal of 
antiangiogenic therapy [85]. Other studies have 
corroborated that hypoxic tumor cells may be 
extraordinarily dependent on fatty acid uptake 
compared to those in normoxia [86, 87]. However, 
this can be differentially driven by oncogenic 
mammalian target of rapamycin complex 1 
(mTORC1), RAS, and/or HIF-1α signaling [85–
87]. Moreover, triple-negative breast cancer is 
reliant on lipid droplet-derived substrates for 
β-oxidation and ATP generation after hypoxia- 
reoxygenation, whereas glioblastoma multiforme 
(GBM) is more dependent on glycolytic path-
ways [85]. This implies that FA uptake is not a 
universal feature of hypoxic cancer cells; there-
fore, inhibiting FA uptake may be a strategy for 
targeting tumor cells in hypoxic microenviron-
ments for certain types of cancers but not others.
The availability of metabolic nutrients can 
also greatly impact the susceptibility of cancer 
cells to inhibition of DNLS. FAS expression was 
observed to be the highest at the edge of tumors, 
suggesting that DNLS is preferred in cancer cells 
that are vascularized and have access to oxygen 
and glucose [88]. Tumors in low-lipid environ-
ments increase de novo fatty acid synthesis and 
thus may demonstrate increased sensitivity to 
FAS inhibition. The fact that lipoprotein supple-
mentation can override DNLS inhibition empha-
sizes the importance of nutrient availability and, 
again, the role of exogenous lipid uptake [89, 90]. 
The availability of glucose for glucose-dependent 
lipogenesis is also important for cancer cell sen-
sitivity to ACLY inhibitors. Low-glucose envi-
ronments result in cancer cells that are less 
susceptible to ACLY inhibition because cancer 
cells can use acetate instead of citrate to produce 
acetyl-CoA for DNLS [90, 91].
3  Targeting Fatty Acid 
Elongation
Once palmitic acid is produced by de novo lipid 
synthesis, it can be modified by having its fatty 
acid chain elongated. Elongation of fatty acids is 
important for creating lipid precursors that are 
involved in cellular signaling and for producing 
phospholipids of cell membranes. Fatty acids that 
consist of 16 carbons or more, such as palmitic 
acid, are elongated in the smooth endoplasmic 
reticulum, while fatty acids consisting of fewer 
than 16 carbons are elongated in the mitochon-
dria. Elongation of fatty acids in the smooth 
endoplasmic reticulum is regulated by four 
enzymes. These enzymes elongate fatty acids by 
using malonyl-CoA.  The first step is the rate- 
determining reaction regulated by the enzyme 
β-ketoacyl-CoA synthase (elongase). There are 
seven types of elongases in humans, known as 
ELOVL1–7. ELOVL7 was identified to be over-
expressed in prostate cancer, and feeding mice a 
diet high in long- and very-long-chain fatty acids 
increased the growth of ELOVL7-expressing 
tumor cells [92]. Meanwhile, inhibiting ELOVL7 
with siRNA attenuated prostate cancer growth 
[92]. ELOVL1 is another elongase implicated in 
cancer growth. ELOVL1 was observed to be 
overexpressed in breast cancer, and inhibition of 
ELOVL1 with siRNA reduced breast cancer cell 
viability in some cell lines [37].
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While inhibiting elongases appears to be a 
therapeutic strategy for cancer treatment, inhibit-
ing ACC1 as described previously may be more 
promising because ACC1 inhibition reduces both 
fatty acid synthesis and fatty acid elongation, 
while elongase inhibition only targets elongation. 
ACC1 inhibition can reduce fatty acid elongation 
by decreasing the availability of malonyl-CoA 
[93]. This is suggested by a study in which silenc-
ing of ELOVL1 with a silencing efficiency of 
70–80% decreased cell viability by greater than 
50% in one breast cancer cell line while silencing 
of ACC1 with a lower silencing efficiency of 
30% decreased cell viability by greater than 50% 
in two breast cancer cell lines [37]. Neoadjuvant 
chemotherapy-resistant breast cancer has been 
associated with increased expression of fatty acid 
elongation proteins in the mitochondria [94]. 
Whether inhibiting mitochondrial fatty acid elon-
gation is a potential therapeutic strategy against 
cancer remains to be determined.
4  The Efficacy of Inhibiting 
Cholesterol Synthesis 
with Adjuvant Statins Is 
Variable
Another anabolic pathway associated with lipid 
metabolism is the mevalonate pathway, which 
synthesizes cholesterol. Cholesterol is a major 
component of cell membranes, influencing mem-
brane fluidity, and function. It also forms 
detergent- resistant microdomains called lipid 
rafts that coordinate the activation of signal trans-
duction pathways. The enzyme 3-hydroxy- 3-
methylglutaryl-CoA reductase (HMGCR) 
catalyzes the rate-limiting step of cholesterol 
synthesis. Increased expression of HMGCR and 
other cholesterol synthesis enzymes is associated 
with reduced survival rates in breast cancer [95]. 
HMGCR is the target of a class of cholesterol- 
lowering drugs called statins. Numerous epide-
miological studies have demonstrated that 
patients who use statins have a reduced risk of 
cancer and cancer mortality [96–98]. This has 
raised the question as to whether statins can 
improve treatment outcomes in cancer patients. 
There are many clinical trials currently investi-
gating whether statins can be prescribed to reduce 
the progression of cancer.
Results from preclinical studies suggest that 
the efficacy of statins can be predicted based on 
the status of gene expression, such as that of 
HMGCR [99]. Breast cancer cells with overactive 
HER2 are also sensitive to statins because of 
HER2 signals through the RAS pathway [100]. 
On the other hand, estrogen receptor-positive 
breast cancer cells appear to be less responsive to 
statins. MYC is another transcription factor that 
regulates cholesterol synthesis. Cancers with 
overactive MYC have been observed with 
increased expression of HMGCR and sensitivity 
to statins [101, 102]. Statins have also been shown 
to reduce metastasis in colon and ovarian cancer 
and selectively induce apoptosis in cancer cells 
[103, 104]. Along with monotherapy of statins 
being efficacious in preclinical studies, statins are 
also efficacious in combination therapy by 
increasing sensitivity to radiation therapy [105].
The ability of statins to bind to HMGCR 
greatly affects their efficacy. Genetic variations 
in HMGCR have been found to modify the thera-
peutic effect that statins have on colorectal cancer 
[106]. A single-nucleotide polymorphism (SNP) 
in the HMGCR–statin-binding domain reduced 
the protective association between statins and 
colorectal cancer. An in vitro experiment demon-
strated that the SNP in the HMGCR gene reduced 
the ability of statins to inhibit HMGCR and cho-
lesterol synthesis. The anticancer activity of 
statins is also dependent on the ability of statins 
to enter cancer cells. For instance, the statin 
pravastatin was found to inhibit tumor growth 
preferentially in cancers that express sodium- 
independent organic anion transporter protein-
 1B1 (OATP1B1), such as liver cancer, because 
this transporter is necessary for cellular uptake of 
pravastatin [107].
While preclinical studies have provided prom-
ising results for statins, clinical trials have not 
been as successful. A phase II clinical trial dem-
onstrated that combining the statin simvastatin 
with the chemotherapy drug afatinib did not 
improve treatment efficacy compared to using 
afatinib in monotherapy [108]. Two additional 
J. K. Park et al.
47
phase II clinical trials found that statins were 
unable to resensitize cancers harboring KRAS- 
activating mutations to the chemotherapy drugs 
cetuximab and panitumumab [109, 110].
5  Fatty Acid Uptake Is 
Associated with Metastasis
As discussed previously, enhanced lipogenesis is 
a frequent alteration of lipid metabolism in can-
cer cells, and therapies targeting it are promising. 
However, studies show that this strategy can be 
undermined by the supplementation of exoge-
nous fatty acids, suggesting that extracellular lip-
ids in the microenvironment may functionally 
substitute for endogenously derived FA [111]. 
After all, the scavenging of circulating nutrients 
is another hallmark of cancer cell metabolism 
[112]. Recently, it was reported that tumors, 
including those of breast cancer and liposarcoma, 
may rely on extracellular lipolysis in addition to 
lipogenesis to fuel cellular lipid requirements 
[113]. Lipoprotein lipase (LPL) is a rate-limiting 
enzyme of this mechanism, hydrolyzing circulat-
ing triglyceride-rich lipoprotein, such as very- 
low- density lipoproteins and chylomicrons, into 
free FAs and monoacylglycerol molecules. Free 
FAs are then imported into cells by FA transport-
ers such as a cluster of differentiation (CD36) or 
those of the fatty acid-binding protein (FABP). 
Both LPL and CD36 expressions have been asso-
ciated with aggressive cancers, including hepato-
cellular carcinoma (HCC) and pancreatic ductal 
adenocarcinoma (PDAC), and negatively corre-
lated with patient prognosis [114–117], but how 
this phenomenon varies among tumors and 
whether it can be inhibited for therapeutic effect 
remain uncertain.
An estimated 90% of all cancer-related deaths 
are attributed to metastasis, but the detailed 
mechanisms of metastasis remain unclear [118]. 
Recently, metastasis was associated with 
enhanced lipid metabolism [14, 119, 120]. One 
study identified an altered gene signature associ-
ated with fatty acid uptake (e.g., caveolin 1 
(CAV1), CD36) in metastatic tumors across can-
cer types [121]. Moreover, this genetic signature 
had a significant effect on patient survival rates, 
suggesting prominent roles of extracellular fatty 
acids, specifically on metastatic progression. 
Corroborating this is a recent report describing 
abnormally high expression of CD36  in 
metastasis- initiating oral cancer cells [12]. 
Treating orthotopic xenografts with CD36- 
neutralizing antibodies inhibited metastasis initi-
ation. These studies suggest that tumor cells of 
high metastatic potential have an outsized need 
for FA uptake compared to those displaying less 
aggressive phenotypes. Interestingly, however, an 
earlier study observed up to a 100-fold lower 
expression of CD36  in breast cancer cells with 
high metastatic potential compared to their less 
aggressive counterparts [122]. This inconsistency 
may be due to alternative mechanisms of CD36 
related to cell adhesion [123]. Nevertheless, these 
data support the overarching concept of asym-
metrical CD36 expression and fatty acid uptake 
even within cancers of the same type.
6  Fatty Acid Oxidation 
Encompasses a Diverse Set 
of Molecular Mechanisms
Lipids are important for cancer proliferation not 
only because of their ability to provide structural 
support as a component of the cell membrane but 
also because they can be broken down to provide 
energy. Lipids can be catabolized after cellular 
uptake via the β-oxidation pathway, also known 
as fatty acid oxidation (FAO). FAO has not been 
examined as thoroughly as glycolysis or glutami-
nolysis, but recent advances have shed light on 
the role of FAO in cancer cells. Recently, lipids 
were also identified as a carbon source for nucle-
otide synthesis and histone acetylation in nonma-
lignant cells, and emerging evidence suggests 
that these mechanisms are relevant to tumor cells 
as well [124, 125]. The tumor microenvironment 
is often depleted of nutrients like glucose, so can-
cer cells often rely on FAO to generate ATP. Lipids 
are energetically dense molecules that cancer 
cells can exploit as an alternative source of 
energy. FAO yields ATP and NADPH, which sup-
port cellular energetics and redox homeostasis, 
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respectively. Several studies have demonstrated 
that certain malignancies, such as those in the 
prostate, breast, and lung, and B-cell lymphoma 
heavily depend on FAO for growth and survival 
[126–128]. Similarly, acetate is a 2-carbon fatty 
acid that is avidly oxidized in tumors, including 
GBM [129, 130].
6.1  Targeting FAO for Cancer 
Therapy May Be Achieved by 
Inhibiting Carnitine 
Palmitoyltransferase 1
The inhibition of the FAO pathway could prevent 
cancer progression. An example of this strategy is 
the inhibition of carnitine palmitoyltransferase 1 
(CPT1), which is the rate-limiting enzyme of FAO. 
CPT1 is a membrane protein that removes an acyl 
group from a fatty acyl-CoA and attaches the acyl 
group to carnitine. This results in the formation of 
acylcarnitine, including palmitoylcarnitine, and 
thereby facilitates the shuttling of fatty acids, such 
as palmitate, into the mitochondrial matrix for FAO 
[124]. There are three subtypes of CPT1. CPT1A is 
expressed throughout several tissue types, but 
CPT1B is restricted mostly to muscle tissue. In 
physiological settings, all isoenzymes are inhibited 
by malonyl- CoA, but due to the greater binding 
efficiency of CPT1A to malonyl-CoA, CPT1A is 
found to be the isoform with the greatest capacity 
to perform the rate-limiting step of FAO [131]. The 
third and final isoform of CPT1 is CPT1C, which is 
normally found only in the brain [132]. However, 
many cancers also express CPT1C [133]. CPT1C 
is thought to confer resistance to oxidative stress in 
many tumors. CPT1C promotes resistance to 
rapamycin, an mTOR pathway inhibitor [133].
Physiologically, it is crucial to note that suc-
cessful inhibition of CPT1 is dependent on the 
source and location of malonyl-CoA.  Malonyl- 
CoA produced via acetyl-CoA carboxylase 1 
(ACC1) is localized in the cytosol and thus will 
not inhibit CPT1. The malonyl-CoA produced 
via the mitochondrial ACC2 enzyme, however, is 
capable of this inhibitory action. Thus, the rela-
tive concentrations of acetyl-CoA to malonyl- 
CoA can influence whether the cell is in a state of 
FAS or FAO [134]. AMP-activated protein kinase 
(AMPK) inhibits both ACC1 and ACC2 and 
increases reactive oxygen species (ROS) in doing 
so. The increase in ROS leads to depletion of 
NADPH and induces oxidative stress on the cell, 
eventually leading to cell death [8]. This finding 
is in accordance with other studies that have 
noted the role of AMPK activation in cancer 
states. For example, metformin exerts anticancer 
effects and activates AMPK, but in tumors lack-
ing CPT1C, the effect of metformin is less pro-
nounced. This suggests that the action of 
metformin on AMPK is upstream of its effect on 
CPT1C [133].
The upregulation of CPT1  in several cancer 
types makes it a potential therapeutic target 
[131]. However, this upregulation does not 
appear to be a universal feature of all tumors, as 
demonstrated by a recent study showing that, in 
clear cell renal cell carcinoma (ccRCC), tran-
scriptional repression of CPT1A is mediated by 
hypoxia-inducible factors (HIF-1α and HIF-2α) 
[135]. However, conflicting reports regarding the 
role of HIFs in FAO have also emerged, and one 
may speculate that this is again due to the hetero-
geneity of metabolism across cancer subtypes. 
Although HIFs are known to inhibit FAO, one 
study performed in liver cancer cells determined 
that HIF-1 also decreases ROS levels and main-
tains redox homeostasis, thereby promoting cell 
proliferation [136]. This effect is thought to be 
mediated by the action of HIF-1 on medium- and 
long-chain acyl-CoA dehydrogenases (MCAD 
and LCAD, respectively). This study further 
pointed to correlations between decreased LCAD 
expression and patient mortality rates [136]. 
Thus, we see that the precise role of HIFs varies 
across cancer types, and as such, therapies target-
ing HIF-related pathways may need to be tailored 
to specific cancers to maximize their impact.
6.2  CPT1 Inhibitors Are Now 
in Clinical Trials
As far as pharmacological interventions for FAO 
are concerned, some CPT1 inhibitors are being 
developed for other conditions such as diabetes 
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[137]. Therefore, the possibility of repurposing 
them for cancer therapy is an intriguing possibil-
ity requiring further clinical trials [137]. One 
CPT1 inhibitor, etomoxir, has been difficult to 
advance through clinical trials due to its toxicity. 
A clinical study examining etomoxir in healthy 
adults found elevated levels of transaminases of 
some patients, and the study had to be terminated 
early [138]. The issue with etomoxir arises from 
its inability to distinguish CPT1 across tissue 
types. However, it has been applied to preclinical 
studies of breast cancer, where an interesting 
degree of heterogeneity has been noted. In one 
study, etomoxir was compared across two triple-
negative breast cancer (TNBC) lines. One line 
expressed high amounts of the oncogenic tran-
scription factor MYC, whereas the other expressed 
low amounts of MYC. In the high-MYC-express-
ing line, the application of etomoxir decreased 
levels of ATP, and this effect was not observed in 
the low-MYC-expressing line [128]. Furthermore, 
this effect was observed in no other breast cancer 
subtypes besides TNBC.  This provides further 
evidence of the ways in which cancer heteroge-
neity should be appreciated and exploited for the 
development of viable treatments.
6.3  FAO for Very-Long-Chain Fatty 
Acids Occurs at the 
Peroxisome Where 
Peroxisome Proliferator-
Activated Receptors (PPARs) 
Act as Ligand-Activated 
Transcription Factors
FAO also occurs in peroxisomes. Oxidation at the 
peroxisome is restricted to very-long-chain fatty 
acids. The peroxisome breaks these very long 
chains into smaller chains, which may then be 
further oxidized in the mitochondria. Peroxisomes 
are built via peroxins, the products of the Pex 
genes. So far, 3 of the 30 known peroxins, Pex3, 
Pex16, and Pex19, have been shown to be neces-
sary for proper peroxisome assembly [139]. One 
of these peroxins, Pex19, was shown in a series 
of experiments to be involved in the transition to 
malignancy in prostate cancer through monocar-
boxylate transporter 2 (MCT2). MCT2 is upregu-
lated in prostate cancer and, like other MCTs, 
serves to facilitate the transport of lactic acid in 
glycolytic tumors. Immunoprecipitation experi-
ments demonstrated that colocalization of MCT2 
with peroxisomes was strongest at disease initia-
tion and decreased as metastasis increased; fur-
thermore, colocalization was absent in 
nonmalignant prostate cancer lines [140].
Other components of peroxisomes are the per-
oxisome proliferator-activated receptors 
(PPARs). Three PPARs (PPARα, PPARγ, 
PPARβ/δ) are known and have been described as 
ligand-activated transcription factors [141]. 
These three PPARs differ predominantly in tissue 
distribution, and their exact functions in cancer 
remain ambiguous. It has been shown that PPARs 
are key regulators that integrate lipid metabolism 
and inflammation [142]. Furthermore, the PPARs 
have been directly implicated in cancers as well 
as in cancer-related processes, including carcino-
genesis and chemoresistance [143, 144].
The theme of heterogeneity persists within the 
various PPARs and across species. For example, 
long-term PPARα agonism in rodents leads to the 
development of liver cancer. Interestingly, 
PPARα is expressed at lower levels in human 
liver relative to rodent liver, and as such, PPARα 
agonism does not lead to liver cancer in humans 
[143, 145]. PPARβ/δ displays tissue-wide distri-
bution. One of its functions is to reduce oxidative 
stress, such as in breast cancer [146]. However, it 
is expressed ubiquitously and has been shown to 
be involved in many cancer types, particularly in 
cancers under hypoxic environments, such as 
breast, colon, lung, and ovarian cancers, as well 
as chronic lymphocytic leukemia [143]. Its pre-
cise role remains controversial, but it appears that 
PPARβ/δ may play a role as a lipid-activated 
mediator of an anti-inflammatory response. Like 
PPARβ/δ, mystery surrounds PPARγ. Although it 
may be coded for by four mRNAs (PPARG1 
through PPARG4), PPARγ1 and PPARγ2 are 
responsible for most PPARγ physiological 
actions [143]. PPARγ1 mRNA is found ubiqui-
tously, whereas PPARγ2 mRNA is restricted to 
adipocytes [147]. Some, but not all, PPARγ ago-
nists induce apoptosis in cancer cells and have 
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also been reported to induce terminal differentia-
tion. Targets of PPARγ include many genes 
involved in the cell cycle and apoptosis in tumors, 
such as p53 and PTEN. The increasing character-
ization of PPARγ as a biomarker in cancer led 
some investigators to speculate that it may be uti-
lized in screens [148]. Together, the PPARs con-
stitute an area of research that may prove critical 
in our understanding of tumor development and 
treatment.
The many aspects of peroxisomal signaling 
further convey the diversity of lipid signaling 
across many different types of cancers. 
Abnormalities within the peroxisomes them-
selves or within PPARs can alter the efficacy of 
the critical lipid signaling that cancer cells rely 
on. Further research, particularly in the form of 
genomic analyses, will be useful in harnessing 
this heterogeneity for personalized medicine 
approaches.
7  Conclusion
Therapeutic strategies targeting lipid metabolism 
are now in various stages of clinical develop-
ment, and one approach worth highlighting is the 
“repurposing” of drugs from cardiology [149]. 
As emphasized, we urge caution based on the sig-
nificance of heterogeneity in cancer lipid metab-
olism as we translate basic science into clinical 
applications. Drug combinations have become a 
cornerstone against refractory and heterogeneous 
tumors, so the question now is how to combine 
treatment options for maximum safety and effi-
cacy [150–152]. Going forward, systems biology 
and bioinformatics will likely become essential 
tools for integrating various levels of -omic data 
[153, 154]. Dissecting the spatial and temporal 
heterogeneity of lipid metabolism with these 
tools will likely accelerate the tailoring of clinical 
care according to patient-specific signatures, as 
envisioned by precision medicine (Fig. 1).
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Key Points
• Glioblastoma (GBM) can be categorized into 
different subtypes based on diverse metabolic 
profiles.
• Characteristic genomic alterations lead to 
transformed metabolism.
• Synergistic therapies are beneficial to combat 
dynamic adaptations of glioblastoma 
metabolism.
• Advanced-grade brain tumors exhibit distinct 
metabolic profiles compared to lower grade 
tumors.
1  Introduction
Glioblastoma multiforme (GBM) develops on 
glial cells and is the most common as well as the 
deadliest form of brain cancer [1]. As in other 
cancers, distinct combinations of genetic altera-
tions in GBM subtypes induce a diversity of met-
abolic phenotypes, which explains the variability 
of GBM sensitivity to current therapies targeting 
its reprogrammed metabolism. Therefore, it is 
becoming imperative for cancer researchers to 
account for the temporal and spatial heterogene-
ity within this cancer type before making gener-
alized conclusions about a particular treatment’s 
efficacy. Standard therapies for GBM have shown 
little success as the disease is almost always 
lethal; however, researchers are making progress 
and learning how to combine therapeutic strate-
gies most effectively. GBMs can be classified ini-
tially into two subsets consisting of primary and 
secondary GBMs, and this categorization stems 
from cancer development. GBM is the highest 
grade of gliomas, which includes glioma I (low 
proliferative potential), glioma II (low prolifera-
tive potential with some capacity for infiltration 
and recurrence), glioma III (evidence of malig-
nancy), and glioma IV (GBM) (malignant with 
features of necrosis and microvascular prolifera-
tion) [2]. Secondary GBM develops from a low- 
grade glioma to an advanced-stage cancer, while 
primary GBM provides no signs of progression 
and is identified as an advanced-stage glioma 
from the onset. The differences in prognosis and 
histology correlated with each classification are 
generally negligible, but the demographics of 
individuals affected and the accompanying 
genetic/metabolic properties show distinct differ-
entiation [3].
2  GBM Classifications 
and Intratumoral 
Heterogeneity
Previously, tumors had been classified based on 
histological and structural similarities without 
accounting for clinical disparities among them 
[4]. More recently, tumor classification has 
shifted toward a more molecular and genetic 
basis in combination with phenotypic informa-
tion. This new-era classification allows practitio-
ners to differentiate between biologically similar 
cases, allowing for more precise treatment and 
prognosis when encountering distinct mutant 
variants [4]. Phenotypic information must be 
used in accordance with genotypic data to deter-
mine tumor type and grade differentiation and to 
account for the rare occurrences when the pheno-
type differs from the usual criteria accompanying 
the defined genotype [5].
2.1  GBM Subtype Classification
A recent study identified four gene expression 
subtypes of GBM: mesenchymal, classical, pro-
neural, and neural (Fig. 1).
• The mesenchymal subtype is characterized by 
high mutation rates of the tumor-suppressor 
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genes: neurofibromatosis type 1 (NF1), phos-
phatase and tensin homolog (PTEN), and phos-
phoprotein 53 (p53). Following aggressive 
treatment, mesenchymal subtypes  frequently 
display substantial increases in length of sur-
vival [6].
The mesenchymal subtype was discovered to 
have a large association with both the tumor- 
promoting M2 macrophage gene and the 
deactivation of NF1 [7]. This suggests a path-
way linking the loss of function of NF1 to pro-
moted macrophage/microglia recruitment and 
invasion of the tumor microenvironment 
(TME), leading to a poorer prognosis for 
patients afflicted with mesenchymal subtype 
expression factors [7]. High-grade gliomas 
containing altered NF1 frequently have an 
associated deactivation of cyclin-dependent 
kinase inhibitor 2A (CDKN2A) that inhibits 
Ras-mediated growth signaling, suggesting 
NF1 as another tumor-suppressor gene in the 
central nervous system. As a consequence of 
losing the NF1 function, Ras activity stimu-
lates Ras effectors (PI3K, PAK, RAF, 
ERK1/2), increasing the proliferation of astro-
cytes, contributing to GBM growth [8].
• Classical GBM is defined by focal epidermal 
growth factor receptor (EGFR) mutation 
events in much larger frequencies than in the 
other three subtypes while containing zero 
mutations of the most altered gene in GBMs: 
p53. Similar to the mesenchymal subtype, 
classical subtypes tend to show the highest 
survival rates of all the subtypes when sub-
jected to aggressive treatments [6].
• The proneural subtype carries mutations of 
p53, platelet-derived growth factor receptor 
alpha (PDGFRA), and isocitrate dehydroge-
nase- 1 (IDH1) [6]. IDH1 and PDGFRA muta-
tions can result in irregular cell/tumor growth. 
Proneural patients are characteristically 
younger than other subtype patients and have 
more prolonged survival, but their survival 













































Fig. 1 Subtypes of glioblastoma, including the major genes altered and effect on prognosis following treatment. NF1 
neurofibromatosis type 1, PTEN phosphatase and tensin homolog, EGFR epidermal growth factor receptor, CDKN2A 
cyclin-dependent kinase inhibitor 2A, IDH1 isocitrate dehydrogenase 1, PDGFRA platelet-derived growth factor 
receptor alpha, NEFL neurofilament light, GABRA1 gamma-aminobutyric acid type A receptor alpha-1, SYT1 synap-
totagmin 1
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aggressive treatment or not. Furthermore, 
studies have demonstrated that classical and 
mesenchymal subtypes have a better response 
to therapy and better prognosis compared to 
the proneural subtype [6].
• The neural subtype is categorized based on the 
overexpression of neurofilament light (NEFL), 
gamma-aminobutyric acid type A receptor 
alpha-1 (GABRA1), synaptotagmin 1 (SYT1), 
and solute carrier family 12 member 5 
(SLC12A5) neural markers. The gene expres-
sions present within the neural subtype have 
been determined to be the most similar to nor-
mal brain tissue and are weakly characterized. 
Data suggests the average efficacy of treat-
ment in the neural subtype, but it is not as 
effective as treatments of classical and mesen-
chymal subtypes [6]. These unique genetic 
alterations leading to subtype classifications 
result in different metabolic profiles of can-
cers depending on the specific genes altered.
There have been speculations that GBM sub-
types do not remain stagnant during disease pro-
gression, nor while being bombarded with 
varying treatments [7]. A study by Wang et  al. 
investigated phenotypic plasticity and genetic 
drivers behind the evolution of proneural, classi-
cal, and mesenchymal subtypes. Samples were 
collected from varying gliomas at the time of 
diagnosis as well as at the first onset of GBM 
recurrence, and genetic profiles were obtained to 
establish their molecular subtypes for compari-
son. After analysis, 50 of 91 (55%) samples had 
their expression subtypes remain constant. After 
recurrence, the quantity of proneural and mesen-
chymal subtypes had increased, and the number 
of classical subtypes had decreased. There was 
no direct correlation observed between proneural 
and mesenchymal subtypes. The intratumoral 
heterogeneity of the initially collected samples 
was taken into account, and the samples with the 
lowest purity were typically the groups to 
undergo a transition of subtype.
GBMs are also divided into different groups 
based on the World Health Organization (WHO) 
classification system. Wild-type IDH accounts 
for 90% of diagnosed GBMs, which have a high 
correlation to primary GBM, especially in elderly 
patients. IDH-mutant GBM occurs in about 10% 
of patients and has a higher correlation to second-
ary GBM, which is GBM progressing from pre-
vious lower grade gliomas. The final classification 
is reserved for cases in which a complete IDH 
evaluation cannot be completed. IDHwt versus 
IDHmu has significant implications on GBM 
cells’ metabolism and needs to be investigated 
further. With all the heterogeneity that exists 
within glioblastomas, the classifications are con-
tinually changing, and the variants and patterns 
must frequently be updated to keep up with the 
evolving characteristics.
2.2  Intratumoral Heterogeneity
There are currently two proposed models that 
lead to tumor heterogeneity. The first model sug-
gests that heterogeneity stems from clonal evolu-
tion, where there are changes in single cells that 
create survival advantages between clonal popu-
lations [9]. The second model relies on cancer 
stem cells to produce phenotypically diverse dif-
ferentiated cells. These models are not mutually 
exclusive as the cancer stem cells have the oppor-
tunity to undergo clonal evolution for them to 
evolve into more aggressive, self-renewing stem 
cells [9].
The complexity of genotype and epigenetic 
states creates the intratumoral heterogeneity of 
metabolism [10–15]. In a study by Patel et  al., 
single-cell RNA sequencing was used to create a 
profile for 430 cells harvested from 5 diverse 
glioblastomas. These cancer cells were catego-
rized based on oncogenic signaling, proliferation, 
complement/immune response, and response to 
hypoxia. Variability between different tumors 
was evident, which led to different stages, gene 
and protein expression, and outcomes for thera-
peutic strategies [16].
2.2.1  Liquid Biopsy as a Method 
for Detecting Heterogeneity 
and Longitudinal Tracking
The existing spatial heterogeneity within indi-
vidual gliomas has made therapy more difficult. 
Distinct cells contained within the same tumor 
A. Quinones and A. Le
63
can present with different mutations and 
 phenotypic or epigenetic states, resulting in dif-
ferent subtypes being found in other compart-
ments of the same tumor. These variances within 
the same tumor ultimately lead to the inefficiency 
of treatment and cancer recurrence. Thus, studies 
suggest that synergistic treatments will be the 
direction of new therapeutic strategies [16]. It is 
becoming more pressing to establish the spatial 
and temporal heterogeneity of any particular 
tumor in order to devise an effective treatment. 
As cancer develops, the longitudinal metabolic 
profile is not stagnant. Therefore, if we wish to 
inhibit metabolic targets, correct timing is essen-
tial. Surgical biopsies are the conventional strat-
egy for gathering pathological information from 
GBM tumors. This fact is troublesome because a 
surgical biopsy will only provide a limited spatial 
and temporal snapshot of cancer, failing to reflect 
the intratumoral heterogeneity, not to mention 
there are significant risks associated with the pro-
cedure [17]. A newer approach is emerging that 
allows for assessment of the entire genetic land-
scape and longitudinal tracking, and is much less 
invasive: the liquid biopsy (Fig. 2).
Liquid biopsy has two potential sources, either 
the peripheral blood supply or the cerebrospinal 
fluid (CSF) via lumbar puncture. The liquid 
biopsy through the peripheral blood supply is 
best for measuring smaller metabolites that can 
cross the BBB easily and could be very important 
for longitudinal tracking of disease progression. 
Nguyen et al. demonstrated how concentrations 
of N-acetyl-aspartyl-glutamate (NAAG) within 
tumor tissue were directly correlated with the 
advancement of GBM and lower grade gliomas 
with very minimal concentrations of 
NAAG. NAAG concentration in plasma was also 
directly correlated with NAAG concentration in 
the tumor and glioma advancement [18].
Additionally, it has been shown that focused 
ultrasound (FUS) enhances the release of bio-
markers into the bloodstream [19]. This tech-
nique, in concordance with the liquid biopsy, 
could be pivotal in establishing precise spatial 
heterogeneity within a tumor. Liquid biopsy via 
lumbar puncture is also a viable, less invasive 
option for patients where surgical resection is too 
dangerous. It has been shown that there are 
greatly enhanced detectable levels of cf-DNA 
from malignant brain tumors. Liquid biopsy is 
highly beneficial as it could provide the entire 
genome of a cancer and allow for personalized 
oncology to target specific biomarkers [20]. 
Liquid biopsy could provide a broader overall 
look at the spatial heterogeneity present within a 
particular tumor. However, there are still obsta-
cles to be overcome with liquid biopsy of the 
CSF because the amount of tumor cf-DNA leak-
age into the CSF appears to be relevant to the 
proximity of the tumor to the CSF reservoir, as 
well as the progression of the tumor.
2.2.2  Glioblastoma Stem Cell 




A recent discovery that has a substantial impact 
on the spatial and temporal pathogenesis is the 
existence of glioblastoma cancer stem-like cells 
(GSCs). GSCs are not traditional stem cells—
they are tumor cells that develop an ultra- 
aggressive phenotype that facilitates resistance 
and survival following standard therapies [21]. 
The effect that GSCs have on spatial pathogene-
sis can be explained with the “Go or Grow 
hypothesis,” which postulates that infiltrative 
cells, such as GSCs, tend to diffuse and spread 
through tissues but have little proliferative poten-
tial. In contrast, tumor cells are proliferative and 
make up the bulk tumor mass (Fig. 3) [22]. The 
infiltration of these GSCs has the potential to 
seed different GBM cell subtype lineages, which 
contributes to the overall spatial heterogeneity.
The temporal pathogenesis of GBM is also 
affected by GSCs as they are the critical driv-
ers for the recurrence of GBM, which is com-
mon following resection. Traits of GSCs that 
allow for recurrence are their diffuse infiltra-
tion, resistance, and initiation of growth fol-
lowing therapy. We have already discussed 
the diffuse infiltration of GSCs, but it is 
important to mention that slower proliferating 
GBM cells are better at initiating tumor 
growth and have increased resistance [23]. A 
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recent discovery has determined that these 
infiltrating GSCs retain residual mitochon-
drial function, allowing them to perform oxi-
dative phosphorylation along with fatty acid 
oxidation [23, 24]. This is the reason for 
resistance and recurrence: GSCs are able to 
withstand glucose deprivation and glycolytic 
disruption because they have other means to 
survive. These GSCs are incredibly adaptable 
to their environment as they are able to sur-
vive in four critical niches: hypoxic, perivas-
cular, invasive, and acidic, allowing them to 
infiltrate various tissues without losing their 
stemness [21]. Recurrence typically occurs in 
resection-adjacent tissue, but even following 
a radical hemispherectomy, there is still con-
tralateral recurrence. There is some evidence 
that injury, such as surgical resection, to the 
tumor may initiate proliferation and recur-
rence, but this process remains obscure [25]. 
Following the recurrence of GBM, when com-
paring the transcriptomes between primary 
and secondary tumors, the tumors have differ-
ent metabolic signatures, with the recurrent 
tumor having similar metabolic activities to 
GSCs [23]. Experts are unsure as to the rea-
son for the metabolic shifts, whether they are 
due to the changes in tumor microenviron-
ment (TME) from first- line therapies or cell 
autonomous.
Fig. 2 Liquid biopsy and the analysis of biopsy: DNA, protein, and metabolites
A. Quinones and A. Le
65




As previously mentioned, GBMs can be classi-
fied according to their genetic and metabolic 
profiles. Genetic mutations are the cause of 
deviation of metabolism from the status quo. As 
genes are overexpressed, inactivated, or 
mutated, it leads to downstream effects. These 
downstream metabolic effects can be identified 
and investigated for therapeutic strategies, 
which is the current goal of cancer metabolism 
research.
3.1  PTEN Mutations Lead to High 
Rates of Glycolysis, 
Facilitating Survival in Harsh 
Microenvironments
In a study by Wolf et  al., GBMs with loss of 
PTEN activity had high expression of the glyco-
lytic enzyme hexokinase 2 (HK2), the first 
enzyme of glycolysis, enabling those GBM cells 
to survive and proliferate in a harsh TME [26]. 
HK2 is expressed in basal levels in adipose and 
skeletal tissues, but it is not expressed in normal 
brain tissue, which typically expresses HK1. 
Inhibition of HK2, without interfering with HK1 
function, by siRNA led to a reverse of the 
Fig. 3 Spatial representation of a GBM tumor exhibiting the proliferating mass of the bulk tumor compared with the 
diffuse infiltration of glioblastoma stem-like cells (GSCs) past the typical perimeter of surgical resection
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Warburg effect to oxidative glucose metabolism, 
which ultimately led to impaired tumor growth. 
Also, HK2 inhibition sensitized GBM cells to 
multiple treatments, including the following: (1) 
temozolomide, the current chemotherapeutic 
GBM treatment; (2) radiation; and (3) hypoxia- 
induced apoptosis. Also, high HK2 expression 
predicted lower overall survival [26]. These find-
ings support the genetically evolved metabolic 
heterogeneity in cancer cells.
3.2  EGFR Mutations Shift Cancer 
Cells toward a Glycolytic 
Phenotype and Permit 
Survival under Glucose- 
Deprived Conditions
Mutations in EGFR provide an additional exam-
ple of genetic alterations that lead to changes in 
cancer cell metabolism [27]. In their study, Babic 
et al. revealed an activating EGFRvIII mutation, 
which causes an intracellular increase in hetero-
geneous nuclear ribonucleoprotein (hnRNP) A1 
splicing factor. This upregulation, in turn, pro-
motes the splicing of MYC-associated factor X 
(MAX), a partner protein of MYC, which ulti-
mately results in an upregulation of glycolysis, 
and shorter patient survival time [27]. There has 
been some success in utilizing the vulnerabilities 
created by the glycolytic phenotype of GBM as 
therapeutic strategies. A glucose analog, 2-deoxy- 
d-glucose (2DG), has been shown to inhibit gly-
colysis and was well tolerated in clinical trials for 
other advanced cancers [28].
Growth factor signaling pathways are respon-
sible for cellular metabolism, proliferation, and 
environmental adaptation [29, 30]. The growth 
factor signaling pathways are heavily dependent 
upon regulation from receptor tyrosine kinases 
(RTKs), showing that genetic mutations in RTKs 
such as EGFR lead to variable progression and 
growth of tumors stemming from the changes in 
the signaling pathways [31]. Furnari et al. used 
mouse models in correlation with clinical sam-
ples wherein the mouse growth factor signaling 
pathways were genetically modified to match the 
clinical samples [32]. The corresponding GBMs 
were determined to be histologically identical, 
indicating the importance of RTK alterations in 
the progression of GBMs. In a study of 251 
patient-derived GBMs comprised mainly of de 
novo GBMs (95%), there were alterations to 
RTKs in 66% of the samples, and the dominant 
alteration was to EGFR. This lesion was usually 
accompanied by activation of other PI3Ks, alter-
ation, and deletion of CDKN2A. EGFRvIII+ cells 
had a higher proliferation rate with less cell death 
in xenograft models when using EGFR-targeted 
therapies and showed increased glycolysis to ful-
fill the energy demand [30, 31, 33, 34]. Further 
studies are required to evaluate the mechanisms 
utilized by GBMs to sustain growth based on 
their environment.
3.3  p53 Mutations Result 
in Activation of the Warburg 
Effect
Tumor-suppressor gene p53 has been identified 
as a gene commonly mutated in many cancers, 
including GBM [35]. p53 serves to initiate cell 
cycle arrest and apoptosis when the cell is sub-
jected to stressors, including hypoxia, hyperpro-
liferative signals, nutrient deprivation, and DNA 
damage [36, 37]. Mutant p53 genes typically lead 
to complete inactivation of p53, which is charac-
terized by a higher malignancy of cancer through 
greater rates of metastasis, genetic instability, 
and cellular differentiation [38–40]. Novel func-
tions of p53 have emerged, showing its potential 
to regulate cellular metabolism. A signature 
 feature of cancer is its reliance on the Warburg 
effect [41]. p53 has been shown to counter this 
oncogenic hallmark by activating the synthesis of 
cytochrome oxidase 2 to promote oxidative 
 phosphorylation and inhibit glycolysis by 
repressing glucose transporters (SLC2A1, 
SLC2A4). Thus, the Warburg effect is more pro-
found when p53 is inactivated [42–44]. Recently, 
there have been contradictory studies showing 
that the impact of p53 as a tumor suppressor is 
not as compelling as initially suggested. These 
studies found evidence to support the claim that 
cell cycle arrest and apoptosis, as a result of DNA 
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damage, are not large contributors to tumor sup-
pression depending on the cancer tissue exam-
ined [35]. These findings have yet to be replicated 
when evaluating GBM development, but further 
examination is necessary.
3.4  GBM Exhibits Upregulated 
Glutamine Metabolism 
Allowing for Targeted 
Vulnerabilities Through GLS, 
GS, and mTOR
As is true for many other cancers, GBM also 
exhibits “glutamine addiction” [45]. Glutamine 
serves as the major contributor to cell growth and 
energy production after it is converted into gluta-
mate via glutaminase (GLS), and then into 
α-ketoglutarate (aKG) via glutamate dehydroge-
nase (GDH) or several aminotransferases. For this 
reason, GLS inhibition has become a popular 
therapeutic strategy to treat cancer patients and 
has reached clinical trials (NCT03528642). Oizel 
et al. showed how metabolic phenotype leading to 
subtype classification could help with targeted 
therapies. In their study, Oizel showed that mes-
enchymal GBM cells had significantly more 
uptake of glutamine and that glutamate derived 
from glutamine was converted to aKG to generate 
ATP.  This altered phenotype was facilitated by 
upregulated SLC1A5 (glutamine transporter), 
GLS, and mitochondrial and cytosolic amino-
transferase. Consequently, mesenchymal GBM 
was shown to be more susceptible to GLS inhibi-
tion [46]. Glutamine is essential in normal brain 
tissue, but it appears to have even higher concen-
trations in GBM tissue [47]. The primary source 
of glutamine in the brain comes from glutamine 
synthase (GS) as it combines glutamate and 
ammonia to form glutamine. GS levels in GBM 
have been shown to correlate with patient survival 
time, as those with lower GS levels could have up 
to a twofold increase in survival time [48]. The 
impact of GS expression levels on GBM progres-
sion, resistance, and patient survival time needs 
further investigation, but GS appears to be a 
 reliable prognostic biomarker and could poten-
tially lead to another therapeutic strategy.
The mechanistic target of rapamycin (mTOR) 
is a protein kinase that promotes oncogenic sig-
naling through the phosphoinositide 3-kinase 
(PI3K) pathway, which in turn promotes cancer 
growth [49]. This has also made mTOR a popular 
target for cancers that use PI3K as a major path-
way [50]. mTOR has been identified as a primary 
factor in downstream signaling for EGFR-mutant 
GBM, which is resistant to kinase inhibitors [51]. 
In a study by Tanaka et  al., they found that 
mTOR-targeted treatments affected glutamine 
catabolism, increasing GLS expression, which is 
already highly expressed in GBM patients. 
mTOR-targeted therapies (by rapamycin or 
PP242) limited cell proliferation, glucose usage, 
and lactate production [50]. However, they were 
ineffective in promoting cell death. Following 
these results, Tanaka et al. performed an experi-
ment in which the U87 and EGFRvIII GBM cells 
were subjected to glutamine deprivation through 
compound 968 (GLS inhibitor) and then treated 
with PP242, which was seen as more effective 
than mTOR-targeted treatment alone. Results 
showed that when used in combination, the GLS- 
and mTOR-targeted therapies yielded a synergis-
tic effect triggering enhanced tumor cell death 
compared to when either treatment was applied 
individually [50]. This combined treatment was 
then tested on normal human astroglial cells, and 
the results revealed that the treatment did not 
cause any normal cell death to occur. This syner-
gistic treatment was then tested on GBM xeno-
graft models of U87 and EGFRvIII GBM 
samples. The treatment resulted in 80% shrink-
age of tumors and a sixfold increase in cell death 
from mTOR-targeted treatment alone. To deter-
mine the effects of the drug on the whole body 
and motor function, the same treatment was 
applied to normal mice. There were no changes 
in body weight, motor function, or cell morphol-
ogy, indicating that the combination of GLS and 
mTOR inhibition has the potential to develop 
into an effective treatment for mTOR-targeted 
resistant GBM cancers [50].
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3.5  Lipid Metabolism 
Dysregulation Following 
BRAF Mutations and EGFR 
Signaling Provides Clues 
for New GBM Therapeutic 
Strategies
Lipid synthesis is a limiting factor for cellular 
proliferation. GBMs must synthesize their own 
lipid components for proliferation leading to a 
potential vulnerability. Indeed, certain lipid lev-
els—specifically free fatty acid levels—in 
 malignant tissue are elevated when compared to 
normal brain tissue [52]. To synthesize fatty 
acids, cells must first generate cytosolic acetyl-
CoA, and both tumor-suppressor genes and 
oncogenes regulate this crucial step in 
GBM. When there is a BRAF mutation concom-
itant with TP53 and PTEN deletion, it results in 
an increased expression of acetyl-CoA synthe-
tase enzyme 2 (ACSS2), the enzyme responsible 
for converting acetate to acetyl-CoA in the cyto-
sol [53, 54]. Another study discovered that 
EGFR-PI3K-Akt signaling, which results in ste-
rol regulatory element- binding protein 1 
(SREBP-1) cleavage and activation of acetyl 
coenzyme A (CoA) carboxylase (ACC) and 
fatty acid synthase (FAS), plays a role in the 
upregulation of lipogenesis in malignant glio-
mas. The reaction catalyzed by ACC has been 
determined as the rate-limiting step for de novo 
lipogenesis. For cells with upregulated EGFR 
signaling, targeting the downstream effectors of 
the pathway (SREBP-1, ACC, and FAS) results 
in GBM cell death but does not affect normal 
cells [55]. GSCs also contain elevated levels of 
lipid metabolites, which contribute to their 
resistance to glycolytic inhibition or glucose 
deprivation because when facing glycolytic 
inhibition or glucose deprivation, they have the 
ability to rely on fatty acid oxidation for energy. 
To combat this, Hoang-Minh et al. experimented 
with pharmacologic inhibition and CRISPR 
intervention of the fatty acid transporter fatty 
acid-binding protein 7 (FABP7) to prevent fatty 
acid uptake, which led to an increase in the 
overall survival of mice carrying GBM in vivo 
model [23].
3.6  GBMs Rely on the TCA Cycle 
and Its Reductants
Alterations of tumor-suppressor genes and 
oncogenes lead to dysregulations of the TCA 
cycle in GBM, which creates aberrant metabo-
lism. IDH enzymes play a significant role in the 
TCA cycle for normal cells by catalyzing the 
oxidative decarboxylation of isocitrate to aKG 
using NADP+ or NAD+ as cofactors. IDHwt 
expression levels are elevated fourfold in GBM 
tumors when compared to normal brain tissue 
making IDH the most significant NADPH-
producing enzyme and thus a promising thera-
peutic target. NADPH is necessary for GBM 
tumors as a reductant for antioxidant biomole-
cules that help to mitigate oxidative stress. The 
knockdown of IDH1 depletes stores of NADPH 
and sensitizes GBM cells to radiation, increas-
ing cellular senescence [56].
In SF188 glioblastoma, high amplification of 
MYC [57, 58] activates glutamate dehydrogenase 
(GDH), enabling cancer cell survival under glu-
cose deprivation [59]. GDH, an enzyme neces-
sary for the conversion of glutamate to aKG for 
incorporation into the TCA cycle, is upregulated 
in the absence of glucose. This upregulation 
allows glioblastoma cells to maximize the use of 
glutamine and thus contributes to the growth and 
proliferation of neoplastic cells in the absence of 
glucose [59].
As seen with the previous metabolic path-
ways, dysregulation of the TCA cycle results in 
aggressive GBM phenotypes resulting in greater 
proliferation and growth.





A study by Dang et al. demonstrated that muta-
tions in IDH1 give rise to a novel function of this 
enzyme, which produces the oncometabolite 
(R)-2-hydroxyglutarate (2HG) from alpha- 
ketoglutarate (aKG) [60]. Struys et  al. reported 
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that “2HG,” in fact, does not exist [61]. The com-
pound has an asymmetric carbon atom that leads 
to L-2HG and D-2HG, which are both stable 
endogenous metabolites in all bodily fluids. 
Routine analytical methods measure the sum of 
these two metabolites, which creates problems 
because IDH1 mutations solely result in increased 
levels of D-2HG.  Therefore, an increase in 
L-2HG could yield false positives, and a small 
rise in D-2HG may be missed. This is why ana-
lytical methods able to distinguish L-2HG from 
D-2HG must be used [61, 62]. D-2HG not only is 
found in glioblastoma but has also been found to 
be sufficient in promoting several other types of 
cancers, such as leukemia, through mutations in a 
homolog to IDH1 and IDH2 [63, 64]. D-2HG 
retains a structure similar to that of aKG, thus 
inhibiting enzymes from binding to aKG.
Both L- and D-2HG inhibit aKG-dependent 
histone demethylases and D-2HG occupies the 
active site of CeKDM7A, which is where aKG 
usually binds. Both L- and D-2HG also interferes 
with 10–11 translocation (TET) family interac-
tions and regulates HIF-1a, which promotes hyper-
methylation, triggering cancer proliferation, and 
preservation [65, 66]. The effect of IDH1mu on 
HIF-1a is currently being debated. HIF-1a-induced 
overexpression of target enzymes GLUT1, vascu-
lar endothelial growth factor (VEGF), and pyru-
vate dehydrogenase kinase 1 (PDK1) leads to 
increased tumor growth, invasion, and angiogene-
sis [67]. These mutations render cancer cells 
addicted to glutamine. Thus, glioblastoma cells 
with IDH1 mutations are more sensitive to GLS 
inhibition by bis-2-(5- phenylacetamido- 1,3,4-
thiadiazol-2-yl)ethyl sulfide (BPTES), a small-
molecule selective inhibitor of GLS, as compared 
to their wild-type counterparts [68] (Fig.  4). 
Metabolic dependence on aKG was confirmed 
through rescue experiments showing that the sup-
plement of aKG reduced the impact of BPTES on 
proliferation hindrance. However, wild-type IDH1 
and IDH1 mutants were equally sensitive to gluta-
mine deprivation, suggesting that there are differ-
ent downstream effectors active when considering 
inhibition of glutamine metabolism versus inhibi-
tion of glutamine uptake. Metabolomics analysis 
[69] provided interesting findings that 2HG levels 
remained constant between the IDH1-mutant 
BPTES-treated group and the IDH1-mutant non- 
treated group. However, the glycolytic intermedi-
ate levels increased, and the TCA cycle 
intermediate levels decreased in the group treated 
with BPTES when compared to the non-treated 
group. The increase of glycolytic intermediates 
and the decrease of TCA cycle intermediates can 
be attributed to compensatory mechanisms 
attempting to maintain aKG levels by reallocating 
glutamine carbon from the TCA cycle to glycoly-
sis [68]. The message from this specific example is 
that the mutations of IDH1 form a subset of glio-
blastomas that exhibit a shift toward glutamine- 
dependent energy pathways. These pathways 
allow tumor cells to best utilize glutamine and its 
products in order to produce ATP as a fuel source 
for biosynthetic pathways. This ability is particu-
larly advantageous when glucose is scarce. This 
signifies that these IDHmu tumors exhibit gluta-
mine addiction, and therapies to target glutamine 
metabolism should prove to be particularly useful 
here. GLS inhibition could serve as a potential 
therapeutic target, and several BPTES analogs 
have been developed [70]. Still, they will most 
likely need to be used in conjunction with other 
treatment regiments to combat the dynamic prop-
erties of cellular metabolism [68].
In a study by Nobusawa et  al., individuals 
with secondary glioblastoma who possessed 
IDH1 mutations had a more favorable prognosis 
than those with IDH1 wild-type [71]. 
Histologically, primary and secondary glioblas-
tomas are identical; thus, clinical data is relied 
upon to determine their subdivision because they 
occur in patients of different ages and develop 
through different pathways [72, 73]. Through 
statistical analyses, it was determined that there 
was a positive correlation between IDH1 muta-
tions accompanied by p53 mutations, diagnosis 
of secondary glioblastoma, more prolonged 
median survival, and younger patient age [74]. 
IDH1wt genes correlated with older patients, 
shorter median survival, and higher EGFR 
amplification. Secondary glioblastomas make up 
a smaller fraction of the disease compared to pri-
mary glioblastomas, but of the secondary cases 
sampled, an IDH1mu affected the majority, 
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while a minority of primary glioblastomas were 
affected by the IDH1 mutation. For the patients 
initially diagnosed as secondary GBM, which 
did not harbor an IDH1 mutation, and for the 
cases initially diagnosed as primary, which con-
tained an IDH1 mutation, further analysis 
showed that these cases were likely misdiag-
nosed. The “primary” diagnosed patients with 
IDH1mu had every characteristic of secondary 
glioblastoma, while the opposite was true for 
“secondary” glioblastomas with IDH1wt. These 
discrepancies suggest incorrect diagnoses for 
gliomas that may have started at a low grade and 
then progressed quickly, making them look like 
a primary or higher grade glioma with some pro-
gression disguising it as secondary. Nobusawa 
et al. accurately identified IDH1 as a reliable sig-
nature marker for secondary glioblastoma with a 
more favorable outcome [71].
Furthermore, another study by Labussiere 
et  al. showed that individuals with IDH1mu 
tumors lived longer than those who had IDH1wt 
tumors, despite all tumors being of the same grade 
[75]. Another classical function of IDH1 is to sup-
port oxidative decarboxylation of isocitrate to 
aKG coupled with the reduction of NADPH, 
allowing NADPH to promote the further reduc-
tion of glutathione (GSH), a crucial antioxidant 
[76, 77]. When glioblastomas have IDH1mu, the 
loss of normal enzymatic function lowers the pro-
duction of aKG and NADPH, subsequently low-
ering GSH, while increasing 2HG [60]. The surge 
of D-2HG increases oxidative stress present in 
cancer cells and the accumulation of reactive oxy-
gen species (ROS), which encourages tumor cell 
growth [78]. These characteristics seemingly cre-
ate a paradox wherein the accumulation of ROS 
could serve to further tumor  development due to 
Fig. 4 The paradoxical nature of downstream effects of 2HG. 2HG inhibition of aKG-dependent histone demethylases, 
2HG regulation of HIF-1a which induces overexpression of target enzymes GLUT1, VEGF, and PDK1 leading to 
increased tumor growth, proliferation, and glutamine addiction. However, that glutamine addiction creates a vulnerabil-
ity within those GBM cells to targeted glutamine inhibition. 2HG also functions to inhibit ATP synthase and interferes 
with mTOR signaling causing decreased cancer cell growth and viability
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the increase of genetic instability, but on the other 
hand, the decrease of GSH levels leaves the tumor 
cells vulnerable for oxidative damage [75]. Both 
L- and D-2HG have also been shown to function 
as an ATP synthase inhibitor and interferes with 
mTOR signaling, which leads to a decrease in 
tumor growth and cell viability [79] (Fig.  4). 
There appears to be a greater response to radiation 
in patients with IDHmu tumors, which may be 
due to the effect D-2HG has as a radiosensitizing 
agent [80]. Both enantiomers of 2HG inhibit 
homologous recombination allowing for the 
greater effect of alkylating agents [81]. 
Controversy exists over the therapeutic potential 
of targeting 2HG because there appear to be both 
oncometabolite and tumor-suppressing capabili-
ties of 2HG. These conclusions suggest the need 
for further analyses on the mechanistic links 
between metabolic phenotype and clinical out-
come. There appears to be a limited therapeutic 
window with IDHmu tumors where inhibition of 
IDH1/2 or 2HG could be beneficial earlier in 
pathogenesis to prevent invasion and progression, 
but further in development, these metabolic aber-
rations could hold the key to increased longevity 
due to the vulnerabilities created. This conflict 
illustrates the need for a deeper dive into the tem-
poral pathogenesis of GBM with IDH mutations.
4  Benefits of Combined 
Therapy
Among the many struggles in treating cancer, 
tackling its inherent metabolic heterogeneity is a 
significant obstacle [69]. Metabolic pathways 
relevant to GBM have been established, but those 
pathways are dynamic, and cancer cells alter 
their metabolism as their environments change 
[82]. When a pathway is hit and deactivated, the 
ability of a cancer cell to work around it contrib-
utes to the complexity of treatments. After mul-
tiple pathways are inhibited, a cancer cell’s 
metabolism will eventually be cornered with 
nowhere to turn (Fig. 5). Tanaka et al. success-
fully combined therapies inhibiting mTOR and 
GLS to limit cancer cell proliferation [50]. As 
mTOR-targeted treatments inactivate the PI3K, 
GBM switches to higher expressions of GLS to 
rescue it from apoptosis [50]. Combining the 
mTOR-targeted treatment with GLS inhibition 
essentially traps specific GBM cells so that their 
metabolism cannot shift pathways to encourage 
cell survival. Heterogeneity creates problems 
when determining treatment because different 
metabolic profiles result in differences as to how 
cancer metabolism will change in response to 
treatment. These synergistic treatments are ben-
eficial because they can work together when 
attempting to target different pathways. Still, the 
challenge remains to affect only the cancerous 
cells while not having a detrimental impact on 
benign, healthy cells.
The current treatment protocol for GBM is 
surgical resection, radiation, and chemotherapy, 
typically through temozolomide (TMZ), which is 
an alkylating agent that causes DNA damage to 
tumor cells to trigger apoptosis. Even with 
aggressive treatment, this disease is universally 
lethal. Interfering with GBM’s metabolic path-
ways through metabolic targeting could serve as 
a way to enhance the effectiveness of standard 
therapies. Glycolytic phenotypes are typically 
accompanied by radiation resistance. Therefore if 
glycolytic inhibition is accompanied by radia-
tion, it could improve the effectiveness of treat-
ment. Indeed, these are the results obtained by 
Wolf et  al. in their in  vitro studies. As they 
depleted HK2 (a glycolytic enzyme) and com-
bined it with radiation therapy, they observed 
reduced proliferation and increased apoptosis 
[26]. As discussed earlier, NADPH is a powerful 
reductant to help mediate oxidative stress created 
by radiation. Decreasing NADPH levels is also 
linked to high rates of cellular senescence in the 
presence of radiation [56]. As IDHwt is the driver 
for increased NADPH concentrations, IDHwt 
inhibition appears to be another potential syner-
gistic strategy. Combination therapy with high 
pharmacological doses of ascorbate, which 
becomes a powerful prooxidant to inflict oxida-
tive damage, and radiation is also a viable strat-
egy to combat radiation resistance. Specifically, 
Herst et al. used in vitro studies to show that high 
doses of ascorbate combined with 1 Gy of radia-
tion (which is lower than the typical amount of 
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2  Gy) resulted in greater cell death than either 
singular strategy and had less harmful effects on 
normal astrocytes [83]. Oxidative stress can be 
mediated by altering glutamine metabolism. 
Glutamine is converted to glutamate via GLS, 
and glutamate is an amino acid incorporated into 
GSH.  Therefore, if GLS inhibition indirectly 
inhibits the formation of GSH, there are fewer 
antioxidants to provide radioprotection. CB-839, 
a potent GLS inhibitor, is currently undergoing a 
clinical trial (NCT03528642) in combination 
with TMZ and radiation.
Currently, it is not well understood how glyco-
lytic metabolites contribute to chemotherapy 
resistance. However, as seen with radiation, the 
depletion of HK2 also appears to sensitize GBM 
to TMZ [26]. Tumor protein 73 antisense RNA 1 
(TP73-AS1) has been found to have connections 
with GSCs that confers TMZ resistance. Mazor 
et al. demonstrated that silencing TP73-AS1 led 
to an increased sensitivity of GBM to TMZ ther-
apy. The mechanism behind this effect is cur-
rently being investigated. TP73-AS1 is known to 
encode aldehyde dehydrogenase 1 family mem-
ber A1 (ALDH1A1), which is an established 
marker for cancer stem cells and promotes resis-
tance. ALDH1A1 inhibition has a very similar 
sensitizing effect on GBM cells to TMZ [84].
5  Advanced Brain Tumors 
(GBM) Display Distinct 
Metabolic Profiles Compared 
to Lower Grade Tumors
While IDH1 mutations can distinguish between 
primary and secondary GBMs, another metabolic 
pathway involving cysteine catabolism is not 
highly activated in lower grade tumorigenesis 
[85]. The GSH synthesis pathway involving cys-
teine begins with a simultaneous efflux of gluta-
mate and influx of cystine, which is then reduced 
to cysteine and converted to GSH when com-
bined with glutamate and glycine. GSH functions 
Fig. 5 Metabolic targets for GBM therapy (indicated by multicolored panels) accompanied by the specific metabolic 
pathways in which they participate. These targeted therapies can be used to supplement the standard therapy for treating 
GBM possibly resulting in synergistic effects. HK2 hexokinase 2, mTOR mechanistic target of rapamycin or mamma-
lian target of rapamycin, GLS glutaminase, GS glutamine synthase, IDH isocitrate dehydrogenase, GDH glutamate 
dehydrogenase, SREBP-1 sterol regulatory element-binding protein 1, FABP7 fatty acid-binding protein 7
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as a central nervous system antioxidant increas-
ing cancer cell survival when subjected to redox 
stress and hypoxia [86]. Prabhu et al. investigated 
another pathway involving cysteine, which 
resulted in the accumulation of cysteine sulfinic 
acid (CSA) through the regulatory enzyme cyste-
ine dioxygenase- 1 (CDO1). When comparing 
with grade 2 gliomas, there was a 23-fold increase 
in the  relative accumulation of CSA in GBM, 
ranking it as the highest change in concentration 
of any metabolite. This increase of metabolite 
concentration correlated with a higher expression 
of the CDO1 enzyme in GBM when evaluated 
using Western blot analysis. The buildup of CSA 
is associated with inhibited cellular respiration 
and decreased both oxidative phosphorylation 
and ATP production. CSA modulates mitochon-
drial function through inhibition of pyruvate 
dehydrogenase (PDH). PDH functions as a chan-
nel enzyme controlling the rate at which glycoly-
sis occurs, and this enzyme was inhibited in a 
dose-dependent manner when treated with CSA 
using an established GBM cell line (U251). 
Further investigation is needed to determine how 
this alternative pathway of cysteine catabolism 
contributes to GBM tumorigenesis [85]. An anal-
ysis was conducted to uncover the impacts PDH 
modulation had on tumorigenesis in GBM and 
showed that PDH phosphatase expression regu-
lated PDH activity as a result of Ras-mediated 
signaling. When the impairment of PDH was 
reversed, it inhibited tumor growth, making this 
pathway a possible therapeutic target to treat 
GBM in the future [87].
Nguyen et al. discovered a metabolite, NAAG, 
that serves as a glutamate reservoir for cancer 
cells in a glutamine-deprived environment, as 
mentioned earlier. Additionally, NAAG was 
found to be significantly elevated in GBM when 
compared to grade II–III gliomas and meningio-
mas [18]. As more of these biomarkers emerge, 
they could provide the key for tracking longitudi-
nal pathogenesis and discovering new metabolic 
targets.
6  Conclusion
Glioblastoma is the most common and deadliest 
form of brain cancer in humans. Its poor progno-
sis and unreliable diagnosis are the results of its 
intricate heterogeneity and evolutionary charac-
teristics. Experts have made substantial progress 
in characterizing this cancer with the use of 
improved technologies; most recently, there has 
been a spotlight on the use of metabolomics to 
discover its underlying molecular mechanisms. 
As more data and results are obtained to deter-
mine how different glioblastomas function and 
why they exhibit certain metabolic phenotypes, 
more therapeutic strategies can be developed to 
treat patients individually with respect to their 
genotypic and phenotypic profiles.
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Pancreatic ductal adenocarcinoma · KRAS 
mutation · Glucose metabolism · Glutamine 
metabolism · Combined therapy
Abbreviations
Asp Aspartate
EGFR Epidermal growth factor receptor
GLS Glutaminase
GLUD1 Glutamate dehydrogenase 1
GLUT Glucose transporter
GOT1 Glutamic-oxaloacetic transaminase 1
HCQ Hydroxychloroquine
HIF-1α Hypoxia-inducible factor 1-alpha
HK2 Hexokinase 2
KRAS Kirsten rat sarcoma viral oncogene 
homolog
LDH Lactate dehydrogenase
MAPK Mitogen-activated protein kinase
MCT Monocarboxylate transporter






PDAC Pancreatic ductal adenocarcinoma
PDH Pyruvate dehydrogenase
PFK1 Phosphofructokinase 1
PPP Pentose phosphate pathway
ROS Reactive oxygen species
TCA Tricarboxylic acid
Key Points
• Oncogenic KRAS regulates glucose and gluta-
mine metabolism in pancreatic cancer cells.
• MUC1 overexpression leads to increased glu-
cose metabolism.
• p53 functions predict the sensitivity of pancre-
atic cancer tumors to glycolytic inhibition.
• Targeting alpha-ketoglutarate dehydrogenase 
function by CPI-613 slows mitochondrial 
metabolism.
• The antidiabetic drug, metformin, targets pan-
creatic cancer stem cells.
• Combined therapy is used to target pancreatic 
metabolism heterogeneity.
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Currently, approximately 95% of pancreatic can-
cers are pancreatic ductal adenocarcinomas 
(PDAC), which are the most aggressive form and 
the fourth leading cause of cancer death with 
extremely poor prognosis [1]. Poor prognosis is 
primarily attributed to the late diagnosis of the 
disease when patients are no longer candidates 
for surgical resection [2]. Cancer cells are depen-
dent on the oncogenes that allow them to prolif-
erate limitlessly. Thus, targeting the expression 
of known oncogenes in pancreatic cancer has 
been shown to lead to more effective treatment 
[3]. This chapter discusses the complexity of 
metabolic features in pancreatic cancers. In order 
to comprehend the heterogeneous nature of can-
cer metabolism fully, we need to take into account 
the close relationship between cancer metabo-
lism and genetics. Gene expression varies tre-
mendously, not only among different types of 
cancers but also within the same type of cancer 
among different patients. Cancer metabolism het-
erogeneity is often prompted and perpetuated not 
only by mutations in oncogenes and tumor- 
suppressor genes but also by the innate diversity 
of the tumor microenvironment. Much effort has 
been focused on elucidating the genetic altera-
tions that correlate with disease progression and 
treatment response [4, 5]. However, the precise 
mechanisms by which tumor metabolism con-
tributes to cancer growth, survival, mobility, and 
aggressiveness represent a functional readout of 
tumor progression (Fig. 1).
2  Oncogenic KRAS Regulates 
Metabolism in Pancreatic 
Cancer Cells (Fig. 2)
2.1  Oncogenic KRAS Regulates 
Glutamine Metabolism
Cancer’s specific metabolic adaptations in nutri-
ent uptake and biosynthesis have been linked to a 
particular genetic mutation. The KRAS (Kirsten 
rat sarcoma) oncogene homolog is a known regu-
lator of glutamine metabolism among other inter-
mediary metabolic pathways that render cancer 
cells addicted to glutamine [6–9]. A range of 
mutations in the KRAS oncogene occur in over 
90% of PDAC [10, 11]. Typically, glutamate 
feeds into the TCA cycle after being converted to 
alpha-ketoglutarate in the mitochondrion via glu-
tamate dehydrogenase 1 (GLUD1) or amino-
transferases. A study by Son et  al. showed that 
KRAS regulated the reprogramming of glutamine 
metabolism through transcriptional regulation of 
key metabolic enzymes of transaminase reac-
tions, which, in turn, determine PDAC tumor 
growth. Notably, they concluded that PDAC cells 
greatly depend on these reactions for redox 
homeostasis. Given that these pathways are non-
essential in normal cells, the unique importance 
of these pathways in PDAC suggests novel 
approaches for therapy in treating PDAC [7]. 
KRAS mutation led to the reprogramming of glu-
tamine metabolism, which was partially due to 
increased cytosolic aspartate aminotransferase or 
glutamic-oxaloacetic transaminase  1 (GOT1) 
expression and decreased GLUD1 expression, 
which led to increased aspartate production via 
the mitochondrial isozyme GOT2. The change in 
the ratio of expression of GOT1 and GLUD1 thus 
shunts glutamine flux through the aspartate ami-
notransferase pathway. According to Lyssiotis 
et al., the observation that the glutamine metabo-
lism pathway is downstream of mutant KRAS 
serves as an explanation for the distinct gluta-
mine dependency of pancreatic cancer. Not only 
do their results yield novel targets for pancreatic 
cancer therapy, but they also suggest that inhibit-
ing glutamine metabolism in pancreatic cancer 
therapies may synergize with therapies that 
increase reactive oxygen species (ROS) [8].
It has been recently found that oncogenic 
KRAS also activates a nuclear factor erythroid 
2-related factor 2 (Nrf2)-dependent antioxidant 
program to suppress ROS levels within the cells 
[12]. The upregulated Nrf2 pathway in cancer 
cells also increases the shunt of both glucose and 
glutamine towards anabolic metabolism, specifi-
cally towards the pentose phosphate pathway 
(PPP), when triggered by proliferative signaling 
[13]. Finally, Nrf2 also promotes pancreatic 
tumorigenesis and proliferation [14], further sug-
gesting the multifaceted role of KRAS in driving 
pancreatic cancers.
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2.2  Oncogenic KRAS Regulates 
Glucose Metabolism
The KRAS oncogene is also known to contribute 
to the glucose metabolism in pancreatic cancer 
cells via the upregulation of glucose uptake and 
the diversion of glucose into the hexosamine bio-
synthesis pathways [15]. Oncogenic KRAS also 
controls the diversion of glycolytic intermediates 
into ribose biosynthesis pathways via the upregu-
lation of the non-oxidative pentose phosphate 
pathway (PPP), a pathway that is fundamental to 
nucleic acid synthesis and thus cancer cell prolif-
eration [15]. Expression of glucose transporter-1 
(GLUT1), hexokinase-II (HK2), a kinase that 
phosphorylates glucose to drive intracellular glu-
cose flux, and lactate dehydrogenase A (LDHA), 
an enzyme that catalyzes the reaction of pyruvate 
to lactate, are greatly enhanced by KRAS in pan-
creatic tumor cells [15]. Consequently, glycolytic 
flux, the production of lactate from glucose, was 
high in KRAS-mutant tumors. It is of note that 
these alterations are not nearly as pronounced in 
the stromal cells of these tumors, which can 
uptake the lactate generated by tumor cells and 
convert the lactate back to pyruvate in order to 
fuel the TCA cycle [16, 17]. Yun et al. found that 
cells with mutated KRAS underwent the Warburg 
effect and survived better in low-glucose 
 environments compared to cells with wild-type 
KRAS due to the fact that KRAS upregulated 
GLUT1 [18, 19], suggesting that KRAS mutation 
is involved in the altering of a cancer cell’s 
 bioenergetics that is seen in most PDAC tumor 
cells, which take advantage of the altered meta-
bolic pathways to proliferate and grow 
successfully.
2.3  Oncogenic KRAS Upregulates 
Macropinocytosis and Lipid 
Scavenging
Fatty acids are required for cancer cells to repli-
cate their cell membranes and undergo essential 
lipid-dependent processes for proliferation. 














































Fig. 1 Overview of 
pancreatic cancer 
metabolic heterogeneity. 
PDAC pancreatic ductal 
adenocarcinoma, MUC1 
mucin 1
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fatty acid synthesis [20, 21], oncogenic KRAS 
also upregulates macropinocytosis, the endocytic 
process of cellular internalization of extracellular 
fluid, and its contents, further demonstrating the 
impact of oncogenic KRAS on PDAC. Recently, 
it was found that Ras-transformed cells utilize 
macropinocytosis as a way to uptake amino acids, 
including glutamine. In Ras-transformed pancre-
atic tumor xenografts, inhibiting macropinocyto-
sis significantly inhibited tumor growth [22]. 
Ras- transformed cells, along with hypoxic cells, 
were also shown to support growth by increased 
scavenging for serum fatty acids [23]. Inhibiting 
low- density lipoprotein receptor (LDLR), which 
facilitates cholesterol intake and is associated 
with increased risk of PDAC recurrence, sensi-
tized PDACs to chemotherapy drugs [24]. The 
metabolic importance of macropinocytosis in 
oncogenic KRAS-transformed cancer cells pro-
vides yet another metabolic target worth consid-
ering for therapy. Contradictorily, multiple 
studies have demonstrated that lipids are 
decreased in both cancerous and noncancerous 
regions of PDACs [25, 26].
3  Other Alternative 
Metabolisms in Pancreatic 
Cancer
3.1  MUC1 Overexpression Leads 
to Increased Glucose 
Metabolism
A study by Chaika et al. revealed that the overex-
pression of transmembrane protein mucin 1 
(MUC1) led to elevated glucose metabolism and 
related activities, such as increased glucose 
uptake and lactate production resulting from 
increases in GLUT1 expression and LDHA 
Fig. 2 Oncogenic KRAS affects multiple metabolic pathways that contribute to cancer cell growth. Of note are increased 
macropinocytosis, increased glutamine metabolism, and increased glucose metabolism. This leads to an increase in 
macromolecules that allow cancer cell growth. GOT1 glutamic-oxaloacetic transaminase s1, GLUD1 glutamate dehy-
drogenase 1, GLUT1 glucose transporter 1, MCT4 monocarboxylate transporter 4, LDHA lactate dehydrogenase A
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expression, respectively. These metabolic effects 
are particularly pronounced under hypoxic con-
ditions, which are associated with the stabiliza-
tion of hypoxia-inducible factor 1-alpha 
(HIF-1α), a transcription factor for many genes 
involved in regulating glucose uptake, through 
the overexpression of MUC1 [27]. Pancreatic 
cancer cells that do not overexpress MUC1 have 
a reduction in lactate and glycolytic intermedi-
ates. Overall, the overexpression of MUC1 is 
capable of influencing glucose metabolism, the 
elevation of amino acid metabolism, and the 
TCA cycle, all of which are important in the bio-
synthesis of cellular building blocks, and thus 
leading to tumorigenesis. The signaling pathway 
between MUC1 and HIF-1α plays an important 
role in the facilitation of tumor growth and metas-
tasis, serving as a potential target for manipula-
tion in the treatment of diseases reliant upon 
these proteins [27].
3.2  p53 Functions Predict 
the Sensitivity of Pancreatic 
Cancer Tumors to Glycolytic 
Inhibition
The heterogeneity of metabolic alterations within 
the same cancer type is best illustrated in a study 
of Rajeshkumar et al. They showed that PDAC’s 
sensitivity to the same metabolic inhibition could 
vary drastically from one tumor to another, 
depending on the specific tumor’s genetic status 
and unique metabolic phenotype [28]. More spe-
cifically, they found that responses to LDHA 
inhibition by the small-molecule FX11 [29, 30] 
were determined by the status of a tumor’s p53, a 
tumor-suppressor gene that is largely inactivated 
in many cancers [28, 31]. Within the same PDAC 
type, tumors with wild-type TP53 demonstrated 
resistance to FX11, while those with mutant 
TP53 exhibited sensitivity in the form of 
increased apoptosis, reduced proliferation, and 
attenuated tumor growth. Their data show that 
FX11 specifically decreased pyruvate-to-lactate 
conversion by LDHA only in the TP53-mutant 
tumor, suggesting LDHA inhibition as a possible 
therapeutic target to reduce TP53-mutant tumor 
growth. Resistance in TP53-WT tumors is 
thought to result from reduced dependence on 
glucose, as corroborated by their data showing 
higher levels of TIGAR, a p53-inducible protein 
that lowers glycolytic flux, in these tumors [28, 
32]. This study supports growing evidence for 
variable metabolic phenotypes not only across 
cancer types but also within cancers of the same 
type. From a clinical perspective, this insight 
emphasizes the importance of metabolic pheno-
types in pancreatic cancer sub-characterization in 
order to pair drug therapies according to the phe-
notypic sensitivity for more selective and person-
alized treatment.
3.3  Alternative Source 
of Glutamate in PDAC




In a recent study, Nguyen et  al. found that in 
addition to the utilization of glutamate through 
traditional metabolic pathways, cancer cells 
actively convert glutamate into N-acetyl-aspartyl-
glutamate (NAAG), a metabolite commonly 
known as a neurotransmitter, which can be hydro-
lyzed back to glutamate when needed by the 
oncogenic cells via glutamate carboxypeptidase 
II (GCP II) [33]. They further demonstrated that 
knocking down GCPII expression or inhibiting 
GCPII led to a reduction in PDAC growth, sug-
gesting that GCPII is a viable target for cancer 
therapy, either alone or in combination with 
 glutaminase inhibition.
3.3.2  Glutaminase II Pathway Is 
Another Source of Glutamate 
in Cancer
Pancreatic cancer cells can utilize the conversion of 
glutamine to glutamate via glutaminase 1 (GLS1) 
to fuel their energetic needs [34]. Although inhibi-
tion of GLS1 led to decreased tumor growth and is 
being explored in clinical trials, there is still room 
for improvement. A recent study uncovered that 
pancreatic cancer cells utilized the glutaminase II 
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pathway, an alternative pathway where glutamine 
is converted to alpha-ketoglutaramate, then eventu-
ally glutamate when GLS1 (glutaminase I path-
way) is inhibited [35]. Knocking down glutamine 
transaminase K (GTK) expression, a key enzyme 
in the glutaminase II pathway, was found to inhibit 
the growth of pancreatic cancer cells in vitro. When 
translating to in vivo models, genetic suppression 
of GTK was found to inhibit tumorigenesis. The 
uncovering of the role of the glutaminase II path-
way as a source of the carbon backbone of gluta-
mate upon single-therapy GLS1 inhibition opens 
up new strategic approaches. Specifically, the study 
suggested a combination therapy of GLS1 and 
GTK inhibition for pancreatic cancer therapy.
4  Pancreatic Tumor 
Microenvironment
Pancreatic tumors were found to be hypovascular 
and constantly deprived of nutrients [36], leading 
to these tumors relying on alternative sources of 
nutrients to continue proliferating. The tumor 
microenvironment (TME) [37] was also found to 
be under such intense physical and oxidative stress 
that the interstitial pressures in pancreatic tumors 
induced vascular collapse [38]. This resulted in 
tumor hypoperfusion, limiting oxygen and nutri-
ents, and drug delivery to cancer cells [39], creat-
ing an intratumoral heterogeneity of metabolism 
[40]. Due to this hindrance in nutrient acquisition, 
pancreatic cancer cells must support themselves 
using alternative sources. Part of sustaining tumor 
viability involved the dense stromal components 
that are largely populated by fibroblasts and 
immune cells [41]. Although this dense fibrotic 
stroma metabolically supported pancreatic cancer 
cells, studies have demonstrated that it could actu-
ally restrain cancer progression, likely due to the 
stroma’s role in restraining angiogenesis [42, 43].
4.1  PDACs are Dependent 
on Autophagy
Yang et al. showed that pancreatic cancer cells 
are dependent on autophagy for tumor progres-
sion [44]. They found that suppression of 
autophagy via genetic depletion or pharmaco-
logical inhibition led to tumor regression in vivo 
and suppressed proliferation of multiple PDAC 
cell lines, along with an increase in ROS and a 
decrease in mitochondrial oxidative phosphory-
lation. However, in a recent study, Bryant and 
colleagues found that suppression of oncogenic 
KRAS or mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated kinase 
(ERK) actually increased autophagic flux [45]. 
These results were surprising since it was previ-
ously believed that oncogenic KRAS increased 
autophagy in PDAC [46]. Bryant et  al. also 
found that ERK inhibition sensitizes PDAC to 
chloroquine (CQ), an autophagy inhibitor, and 
decreased tumor cell proliferation and tumor 
growth in vivo. Similar results were obtained in 
a study by Kinsey et  al., who found antitumor 
activity when combining hydroxychloroquine 
(HCQ) with MEK inhibitors [47]. These two 
studies point towards a combined therapy of 
HCQ with downstream KRAS inhibitors, with a 
current clinical trial of HCQ and MEK inhibitor 
combined treatment (NCT03825289) in prog-
ress. It is also worth noting that autophagy plays 
a paradoxical role in PDAC progression, in that 
genetic ablation of autophagy in the pancreas 
resulted in increased tumor initiation but 
impaired the tumor’s ability to develop into inva-
sive cancer [48]. Therefore, more studies into the 
role of autophagy in PDACs are required to bet-
ter understand the clinical complexities of 
PDACs.
4.2  Stromal Interactions Create 
Complex PDAC Metabolic 
Networks
Metabolic networks within tumors can have pro-
found effects on tumor progression and aggression. 
One example includes differences in regions of 
hypoxia and normoxia, where pancreatic  cancer 
cells in hypoxic areas export lactate via monocar-
boxylate transporter 4 (MCT4) and PDAC cells in 
normoxic regions import this lactate via monocar-
boxylate 1 (MCT1) [49]. This increases the prolif-
eration of PDAC cells in normoxic areas of the 
tumor. On the other hand, MCT4 expression has 
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also been shown to promote an immunosuppressive 
environment and is associated with worse patient 
outcomes [50]. While PDAC cells can alter the 
tumor microenvironment to be immunosuppressive, 
PDAC cells can also stimulate stromal cells to 
release nutrients. Specifically, Sousa et  al. found 
that stroma- associated pancreatic-stellate cells 
(PSC) secrete nonessential amino acids via autoph-
agy and are critical for PDAC metabolism [51]. In 
fact, Sousa and colleagues found that alanine out-
performs glucose and glutamine-derived carbon in 
PDAC to fuel TCA cycle intermediates by being 
converted to pyruvate. Other nutrients may also be 
taken up by PDAC cells via exosomes released by 
cancer-associated fibroblasts [52, 53]. Ultimately, 
there appears to be an incredibly complex metabolic 
network within PDAC tumors and the TME.
5  Suggested Therapy (Fig. 3)
Restricting fuel sources for homeostasis and pro-
liferation in PDAC are the new therapeutic ave-
nues for pancreatic cancer treatment [54]. KRAS 
appears to have a prominent role in the metabolic 
rewiring of PDAC tumors and PDAC pathogenesis 
[11]. Subsequently, it requires the cancer cell to 
become dependent on the oncogenic KRAS to con-
tinue proliferation [55]. This is known as onco-
gene addiction, in which the cancer cell becomes 
dependent on the activity of the oncogene for sur-
vival and proliferation [3]. Since KRAS mutations 
are found in a majority of PDAC cancer cells, and 
KRAS regulates cancer cell’s metabolism, target-
ing these regulations for cancer therapy is an 
approach that researchers are taking [55].
5.1  Targeting Alpha- 
Ketoglutarate Dehydrogenase 
Complex Function by CPI-613 
to Slow Mitochondrial 
Metabolism
Drugs have been developed to target mitochon-
drial metabolism in cancers [55]. One of these 
drugs is CPI-613, an inhibitor of cancer-specific 
mitochondrial energy metabolism. The drug 
causes tumor cell apoptosis, necrosis, and 
autophagy by selectively targeting alterations in 
mitochondrial enzyme activities and redox status 
[56]. CPI-613 is a small molecule that attacks 
alpha-ketoglutarate dehydrogenase complex, an 
enzyme complex involved in the TCA cycle, in 
tumor cells through a redox process [57]. The 
drug is known to simultaneously attack multiple 
essential components of tumor cell regulation 
[57]. However, the exact mechanism is not well 
understood. Nevertheless, CPI-613 has been rec-
ognized to be effective against various types of 
cancers [58], including metastatic pancreatic 
cancer [56]. CPI-613 used in combination with 
modified FOLFIRINOX (mFOLFIRINOX) in 
patients with metastatic pancreatic cancer dem-
onstrated better survival. However, since this 
phase I study was not designed to determine the 
efficacy of combining CPI-613 with mFOLFIRI-
NOX, the results should be interpreted with cau-
tion. Nevertheless, Alistar et  al. have obtained 
encouraging results from the phase I study and 
are currently performing a randomized phase III 
trial to compare FOLFIRINOX against mFOL-
FIRINOX with CPI-613 (NCT03504423). These 
results suggest that targeting mitochondrial 
metabolism holds enormous potential in combat-
ing pancreatic cancer.
5.2  Antidiabetic Drug, Metformin, 
Targets Pancreatic Cancer 
Stem Cells
Recent studies have shown that tumorigenic can-
cer stem cells (CSCs), a highly chemoresistant 
subclass of PDAC, are strongly dependent on 
oxidative metabolism [59, 60]. Retrospective 
analysis showed that oral administration of met-
formin in patients with type 2 diabetes was asso-
ciated with a reduced risk of developing PDAC 
[61], along with a better outcome for patients that 
had established PDAC [62]. More recently, it has 
been discovered that metformin targets pancre-
atic CSCs but not the differentiated progenies 
(non-CSCs) [59]. KRAS targeting has resulted in 
tumor shrinkage but failed to kill all the CSCs 
[63]. Viale et al. established that dormant tumor 
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cells that survived oncogene ablation have high 
sensitivity to oxidative phosphorylation inhibi-
tors [63]. Lonardo et al. showed that metformin 
uniformly reduced ATP levels in CSCs, but not in 
non-CSCs [60]. Although the mechanism of 
action for metformin in CSCs is largely unknown, 
what is known is that metformin slowly accumu-
lates in the mitochondria and directly inhibits 
complex 1 (NADH dehydrogenase) in the elec-
tron transport chain, affecting oxidative phos-
phorylation [60]. However, phase II clinical trials 
found no benefit of metformin treatment when it 
is administered to patients with advanced or met-
astatic pancreatic cancers [64, 65]. Although dis-
appointing, there is still evidence to support the 
use of metformin as maintenance therapy in 
patients with stabilized metastatic PDAC [66], 
along with a recently finished clinical trial 
(NCT02048384). In addition, there may be more 
antitumor potential in metformin analogs with 
improved mitochondrial targeting ability [67]. 
Therefore, a potentially strong therapeutic strat-
egy to manage pancreatic cancer is the combined 
targeting of the KRAS pathway and mitochon-
drial respiration [63].
5.3  Combined Therapy to Target 
Pancreatic Metabolism 
Heterogeneity
Combination therapy to target multiple metabolic 
pathways in pancreatic cancer has been demon-
strated as a favorable therapeutic solution. 
Elgogary et  al. found that targeting glutamine 
metabolism using the glutaminase inhibitor bis- 
2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)
ethyl sulfide (BPTES) encapsulated in nanopar-
ticles effectively shrank pancreatic cancer tumor 
size and slowed proliferation [34]. They also 
found, using metabolomics technologies [68], 
that the tumor cells remaining after glutaminase 
inhibition were dependent on glycolysis and gly-
cogen synthesis. Elgogary et  al. continued the 
study by using both BPTES nanoparticles and 
metformin to target both glutamine and glucose 
metabolisms in pancreatic cancer cells. They dis-
covered that the combined therapy provided 
enhanced efficacy that inhibited tumor growth 
significantly more compared to the single treat-
ment of BPTES or metformin alone. This high-
lights the fact that there is great heterogeneity in 
Fig. 3 Overview of therapeutic options targeting pancreatic cancer metabolism. Clinical trials in various stages are 
currently being conducted to determine the efficacy of these therapies. MEK mitogen-activated protein kinase kinase
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pancreatic cell metabolism since targeting only 
glutamine metabolism did not kill all the pancre-
atic cancer cells, but targeting both glutamine and 
glucose metabolisms reduced tumor growth with 
considerably larger efficacy than targeting either 
glutamine or glucose metabolism alone. More 
clinical trials must be done in order to see whether 
combination therapy can assist in pancreatic can-
cer patient survival. BPTES analogs are being 
developed and investigated in glutamine-depen-
dent tumors [34, 69–73].
5.4  Targeting PDACs Based 
on Metabolic Subtype within 
the PDAC Tumor 
Microenvironment
Increasing evidence within the past decade shows 
that PDAC heterogeneity can be characterized by 
the cell’s molecular biology and tumor microen-
vironment. Daemen et al. investigated metabolic 
profiles of PDACs and defined two subtypes: gly-
colytic and lipogenic [74]. The glycolytic sub-
type have elevated gene expression associated 
with glycolysis and PPP, while the lipogenic sub-
type have increased gene expression associated 
with lipogenesis. Daemen et  al. found strong 
associations between the glycolytic subtype with 
a mesenchymal phenotype and the lipogenic sub-
type with an epithelial phenotype. These results 
were consistent with the results of previous 
PDAC classification by Collison et  al. [75]. 
Daemen et al. proposed a model where glycolytic 
(mesenchymal) PDACs favor utilizing glucose 
for glycolysis and lactate production and gluta-
mine for the TCA cycle while lipogenic (epithe-
lial) PDACs favor utilizing glucose for the TCA 
cycle and de novo lipogenesis. Using xenograft 
models, Daemen et al. found that patient-derived 
PDACs characterized as glycolytic were sensitive 
to LDHA knockdown, while those characterized 
as lipogenic were mildly affected, demonstrating 
functionally distinct PDAC subtypes with vary-
ing metabolic inhibition sensitivity [74]. It is 
worth noting that the PDAC subtype classifica-
tion varies depending on what system each group 
utilized [76–78]. However, developing personal-
ized therapies based on patients’ PDAC subtypes 
appears to be a valid strategy as certain treat-
ments appear to be better equipped in treating 
specific PDAC subtypes due to phenotypic 
differences.
5.5  Autophagy Inhibition via 
Hydroxychloroquine
As previously discussed, PDAC cells rely on 
autophagy. The Yang group furthered their study 
by taking the known autophagy inhibitor, 
hydroxychloroquine (HCQ), and demonstrating 
its antitumor effects in a mouse preclinical model 
using patient-derived xenografts [48]. Although 
HCQ has not demonstrated much success as a 
monotherapy [79], surgical outcomes have 
improved with combination therapy of HCQ with 
gemcitabine and nab-paclitaxel as a preoperative 
treatment in PDAC patients (NCT01978184) 
[80]. There may be more promise with the com-
bination therapy of HCQ and MEK inhibitors 
(NCT03825289).
6  Conclusion
Pancreatic ductal adenocarcinoma (PDAC) is the 
fourth leading cause of cancer death in the United 
States and is expected to be the second largest by 
2030 [81, 82]. The deadliness of this disease can 
be attributed to its metabolic heterogeneity, 
which develops through cancerous evolution. 
With that in mind, the investigation of PDAC 
within the past few years has been exponentially 
increasing with improved technologies and 
research methods that allow us to understand 
these intricate mechanisms better. It has also 
become clear that the heterogeneity in PDAC 
metabolism raises questions on how to approach 
new therapies that take into account a personal-
ized approach to a patient’s specific PDAC meta-
bolic characteristics. Exploration of more aspects 
of pancreatic cells enables scientists and clini-
cians to better target multiple facets of pancreatic 
cancer cells, resulting in more effective therapeu-
tic and diagnostic methods.
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• Aberrant metabolic pathways present in breast 
cancer contribute to breast cancer 
heterogeneity.
• Differences in glycolytic upregulation among 
breast cancer subtypes can be attributed to 
GLUT expression.
• Choline metabolism in breast cancer is 
strongly associated with tumor grades.
• Metabolic profiling of breast cancers can be 
used for clinical breast cancer diagnosis and 
prediction of recurrence or metastasis.
• Breast cancer metabolism has heterogeneous 
and adaptive characteristics from a spatial and 
temporal basis.
• Metabolic adaptability confers chemotherapy- 
resistant phenotypes and promotes tumor 
evolution.
1  Introduction
Despite advances in screening, therapy, and sur-
veillance that have improved patient survival 
rates, breast cancer is still the most commonly 
diagnosed cancer and the second leading cause 
of cancer mortality among women [1]. Breast 
cancer is a highly heterogeneous disease rooted 
in a genetic basis, influenced by extrinsic stim-
uli, and reflected in clinical behavior. The diver-
sity of breast cancer hormone receptor status 
and the expression of surface molecules have 
guided therapy decisions for decades; however, 
subtype- specific treatment often yields diverse 
responses due to varying tumor evolution and 
malignant potential. Although the mechanisms 
behind breast cancer heterogeneity is not well 
understood, available evidence suggests that 
studying breast cancer metabolism has the 
potential to provide valuable insights into the 
causes of these variations as well as viable tar-
gets for intervention.
2  Aberrant Metabolic 
Pathways Present in Breast 
Cancer Contribute to Breast 
Cancer Heterogeneity (Fig. 1)
In order to sustain tumorigenic proliferation, can-
cer cells exploit diverse metabolic pathways. The 
diversity of hormone receptors present within 
breast cancer cells is classified into different sub-
types. Breast cancers with hormone-positive 
receptors such as estrogen receptors (ER) and 
progesterone receptors (PR) rely on their respec-
tive hormones for growth. Patients with HER2+ 
breast cancer have overexpression of human epi-
dermal growth factor receptor 2 (HER2). Patients 
negative for all three receptors are considered to 
have triple-negative breast cancer (TNBC)—the 
most heterogeneous molecular profile. This 
diversity, in turn, reflects the different metabolic 
phenotypes of breast cancer. Some of these core 
metabolic aberrations have fundamental effects 
on breast cancer tumorigenicity and offer ratio-
nale behind the aggressiveness of specific sub-
types. Tumor evolution results in the 
reprogramming of cell metabolism in order to 
adapt to support cell proliferation. Specific muta-
tions in oncogenes and tumor-suppressor genes 
are hypothesized to cause metabolic reprogram-
ming within different breast cancer subtypes. 
Although several mutations are commonly seen 
in breast cancers, they appear in various combi-
nations that are reflective of the diverse metabolic 
behaviors of breast cancers. For example, muta-
tions in BRAF, KRAS, and HRAS were found to 
be metabolic regulators of TNBC [2]. These 
genetic alterations are known to regulate gluta-
mine metabolism, which renders cancer cells 
dependent on glutamine for proliferation and sur-
vival [3, 4]. The BRCA1 mutation is a good 
example of how genetic alterations lend to spe-
cific metabolic phenotypes that promote tumori-
genesis. A study by Martinez-Outschoorn et  al. 
showed that loss-of-function mutations in the 
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BRCA1 tumor-suppressor gene resulted in the 
production of hydrogen peroxide and oxidative 
stress in epithelial breast cancer cells and stromal 
fibroblasts [5]. This loss of function also causes 
elevated expression of monocarboxylate trans-
porter 4 (a functional marker of oxidative stress 
and glycolytic activity) to shuttle l-lactate out of 
cells.
Furthermore, the loss of caveolin-1 in 
cancer-associated fibroblasts associated with 
elevated production of reactive oxygen species 
(ROS) and increased glycolysis in stromal 
cells, both of which play a fundamental role in 
tumorigenesis [6]. This encourages therapeutic 
targeting of cancer-associated fibroblasts that 
favor cancer progression [7]. Mutations in 
BRCA1 are marked by high rates of prolifera-
tion and substantial cellular inflammation. This 
study suggests that antioxidant agents present 
promising therapies for BRCA1-mutated 
breast cancer.
2.1  Differences in Glycolytic 
Upregulation Among Breast 




First postulated by Otto Warburg in 1927 [8] and 
firmly established in the literature thereafter, a 
hallmark of cancer malignancy is an upregulation 
in aerobic glycolysis even in the presence of oxy-
gen, known as the Warburg effect [9, 10]. Lactate 
dehydrogenase A, a key enzyme of the Warburg 
effect that catalyzes the conversion of pyruvate to 
lactate, has been a studied target in several can-
cers [11–13]. Breast cancer tumors are no excep-
tion to the Warburg effect; however, there are 
variations in glycolytic rates and metabolite- 
related protein expression among breast cancer 
subtypes that correlate with tumor aggressive-
ness. Previous in vitro studies have first observed 
that the glucose-dependent MCF-7 cell line is 
more sensitive to FX11, a lactate dehydrogenase 
A inhibitor, than the non-glucose- dependent 
MDA-MB-453 cell line [11]. Another in  vitro 
study found that noninvasive breast cancer cell 
lines showed a significantly lower rate of glucose 
intake compared to more aggressive, metastatic 
cells [14]. Higher rates of glucose uptake are 
accompanied by altered gene expression and 
translation of metabolism-related proteins as well. 
Glucose transporter (GLUT) expression has been 
studied extensively in breast cancer. GLUTs are 
integral transmembrane proteins that facilitate 
glucose delivery across the plasma membrane. 
They serve as a rate-limiting step that controls the 
amount of glucose accessible to the cell [15]. 
Studies have shown that different isoforms of 
GLUTs have been detected and/or overexpressed 
in breast cancer cells. Different GLUT expression 
patterns are found to be associated with various 
pathological grades and tumor aggressiveness in 
patient-derived samples. Choi et  al. discovered 
that GLUT1, one of the isoforms of the GLUT 
family, had the highest expression in the TNBC 
subtype and tumors with high histologic grade 
[16]. As a result of increased glucose uptake, the 
increased rate of glycolysis subjects the cell to 
intracellular lactic acidosis—leading to cell death. 
Interestingly, the same group showed that TNBC 
had the highest expression of carbonic anhydrase 
IX, an enzyme that prevents acidosis and provides 
TNBC with an acid-resistant phenotype [16], sug-
gesting that aggressive breast cancer subtypes 
adopt metabolic phenotypes able to suppress 
apoptosis. GLUT1 overexpression has also been 
linked to invasiveness in breast cancer [17].
The link between metabolic reprogramming 
and protein expression offers an adaptive advan-
tage that contributes to a level of aggression spe-
cific to certain subtypes of breast cancer like 
TNBC, making them characteristically resilient 
and harder to treat.
2.2  Choline Metabolism in Breast 
Cancer Is Strongly Associated 
with Tumor Grades
The deregulation of choline metabolism and ele-
vated levels of choline-containing compounds are 
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frequently observed in breast cancer progression 
[18–21]. Choline plays an important role in sup-
plying methyl groups through its metabolism and 
is essential for cellular structure as a precursor of 
phospholipids. Choline metabolism in breast tis-
sue is distributed between two central pathways: 
(1) the biosynthesis of phosphatidylcholine 
(PtdCho) known as the Kennedy pathway and (2) 
the oxidation to betaine, a methyl group donor in 
many methylation reactions. A study by Katz-
Brull et al. revealed that breast cancer cells exhib-
ited a higher choline transport rate compared to 
normal breast cells, and a majority of the choline 
was converted to phosphocholine (Pcho) through 
the Kennedy pathway while around approxi-
mately 25% was oxidized to betaine [19]. 
Although levels of phospholipid- related metabo-
lites are enhanced in most breast cancers [22], sig-
nificantly higher levels of Pcho were found to be 
associated with ER tumors and the more aggres-
sive histologic grade 3 tumors [23]. Because of 
this, choline- containing compounds have often 
been seen as biomarkers for breast tumor malig-
nancy. Oncogenic expression of choline kinase 
(CK), the enzyme responsible for the conversion 
of choline to Pcho, is responsible for elevated lev-
els of Pcho in breast cancer cells [19]. Furthermore, 
CK also showed a strong association with high 
histologic grade and ER− subtypes [24]. For this 
reason, CK is an attractive antitumor target for 
subsequent studies. Whether or not choline 
metabolism represents an agent of disease pro-
gression or merely a marker for transformation 
has still not been defined. CK inhibitors blocking 
choline metabolism have shown promising antitu-
mor results. A study by Rodríguez-González et al. 
discovered that blocking the enzyme had no effect 
on normal cells but disrupted phospholipid pro-
duction in tumor cells—resulting in apoptosis due 
to the accumulation of cytotoxic ceramide, the 
simplest class of sphingolipids [25].
3  Different Roles of Estrogen 
in Estrogen Metabolism 
and ER Binding Promote 
Breast Cancer 
Tumorigenicity
Endogenous estrogens and their metabolism have 
been linked to breast carcinogenesis, especially 
in postmenopausal women [26]. 17b-Estradiol 
(E2), the main estrogen in breast tissue, acts as 
both a ligand for ER and a substrate in metabo-
lism—roles which contribute to estrogen as a 
 carcinogen. The mechanism of estrogen carcino-
genesis is a combination of ER signaling and 
estrogen metabolism.
ERs, when activated, are responsible for the 
mediation of many downstream signaling path-
ways that function as transcription factors pro-
moting cancer development [27]. In addition, ER 
signaling interacts with growth factor receptors 
and other signaling molecules to promote growth 
and anti-apoptotic signals [28]. ER activation has 
also been shown to promote downstream repro-
gramming in choline metabolism, an aberration 
in breast cancer [29].
As a substrate, the metabolism of estrogen 
through the 4-hydroxylation pathway produces 
specific catechol estrogens and estrogen qui-
nones known to be carcinogenic. Estrogen is 
hydroxylated by cytochrome P450 enzymes and 
shuttled into three main pathways depending on 
the three different carbons hydroxylated: C2, C3, 
and C16. The catechol estrogens (2-OH E1, 
2-OH E2, 4-OH E1, 4-OH E2) are either 
 methylated by catechol-O-transferase (COMT), 
thereby reducing their mutational potential, or 
oxidized further to semiquinones or quinones. 
4-OH  catechol estrogen, when oxidized to a 
 reactive estrogen quinone, leads to DNA damage 
by forming unstable DNA adducts between 
 adenine and guanine nucleotides [30, 31]. 
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Mutations caused by this mechanism have the 
potential to initiate breast cancer or increase can-
cer risk. In contrast, metabolites formed through 
the 2-OH pathway form stable DNA adducts and 
are anticarcinogenic—dubbing the 2-OH metab-
olites as “the good estrogen” in some cases [32]. 
Protective mechanisms such as estrogen quinone 
conjugation with glutathione via glutathione 
S-transferase P (GSTP) help lower the risk of 
cancerous mutations by detoxifying the estrogen 
quinones [30]. However, estrogenic imbalances 
lead to competition between the pathway form-
ing the unstable DNA adducts and the detoxifica-
tion of its cancer-promoting substrates [30]. 
Accordingly, hormone therapy for breast cancer 
has targeted ER+ subtypes with drugs such as 
tamoxifen, which acts as a competitive inhibitor 
that prevents estrogen from binding to the 
ER.  Another important class of drugs inhibits 
aromatase, an important rate-limiting enzyme 
that converts androgens to estrogens, to lower 
estrogen levels in the body.
3.1  PHGDH Overexpression 
in Serine Biosynthesis Fuels 
TCA Anaplerosis
Serine biosynthesis is an essential pathway for 
breast cancer progression in specific subsets of 
breast tumors. Using RNAi-based loss-of- 
function screening, Possemato et  al. identified 
phosphoglycerate dehydrogenase (PHGDH) in 
breast cancer with enhanced protein levels in 
70% of aggressive ER− subtypes [33]. PHGDH 
catalyzes the committed-limiting step that oxi-
dizes 3-phosphoglycerate (3PG) to 
3- phosphohydroxypyruvate (3HP) substrates in 
the serine synthesis pathway. Enhanced PHGDH 
expression was associated with increased serine 
synthesis and glutamine uptake. Suppression of 
PHGDH expression led to a significant decrease 
in cell proliferation but did not affect intracellu-
lar serine levels; instead, researchers found a 
resulting drop in phosphoserine aminotransfer-
ase 1 (PSAT1)-dependent alpha-ketoglutarate 
(α-KG), an output of the serine pathway [33]. In 
cancer cells with overexpression of PHGDH, the 
serine synthesis pathway plays an important role 
in tricarboxylic acid (TCA) cycle anaplerosis—
supplying α-KG to support cell proliferation 
[33]. In addition, suppression of PSAT1 and 
phosphoserine phosphatase (PSPH) enzymes 
downstream in the serine pathway inhibits cell 
proliferation in PHGDH-enhanced cell lines as 
well [33]. Subsequent studies have revealed that 
in addition to 3PG oxidation, PHGDH also cata-
lyzes the reduction of α-KG to d-2-hydroxyglu-
tarate (D-2HG) [34], an established 
oncometabolite [35, 36]. D-2HG acted as a com-
petitive inhibitor of α-KG-dependent dioxygen-
ases, resulting in aberrations in histone 
methylation and DNA hypermethylation [37]. 
High levels of D-2HG and N-acetyl-aspartate 
were found to accumulate preferentially in ER− 
and basal-like tumors, which may contribute to 
their aggressive phenotypes [36] in contrast to 
the mixed effects on glioblastoma [38] and other 
cancers. In vitro experiments revealed that accu-
mulation of D-2HG is associated with increased 
cell proliferation and inhibited apoptosis [36]; 
however, the oncogenic effects of D-2HG on 
breast cancer still need to be defined. Because of 
its deregulated expression and oncogenic effects, 
PHGDH is considered a promising target for 
therapy in breast cancers that exhibit PHGDH 
overexpression. Although a preliminary PHGDH 
inhibitor has been recently developed [39], 
PHGDH-targeted therapy is still in its infancy.
Using a novel computational method, Jerby 
et al. contributed further evidence that the meta-
bolic profiles of ER+ and ER− subtypes are vastly 
different [40]. The stoichiometric analysis 
revealed serine metabolism to be coupled with 
glutamine uptake [40]. ER+ tumors exhibit a 
stronger preference for glutamine biosynthesis 
and secretion than ER− tumors [40]. In addition, 
their model identified ER+ phenotypes as having 
more capacity to convert glucose to lactate than 
ER− tumors. Due to higher rates of serine metab-
olism, ER− subtypes are rationalized to prefera-
bly divert 3PG toward serine metabolism via 
PHGDH to exploit alternative pathways for gluta-
minolysis [40]. In addition, a high MYC overex-
pression [41, 42], and low thioredoxin-interacting 
protein expression, an inhibitor of glucose utiliza-
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tion, was found to be a characteristic gene signa-
ture of TNBC and no other subtypes [43].
4  The Clinical Applications 
of Metabolic Profiling
Metabolic profiling has garnered much research 
interest within the past decade [44]. Although the 
mechanisms behind breast cancer transformation 
have not been firmly established, changes in 
tumor evolution have been investigated through 
metabolic variation. The exploitation of these 
metabolic signatures has the potential to improve 
clinical results through diagnosis confirmation, 
early detection, and prediction of disease pro-
gression [45, 46] (Fig. 2).
4.1  Breast Cancer Diagnosis 
and Subtyping Using 
Metabolomics
Studies have used metabolic profiling for the 
general diagnosis of breast cancer—using differ-
ent techniques to build prediction models that 
distinguish specific metabolic fingerprints of 
breast cancer hormone receptor status, histologic 
grade, and axillary lymphatic spread [47–49]. 
Jove et al. used a combination of random forest 
classification and multivariate statistics to iden-
tify combinations of metabolites that were used 
to distinguish breast cancer plasma samples from 
healthy control samples [47]. On the other hand, 
Huang et al. sought out a model more tolerant of 
breast cancer heterogeneity by following meta-
bolic pathways rather than metabolite-based bio-
markers for early diagnosis of breast cancer [48]. 
Other studies have used metabolic profiling to 
build models to distinguish breast cancer stages 
[49] and levels of malignancy [50].
4.2  Metabolic Profiling 
as a Strategy for Prediction 
of Recurrence in Breast Cancer
Recurrence after initial therapy causes significant 
morbidity and mortality in breast cancer patients. 
Current methods for detecting recurrences such 
as medical imaging and serum tumor markers are 
not considered specific enough to be routinely 
recommended; therefore, there is still much room 
for improvement. A combination of nuclear mag-
netic resonance (NMR) and mass spectroscopy 
(MS) analysis and multivariate statistics on 
patient serum samples has been used to explore 
potential metabolic profiles sensitive to cancer 
recurrence [51]. Asiago et al. developed a predic-
tion model built upon 11 biomarkers that cor-
rectly detected 55% of patients with breast cancer 
recurrence an average of 13 months prior to their 
clinical diagnosis using serum samples [51]. 
Although there is vast room for improvement on 
Fig. 2 The potential clinical applications of metabolic profiling for breast cancer using patient tumor, plasma, and 
serum samples
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more specific and accurate models for early 
detection of recurrence, metabolic profiling of 
serum can be viewed as a promising noninvasive 
method for breast cancer surveillance.
4.3  Metabolic Fingerprinting 
in Breast Cancer Metastasis
Oakman et  al. identified a preliminary metabolic 
fingerprint from patient serum samples that detected 
early and metastatic disease in breast cancer 
patients. In their study, higher levels of phenylala-
nine, glucose, proline, lysine, and N-acetyl cysteine 
and lower levels of lipids contributed to the meta-
bolic profile of metastatic individuals [52]. Jobard 
et al. used similar serum NMR analysis to identify 
metabolic profiles between localized and metastatic 
breast cancer. They found eight statistically signifi-
cant elevations of metabolite biomarkers in meta-
static disease: histidine, acetoacetate, glycerol, 
pyruvate, N-acetyl glycoproteins, mannose, gluta-
mate, and phenylalanine [53]. Although there are 
differences in biomarkers between the two studies, 
it is notable that the same trends of variation in glu-
cose concentration and lowered lipid levels were 
seen between early and metastatic breast cancer 
[53]. Defining an accurate metabolic fingerprint 
specific across all metastatic breast cancers is a 
challenge due to the variability and high mutational 
load of metastatic disease. Under changing tumor 
microenvironments [54], metastatic breast cancer 
cells readily switch between glycolysis and oxida-
tive phosphorylation [55]. The metabolic plasticity 
of metastatic breast cancer may contribute to the 
inconsistencies of biomarkers across different 
tumors. However, studies attempting to identify 
these metabolic patterns provide great insights into 
the general characteristics of advanced diseases.
4.4  Prediction of Response 
to Therapy Based 
on Metabolic Phenotypes
Metabolic fingerprinting has also been used to 
predict responses to therapy and drug resistance. 
Using a combination of NMR and liquid 
chromatography- mass spectrometry (LC-MS), 
Wei et  al. were able to identify four altered 
metabolites (threonine, glutamine, isoleucine, 
and linolenic acid) as indicators of adjuvant che-
motherapy response within breast cancer [56]. A 
prediction model derived from these metabolic 
markers was able to distinguish between com-
plete, partial, and no tumor response to chemo-
therapy in a neoadjuvant setting using patient 
samples [56]. The model was able to correctly 
identify 80% of patients whose tumors did not 
show a complete pathologic response to chemo-
therapy [56]. Collectively, these studies highlight 
the potential impact of metabolic profiling on the 
integration of metabolomics into clinical prac-
tice. Further advancements in profiling could 
improve diagnosis and early detection or at least 
offer confirmation in the treatment of breast can-
cer quickly and at low cost. Although most of the 
prediction models and metabolic phenotypes pre-
sented in these studies are in their preliminary 
stages, improvements could make way for more 
individualized treatments specific to each patient.
5  Additional Perspectives 
on Breast Cancer 
Heterogeneity
5.1  Spatial Pathogenesis 
Observed in Breast Cancer 
Metabolism
Metabolic heterogeneity within a single tumor 
adds another layer of complexity when trying to 
understand the dynamic processes of breast cancer 
metabolism [57]. Several studies have identified 
metabolic distinctions between breast tumor 
periphery and center. A study by Xu et al. analyzed 
the mitochondrial redox states of breast cancer 
xenografts of varying aggressiveness. In general, 
the researchers found more oxidized metabolic 
states in central regions and more reduced states in 
peripheral regions of the tumors [58]. The tumors 
also exhibited higher glucose uptake and NADH 
levels in tumor peripheries compared to the cen-
ters [58]. The authors presumed this was due to 
higher substrate availability at the peripheries 
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from the tumor microenvironment. Furthermore, 
higher degrees of metabolic heterogeneity were 
consistently observed in larger and higher staged 
tumors [58, 59]. When comparing metabolic pro-
files of clinical breast tumor samples, studies have 
observed higher levels of Pcho and phosphoetha-
nolamine in the tumor core compared to tumor 
periphery [60]. Lactate and pyruvate were 
observed in higher levels in the tumor periphery 
compared to the tumor core [61]. Because the 
tumor periphery has direct interactions with the 
tumor microenvironment compared to the center, 
the differences in inputs translate into differences 
in metabolic phenotypes. In normal breast anat-
omy, the epithelia receive similar concentrations 
of oxygen, growth factors, and nutrients. The ana-
tomic disorganization caused by breast cancer 
pathology alters the tumor microenvironment and 
intratumoral metabolism [57, 62]. It is unclear 
whether these observed differences are solely due 
to extrinsic inputs, genetic manifestations, or per-
haps an interplay between both.
5.2  Temporal Pathogenesis 
Observed in Breast Cancer 
Metabolism: Metabolic 
Differences Between Early 
Stage and Advanced Stage
Temporal pathogenesis refers to tumor progres-
sion over time, starting from a single cancer cell to 
the formation of a primary tumor and then meta-
static spread. The epithelial-to- mesenchymal tran-
sition (EMT) is one of the prerequisites of early 
metastasis. It describes the transition in which epi-
thelial cells lose their polarity and cell adhesions 
to become mesenchymal cells with migratory 
properties. Cancer cells detach from their extracel-
lular matrix (ECM) when they decide to metasta-
size. It has been shown in  vivo that mammary 
epithelial cells with lost ECM attachment are 
unable to survive due to ATP deficiency from glu-
cose deprivation [63]. ECM detachment is also 
accompanied by increased ROS [63, 64]. 
Overexpression of the HER2 oncogene rescued 
these cells by restoring glucose uptake and reduc-
ing ROS through the oxidative pentose phosphate 
pathway (PPP) [63]. Nicotinamide adenine dinu-
cleotide phosphate (NADPH), a product of the 
PPP, serves as a reducing agent able to combat oxi-
dative stress. The study by Schafer et  al. also 
showed that the treatment of antioxidants alone 
was able to rescue matrix- detached cells—identi-
fying oxidative resistance as an important property 
needed for metastatic migration [63]. Once cancer 
cells detach from the ECM, they will need to sur-
vive the journey in the oxidizing bloodstream. 
Many cells will undergo apoptosis in this environ-
ment, but the cells that acquire oxidative resistance 
have the adaptive advantage to metastasize. 
Although aerobic glycolysis is the most well-
known hallmark of cancer metabolism [10], 
research has also identified the importance of oxi-
dative phosphorylation in cancer progression as 
well [65]. Increased  mitochondrial biogenesis and 
respiration have been observed in cancer cell 
metastases through the modulation of peroxisome 
proliferation-activated receptor gamma coactiva-
tor-1a (PGC-1a)—a regulator of mitochondrial 
biogenesis and energy metabolism [66]. This is 
corroborated by the correlation between PGC-1a 
expression and formation of distant metastasis 
from patient breast tumors and breast cancer cell 
lines [66]. These changes in metabolic phenotype 
seen in migrating breast cancer cells are examples 
that highlight the importance of metabolic plastic-
ity for cancer progression.
5.3  Metabolic Heterogeneity 
Influences Effective Breast 
Cancer Drug Treatment
In silico modeling of tumor progression by 
Robertson-Tessi et al. proposed that early stages 
of tumor growth have a stratified composition. 
Tumor centers have higher glycolytic activity 
and are, therefore, more aggressive compared to 
the periphery [67]. It is argued that cancer treat-
ments should decrease or slow selective pres-
sures in cells through the maintenance of less 
aggressive cancer cells within a tumor rather 
than aiming for eradication [67, 68]. This con-
cept is demonstrated in the antiangiogenic treat-
ment of breast cancer. Antiangiogenic therapies 
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aim to starve cancer cells of oxygen and nutri-
ents by inhibiting tumor vascularization, creat-
ing pockets of intratumoral hypoxia. Cutting off 
nutrient supply in this way may be effective in 
stopping cancer cell growth, but it may also 
select for cells that are able to alter metabolism 
to adapt to hypoxic conditions [54], resulting in 
a drug-resistant phenotype. Although antiangio-
genic therapies in breast cancer patients have 
been able to lengthen progression- free survival, 
data has shown that it does little to improve over-
all patient survival [69]. Aggressive relapse and 
enhanced metastasis in treated patients are not 
uncommon either [70]. Conley et al. were able to 
show that breast cancer xenografts, when treated 
with antiangiogenic drugs, developed hypoxia-
driven cancer stem cell stimulation, which pro-
moted tumorigenesis—opposite to the intended 
effect [70]. It would seem that the goal of che-
motherapy is to halt tumorigenesis and shrink 
existing tumor populations as quickly and effec-
tively as possible by delivering the drug at the 
highest dosage allowed. This objective, however, 
is a double-edged sword: if treatment is too 
aggressive, it puts selective pressure on the cells 
to enhance drug- resistant phenotypes that, in 
turn, escalate cancer progression. The adaptive 
nature of cancer metabolism is a significant 
obstacle for creating effective drug therapies. An 
effective treatment aims to find the delicate bal-
ance of delivering maximum cytotoxic effects 
while avoiding selective resistance.
6  Conclusion
Metabolomics serves as an essential utility in breast 
cancer research by offering a perspective that rep-
resents the net interactions between the tumor, the 
host, and the environment and within the tumor 
itself. The metabolic nuances across different 
breast cancer subtypes and treatment timelines can 
be taken advantage of when thinking about poten-
tial prognostic markers, prediction models, and 
mechanisms involved with breast cancer. Metabolic 
heterogeneity in breast cancer can be seen within a 
single tumor and in the different stages of the 
tumor’s progression (Fig. 3). Understanding these 
dynamic processes and applying them to drug dis-
covery and clinical practice have the potential to 
improve the lives of not only breast cancer patients 












Fig. 3 Summary of the different levels of metabolic heterogeneity seen in breast cancer. Metabolic heterogeneity is 
demonstrated between molecular subtypes of breast cancer, between tumor core and periphery, in different stages of 
cancer progression, and in response to selective pressures from clinical treatment
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Key Points
• Aggressive lymphomas exhibit the Warburg 
effect.
• Lactic acidosis is a result of the overproduc-
tion of lactate and leads to a fatal prognosis.
• Mutation of p53 helps cancer cells survive 
glutamine deprivation.
• PI3K regulates fatty acid synthesis (FAS) in 
primary effusion lymphoma (PEL) and other 
B-NHLs.
• AMPK regulates NADPH balance for fatty 
acid oxidation (FAO) to supplement the TCA 
cycle.
• PRPS2 couples protein and nucleotide biosyn-
thesis to drive lymphomagenesis.
• mTOR activation promotes fatty acid synthe-
sis (FAS).
• MYC regulates cancer cell metabolism under 
glucose-deprived and hypoxic conditions.
• HIF-1 acts as a regulator in hypoxia adaption 
and the related metabolic changes.
• Knowledge of metabolic phenotypes in cancer 
can be used in tandem with genetic alterations 
to develop effective treatment strategies.
• [18F]FDG PET/CT is a valuable tool to visual-
ize tumor glycolytic activity and characterize 
metabolic heterogeneity.
1  Introduction
Non-Hodgkin lymphomas (NHLs) are a hetero-
geneous group of lymphoid neoplasms with dif-
ferent biological characteristics. About 90% of 
all lymphomas in the United States originate 
from B lymphocytes, while the remaining 
 originate from T cells [1]. The treatment of NHLs 
depends on the neoplastic histology and stage of 
the tumor, which will indicate whether  radiotherapy, 
chemotherapy, or a combination is the best suit-
able treatment [2]. The American Cancer Society 
describes the staging of lymphoma as follows: 
Stage I is lymphoma in a single node or area. 
Stage II is when that lymphoma has spread to 
another node or organ tissue. Stage III is when it 
has spread to lymph nodes on two sides of the 
diaphragm. Stage IV is when cancer has signifi-
cantly spread to organs outside the lymph sys-
tem. Radiation therapy is the traditional 
therapeutic route for localized follicular and 
mucosa-associated lymphomas. Chemotherapy 
is utilized for the treatment of large-cell lympho-
mas and high-grade lymphomas [2]. However, 
the treatment of indolent lymphomas remains 
problematic as the patients often have metastasis, 
for which no standard approach exists [2].
Follicular lymphoma (FL), a form of non- 
Hodgkin lymphoma, is the second most common 
form of B-cell lymphoma and remains incurable 
in the majority of cases, despite recent advances, 
including anti-CD20 antibodies (rituximab) and 
kinase inhibitors (ibrutinib) [3]. Following an 
indolent phase, 50% of patients suffer from dis-
ease transformation to an aggressive form of 
lymphoma (transformed FL; tFL) [4]. This dra-
matic switch in disease behavior typically culmi-
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nates in rapid deterioration and is usually fatal. 
Accordingly, much effort has been focused on 
understanding the genetics of transformation, 
which has resulted in the identification of key 
genetic lesions (e.g., MYC activation, loss of p53, 
activation of nuclear factor kappa-light-chain- 
enhancer of activated B cells (NF-κB), loss of 
tumor necrosis factor-alpha-induced protein 3 
A20 (TNFAIP3/A20)) [5–8]. However, exactly 
how tumor metabolism, which is altered by these 
genetic lesions, contributes to disease aggressive-
ness is not known. Therefore, the metabolic 
changes that occur during FL transformation are 
poorly understood. We need to understand the 
biological and metabolic changes upon disease 
transformation in order to develop effective treat-
ment strategies.
Malignant cells have metabolic adaptations 
supporting bioenergetics, biosynthesis, and redox 
homeostasis in response to the development of 
the tumor microenvironment [9]. Metabolic het-
erogeneity is present in the tumor microenviron-
ment, where concentrations of key resources can 
be spatially (localization) and temporally (stage 
of the diseases) varied [10], creating the hetero-
geneity of metabolism within the same tumor 
[11]. Cancer metabolism is influenced by tumor 
localization and vascularization status. Cancer 
cells can uptake nutrients and oxygen from the 
blood supply, which results in the production of 
ATP via aerobic oxidative phosphorylation 
(OXPHOS) as well as through anabolic path-
ways, supporting rapid cell proliferation.
In this chapter, we describe the intricacies of 
NHLs’ metabolism resulting from alterations in 
gene expressions, which subsequently lead to 
poor prognosis. Furthermore, we explore how 
metabolomics technologies [12] and analysis can 
be applied to treatment strategies.
2  Lymphoma Metabolism 
Exhibits Multifaceted 
Characteristic Features 
Which Are Correlated to Poor 
Prognosis
2.1  Aggressive Lymphomas 
Exhibit the Warburg Effect
As described in the previous chapters, the drastic 
increase in glucose uptake of cancer cells is a fea-
ture of the distinctive metabolic rewiring known as 
the Warburg effect [13]. Recently, researchers 
have taken advantage of this metabolic shift to 
clinically detect localized glucose uptake of can-
cer cells using 18F-fluorodeoxyglucose positron- 
emission tomography ([18F]FDG PET). High-grade 
NHL patients and intermediate-grade NHL 
patients with poor prognoses showed a high accu-
mulation of [18F]FDG in their tumors [14, 15].
Primary effusion lymphoma (PEL) exhibits 
high glycolytic activity due to its hypoxic envi-
ronment. This form of lymphoma requires 
aggressive treatment, but no standard therapy 
exists [16]. PEL is, however, highly sensitive to 
glucose withdrawal and glycolysis inhibitors, 
such as 2-deoxyglucose (2-DG) [16]. In this situ-
ation, the distinctive metabolic phenotype, glu-
cose dependency, offers hope for effective 
treatments.
Cancer cells exhibiting the Warburg effect 
avidly take up glucose. After glucose uptake, 
cancer cells favor the conversion of glucose- 
derived pyruvate to lactate. Recent reports 
showed that NHL patients had elevated plasma 
lactate and lactate dehydrogenase (LDH) levels, 
which were linked to poor survival rates [17–19]. 
Furthermore, inhibition of LDHA, the enzyme 
that catalyzes the conversion of pyruvate to 
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 lactate, has yielded positive results in tumor 
reduction in a MYC-transformed Burkitt lym-
phoma model in  vivo [20, 21]. Taken together, 
the characteristic metabolic features of the 
Warburg effect offer diagnostic tools as well as 
relevant therapeutic targets for NHL.
2.2  Lactic Acidosis Is a Result 
of Overproduction of Lactate 
and Leads to a Fatal Prognosis
Following the Warburg effect, lactic acidosis can 
occur when lactate homeostasis is dispropor-
tioned, due to overproduction and/or underuti-
lization. Lactic acidosis is divided into two 
categories: type A and type B.  Type A results 
from poor oxygenation in the tissue. Type B 
occurs in normoxic tissue as a result of a drug or 
toxin [22]. Type B lactic acidosis is the result of 
the alteration of glycolytic processes and their 
effects on redox [23, 24]. Type B lactic acidosis 
is present in many human malignancies, but nota-
bly in lymphomas and leukemias [22, 23, 25–27]. 
Once cancers exhibit type B lactic acidosis, these 
cases show poor prognoses and outcomes if not 
immediately treated [22].
Another notable cause of lactic acidosis is 
thiamine deficiency, an observable characteristic 
connected to type B lactic acidosis in some can-
cers. Thiamine is a cofactor that is necessary for 
the conversion of pyruvate into acetyl-CoA via 
pyruvate dehydrogenase. When malignant cells 
exhibit thiamine deficiency, pyruvate is heavily 
converted to lactate [28, 29]. Subsequently, thia-
mine deficiency leads to lactic acidosis (Fig. 1).
3  Genetic Alterations Lead 
to Different Metabolic 
Phenotypes in NHL (Fig. 2)
NHLs often have abnormal activation of the 
mammalian target of rapamycin complex 1 
(mTORC1) that reprograms multiple metabolic 
pathways, including nucleotide synthesis, amino 
acid synthesis, fatty acid synthesis, and 
glutaminolysis. Additionally, MYC is another 
important trigger for inducing many genes 
correlated with anabolic growth, including 
transporters and enzymes involved in glycolysis, 
mitochondrial biogenesis, fatty acid synthesis, 
and glutaminolysis [30–34]. MYC is a gene 
involved in cellular proliferation whose 
dysregulation was found in B-cell lymphomas 
[35]. Metabolic reprograming by transcription 
factors such as MYC and hypoxia-inducible 
factor 1 (HIF-1) in malignant tissues allows them 
to better survive the tumor microenvironmental 
alterations. These various genes can often 
influence each other; for instance, mTOR can 
also activate HIF-1 expression even under 
normoxic states [36] (Table 1).
3.1  Mutation of p53 Helps Cancer 
Cells Survive Glutamine 
Deprivation
As described in a previous chapter, many cancers 
depend on glutamine for bioenergy, redox 
homeostasis, and DNA synthesis, which are 
essential requirements for cancer cell survival. 
Therapeutic strategies often target cancer’s gluta-
mine dependency [37]. However, these treat-
ments do not always have the intended impact, as 
many cancers are resistant to treatment. One such 
example is that of TP53, a protein responsible for 
tumor suppression, and its mutant form [38]. 
Specifically, in lymphoma cell lines, Tran et al. 
reported that mutp53 proteins could directly bind 
to the promoters of p53 target genes that regulate 
the cell cycle, which leads to cell cycle arrest and 
helps cancer cells survive in glutamine depriva-
tion conditions [38]. Cancer cells expressing 
mutp53 proteins are able to survive the metabolic 
stress of glutamine deprivation in poorly vascu-
larized tumor microenvironments, whereas 
p53-deficient cells and wtp53-expressing cells 
experience impaired proliferation and increased 
cell death [38]. The resistance to glutamine depri-
vation in mutp53-expressing malignant cells 
allows these cells to survive in metabolically 
restrictive environments.
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3.2  PI3K Regulates Fatty Acid 
Synthesis (FAS) in Primary 
Effusion Lymphoma (PEL) 
and Other B-NHLs
While many lymphomas rely on glucose to pro-
duce lactate and energize their metabolism, this 
is not always the case. Dysregulation of cell 
metabolism in primary effusion lymphoma 
(PEL), an aggressive type of B-cell lymphoma, 
increased not only aerobic glycolysis but also 
fatty acid synthesis [39, 40]. By using 14C-labeled 
glucose, Bhatt et  al. showed that PEL created 
more lipids from glucose compared to primary B 
cells. Furthermore, these cells were sensitive to 
both an inhibitor of fatty acid synthase, C75, and 
an inhibitor of glycolysis, 2-DG. Each of these 
inhibitors affected both glycolysis and fatty acid 
synthesis (FAS) [39]. Bhatt et al. showed a sig-
nificant difference in the metabolic profiles of 
primary B cells and those of human B-cell non-
Hodgkin lymphomas (B-NHL), including 
PEL.  Poor-prognosis PEL and other B-NHLs 
exhibit high levels of aerobic glycolysis and FAS. 
This suggests that different types of malignant 
lymphomas can be distinguished by the rate of 
fatty acid biosynthesis, which may have the 
potential for targeted therapy against these 
aggressive lymphomas [39].
Previous work of Bhatt et  al. and others 
showed that PEL cells exhibit high activities of 
phosphatidylinositol 3-kinase (PI3K), protein 
kinase B (AKT), and mTOR, genes related to 
proliferation and survival as well as glycolysis 
Fig. 1 The effect of thiamine on lactate and acetyl-CoA production. Some cancer cells produce lactate even in the pres-
ence of oxygen, an effect known as the Warburg effect. Lactic acidosis can result from unregulated lactic acid (lactate) 
buildup. When thiamine is present, there is a mixture of lactate and acetyl-CoA (left). When thiamine is deficient, ace-
tyl-CoA production is impaired, and pyruvate is mainly converted to lactate resulting in lactate buildup (right)
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[41–43]. In their more recent work, they showed 
that inhibiting PI3K by LY294002 decreased not 
only glycolytic flux but also the incorporation of 
14C glucose into lipids [39].
In summary, glucose was important to PEL 
cells for providing not only energy but also 
 acetyl-CoA for lipid synthesis. This illustrates 
that lymphoma’s metabolism is complex and can 
exhibit multidimensional alterations.
3.3  AMPK Regulates NADPH 
Balance for Fatty Acid 
Oxidation (FAO) as a Means 
of Supplementing 
the Tricarboxylic Acid (TCA) 
Cycle
Jeon et  al. showed that AMPK orchestrates 
NADPH consumption (by FAS) and production 
(from fatty acid oxidation (FAO)) in lymphoma 
to support ATP synthesis, redox-homeostasis, 
and biosynthesis under low-glucose 
 environments [44]. By doing so, AMPK 
decreases pentose phosphate pathway activity 




Fig. 2 Genetic 
alterations lead to 
different metabolic 
phenotypes in non- 
Hopkin lymphoma. 
Various lymphomas 
show these alterations in 
gene expression and the 
resulting changes in 
metabolism
Table 1 Genetic alterations lead to different metabolic 
phenotypes in NHL
Gene Metabolic effect Lymphoma type
Mutant 
TP53
Allows cells to survive 
glutamine deprivation
B- and T-cell 
lymphoma
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Diffuse large B-cell lymphoma (DLBCL), a 
common lymphoma, utilizes FAO to support 
energy production and growth [45]. Fatty acids 
provide fuel for oxidative phosphorylation 
(OXPHOS), and to increase glutathione levels, 
and attenuate oxidative stress [45]. The DLBCL 
with OXPHOS is aggressive and resistant to ibru-
tinib, an inhibitor of B-cell receptor (BCR) sur-
vival signaling [46, 47]. More research into the 
combination of fatty acid oxidation-targeting 
drugs and the BCR inhibitor could provide poten-
tial therapeutic approaches for patients with 
DLBCL [45–48].
3.4  PRPS2 Couples Protein 
and Nucleotide Biosynthesis 
to Drive Lymphomagenesis
One of the current mainstay chemotherapeutic 
strategies involves targeting one-carbon metabo-
lism in malignant cancers. This strategy reduces 
the production of nucleotides and ATP, as well as 
alters redox homeostasis. Individual drugs often 
inhibit the metabolism of folate, nucleotides, 
and, most notably, thymidine [48, 49]. Key 
enzyme targets of nucleic acid synthesis include 
dihydrofolate reductase, thymidylate synthase, 
adenine/adenosine deaminase, and DNA poly-
merase/ribonucleotide reductase [48–51]. As 
indicated by Cunningham et al., nucleotide bio-
synthesis is coupled to protein biosynthesis by a 
critical enzyme, phosphoribosyl-pyrophosphate 
synthetase 2 (PRPS2), which specifically pro-
motes increased nucleotide biosynthesis in MYC- 
driven lymphoma. In these lymphomas, PRPS2 
may be an effective anticancer target, and other 
enzymes in this pathway utilized by oncogenes 
may also exist as potential targets [52].
3.5  mTOR Activation Promotes 
Fatty Acid Synthesis (FAS)
mTOR activation during nutrient abundance 
enhances aerobic glycolysis and lipid synthesis, 
which is mediated by the sterol regulatory 
element- binding protein (SREBP) group by 
inducing the transcription of the fatty acid- 
synthesizing enzyme (FASN) [53]. FASN is pres-
ent at elevated levels in the liver and at lower 
levels in other tissues, but cancerous tissues 
express excessive FASN, which has been identi-
fied as a metabolic oncogene [40, 54–56].
In PEL, rapamycin treatment improves sur-
vival time in the in vivo model by inhibiting auto-
crine signaling and vascular endothelial growth 
factor (VEGF) [43, 57]. On the other hand, 
Shestov et  al. revealed that inhibition of mTOR 
has an impact on the flux of glycolysis, pentose 
phosphate pathway, and TCA cycle [58]. Thus, 
while mTOR activation is linked to FAS, inhibi-
tion of mTOR can impact other metabolic path-
ways critical to cancer growth.
3.6  MYC Regulates Cancer Cell 
Metabolism under Glucose- 
Deprived and Hypoxic 
Conditions
MYC is considered to be a regulator in glycolysis 
and mitochondrial respiration [33, 34, 59–63]. 
Using stable isotope-resolved metabolomics [12], 
Le et  al. explored the metabolic alterations that 
occur in the oncogenic transcription factor 
c-MYC-inducible human Burkitt lymphoma 
model P493 cell line under aerobic and hypoxic 
conditions as well as glucose deprivation. They 
found the coexistence of oxidative and aerobic 
glycolysis. They also documented the prominent 
contribution of glutamine to the TCA cycle of 
proliferating cells and that hypoxic cancer cells 
continue to oxidize glutamine for cell growth and 
survival. Furthermore, this study showed that glu-
tamine metabolism alone could sustain the TCA 
cycle for cell survival and growth in the absence 
of glucose [64]. This glucose- independent path-
way reflects the dependence of cancer cells on 
metabolic reprogramming, allowing for the sur-
vival and proliferation of cancer cells under the 
harsh hypoxic and nutrient- deprived conditions of 
the tumor  microenvironment. Their study 
 demonstrated that inhibition of glutaminase, the 
enzyme that catalyzes the reaction of glutamine to 
glutamate, by BPTES, impaired MYC-transformed 
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B lymphoma growth in vivo [64]. Other glutamin-
ase inhibitors, such as BPTES analogs, have been 
developed to target glutamine metabolism in can-
cers [65].
MYC also regulates proline metabolism, as 
found by Liu et al. [66]. They found that proline 
dehydrogenase (POX/PRODH), the first enzyme 
in proline catabolism, was suppressed by MYC 
through upregulating miR-23b*. This study pro-
vided a deeper understanding of cancer metabo-
lism while enabling the development of novel 
therapeutic strategies.




HIF-1 activity is enhanced by mTOR-altered 
metabolism and promotes glycolysis as a 
hypoxia-adaptive transcriptional program. The 
HIF-1 and HIF-2 heterodimers respond to and 
are stabilized by hypoxia, resulting in metabolic 
changes [67]. Of these two heterodimers, HIF-1 
is a critical component involved in tumor metab-
olism that upregulates glucose transporters, gly-
colytic enzymes, and pyruvate dehydrogenase 
kinase, isozyme 1 (PDK1), an enzyme which pre-
vents pyruvate from entering the TCA cycle [36]. 
Qiao et al. demonstrated that malignant lympho-
mas exhibit constitutive expression of HIF-1α. 
This expression is mediated by NF-κB, and ion-
izing radiation treatment of lymphoma showed 
increased NF-κB activation and elevated HIF-1α 
levels. This indicates that additional treatment 
targeting HIF-1α in combination with radiation 
therapy of lymphoma cells could potentially 
improve patient outcomes [68].
3.8  Understanding the PI3K/AKT/
mTOR Pathway in Lymphoma 
Can Lead to a Variety 
of Treatments
Thus far, we have discussed how metabolic anal-
ysis has-improved-our-understanding-of NHL 
metabolism. In some cases, the genetic altera-
tions that lead to unique metabolic phenotypes, 
such as those discussed in Sect. 3, have been tar-
geted for therapy and have resulted in clinical 
 trials. Additionally, other tools such as [18F]FDG 
PET/computed tomography (CT). can help gauge 
the lymphoma metabolism to inform therapy and 
predict outcomes.
Sections 3.2 and 3.5 of this chapter have high-
lighted how PI3K and mTOR play key roles in 
controlling lymphoma metabolism. Due to the 
importance of the PI3K/AKT/mTOR pathway, 
targeting this pathway has already begun to show 
promising results in the treatment of different 
lymphoma types. For instance, in a 220-patient 
study of chronic lymphocytic leukemia (CLL), 
dual therapy with both idelalisib, a PI3Kδ 
 inhibitor, and rituximab, an established CD20 
antibody commonly used against many lympho-
mas, improved the rate of progression-free sur-
vival (PFS) from 46% to 93% compared to 
monotherapy with rituximab alone [69].
However, in clinical studies, sometimes a less 
straightforward approach may be required for 
treatment due to unforeseen pathway changes. 
For instance, the PI3K/AKT/mTOR pathway is 
thought to play a role in refractory mantle cell 
lymphoma (MCL) resistance to ibrutinib [70–
72]. As such, one may logically reason that PI3K/
AKT/mTOR inhibitors would be a potential 
therapy for refractory MCL. However, the use of 
the PI3K inhibitor idelalisib and the rapamycin 
analog temsirolimus has provided underwhelm-
ing clinical outcomes [70, 73–75]. To explain this 
ineffective treatment, consider a study by Garcia 
et  al. focusing on multidrug resistance (MDR), 
which coincided with an upregulated PI3K/AKT 
pathway. In this study, inhibition of PI3K via 
wortmannin and LY294002 induced cell death, 
but also coincided with the activation of NF-κB, 
which can promote cell survival, thus mitigating 
the effect of PI3K-targeting treatment [76]. 
Zhang et  al. postulate that understanding the 
 metabolic reprogramming coincident with 
genetic alterations will be critical to a successful 
treatment approach. They identified a strong reli-
ance on OXPHOS in refractory MCL, and subse-
quent treatment with IACS-010759, a clinically 
relevant inhibitor of complex 1 of the electron 
transport chain (ETC), yielded more promising 
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results [70]. Additionally, glutamine uptake was 
also upregulated, and treatment with amino- 
oxyacetate, which inhibits glutaminolysis, 
induced ROS formation and oxidative stress [70]. 
Thus, knowledge about both the genetic 
 alterations and the metabolic shifts is key to 
developing effective treatment strategies.




4.1  [18F]FDG PET/CT
Regions of the body exhibiting elevated levels of 
glycolysis, such as many tumors, will show accu-
mulation of the [18F]FDG as assessed by PET/
CT.  Various metabolic parameters can be 
 determined and used to diagnose a particular 
lymphoma case. The most frequently measured 
parameter is the standardized uptake value 
(SUV). The mean SUV and the max SUV are 
also useful parameters [77]. From the SUV, the 
metabolic tumor volume (MTV) and total lesion 
glycolysis (TLG) can be determined. MTV is the 
volume of the tumor that is metabolically active 
and is also sometimes referred to as total meta-
bolic tumor volume (TMTV) when distinct 
regions are totaled. TLG is a dimensionless index 
rating the average glycolysis activity for the 
entire tumor and calculated by multiplying the 
mean SUV by the MTV [77, 78]. Additionally, 
metabolic heterogeneity can be approximated by 
the “area under the curve of the cumulative SUV 
histogram” (AUC CSH) method, where a lower 
AUC implies greater variability in metabolism 
[79]. Figure 3 shows a simplified visualization of 
the process for determining these key parameters 
and terms.
In DLBCL, patients with high TMTV and 
TLG exhibited a more advanced stage of lym-
phoma, and these parameters were strong inverse 
predictors of progression-free survival and over-
all survival (OS) outcomes [80, 81]. For instance, 
high TLG indicated a higher progression rate 
(41% PFS) and worse overall survival (45% OS) 
compared to low TLG (72% PFS and 73% OS) 
[80]. Additionally, patients with overexpression 
of MYC were also at a greater risk for relapse and 
progression. In this study, Cottereau et al. com-
bined molecular evaluation (MYC expression) 
and metabolic imaging (TMTV measurements) 
characteristics to more accurately diagnose and 
monitor patients and concluded that this approach 
could lead to patient-tailored therapies [80].
Interestingly, estimations of intertumoral met-
abolic heterogeneity (MH) were shown to be an 
accurate predictor of poor outcomes in patients 
with higher MTV, coinciding with shorter PFS 
and OS. Models taking into account both MTV 
and MH improved upon MTV alone as a predic-
tor for PFS and OS [81, 82]. Similar results were 
found in primary mediastinal B-cell lymphoma 
(PMBCL), where a model combining both MH 
and TLG was found to be a more effective predic-
tive tool than models using only one of these 
parameters [83]. Thus, [18F]FDG PET/CT can be 
used to determine key parameters relevant to the 
diagnosis and predicted outcomes of patients.
Evaluation of metabolism is not only helpful in 
evaluating DLBCL but also useful for other lym-
phomas as well. In FL, baseline TMTV was a 
strong predictor of outcome, where a TMTV of 
510 cm3 cutoff is related to a less than 3-year PFS 
[84]. In primary brain lymphoma (PBL), MTV 
and TLG were the only [18F]FDG-measured 
parameters shown to be correlated with PFS and 
OS [85]. Additionally, [18F]FDG PET/CT  analysis 
is also a beneficial tool to monitor disease progres-
sion during treatment. In relapsed or refractory 
B-cell lymphoma treated with yttrium 90 (90Y) 
ibritumomab tiuxetan radioimmunotherapy, a drop 
in SUV of 49% or higher after either 2 or 6 months 
was shown to be an indicator of successful treat-
ment, and lesser changes  indicated a need for a 
different strategy [86]. [18F]FDG PET/CT is a 
flexible tool that can be applied to different forms 
of lymphoma and various therapeutic strategies.
[18F]FDG PET/CT is also useful to predict 
disease transformation over time, such as 
Richter’s transformation (RT), which is the con-
version of CLL to DLBCL. In multiple studies, 
RT was shown to coincide with a max SUV 
greater than 5.0 with a relatively high predictive 
Non-Hodgkin Lymphoma Metabolism
112
potential [87–89]. Of particular note, a heteroge-
neous distribution of the [18F]FDG also coin-
cided with lower survival, suggesting greater 
proliferation for these lymphomas [89].
[18F]FDG PET/CT has become a powerful 
metabolic tool for medical professionals for diag-
nosis and progression monitoring in various 
types of lymphoma. It can be used to visualize 
the glucose uptake and glycolytic activity of a 
tumor, as well as to characterize metabolic het-
erogeneity. Furthermore, it has been used as a 
methodology to direct patient treatment, where it 
can be used to confirm successful approaches or 
provide suggestions for alternative strategies for 
personalized medicine.
4.2  Systemic NAAG 
Concentrations for Tumor 
Growth Monitoring
One recent study found that concentrations of 
N-acetyl-aspartyl-glutamate (NAAG) in brain 
tumors positively correlated with patient tumor 
grades [90]. The authors of this study then investi-
gated the role of plasma NAAG concentrations in 
tumor growth monitoring using the MYC-
transformed human P493-6 model in vivo. They 
found that systemic NAAG concentrations in 
plasma of the mice bearing MYC-transformed 
P493-6 tumors strongly mirrored tumor growth 
where increases in NAAG concentrations pre-
Fig. 3 Simplified [18F]FDG PET/CT process. Injection of the isotopic glucose analog [18F]FDG and subsequent analy-
sis by PET/CT can determine key metabolic parameters (SUV, MTV, TLG, and MH) for research or clinical 
applications
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ceded the rise of tumor sizes when MYC was 
expressed and decreases in NAAG concentrations 
preceded the decrease of tumor sizes when MYC 
was suppressed. These findings suggest that 
plasma NAAG concentrations are linked to tumor 
growth rates and that changes in systemic NAAG 
concentrations are detectable before the corre-
sponding changes in tumor sizes. Measurement of 
NAAG concentrations in peripheral blood is thus a 
promising non-invasive strategy for timely tumor 
growth monitoring during cancer treatment [90].
5  Conclusion
The therapeutic challenges in malignant lympho-
mas include chemoresistance, radiation toler-
ance, and multidrug resistance. Novel therapeutic 
strategies, which are based on the metabolic phe-
notypes of aggressive lymphomas are being 
 pursued [51]. The malignant cells exhibit differ-
ent pathways for altering catabolism and enhanc-
ing anabolism for rapid cell proliferation in order 
to adapt to the tumor microenvironment [9]. The 
metabolic differences can occur in many lympho-
mas; therefore, understanding and learning about 
these specific differences can lead to new targets 
for therapy, both individually and in combination 
with other treatments. Furthermore, metabolo-
mics technologies can be critical to predict out-
comes and to elucidate appropriate and novel 
treatment strategies going forward.
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• Different oncogenic mutations lead to various 
metabolic phenotypes in renal cell carcinomas 
(RCC).
• Loss of the von Hippel-Lindau (VHL) tumor- 
suppressor gene results in metabolic altera-
tions, including shifts toward aerobic 
glycolysis in RCC.
• Fumarate hydratase mutations result in an 
increase in aerobic glycolysis in RCC.
• The upregulation of glycolysis enzymes is 
correlated with high-grade RCC.
• An increase in glutathione (GSH)/glutathi-
one disulfide (GSSG) ratio protects RCC 
against oxidative stress in a grade-dependent 
manner.
• Metabolic spatial heterogeneity can be 
induced by both gene-dependent and indepen-
dent processes.
• Metabolic intratumoral heterogeneity explains 
the failure of monotherapy and necessitates 
the need for personalized and/or combination 
therapies for RCC.
1  Introduction
According to data from the American Cancer 
Society, cancer is one of the deadliest health 
problems globally. Annually, renal cell carci-
noma (RCC) causes more than 100,000 deaths 
worldwide [1–4], posing an urgent need to 
develop effective treatments to increase patient 
survival outcomes. New therapies are expected to 
address a major factor contributing to cancer’s 
resistance to standard therapies: oncogenic het-
erogeneity. Gene expression can vary tremen-
dously among different types of cancers, different 
patients of the same tumor type, and even within 
individual tumors; various metabolic phenotypes 
can emerge, making single-therapy approaches 
insufficient. Novel strategies targeting the diverse 
metabolism of cancers aim to overcome this 
obstacle. Though some have yielded positive 
results, it remains a challenge to uncover all of 
the distinct metabolic profiles of RCC.  In the 
quest to overcome this obstacle, the metabolic 
oriented research focusing on these cancers has 
offered freshly new perspectives, which are 
expected to contribute heavily to the develop-
ment of new treatments.
2  Different Oncogenic 
Mutations Lead to Different 
Metabolic Phenotypes 
in RCC (Fig. 1)
Renal cell carcinoma (RCC), or hypernephroma, 
is the most common type of kidney cancer in 
adults, responsible for approximately 90–95% of 
all cases. RCC originates from the network of 
convoluted tubules of the nephron [5] and con-
sists of diverse histological subtypes, each with 
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unique sets of metabolic rearrangements that can 
be traced back to gene alterations [6, 7]. These 
genomic abnormalities provide cancer cells with 
the advantageous abilities to adapt to the limita-
tions of their microenvironments and meet the 
demands of rapid and deleterious cell division.
2.1  Loss of the von Hippel-Lindau 
Tumor-Suppressor Gene 
Results in Metabolic 
Alterations Including Shifts 
Toward Aerobic Glycolysis 
in RCC
Loss of the von Hippel-Lindau (VHL) tumor- 
suppressor gene is the most prominent genetic 
alteration in RCC, commonly associated with 
over 80% of clear-cell renal cell carcinoma 
(ccRCC) tumors [8, 9]. The protein product of 
VHL facilitates the degradation of hypoxia- 
inducible factor (HIF) [10]. Thus, the loss of VHL 
leads to the accumulation of HIF-1α and the con-
stitutive activation of hypoxia-inducible genes, 
even in oxygenated conditions. This includes the 
enhanced expressions of glucose transporter 2 
(GLUT2), hexokinase 2 (HK2), and lactate dehy-
drogenase A (LDHA), which are keys to the meta-
bolic shift towards aerobic glycolysis in tumors 
with this genotype [11, 12]. In fact, enhanced 
HIF-1α activity is thought to mediate the Warburg 
effect in RCC [13, 14]. Moreover, a study by Gill 
et al. found that HIF upregulation led to increases 
in glucose and amino acid uptake, lipogenesis, 
and augmentation of glycolysis through upregula-
tion of MET protein expression and subsequent 
phosphatidylinositol 3-kinase (PI3K)/Akt signal-
ing pathway activation [14–16].
In addition, pentose phosphate shunt depen-
dence, increases in glutamine transport, and fatty 
acid production all have been documented as 
VHL-associated metabolic alterations in ccRCC 
[17]. The increased activity of the pentose phos-
phate pathway (PPP) plays a significant role in 
protecting cancer cells from oxidative stress as 
this pathway generates NADPH and enables the 
maintenance of glutathione levels [13]. The 
Consortia of The Cancer Genome Atlas Research 
Network revealed that upregulation of PPP genes 
(G6PH, PGLS, TALDO, and TKT), fatty acid 
synthesis genes (ACC and FASN), and PI3K 
pathway-enhancing genes (MIR21) correlated 
with worse survival. In contrast, upregulation of 
AMP-activated protein kinase (AMPK) complex 
genes, multiple Krebs cycle genes, and PI3K 
pathway inhibitors (phosphatase and tensin 
Fig. 1 Heterogeneous metabolic phenotypes in renal cell carcinoma as a result of different oncogenic mutations. AKT 
protein kinase B, AMPK AMP-activated protein kinase, ePC ether-type phosphatidylcholine, ePE ether type, FH fuma-
rate hydratase, G6P glucose-6-phosphate, GLUT 2 glucose transporter 2, GSH glutathione, HIF-1α hypoxia-inducible 
factor 1-alpha, mTOR mammalian target of rapamycin, PEP phosphoenolpyruvic acid, ROS reactive oxygen species, 
SM sphingomyelin, TCA cycle tricarboxylic acid cycle
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homolog deleted in chromosome 10 (PTEN), 
tuberous sclerosis 2 (TSC2)) correlated with bet-
ter survival [17].




Studies by Tong et al. indicated that RCC cells 
carrying inactivated fumarate hydratase (FH), 
a tricarboxylic acid (TCA) cycle enzyme, 
demonstrated metabolic changes that were 
distinct from other genetically defined RCC, 
such as an increase in aerobic glycolysis and 
advanced tumorigenicity. Thus, fumarate 
hydratase- deficient kidney cancer has low 
oxygen consumption rates as well as low mito-
chondrial complex I activities [18, 19]. In 
addition to having a glycolytic shift, 
FH-deficient kidney tumors and cell lines 
from patients with hereditary leiomyomatosis 
and RCC also exhibited decreased levels of 
AMPK, a key metabolic regulator. Glycolytic 
upregulation allows the cells to adapt to 
growth demands by generating NADPH, 
acetyl- CoA, and precursors for ribose, protein, 
and fatty acid biosynthesis through reduced 
AMPK signaling. Furthermore, another study 
by Massari et al. demonstrated that intracellu-
lar augmentation of fumarate has an inhibitory 
effect on HIF prolyl hydroxylase (PHD) and 
consequently inhibited the activity of the VHL 
ubiquitination complex, which, in turn, led to 
the upregulation of HIF-target genes (VEGF 
and GLUT1) in a VHL-independent manner 
by stabilizing HIF1a [20]. On the other hand, 
intracellular reactive oxygen species (ROS) 
accumulation under glycolysis can also result 
in HIF1a stabilization [21].
LDHA inhibition has shown promise against 
FH-deficient RCC cells in vitro and in vivo [22] 
and other cancers [23–26]. Metformin, an antidi-
abetic medication, was reported to activate 
AMPK and inhibit RCC growth in  vitro and 
in vivo [27].
3  Metabolic Signatures of RCC
3.1  Metabolic Differences 
Between Normal Renal Cells 
and RCC
To compensate for the high demands of energy 
and biosynthetic macromolecules for prolifera-
tion, RCC cells change their metabolic 
 phenotypes from that of normal renal cells to sat-
isfy the demands. This leads to the different met-
abolic signatures of RCC cells as compared to 
normal renal cells. One of the metabolic signa-
tures presenting in RCC cells found by Saito 
et al. is the decrease in the level of phosphatidyl-
ethanolamine (PE) in RCC cells as compared to 
normal cells [28]. PE is one of the most abundant 
glycerophospholipids in eukaryotes and plays a 
crucial role in autophagy, cell division, and pro-
tein folding and acts as a precursor for synthesiz-
ing phosphatidylcholine (PC), phosphatidylserine 
(PS) N-acylethanolamine (NAE) [29–32]. 
Furthermore, the study by Saito et al. shows that 
increased PE, which is induced by ethanolamine, 
inhibits RCC cell proliferation [28]. Low levels 
of PE inhibit cell apoptosis, which explains why 
the downregulation of PE benefits RCC cells. 
The study also found that increases in ether-type 
PE (ePE) and ether-type phosphatidylcholine 
(ePC) are associated with ccRCC metastasis [28].
Interestingly, other studies showed that there 
is an upregulation of the fetal isoform of pyruvate 
kinase, isoform M2 (PKM2), across all grades of 
RCC, suggesting that tumor cells utilize different 
enzymes from those found in normal tissue to 
enhance their growth [33, 34].
Moreover, another metabolic feature of RCC is 
the decrease of sphingomyelin (SM), an essential 
component of the plasma membrane that regulates 
the formation of lipid microdomains through inter-
acting with cholesterol and glycerophospholipids 
[28, 35]. A high level of SM was reported to make 
the cells more vulnerable to apoptosis [36].
In addition to the metabolic signatures of RCC 
reported by Saito et  al., the study by Catchpole 
et  al. found that the upregulation of fatty acid 
 levels was potentially linked to the metastatic 
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stage of the malignancy [37]. The high fatty acid 
levels were the results of an increase in de novo 
fatty acid synthesis and/or a decrease in fatty acid 
oxidation, which often occurred during the inva-
sive and metastatic stage of RCC [37, 38]. Another 
compound with high concentration, α-tocopherol, 
was found in RCC and ovarian cancer to protect 
tumor cells against oxidative stress [37, 39].
Another interesting metabolic signature in 
RCC cells is related to amino acid metabolism. 
Specifically, while arginosuccinate synthase 1 
(ASS1) is known to play an important role in the 
urea cycle via ammonia detoxification through the 
conversion of citrulline to arginine [40], the study 
by Yoon et al. revealed an absence or decrease of 
ASS1 in ccRCC; therefore, arginine was identified 
as an auxotrophic marker for ccRCC [41]. With 
the use of proteomics, another study by Perroud 
et  al. similarly demonstrated the downregulation 
of ASS1 across all the grades of ccRCC [34]. 
Metabolic profiling using metabolomics technolo-
gies [42] has revealed different key metabolic phe-
notypes of RCC and identified potential targets for 
new treatments for RCC patients.
3.2  Temporal Impact of RCC 
Metabolism (Fig. 2)
Using the Fuhrman grading system, Wettersten 
et al. demonstrated that different grades of RCC 
were associated with different biochemical pro-
cesses that have distinctive and prominent meta-
bolic reprogramming, which is supported by the 
observation of clinically distinguishable features 
within various tumor grades [43]. In addition, 
Kang et  al. confirmed the metabolic reprogram-
ming in ccRCC by demonstrating the stage- 
dependent alteration in the expression of solute 
carriers (SLCs) [44]. SLCs have an important role 
in transmembrane transportation of specific meta-
bolic substrates, including inorganic ions, nucleo-
tides, amino acids, fatty acids, and sugars [45].
Using a combination of proteomics and 
metabolomics analysis, Wettersten et  al. corre-
lated increasing amounts of metabolites in the 
aerobic glycolysis pathway, including glucose, 
glucose-6-phosphate, and fructose-6-phosphate, 
with higher tumor grade. Likewise, an indication 
that glucose metabolism is reprogrammed to the 
Fig. 2 Spatial and temporal intratumoral heterogeneity in renal cell carcinoma. Gal galactose, GSH glutathione, GSSG 
glutathione disulfide, Man mannose, MCFAs medium-chain fatty acids
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lactate fermentation pathway, especially in 
advanced disease, is supported by the grade- 
dependent upregulation of lactate [43]. 
Consistently, a study by Hakimi et al. reported a 
more than twofold downregulation of citrate con-
centration in high-stage tumors [46] that may 
contribute to a reduction in oxidative phosphory-
lation capacity. However, in a study conducted by 
Perroud et al., the correlation of the upregulation 
of phosphoglycerate kinase 1 (PGK1) and grade 
1 and 2 tumors is debatable [34]. On the other 
hand, Hakimi et  al. showed that high levels of 
galactose and mannose were associated with an 
advanced stage of tumor progression [46].
A study by Horiguchi et al. first revealed the 
correlation between fatty acid synthase expres-
sion and high grade and metastasis of RCC [47]. 
On the other hand, Wettersten et al. found a broad 
reduction in shorter chain free fatty acid (FFA) 
oxidation in high-grade tumors, whereas there 
was an increase in carnitine and acylcarnitine lev-
els in all grades of RCC. In accordance with this 
finding, Hakimi et  al. discovered in high-stage 
tumors a reduction in cis-aconitate and medium- 
chain fatty acids [43, 46]. Furthermore, Xiao 
et  al. showed that genes related to fatty acid 
β-oxidation enzymes, EHHADH (3-hydroxyacyl 
CoA dehydrogenase and enoyl-CoA hydratase) 
and ACADM (medium-chain acyl-CoA dehydro-
genase), were simultaneously downregulated at 
the mRNA and protein levels in opposite propor-
tion to stages of ccRCC [48].
Glutathione (GSH)/glutathione disulfide 
(GSSG) ratio is an important indicator of oxidative 
stress. Wettersten et  al. revealed that this ratio is 
grade dependent and consistent with the downregu-
lation of the catabolic enzymes responsible for uti-
lizing glutamine and glutamate in the TCA and 
urea cycles, indicating a protective role of gluta-
mine reprogramming against oxidative stress in 
high-grade tumors [43, 49]. Similarly, upregulation 
of the majority of metabolites involved in the gluta-
thione synthesis such as cysteine, γ-glutamyl cyste-
ine (GLU-CYS), and GSH was observed by 
Hakimi et  al. in a stage-dependent manner [46]. 
Furthermore, they demonstrated that methionine 
augmentation at higher tumor stages could be 
related to the upregulation of glutathione metabo-
lism. In fact, the glutathione regeneration pathway 
is carried out by homocysteine being converted to 
cysteine via cystathionine [50].
Interestingly, Hakimi et  al. found a grade- 
dependent increase in the level of methylthio-
adenosine (MTA). MTA is a downstream product 
of the polyamine biosynthetic pathway, imply-
ing that alterations in the polyamine pathway are 
correlated to tumor progression [46]. MTA is 
also part of the methionine and adenine salvage 
pathway, where phosphorylation of MTA via 
methylthioadenosine phosphorylase (MTAP) 
leads to the regeneration of adenine and methio-
nine [51]. Using metabolomic approaches, Xu 
et  al. recently identified a stage-dependent 
decrease in the expression of MTAP that conse-
quently resulted in the accumulation of MTA in 
RCC cells [52].
3.3  Intratumoral Heterogeneity 
of RCC (Fig. 2)
3.3.1  Gene Independence
While intratumoral genetic heterogeneity has 
been extensively investigated in ccRCC [53, 54], 
only a small number of recent studies has docu-
mented the regional variations in metabolic pat-
terns [55–57]. Specifically, mutations of SET 
domain containing 2 (SETD2), PTEN, and 
lysine-specific histone demethylase (KDM5C) 
were found within the same tumor, suggesting 
that convergent phenotypic evolution and muta-
tions of VHL were ubiquitously detected by 
multi-region sequencing in all analyzed regions 
[54]. Using global metabolomics analyses, 
Okegawa et al. investigated the heterogeneity of 
intratumoral metabolic profile and gene muta-
tions in multiple regions of a single primary RCC 
tumor. Two major metabolically different tumor 
clusters, metabolic cluster 1 (MC1) and meta-
bolic cluster 2 (MC2), were identified among 32 
spatially separated sections of the tumor tissue. 
They observed an upregulation of the glycolysis-
PPP, glutathione, and amino acids in the MC1 
region as opposed to the downregulation of gly-
colysis-PPP metabolites and glutathione 
(reduced) in MC2 region. They also showed that 
the MC2 region had elevated levels of pyruvate, 
cystine, and 2-oxobutyric acid. This suggested 
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that tumor cells are dependent on the presence of 
pyruvate in MC2 regions for growth stimulation, 
which may make pyruvate metabolism an ideal 
therapeutic target [55]. Importantly, they showed 
that the Warburg- like effect is present in all tumor 
sites without any correlation to the status of the 
VHL gene. Ultimately, the clear intratumoral 
metabolic heterogeneity identified within a single 
tumor may contribute to treatment resistance [56, 
57]. In contrast, an almost uniform pattern of 
lipid profile was observed across the samples [55, 
58]. Interestingly, the study also showed no cor-
relation between the mutational status of genes 
and metabolic patterns, suggesting that other fac-
tors, such as noncanonical metabolic flux, tumor 
microenvironment, and epigenetics, may regulate 
the metabolic phenotype [55].
Accumulating evidence from various cancer 
studies suggests the important role of long non-
coding RNAs (lncRNAs) in different cellular 
processes, including metabolism [59–61] through 
regulation of gene expression at the epigenetic 
level [62, 63]. Specifically, a study by Li et  al. 
found intertumoral heterogeneity of lncRNAs in 
ccRCC that can contribute to the regulation of the 
HIF-1 signaling pathway [64].
Using hyperpolarized carbon-13 (13C) mag-
netic resonance imaging (HP-MRI) technique, 
Tran et  al. noted the intertumoral heterogeneity 
of pyruvate delivery, pyruvate-to-lactate meta-
bolic conversion, and ratio of lactate to pyruvate 
across the RCC but did not investigate whether 
this heterogeneity is gene dependent or not [65].
Using Dixon-based MRI technique, Zhang 
et  al. demonstrated the correlation between fat 
fraction and intratumoral heterogeneity of metab-
olites; however, the heterogeneity was more 
prominent between different tumor types [66].
3.3.2  Gene Dependence
Using [18F] fluorodeoxyglucose (FDG) and 
positron- emission tomography (PET)/MR imag-
ing, Brooks et al. also demonstrated that the pres-
ence of glycolytic enzyme FBP1, higher levels of 
glucose transporter GLUT1, and lower expres-
sion of FBP1 and HIF-1α transcription factor led 
to regional variation in metabolic heterogeneity. 
This study revealed an association between 
 [18F]FDG avidity and distinct patterns of meta-
bolic genes and protein expression. The  [18F] 
FDG-avid region had a lower expression of FBP1 
and HIF1a and higher expression of glucose 
transporter GLUT1, which could be related to a 
higher metabolic activity supported by boosting 
glucose uptake [22].
Polybromo-1 (PBRM1) gene is one of the 
major subunits of PBAF (polybromo-associated 
BRG1 or BRM-associated factors). Loss of its 
expression is considered as another common 
mutation in tumor-suppressor gene in ccRCC, 
besides VHL [67, 68]. Interestingly, Chowdhury 
et al. demonstrated that re- expression of PBAF in 
a PBAF-deficient ccRCC could lead to the rever-
sion of several important metabolic signatures in 
RCC, including glucose and cholesterol metabo-
lism [69]. Using tissue microarray (TMA)-based 
immunohistochemistry from each tumor, a study 
by Jiang et al. revealed different expressions of 
PBRM1, AT-rich interaction domain 1A 
(ARID1A), SETD2, brahma-related gene 1 
(BRG1), and brahma gene (BRM) among 160 
ccRCCs, indicating high intratumoral heteroge-
neity of PBRM1 expression and its associated 
proteins of the same tumor [70].
4  RCC Therapy
The current standard frontline therapies for meta-
static RCC are largely VEGFR inhibitors, such as 
sunitinib and sorafenib. However, about 20–30% 
of patients do not respond to these therapies, and 
among those, nearly all the patients become 
resistant to these drugs [71].
Activation of the mammalian target of 
rapamycin (mTOR), a member of PI3K-related 
kinases, through VEGF signaling pathways, can 
lead to protein synthesis and energy production 
in RCC [72]. Although a variety of agents have 
been investigated to target the mTOR pathway, 
only recently three mTOR inhibitors have been 
approved as second-line therapy in patients with 
RCC: temsirolimus (Torisel®–CCI-779, 4), 
everolimus or rad001 (Afinitor®, 4a), and 
 sirolimus (Rapamycin®, 4b) [73, 74]. Interestingly, 
a study by Li et al. revealed that mTOR inhibitor 
(everolimus) treatment could overcome the 
Warburg effect via mTOR pathway blocking and 
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HIF1α expression inhibition [75]. Recent work 
by Gameiro et  al. found that loss of VHL ren-
dered RCC cells sensitive to glutamine depriva-
tion [76]. In line with this finding, they found that 
systematic treatment with glutaminase inhibitors 
suppressed ccRCC growth both in  vitro and 
in  vivo. Other metabolic targeting therapies for 
RCC include mitochondrial inhibition by aurap-
tene [77] and GLUT1 inhibition by STF-3 [78].
5  Conclusion
Metabolic spatial and temporal heterogeneity 
represents one of the main mechanisms behind 
the high therapy resistance of RCC. Recent find-
ings suggest that initial monotherapy failure can 
be associated with subclonal variation in meta-
bolic heterogeneity. Targeting several metabolic 
pathways is the key strategy for effective therapy 
[79, 80]. It is also important to mention that met-
abolic phenotypic heterogeneity is regulated 
through both gene-dependent and gene- 
independent manners. Taken together, RCC treat-
ment has a variety of challenges posed by 
intratumoral metabolic heterogeneity, highlight-
ing the need for the further development of novel 
approaches to identify clonally dominant meta-
bolic targets for the future development of effec-
tive therapies for RCC.
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• Different oncogenic mutations lead to differ-
ent metabolic phenotypes in primary liver 
cancer.
• MYC and MET mutations regulate glucose and 
glutamine metabolism differently in primary 
liver cancer.
• Glucose metabolism increased by acetylated 
phosphoglycerate kinase 1 (PGK1) leads to 
the promotion of cancer cell proliferation and 
tumorigenesis in the liver.
• There exist metabolic differences between 
hepatocellular carcinoma (HCC) and normal 
liver tissue or other liver diseases.
1  Introduction
Primary liver cancer is the fourth leading cause of 
cancer death around the world. Histologically, it 
can be divided into two major groups, hepatocel-
lular carcinoma (75% of all liver cancer) and 
intrahepatic cholangiocarcinoma (15% of all liver 
cancer) [1, 2]. Primary liver cancer usually hap-
pens in liver disease or cirrhosis patients [1], and 
the risk factors for developing HCC depend on the 
etiology [3] and the country of provenance [1]. 
There is an urgent need for an accurate diagnostic 
test given the high proportion of false positives 
and false negatives for alpha-fetoprotein (AFP), a 
common HCC biomarker [4]. Due to often being 
diagnosed in advanced stages, HCC- related 
deaths per year have doubled since 1999 [3]. With 
the use of metabolomics technologies [5], the 
aberrant metabolism characteristics of cancer tis-
sues can be discovered and exploited for the new 
biomarkers and new therapies to treat HCC [6, 7].
2  Different Oncogenic 
Mutations Lead to Different 
Metabolic Phenotypes 
in Primary Liver Cancer
Most patients with HCC are diagnosed at 
advanced stages, and the current effective treat-
ments for these patients are limited. Nevertheless, 
if HCC patients are diagnosed at an early stage, 
the tumors can be resected or ablated. However, 
these patients often experience recurrence after 
resection/ablation [8]. Strategies to improve 
patient survival outcomes involve therapies 
exploiting the metabolic vulnerabilities of cancer 
cells. However, within the tumor microenviron-
ments, the alterations in metabolic pathways [9, 
10], resulting from the combinational effect of 
genetic, epigenetic, and transcriptomic variations 
[11, 12], occur frequently to accommodate the 
high energy demands of tumor growth. 
Consequently, the complexity of the heterogene-
ity of altered cancer metabolism leads to resis-
tance in therapeutic cancer treatments [13, 14]. 
Additionally, different patients also exhibit dif-
ferent forms of liver cancer that correspond to 
genetic differences [11, 15–19]. Given the genetic 
and metabolic complexities of HCC, identifying 
core metabolic pathways utilized by the tumors 
to drive metabolic phenotypic plasticity of this 
neoplasm will substantially contribute to the 
development of effective metabolic therapies.
2.1  MYC and MET Mutations 
Regulate Glucose 
and Glutamine Metabolism 
Differently in Primary Liver 
Cancer
MYC is a well-known regulator of metabolism in 
cancer [20, 21]. Yuneva et  al. found that the 
reprogramming of glucose and glutamine metab-
olism was different depending on the activation 
of the MYC oncogene or the MET proto- oncogene 
even within a specific liver cancer type [22]. They 
found an increased uptake and catabolism of glu-
cose in primary liver cancer as compared to the 
normal liver in both MET- and MYC-induced 
liver tumors. However, MYC-induced liver 
tumors exhibited the Warburg effect [23] in which 
these tumors produced significantly high levels 
of lactate, a phenotype not observed in MET- 
induced tumors [22]. This study suggests that 
within the same cancer type, cells exhibit diverse 
genetic abnormalities that result in diverging and 
distinct metabolic manifestations. These numer-
ous and remarkably pliant alterations appear to 
be essential for meeting the variety of demands 
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of cell proliferation, which include ATP produc-
tion, biosynthesis of cellular building blocks, 
reactive oxygen species (ROS) detoxification, 
and degradation of the extracellular matrix scaf-
folding to allow for angiogenesis and thus 
tumorigenesis.
Tumor cell metabolism of the same tissue 
type has been shown to depend on the identities 
of the genetic mutations. While MYC-induced 
mouse liver tumors exhibit enhanced glutamine 
[24] and glucose [23] metabolism, accompanied 
by an increase in lactate production and Krebs 
cycle intermediates, MET-induced mouse liver 
tumors are found to consume glucose as a means 
of synthesizing glutamine [22] (Fig. 1). Thus, it 
is reasonable to conclude that these two genes 
dictate radically opposite roles for glutamine, a 
central player in cancer metabolism. This fact 
illustrates, once again, that cancer metabolism 
can be determined by the nature of the genetic 
alterations and that how the metabolism is 
altered across different tumors can be extremely 
substantial. This helps to explain how the same 
tissue of origin in different patients, in this case, 
can have different genetic alterations and meta-
bolic phenotypes, thus substantiating the poten-
tial role of heterogeneity, even in a single tumor 
of the same patient.




The study led by Xu et al. has revealed the crucial 
role of liver receptor homolog 1 (LRH-1) in regu-
lating mitochondrial glutamine metabolism, 
which eventually leads to the production of 
NADPH through a noncanonical glutamine path-
way. Specifically, the study found that the regula-







• NADPH production 
through non-canonical glutamine 
pathway via Me1 
• mTORC1 signaling pathway by 
indirectly controlling α-KG 
production from Gln 
via GLS2




Lactate, citrate, succinate 
production in LCSCs.
MYC expression in LCSCs
Fatty acid oxidation in                   
LCSCs
Fig. 1 The heterogeneity of liver cell carcinoma metabolism and its associated oncogenic mutations
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catalyzes the conversion of malate to pyruvate to 
produce NADPH through a noncanonical gluta-
mine pathway [25], is dependent on LRH-1 [26].
Furthermore, using 13C5-labeled glutamine, 
the study highlighted the essential role of 
LRH-1 in promoting the production of glutamate 
from glutamine via controlling mitochondrial 
glutaminase 2 (GLS2) [26]. Consequently, the 
production of α-ketoglutarate (α-KG) from gluta-
mate activates the mechanistic target of the 
rapamycin complex 1 (mTORC1) signaling path-
way [26], a regulator of cell growth metabolism 
including proteins, lipids, and nucleotides [27]. 
Due to its pivotal role in the production of the 
reductive biosynthetic product NADPH and the 
activation of the mTORC1 signaling pathway 
through glutamine metabolism, LRH-1 promotes 
cell proliferation. Thus, loss of LRH-1 prevents 
diethylnitrosamine (DEN)-induced liver carcino-
genesis [26]. Targeting glutamine metabolism as 
a strategy for the treatment has been studied in 
several cancers [24, 28–34] (Fig. 1).
2.3  Glucose Metabolism 
Increased by Acetylated 





Compared to normal liver cells, cancerous liver 
cells, and cancer cells, in general, need a much 
greater amount of energy to fuel their prolifera-
tion. One of the ways to satisfy these high 
demands of energy is to adjust the energy- 
yielding pathways accordingly to produce energy 
in the most efficient manner. Deciphering differ-
ent energy production-enhancing mechanisms in 
cancers has attracted a lot of attention because 
having a better understanding of these mecha-
nisms provides strategies to advance treatments 
for cancers. Similarly, the study led by Hu et al. 
elucidated the role of phosphoglycerate kinase 1 
(PGK1), an enzyme catalyzing the conversion of 
1,3-bisphosphoglycerate to 3-phosphoglycerate 
yielding one ATP equivalent, in glycolysis, cell 
proliferation, and tumorigenesis. The formation 
of acetylated PGK1 at position K323 is required 
to activate PGK1 [35]. Activated PGK1, in turn, 
regulates cancer cell metabolism. Specifically, 
acetylated PGK1 enhances the production of 
energy in the form of ATP [35]. Ultimately, the 
acetylation of PGK1 at K323 promotes liver 
tumorigenesis. With this understanding of how 
PGK1 K323 acetylation functions in liver cancer, 
the emergence of new effective treatments using 
PGK1 as a therapeutic target for patients with 
liver cancer is promising (Fig. 1).
3  Metabolic Differences 
Between Liver Cancer Stem 
Cells (LCSCs) and Non-liver 
Cancer Stem Cells 
(Non-LCSCs)
Given their metabolic heterogeneity, LCSCs are able 
to adapt to many different environments, which 
causes therapeutic resistance to many available treat-
ments for HCC. Understanding the metabolism of 
LCSCs is crucial not only for the improvement of 
currently available therapies but also for paving a 
new path for developing other therapies targeting the 
revealed metabolic pathways. In an effort to elabo-
rate on the understanding of the metabolism of 
LCSCs, Hur et al. found the following differences in 
the metabolism of LCSCs as compared to non-
LCSCs. The increased proliferation of LCSCs can 
be explained based on the metabolomics analysis, 
which reveals the higher presence of essential 
metabolites that are either resulting from highly acti-
vated catabolism or acting as substrates to promote 
other energy-yielding processes. Specifically, the 
study found a higher concentration of lactate, the 
final product from glycolysis, citrate, succinate, and 
several amino acids such as aspartate, glutamate, 
isoleucine, leucine, phenylalanine, tyrosine, and 
valine in LCSCs as compared to non-LCSCs. 
Moreover, they showed that MYC, a known regula-
tor of glycolytic metabolism [20, 36], is highly 
expressed in LCSCs as compared to non-LCSCs, 
and this resulted in an increased amount of energy 
available for the rapid proliferation of the cancer 
cells [37]. This study also found that fatty acid oxi-
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dation in LCSCs is less active than that in non- 
LCSCs [37]. Consequently, the production of 
NADPH from fatty acid oxidation, contributing to 
oxidative phosphorylation to generate ATP, is less 
for LCSCs. Nevertheless, the assessment of three 
genes—cytochrome C oxidase subunit 5B (COX5B), 
adenosine triphosphate-5-alpha (ATP5α), and estro-
gen-related receptor Α (ERRα)—involved in oxida-
tive phosphorylation showed no differences between 
LCSCs and non- LCSCs [37]. This means that 
LCSCs must have utilized more glycolysis to pro-
duce ATP to satisfy the demands of energy for their 
rapid proliferation (Fig. 1).
4  Metabolic Signatures 
of Liver Cancer
4.1  Metabolism of HCC Is 
Different from that of Normal 
Liver Tissue
This section presents evidence of changes in the 
concentrations of specific metabolites in liver 
cancer as compared to normal hepatocytes and 
how this knowledge allows the development of 
new therapeutic models.
From recent studies, it is known that glucose 
metabolism is reprogrammed in HCC with the 
aim of allowing its growth, proliferation, and 
metastasis. One of the most outstanding charac-
teristics of cancer cell metabolism is the high 
demand for glucose [38]. Cassim et al. found that 
GLUT1 expression is increased in HCC tumori-
genic cells as opposed to normal liver cells, 
which have high GLUT2 expression [39]. 
Furthermore, Kim et al. found that the expression 
of GLUT1 (SLC2A1) is increased in advanced 
stages of HCC [38] (Fig. 2). Moreover, there is a 
switch in the expression of hexokinase (HK) 
enzyme from low-affinity glucokinase (GCK) 
isoenzyme in normal hepatocytes to high-affinity 
hexokinase 2 (HK2) isoenzyme. DeWaal et  al. 
showed that HCC cells predominantly use HK2, 
unlike noncancerous liver cells that use GCK (or 
HK4) [40]. In addition, they showed that there is 
an increased expression of HK2 in HCC cells and 
cells with evidence of dysplasia [40].
On the other hand, Fang et  al. studied the 
influence of miR-383 on the expression of lac-
tate dehydrogenase A (LDHA), which plays a 
key role in the progression of many types of can-
cer [41]. An overexpression of miR-383, an 
endogenous non-coding microRNA, has been 
reported to markedly inhibit HCC cells’ glycoly-
sis, proliferation, and invasion, through its bind-
ing to the LDHA-expressing gene [41] (Fig. 2). 
The LDHA inhibitor, FX11, has also shown 
promising results in several studies [42–44]. 
While it is known that there is an increase in the 
activity of aerobic glycolysis in HCC, Wang 
et al. showed that there is also a decrease in glu-
coneogenesis activity in HCC [45]. Björnson 
et  al. discovered downregulation of phospho-
enolpyruvate carboxykinase (PCK1 and PCK2), 
the first gluconeogenesis enzyme in HCC [46]. 
Hirata et al. also discovered that in HCC samples 
there is low expression of fructose-1,6-bisphos-
phatase (FBP1), a gene that encodes the gluco-
neogenic enzyme FBP1 [45].
Furthermore, they also discovered that FBP1 
overexpression is associated with decreased 
expression of hexokinase-2 (HK2) and phospho-
fructokinase- 1 (PFK1), key enzymes of aerobic 
glycolysis in cancer cells [45]. It was also shown 
that low FBP1 levels were associated with tumor 
progression in HCC samples [45] (Fig. 2).
Regarding the altered lipid metabolism [47], 
Björnson et  al. found evidence of a significant 
increase in the expression of key genes related to 
fatty acid biosynthesis (FAB) and pentose phos-
phate pathway (PPP) in HCC samples compared 
to noncancerous liver samples [46] (Fig. 3). The 
upregulation of these genes and the corresponding 
enzymes thus provide the necessary supplies for 
the synthesis of fatty acids, nucleotides, and 
NADPH, essential for tumor growth and prolifera-
tion [46]. Acetyl-CoA is required for fatty acid 
biosynthesis, and it is commonly produced by the 
oxidation of fatty acids [46]. However, Björnson 
et al. found that fatty acid oxidation is decreased in 
HCC and the main supply for the generation of 
fatty acids is exogenously acquired acetate [46]. 
According to this study, fatty acid oxidation (FAO) 
enzymes such as carnitine palmitoyltransferase 2 
(CPT2), acyl-CoA dehydrogenase family 
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(ACADSB), and hydroxyacyl-CoA dehydroge-
nases (HADH) are significantly downregulated in 
HCC tumors [46]. Acetate of exogenous origin 
enters the cell and, through acetyl-CoA synthases, 
is transformed into acetyl- CoA, a necessary sub-
strate for the biosynthesis of fatty acids [46]. In 
addition, the expression of the acyl-CoA synthe-
tase short-chain family member 1 (ACSS1) sub-
type, which resides in the mitochondria, 
ATP-citrate lyase (ACLY), acetyl- CoA carboxyl-
ase (ACC), and fatty acid synthase (FASN), are 
significantly increased in patients with HCC com-
pared to noncancerous liver samples [46]. 
Furthermore, in the same study, two groups with 
highly differentiated ACSS1 expression levels 
were observed within the HCC patient samples 
[46] (Fig.  3). Further analysis revealed that the 
group with high levels of ACSS1 had a greater 
suppression of the enzymes related to FAO as 
compared to the group with low levels of ACSS1 
[46]. Furthermore, it was also observed that the 
group with high ACSS1 expression had four times 
Fig. 2 The alteration of glucose metabolism involves upregulation of glycolysis enzymes and downregulation of glu-
coneogenic enzymes and mitochondrial aerobic activity. GLUT glucose transporter, MCT1 protein monocarboxylate 
transporter isoform 1, HK2 hexokinase 2, PFK1 phosphofructokinase-1, FBP1 fructose-1,6- bisphosphatase, PCK phos-
phoenolpyruvate carboxykinase, GCK glucokinase, TCA cycle tricarboxylic acid cycle, miR-383 microRNA-383
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the expression of pyruvate kinase (PKM) com-
pared to the group with low levels of ACSS1 [46] 
(Fig. 3). Increased expression of PKM is related to 
a greater capacity for metabolic adaptation to dif-
ferent concentrations of nutrients and oxygen [46].
4.2  Oxidative Stress Signature 
in HCC
Oxidative stress, which is determined by the 
balance of oxidant and antioxidant species, 
also plays an important role in HCC.  Among 
the antioxidant species, glutathione (GSH) is 
the major nonenzymatic regulator of intracel-
lular redox homeostasis [48], and it is the most 
abundant antioxidant in hepatocytes [49]. In 
the serum of patients with HCC, a significant 
increase in amino acids related to the synthesis 
of GSH, the reduced form of glutathione, and 
glucose 6- phosphate (G6P), a compound nec-
essary to form NADPH, has been evidenced 
[50]. On the other hand, the quantification of 
oxidative damage is made possible through 
measuring oxidative products, and in HCC, 
8-hydroxydeoxy guanosine and 4-hydroxynon-
enal (oxidative products of DNA and lipids, 
respectively) were found [49]. De Matteis et al. 
also found that there were elevated levels of 
8-hydroxydeoxy-guanosine in the serum of 
patients with chronic hepatitis, which can lead 
to an increased risk of HCC [49].
It is important to note that Wang et al. found 
that a large elevation of canavaninosuccinate 
(CSA) in HCC patients from the first affiliated 
hospital of the medical school of Zhejiang 
University, as opposed to samples from cirrhosis 
patients, is a signature of oxidized stress [51]. 
CSA produces fumarate, which is a key metabo-
lite of the tricarboxylic acid (TCA) cycle, and 
elevated CSA levels indicate that its conversion 
to fumarate is impaired and thus negatively 
impacting the subsequent TCA cycle intermedi-
ate formation while promoting Warburg’s gly-
Fig. 3 The alteration of lipid metabolism involves upregulation of fatty acid biosynthesis enzymes and downregulation 
of fatty acid oxidation enzymes. FASN fatty acid synthase, ACC acetyl-CoA carboxylase, ACLY ATP citrate lyase, 
ACSS1 acyl-CoA synthetase short-chain family member 1, ACADSB acyl-CoA dehydrogenase family, HADH hydroxy-
acyl-CoA dehydrogenases, CPT carnitine palmitoyltransferase 2, ACS acetyl-coA synthase
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colysis [52]. They also discovered the sensitivity 
and specificity of alpha-fetoprotein (AFP) and 
CSA to distinguish HCC patients from cirrhosis 
controls [51]. It is important to note that these 
authors do not discuss dietary factors due to the 
plant origin of canavanine.
5  New Therapeutic 
Investigations Based 
on Metabolism Studies
Currently, the multikinase inhibitor sorafenib is 
the main drug for the treatment of advanced HCC 
that delays tumur progression and improves over-
all survival. However, its ability to shrink the 
tumor in patients is very modest [53]. Therefore, 
other treatments that may potentiate or replace 
sorafenib are being studied. DeWaal et al. studied 
the synergism between HK2 silencing and 
sorafenib because the first one can induce cell 
death, and the second one can inhibit growth fac-
tor receptors. It was observed that HK2 silencing 
made HCC cells more sensitive to sorafenib. 
Therefore, the combination therapy using 
sorafenib and HK2 silencing decreased tumor 
growth substantially more than either treatment 
alone [40].
Another protein that has garnered attention 
because it is expressed in high amounts in many 
types of malignant cells is a transmembrane 
protein known as CD147 (Fig. 2). It is associ-
ated with the lactate transporter monocarboxyl-
ate transporter isoform 1 (MCT1), a key protein 
that exports lactate to the extracellular environ-
ment from HCC cells and is necessary for the 
proliferation of HCC [49]. Huang et al. found 
that CD147 overexpression significantly pro-
moted glycolysis via p53/TIGAR/PFK and 
inhibited mitochondrial activity via p53 in HCC 
cells [54]. Furthermore, the silencing of CD147 
was associated with a relative increase in 
mtDNA content in HCC cells compared to con-
trol cells [54]. Additionally, this silencing was 
associated with a high oxygen consumption 
rate, a decrease in the intracellular concentra-
tion of glucose and pyruvate, a high intracellu-
lar lactate concentration, and a significant 
decrease in cell growth [54]. Inhibition of 
CD147 phosphorylation was found in HCC 
samples from patients with distant metastases 
and was associated with elevated levels of 
AFP.  This phosphorylation requires further 
studies as a potential prognosis biomarker, as 
well as a potential strategy for the development 
of treatments against HCC metastasis [55].
6  Conclusion
Given the complex heterogeneity and intricate 
evolutionary characteristics of liver cancers, the 
increase in resistance rate to current therapies 
has emerged as the main obstacle that many 
studies focusing on HCC have been trying to 
overcome. Among the different methods avail-
able to tackle the problem, metabolomics-based 
approaches serve as powerful strategies— 
allowing researchers to uncover metabolic pro-
files of different cancers. In addition, using 
metabolomics technologies to track a variety of 
metabolites in cancers offers researchers a bet-
ter picture of the interactions that occur within 
the tumor microenvironments. Understanding 
the heterogeneity of cancer metabolism will 
pave a new path for the development of metabo-
lism-based therapies to improve the outcome of 
cancer therapy. As has been shown, genes such 
as MYC, MET, or LRH-1 activate various meta-
bolic pathways for cell growth and survival. On 
the other hand, the combination of AFP with 
CSA has shown good results as a diagnostic 
test, which compels us to continue studying the 
metabolic pathway of CSA within HCC cells. 
However, more research is required to under-
stand the progression of liver cancer and how to 
evaluate it at different stages for a more favor-
able prognosis, as well as less invasive and more 
effective treatments. The study of the metabo-
lome is yielding good results, but it is still nec-
essary to discover new relationships between 
the different metabolic pathways.
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• Cancer cells adapt to changes in nutrient and 
oxygen availability by adopting alternative 
metabolic pathways.
• Fatty acid oxidation in cancer cells is a sur-
vival mechanism under glucose deprivation.
• Lipid scavenging is utilized to enable cancer 
cells to survive periods of tumor regression.
• There is persistent glutamine oxidation under 
hypoxic and glucose deprivation conditions.
• Nutrient utilization can predict a tumor’s met-
abolic dependencies in vivo.
• Distinct, and often complementary, metabolic 
processes operate concurrently within a single 
tumor.
1  Introduction
The beginning of the twenty-first century offered 
new advances in cancer research, including new 
knowledge about the tumor microenvironment 
(TME). Because TMEs provide the niches in which 
cancer cells, fibroblasts, lymphocytes, and immune 
cells reside, they play a crucial role in cancer cell 
development, differentiation, survival, and prolifer-
ation. Throughout cancer progression, the TME 
constantly evolves, causing cancer cells to adapt to 
the new conditions. The heterogeneity of cancer, 
evidenced by diverse proliferation rates, cellular 
structures, metabolisms, and gene expressions, 
presents challenges for cancer treatment despite the 
advances in research. This chapter discusses how 
different TMEs lead to specific metabolic adapta-
tions that drive cancer progression.
2  The Tumor 
Microenvironment
The TME, the environment surrounding the 
cancer cells, is a heterogeneous mixture of 
immune cells, endothelial cells, materials 
secreted from cells and their organelles, and 
fibroblasts [1] (Fig.  1). Within this miniscule 
niche, the tumor survives in seemingly hostile 
conditions—hypoxia, nutrient deficiency, and 
necrosis—thanks to metabolic reprogramming 
[2]. The question is: How does a tumor micro-
environment offer advantages for cancer cell 
survival under such conditions?
Hanahan and Weinberg suggest that there 
are six general characteristics of cancerous 
cells important for advancements toward 
malignant growth: (1) self-sufficiency in 
growth signals, (2) insensitivity to anti-growth 
signals, (3) evasion from apoptosis, (4) 
 limitless replication potential, (5) sustained 
angiogenesis, and (6) tissue evasion and 
metastasis [3]. Despite the diversity of out-
comes in tumor progression, these same capa-
bilities are shared by most, if not all, tumor 
types. Moreover, these features develop dif-
ferently in various tumor types through dis-
tinct mechanisms and at different time points 
during the multistep tumorigenesis enabled 
by genomic instability in cancer cells and 
tumor-promoting inflammation [4]. The hall-
marks of cancer provide further insight into 
potential opportunities for early interventions 
for cancer treatment.
Among their basic needs, cancer cells 
require rapid ATP generation, biosynthesis of 
macromolecules, and maintenance of cellular 
redox status [5]. The insidious nature of can-
cer cells does not stop at their determination to 
live but also extends to the factors that sacri-
fice adjacent living tissue to propagate cancer-
ous cells. Tumors create alternate pathways 
for nourishment and, most importantly, 
survival.
The differences in cancer origin and stage of 
progression ultimately lead to the heterogeneity 
of cancer and the corresponding components 
involved in cancer metabolism.
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3  Different Tumor 
Microenvironments (TMEs) 
Lead to Different Metabolic 
Phenotypes
3.1  Cancer Cells Adapt 
to Changes in Nutrient 
and Oxygen Availability  
by Adopting  
Alternative Metabolic 
Pathways (Fig. 2)
The harsh tumor microenvironment (TME), hypoxia, 
low pH, and low nutrient concentrations are key char-
acteristics in determining metabolic phenotypes. 
Various studies have demonstrated that cancer cells 
adapt to changes in nutrient and oxygen availability by 
adopting alternate metabolic pathways in order to con-
tinue providing the energy and macromolecules 
needed for cell proliferation. These pathways include 
fatty acid oxidation, lipid scavenging, and alternative 
cellular respiration pathways adopted by cancer cells 
under different TMEs [6–9].
Fig. 1 The tumor microenvironment is composed of several components such as lymphocytes, adipocytes, fibroblasts, 
and dendritic cells
Different Tumor Microenvironments Lead to Different Metabolic Phenotypes
140
The nutrient- and oxygen-poor internal condi-
tions of TMEs incite cancer-friendly metabolic 
changes to help cancer cells survive in these 
harsh environments [10]. Under hypoxic condi-
tions, oxidative phosphorylation or other aerobic 
reactions are limited. This state disrupts the redox 
balance and affects cell signaling. An increase in 
the levels of reactive oxygen species (ROS) is 
defined as oxidative stress [11]. Due to decreased 
oxygen tension, hypoxic cells depend mainly on 
anaerobic glycolysis for energy production, 
while their low oxygen supply allows limited 
ATP production via oxidative phosphorylation 
[12]. For example, breast cancer growth is attrib-
uted to the TME, which reacts to oxidative stress 
leading to the production of ROS [13, 14]. 
Similarly, a study by Le et al. found that there is 
an increase in ROS production in response to oxi-
dative stress under hypoxia [15]. Thus, this study 
concluded that cancer cells become dependent on 
glutamine for bioenergetics and redox homeosta-
sis as a way to survive in hypoxia [15].
Extracellular acidity is another crucial compo-
nent of the TME [16]. When cancer cells undergo 
anaerobic glycolysis in hypoxia, lactic acid levels 
increase, causing the TME’s extracellular pH 
(pHe) to diminish. This reaction generates an 
acidic TME [16]. Tumors that have an acidic 
TME have been shown to display more malignant 
phenotypes. Rofstad et al. treated melanoma cells 
with an acidic medium resulting in increased mel-
anoma cells metastasizing to the lungs in mice 
[17]. The results seen in the study suggest that 
lower pHe can exacerbate malignant metastasis.
The heterogeneity of nutrient and oxygen sup-
ply and uptake within individual tumors, in con-
junction with the evidence of the adaptive process 
of cancer cells in response to differing condi-
tions, illustrates that cancers are composed of 
many different cells that are each capable of 
employing distinct metabolic pathways to supply 
energy and fuel biosynthesis as a means of main-
taining tumorigenesis. Thus, the local TME holds 
the determining factors by which metabolic 
adaptation is acquired [8, 9, 12, 13].
The hypoxic conditions lead to pathways that 
would only be present due to the alterations made 
necessary by metabolic stress. Other cells 
respond to glucose deprivation by requiring less 
energy to survive or utilize alternative com-
pounds to take glutamine’s place in the tricarbox-














Fig. 2 The fundamental concept of how the tumor microenvironment (blue) leads to different metabolic phenotypes. 
Genetic alterations also contribute to the metabolic phenotype. The metabolic phenotype then propels bioenergetics, 
biosynthesis, and redox reactions in the tumor cells
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cancer cells take varying initiatives in order to 
survive, further exemplifying the heterogeneity 
of cancer metabolism.
3.2  Fatty Acid Oxidation (FAO) Is 
Used as a Survival Response 
to Glucose Deprivation
Recently, with further study of the fatty acid oxi-
dation pathway, there has been significant 
evidence presented to support a “lipolytic pheno-
type” of cancer. FAO is a part of various steps of 
tumorigenesis, including cancer cell growth and 
survival [18, 19]. In addition, FAO also occurs in 
tumor-associated immune cells, endothelial cells, 
and adipocytes, which may lead to immune 
 suppression in the tumor microenvironment [18]. 
As stated before, adipocytes are major elements of 
various tumor microenvironments. In a study of 
invasive melanoma by Lazar et  al., adipocytes 
were found to secrete high numbers of exosomes, 
which are integrated by cancer cells, subsequently 
contributing to their migration and invasion [20]. 
Lazar et al. observed that the presence of adipo-
cyte exosomes increased FAO in melanoma cells. 
Therefore, through the uptake of fatty acids from 
surrounding adipocytes, FAO was promoted in 
cancer cells [20]. Similarly, in a study by Wen 
et al., adipocytes promoted xenograft colon tumor 
growth in vivo [21]. In addition, they observed that 
adipocytes are crucial components for cancer stem 
cell (CSC) gene expression and downregulated 
intestinal epithelial cell differentiation gene 
expression in vitro [21]. Furthermore, Wen et al. 
also demonstrated how adipocytes within the 
tumor microenvironment lead to cancer cell prolif-
eration and survival due to fatty acid uptake and 
FAO promotion [21]. Lazar et al. and Wen et al. 
both demonstrate how a lipolytic phenotype is pro-
moted by the tumor microenvironment’s associ-
ated components. Their findings suggest potential 
players to target within the FAO metabolic path-
way to prevent tumorigenesis.
Cancer cells employ FAO as a means to 
survive in response to glucose deprivation [6, 7]. 
FAO is utilized by tumor cells to produce ATP as 
an energy source [7, 22]. Over twice the amount 
of ATP can be made under mitochondrial oxida-
tion of one mole of fatty acid as compared to oxi-
dation of one mole of glucose [7]. Due to harsh 
TME conditions, for example, lack of nutrition, 
cancer cells adapt different metabolic phenotypes, 
such as transitioning from glycolytic to fatty acid 
oxidation phenotype [6, 22]. The lack of nutrition 
also enhances both fatty acid synthesis and lipid 
droplet biogenesis to propel lipid oxidation for the 
maintenance of energy levels [6].
In a study conducted by Wang et al., the roles of 
the hepatitis B virus X protein (HBx) in hepatocel-
lular carcinoma (HCC) adaption to metabolic 
stress were investigated. Wang et  al. found that 
HBx activates FAO in glucose withdrawal [6], 
maintaining nicotinamide adenine dinucleotide 
phosphate (NADPH) and adenosine triphosphate 
(ATP) homeostasis. HBx promotes dynamic equi-
librium, mobilizing, and oxidizing lipids to meet 
the demands for ATP [6]. These results suggest 
that HBx plays a key role in maintaining redox and 
energy levels by activating FAO, a necessary part 
of HCC cell survival under metabolic stress.
Most cancer cells synthesize de novo fatty 
acids during normoxia without nutrition depriva-
tion [7, 22]. Fatty acid synthesis is a crucial step 
for tumor cell survival [22]. Cancer cells synthe-
size de novo fatty acids in order to sustain prolif-
eration and energy production through 
FAO. Acetyl-CoA carboxylase (ACC) and fatty 
acid synthase (FASN) are essential enzymes in de 
novo fatty acid synthesis. Acidic and hypoxic 
environments induce FASN expression in cancer 
cells, which is an observable phenotype in a 
 variety of human cancers [22].
According to Ackerman and Simon, adipocytes 
within TMEs play a key role in increasing lipoly-
sis and secreting fatty acids for energy production, 
contributing to an aggressive growth phenotype 
[23]. Lipids produced from adipocytes were used 
by ovarian cancer cells in order to help tumor 
growth. These findings suggest that adipocytes are 
key players in tumor growth by supplying fatty 
acids [24]. Moreover, this study uncovered fatty 
acid-binding protein 4 (FABP4) as a potential tar-
get for cancer therapy.
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3.3  Lipid Scavenging Is Utilized 
to Enable Cancer Cells 
to Survive Periods of Tumor 
Regression
Under hypoxic conditions, oncogenic Kirsten rat 
sarcoma viral oncogene homolog (KRAS) regu-
lates lysophospholipids to replenish lipids for 
growth. The inhibition of stearoyl-CoA desatu-
rase 1 (SCD1), which catalyzes the bypassing of 
saturated de novo fatty acids into lipids, was 
resisted by KRAS-derived tumor cells because of 
their adaption of lipid scavenging [7]. The 
increase in protein synthesis and a decrease in 
lipid desaturation ultimately resulted in cell death 
[25, 26]. During tumor regression, cancer cell 
survival is made possible by FAO and other oxi-
dative mitochondrial pathways. As demonstrated 
by KRAS-driven pancreatic cancer, tumor regres-
sion caused by kinase inhibitors or KRAS with-
drawal resulted in inhibited oxidative respiration 
in tumor cells [27]. Lipid scavenging is an alter-
native pathway to gain fatty acids in hypoxia and 
fulfill the requirements for cell monounsaturated 
fatty acids by Ras-driven cancer cells [28]. The 
reduction of the need for de novo fatty acid syn-
thesis is attributed to the increase in fatty acids 
being brought into the TME. Ras-driven cancer 
cells become immune to SCD1 inhibition, dem-
onstrating the lipid scavenging phenotype [28].
3.4  Persistence of Glutamine 
Oxidation Under Hypoxic 
and Glucose Deprivation 
Conditions
As established in previous chapters, the tricarbox-
ylic acid (TCA) cycle is crucial for producing 
energy and biosynthesis [29, 30]. However, how 
hypoxic TMEs influence the TCA cycle is still 
being investigated. Le et  al. determined how 
hypoxic conditions could influence glutamine 
metabolism [15]. Their study showed that when 
deprived of glucose and oxygen, B-cell lym-
phoma exhibit an addiction to glutamine, where 
glutaminolysis is employed with a glucose- 
independent TCA cycle to fuel cell proliferation 
[15]. In this scenario, the glucose- independent 
TCA cycle is supported by glutamine. Similarly, 
hypoxic cells use glutamine to generate citrate 
from α-ketoglutarate (α-KG) in response to a 
reduced supply of glucose- derived citrate [15]. 
Targeting glutamine metabolism was further 
investigated not only by their follow-up works 
[31–33] but also by other teams [34–36]. This 
dependence of cancer cells on glutamine metabo-
lism has translated into clinical trials as a novel 
therapy for cancer patients. Collectively, these 
findings offer a cautionary note that therapeutic 
strategies targeting cancer metabolism should 
consider the metabolic heterogeneity in hypoxic 
cancer cells, particularly the non-Warburg cells 
that have so far been underrepresented in the can-
cer metabolism literature [37].
4  Nutrient Utilization Can 
Predict a Tumor’s Metabolic 
Dependencies In Vivo [38]
As described by Sir Hans Kornberg, anaplerosis 
is the reloading of metabolic intermediates in the 
TCA cycle, which is a crucial part of energy pro-
duction and biosynthetic pathways. Glutamine 
and glucose both contribute to TCA anaplerosis 
in non-small cell lung cancer (NSCLC) cells 
[38]. In this study by Davidson et al., the authors 
found that glucose is a carbon source of the 
metabolites in the TCA cycle, which is needed 
for tumorigenesis.
For continuous proliferation, cancer cells 
must maintain the necessary precursors of bio-
synthetic pathways, and glutamine serves as a 
major substrate for anaplerosis in many cancer 
cells [30]. For example, both hypoxic and nor-
moxic renal cell carcinomas with a mutation in 
the von Hippel-Lindau (VHL) tumor-suppressor 
gene sustain lipogenesis by converting α-KG, 
derived from glutamine, to acetyl-CoA, which 
then allows them to utilize the glucose- 
independent TCA cycle as a means of energy 
production [8, 9]. On the other hand, when gluta-
minase is inhibited, the breakdown of glutamine 
is partially prevented and some cancer cells 
employ pyruvate carboxylase and use glucose-
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derived  pyruvate as a substitute for glutamine to 
fuel anaplerosis [8].
Similarly, a study by Cheng et al. demonstrated 
that “glutamine-addicted” cells accomplished 
anaplerosis by utilizing pyruvate carboxylase [8, 
39]. It was found that the glutamine- addicted cells 
utilized glucose-derived pyruvate for anaplerosis 
when glutaminase (GLS) was silenced. The data 
from this study supported the model of pyruvate 
carboxylase’s role in cancer cell resistance against 
GLS inhibition or glutamine deprivation. Cells 
such as a hepatocellular carcinoma cell line, Huh-
7, use pyruvate carboxylase as a primary mecha-
nism to resist the treatment of glutamine 
metabolism inhibition [8].
4.1  Inhibition of mTORC1 
Decreases Energy 
Consumption for Cancer Cell 
Survival
The mammalian target of rapamycin complex 1 
(mTORC1) is a protein that translates the TME 
into a growth phenotype through its control of 
autophagy and fatty acid oxidation (FAO). The 
inhibition of mTORC1 represses the AMPK- 
dependent activation of tuberous sclerosis pro-
teins ½ (TSC½) as a result of the withdrawal of 
glucose [9]. When energy consumption is reduced, 
oxaloacetate (OAA) or methyl pyruvate (MP) can 
be substituted for glutamine and still be able to 
maintain ATP levels and prevent cell death. The 
TSC-mTORC1 pathway balances energy supply 
and demand in a way that leads to a reduction of 
the energy needed to survive [9]. Choo et al. dem-
onstrated that, under glucose deprivation, a 
decrease in anabolic reactions occurs in order to 
prevent cell death [9]. As shown with the decrease 
of energy consumption, the balance keeps the 
cancer cells alive through the dependence of 
TSC½ cells on glutamate dehydrogenase- 
dependent glutamine metabolism [9]. The results 
found in this study support the concept that tumor 
cells under stress create alternative pathways out 
of necessity. With glucose or glutamine metabo-
lism inhibition, the potential treatment of TSC-
deficient tumors may be possible.







In normal cells, mitochondria play vital roles in 
regulating metabolic pathways and physiologi-
cal states of the cell: they generate cellular 
energy, monitor cellular redox, and initiate cel-
lular apoptosis. However, through investigation 
of mitochondria in cancer cells, it has become 
evident that mutations in mitochondrial genes 
correlate with tumorigenesis and metabolic 
adaptability [40]. Mitochondria in cancer cells 
subjected to hypoxia respond by releasing 
metabolites and proteins regulating metabolic 
pathways [40].
Cancer cells with functionally defective mito-
chondria employ glutamine-dependent reductive 
carboxylation, where glutamine is converted to 
citrate and then to acetyl-CoA and oxaloacetate, 
as an alternative to normal oxidative metabo-
lism. Oxidative metabolism is favored in cells 
with normal mitochondria and provides the ace-
tyl-CoA needed for lipogenesis and production 
of other metabolites of the TCA cycle, which 
serve as precursors of other biosynthetic path-
ways. Even in cells with altered mitochondrial 
function, the glutamine-dependent reductive 
metabolism still allows for the formation of 
these necessary metabolic precursors [41]. The 
glutamine-dependent reductive pathway permits 
glutamine to support cancer cell growth [41].
5  Distinct, and Often 
Complementary, Metabolic 
Processes Operate 
Concurrently Within a Single 
Tumor
The particular alternative metabolic pathways 
adopted by cancer cells are associated with spe-
cific genetic alterations that allow the cancer 
cells to express certain enzymes in higher than 
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usual amounts. The production of these enzymes 
allows cancer cells to use the available nutrients 
in their microenvironment to fuel cell survival 
and proliferation. For example, genetic altera-
tions that result in the deactivation of caveolin- 1 
(Cav-1) expression lead to autophagy and aero-
bic glycolysis in cancer-associated fibroblasts 
[42]. Subsequently, lactate, glutamine, and other 
metabolites that fuel biosynthesis are synthe-
sized and exported to initiate oxidative metabo-
lism in neighboring cancer cells [42].
Other studies have revealed that distinct, and 
often complementary, metabolic processes oper-
ate concurrently within a single tumor. Hypoxic 
breast cancer cells and stromal cells in the TME 
exhibit a mutualistic relationship employing 
complementary metabolic processes [43]. When 
subjected to hypoxia, breast cancer cells demon-
strate an increase in lactate secretion. The eleva-
tion in lactate concentration in the TME results in 
the migration of specific stromal cells called 
human mesenchymal stem cells (hMSCs) toward 
hypoxic tumor cells. These hMSCs, along with 
stromal cancer-associated fibroblasts (CAFs), 
consume the newly produced lactate and convert 
it to pyruvate to be used in the TCA cycle. Lactate 
consumption by stromal cells serves two pur-
poses: the breakdown of lactate serves as an 
energy source for the proliferating cancer cells, 
and the conversion of lactate to pyruvate, and 
ultimately to α-KG in the TCA cycle, prevents 
acidification of the TME [43].
Another example of this phenomenon of cells 
in the TME pairing metabolic processes is evi-
dent in ovarian cancers. Adipocytes in breast can-
cer microenvironments employ lipolysis to 
release fatty acids which provide energy to fuel 
rapidly proliferating ovarian cancer cells [24]. 
Within one region of the TME, two different 
types of cells undergo vastly different, yet com-
plementary, metabolic processes in order to fuel 
tumorigenesis, thus demonstrating the heteroge-
neity of cancer metabolism.
5.1  Metabolic Symbiosis 
as a Result of Tumor 
Angiogenesis Inhibition Can 
Be Stopped by mTOR 
Signaling Inhibition [44]
Coordinated metabolic pathways with respect 
to glucose and lactate metabolism between 
cells within the TME have been observed in 
various cancers [45]. Allen et al. observed met-
abolic symbiosis with their work in tumor 
angiogenesis inhibition [44]. When angiogene-
sis is targeted using VEGF inhibitors in mice 
bearing pancreatic neuroendocrine tumors 
(PanNET), cancer cells formed next to the 
remaining blood vessels [44]. The cancer cells 
compartmentalized in response to insufficient 
vascularization—creating distal hypoxic cells 
and proximal normoxic cells [44]. Upon further 
observation, increased glucose transporter 1 
(GLUT1) and monocarboxylate transporter 4 
(MCT4) were found in tumor cells far from 
blood vessels indicating glycolysis [44]. 
Moreover, signs of mTOR signaling, in the 
form of ribosomal protein s6 (p-S6) expression, 
were found in tumor cells near blood vessels 
[44]. In these metabolic pathways known as 
metabolic symbiosis, the hypoxic cells take up 
glucose and secrete lactate, which is then taken 
up and catabolized by normoxic cells [44]. As a 
result of increased lactate catabolism, the nor-
moxic cells’ mTOR signaling through gluta-
mine metabolism is increased [44].
The metabolic symbiosis that Allen et  al. 
found is due to the compartmental expression of 
GLUT1/MCT4 [44]. For metabolic symbiosis to 
occur, the lactate that is secreted must be taken up 
and used for energy metabolism by the normoxic 
cancer cells. Within their study, Allen et al. also 
demonstrated that normoxic cancer cells in vitro 
and in vivo take up and catabolize lactate—which 
reinforces the notion that lactate is used for 
energy metabolism [44].
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Allen et  al.’s experiments demonstrate how 
PanNET tumor cells adapt to evade targeted anti-
angiogenesis therapy. While Allen et  al. were 
able to target the metabolic symbiosis by inhibit-
ing mTOR signaling [44], the initial adoption of 
metabolic symbiosis demonstrates how the tumor 
cells circumnavigate the initial treatment by cre-
ating new pathways for energy production. 
Furthermore, metabolic symbiosis as a result of 
tumor angiogenesis inhibition reflects how dis-
tinct and complementary metabolic processes 
occur within the same tumor.
6  Conclusion
As cancer cells seek to survive, alternate meta-
bolic pathways adapt to different TME stresses. 
These adaptations, often through genetic altera-
tions or coordination with other metabolic pro-
cesses, illustrate how precisely the TME can alter 
metabolic characteristics. With the advancements 
in research into TMEs and the use of metabolo-
mics technologies [46], there is a tremendous 
opportunity for uncovering new therapeutic tar-
gets and creating treatments that target TMEs 
[47, 48]. The heterogeneity of cancer metabolism 
is evident in genetic mutations in oncogenes and 
tumor-suppressor genes, as well as the diversity 
of the TME.
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Key Points
• Heterogeneity is a hallmark of cancer.
• Clonal evolution theory and cancer stem cell 
theory explain tumor subpopulation growth.
• Intratumoral metabolic heterogeneity follows 
intratumoral genetic alterations.
• Epigenetics alterations lead to intratumoral 
metabolic heterogeneity.
• Intratumoral metabolic adaptation and hetero-
geneity are due to the extreme conditions of 
the tumor microenvironment.
• Spatial and temporal heterogeneity provides 
survival advantages to tumors.
• Metabolic profile-targeted therapeutics can 
result in successful clinical outcomes.
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Cancer is one of the deadliest diseases in the 
world, causing over half a million deaths a year 
in the USA alone. Despite recent advances made 
in the field of cancer biology and the therapies 
that have been developed [1, 2], it is clear that 
more advances are necessary for us to classify 
cancer as curable. The logical question that 
arises is simple: Why, despite all the technolo-
gies and medical innovations of our time, has a 
complete cure eluded us? This chapter sheds 
light on one of cancer’s most impactful attri-
butes: its heterogeneity and, more specifically, 
the intratumoral heterogeneity of cancer metab-
olism. Simply put, what makes cancer one of the 
deadliest diseases is its ability to change and 
adapt. Cancer cells’ rapid evolution, coupled 
with their irrepressible ability to divide, gives 
most of them the advantage over our immune 
systems. In this chapter, we delve into the com-
plexities of this adaptability and the vital role 
that metabolism plays in the rise and progression 
of this heterogeneity.
2  Multiple Theories Explain 
Cancer’s Heterogeneous 
Nature
In any observable tumor, there is much more than 
what meets the eye. In the carcinogenic environ-
ment, we can observe a microcosm of the theory 
of evolution at play. While Darwin’s theory was 
proposed to explain the evolution of species due 
to slowly cumulative changes that arise from nat-
ural selection, cancer cells, driven by their genetic 
instability and high reproductive rates, develop 
and evolve in a fraction of our lifetime, leading to 
dangerous and unpredictable outcomes. The 
genetic instability associated with cancerous 
cells gives rise to a plethora of downstream 
 metabolic phenotypes. These phenotypes offer 
cancerous cells one of the most valued assets in 
their battle for survival: their metabolic diversity, 
which can explain why it is so difficult to find 
effective therapies for most cancers.
The explanation of intratumoral heterogeneity 
using the theory of evolution provides a solid basis 
for understanding why and how tumors possess 
this medley of metabolic phenotypes. Tumors 
have different genetic and metabolic phenotypes 
due to different environmental pressures such as 
vascularization, oxygen supply, and other factors 
such as drug treatments. While certain subpopula-
tions with defined metabolic phenotypes may be 
sensitive to a suitable metabolic inhibitor, other 
subclones with different metabolic phenotypes 
may well be resistant to that drug. This explains 
why patients may become unresponsive to second-
round treatment after an initial successful first 
round in which most of the tumor was targeted and 
eliminated by the treatment, but small subpopula-
tions were not [3]. These selective pressures pro-
mote the survival and propagation of genetically 
and even epigenetically diverse subclones that 
lead to the downstream array of distinct metabolic 
phenotypes in each subclone (Fig. 1). It is impor-
tant to mention another heterogeneity-emerging 
theory, namely the cancer stem cell (CSC) theory, 
which challenges the previously mentioned clonal 
evolution theory. The clonal evolution theory 
claims that genetically and metabolically distinct 
subpopulations arise from a previously larger pop-
ulation of cancer cells due to the expansion of the 
population, genetic diversification, and selection 
of certain subclones over others. On the other 
hand, the CSC theory states that a significant 
source of heterogeneity in cancer cells is due to 
CSCs, which are undifferentiated and have high 
rates of division. These cancer stem cells possess 
largely variable metabolic phenotypes through 
their differentiation into different types of cells [4]. 
They are also capable of differentiating into meta-
bolically and functionally diverse subclones within 
a single tumor. Moreover, they are usually resis-
tant to many therapeutic methods due to their 
undifferentiated state. This fact is supported by 
findings suggesting that more differentiated cancer 
stem cells tend to lead to better prognoses due to 
their decreased tumorigenic potential [5]. In fact, 
the mechanism behind many therapies for cancer 
patients induces differentiation of CSCs. The ori-
gin of these CSCs ranges from tumor cells that 
acquired stem cell properties to differentiated stem 
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cells that simply accumulated mutations that turn 
them into CSCs [6].
Cancer is further complicated by the fact that 
the different sources of heterogeneity, namely 
CSC-derived heterogeneity, evolution-derived het-
erogeneity, and heterogeneity related to environ-
mental factors, can all coexist at once [7]. This 
makes it a much more arduous feat to eradicate all 
subclones within any given tumor which then leads 
to the following question: Why do cancer cells 
employ various biological processes, even within a 
single tumor from a single patient? The ultimate 
advantage of intratumoral heterogeneity of cancer 
cell metabolism is that it confers on the cancer cells 
an ability to survive and proliferate within the 
tremendously variable, and often harsh, tumor 
microenvironment. The diversity of the tumor 
microenvironment—characterized by areas of poor 
oxygenation, increased acidity, sparse nutrients, or 
growth factors—is the challenge that cancer cells 
must overcome in order to achieve the goals of 
 survival and continued rapid cell proliferation.
How do these diverse metabolic phenotypes 
arise? We know that the different microenviron-
ments in any given tumor provide different 
selective pressures that lead to the propagation 
of specific advantageous mutations in each 
respective cancer subclone. We also know that 
CSCs can contribute to the heterogeneous aspect 
of a tumor by providing differentiated subpopu-
lations with varied genetic expressions and met-
abolic pathways. These changes result in a 
variety of proteins and, most importantly among 
them, enzymes necessary to effectively convert 
locally available nutrients into energy and useful 
products suited for each microenvironment to 
obtain what is required for the production of a 
specific metabolic phenotype for each subclone.




The intricate relationship between genetics and 
metabolism in cancer is arguably the main reason 
why the diverse metabolic phenotypes within a 
given tumor can arise. All of the genetic changes, 
if occurring in different regions of a tumor, can 
Fig. 1 Bottleneck effect 
in tumors. Metabolically 
different subclones of a 
tumor, each represented 
by a different color. 
Survival and growth 
rates of subclones 
depend on the various 
selective environmental 
pressures applied such 
as blood supply 
shortage, low oxygen 
levels, and drug 
treatment
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lead to a diverse array of differently regulated 
metabolic processes in a tumor.
Genetic alterations, which are often the result 
of a response to the tumor microenvironment, are 
the means by which cancer cells are able to pro-
duce the enzymes necessary to effectively con-
vert locally available nutrients into energy and 
useful products to achieve their goals. Oxygen 
and nutrient supply varies across individual 
tumors. Thus, intratumoral gene expression is 
diverse, and it is this genetic heterogeneity that 
allows cancer cells to adapt to the diverse and 
taxing conditions of the tumor microenviron-
ment. These adaptations in nutrient uptake and 
biosynthesis, which have been linked to particu-
lar genetic mutations, must follow from altered 
gene expression in cancer cells. As such, the 
enzymes produced are the proximate causes of 
the adoption of alternative metabolic pathways, 
which contribute to the cancer cells’ successful 
survival and growth.
In light of the evidence of intratumoral genetic 
heterogeneity, along with the fact that changes in 
cancer cell metabolism are the consequences of 
alterations in gene expression, cancer metabo-
lism must be vastly diverse across a single tumor. 
A recent study noted the coexistence of various 
genetically different subclones in advanced 
tumors, challenging the previously held notion 
that a dominant subclone usually appears in a 
given tumor [8]. Furthermore, based on the 
expression of 110 genes, another study showed 
that different subpopulations in one clear cell car-
cinoma could be classified as either clear cell A 
(associated with good prognosis) or B (associ-
ated with poor prognosis) [8, 9]. These results 
emphasize not only how varied gene expression 
within a single tumor can be, but also the need to 
accurately use prognostic markers due to the dif-
ferent genotypes within each subclone, as not 
doing so could potentially lead to erroneous 
prognoses (Fig. 2).
Another study has shown that intratumoral 
genetic diversity is also widely prevalent within 
tumor cell populations in breast carcinomas [10, 
11]. These tumor cell populations are composed 
of stem cell-like or more differentiated cell popu-
lations expressing different clusters of differenti-
ation and antigens on their surface [10]. These 
subpopulations were further found to exhibit 
highly heterogeneous genetic compositions, 
implying different biological and metabolic func-
tions and, most likely, different responses to the 
same treatments [10].
4  Epigenetics Alterations Lead 
to Intratumoral Metabolic 
Heterogeneity
It is important to note that not all heterogeneity 
arises from genetic alterations. New studies point 
to the important role of epigenetics in tumor het-
erogeneity. Epigenetics studies have recently 
uncovered increased methylation in promoters of 
a variety of important genes in tumor progres-
sion, such as tumor-suppressor genes [12]. Other 
findings also showed similar roles of epigenetics 
in cancer evolution. We can observe an example 
of the effect of intratumoral epigenetic heteroge-
neity in a study which revealed that in a given 
glioblastoma [14] tumor, 40% transcriptional 
heterogeneity was observed in a gene encoding a 
DNA repair enzyme: O6-methylguanine DNA 
methyltransferase (MGMT) [13]. Furthermore, 
14% of the heterogeneity was attributed to the 
methylation levels of the promoter of that gene, 
whose methylation status has been used for clini-
cal purposes as a marker that correlates with ther-
apeutic response [13]. However, these variations 
in expression across a single tumor pose a threat 
to the effectiveness of this enzyme as a clinical 
marker. In addition to the genetic heterogeneity 
observed, researchers and clinicians need to keep 
in mind the variability displayed on an epigenetic 
level across a single tumor. Therefore, it is fair to 
keep in mind the potential effect epigenetics 
could have on metabolism.
In a study by Okegawa et al., the characteriza-
tion of kidney tumors revealed distinct metabolic 
profiles in different regions of the same tumor 
[15]. The study identified two distinct tumor met-
abolic clusters, MC1 and MC2, where MC2 dis-
played upregulated pyruvate metabolism, which 
was confirmed using isotope tracing in tumor 
slices. This suggests that pyruvate metabolism 
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may be a potential therapeutic target due to some 
clones’ reliance on it. However, genetic differ-
ences between subpopulations did not match the 
metabolic profiles of such subclones, suggesting 
that factors other than genetics, such as epi-
genetics, may play a role in developing distinct 
metabolic phenotypes.






Now we will take a closer look at how a tumor 
can metabolically adapt to its ever-changing 
environment. These adaptations also reflect an 
evolutionary advantage in cancer cells and give 
rise to the heterogeneity found in cancer. As a 
tumor grows in size, it develops hypoxic regions 
that are beyond the diffusion limits of oxygen in 
existing vasculature. Tumor hypoxia, in addi-
tion to its role in the mutation of oncogenes and 
tumor-suppressor genes, plays a major role in 
the overexpression of hypoxia-inducible 
factor-1α (HIF-1α) in cancer. HIF-1α is part of a 
heterodimeric protein that acts as a transcrip-
tional regulator for many genes involved in 
angiogenesis, erythropoietin production, and 
cell survival. While HIF-1α usually degrades 
quickly under normal conditions, degradation is 
suppressed in hypoxic environments. Therefore, 
increased HIF-1α level upregulates the expres-
sion of genes that code for adaptive metabolic 
changes, switching cancer cell metabolism from 
oxidative phosphorylation (OXPHOS) to gly-
colysis, increasing the conversion of glucose to 
glycogen as a glucose reservoir, and using glu-
tamine as the major substrate for fatty acid syn-
thesis [16, 17]. Furthermore, HIF-1 directly 
transactivates lactate dehydrogenase A (LDHA) 
expression under hypoxia [17], which explains 
how hypoxia further promotes glycolysis 
[18–20].
In order for the tumor to metastasize and grow 
beyond a few millimeters, angiogenesis is neces-
sary [21]. HIF-1α also upregulates the expression 
of genes that code for angiogenesis. One of the 
most notable of such genes is the gene encoding 
proangiogenic vascular endothelial growth factor 
(VEGF), which induces the proliferation of endo-
thelial cells (ECs), a key process in angiogenesis 
[22–24]. Surprisingly, several studies found that 
ECs mainly rely on glycolysis rather than oxida-
tive phosphorylation (OXPHOS) despite their 
ideal location that promotes their function as 
endothelium and in maintaining vascular barrier 
homeostasis and bioenergetics [25–30]. Similar 
to cancer cells, ECs choose aerobic glycolysis 
over OXPHOS due to their rapid growth, which 
is necessary to fulfill the demands of forming 
new blood vessels [25]. Reducing glycolysis by 
Fig. 2 The intratumoral 
heterogeneity of cancer 
metabolism. Clear cell 
carcinoma tumor (shown 
in blue) with subclones 
(shown in orange and 
gray). The orange 
subclone consists of 
clear cell A cells 
(associated with good 
prognoses), and the gray 
subpopulation consists 
of clear cell B cells 
(associated with poor 
prognoses). Single 
biopsies taken from one 
population may indicate 
misleading prognoses
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silencing its stimulator phosphofructokinase-2/
fructose-2,6-bisphosphatase 3 (PFKFB3) 
decreased angiogenesis [25]. Moreover, 
PFKFB3-deficient ECs display poor vessel 
growth in several in vivo models of angiogenesis. 
VEGF, in turn, also promotes glycolysis through 
the upregulation of glucose transporter type 1 
(GLUT-1), which facilitates glucose uptake [31].
The tumor microenvironment is tremendously 
dynamic and diverse regarding nutrient and oxy-
gen supply, both spatially and temporally within 
a single tumor. Temporal variations of the partial 
pressure of oxygen within a specified region of 
the tumor referred to as intermittent or cyclic 
hypoxia occur in different regions throughout the 
tumor [32]. The occurrence of cyclic hypoxia is 
attributed to variations in red blood cell flux, 
which is thought to be a result of changes in 
blood flow resistance that arise from angiogene-
sis and other structural changes to the vasculature 
[32, 33]. Regions of the tumor with adequate vas-
culature are much more resistant to intermittent 
hypoxia than regions with insufficient vascula-
ture [34]. Although reduced oxygenation to select 
either regions or the entire tumor can induce 
hypoxia, an increase of equal magnitude in oxy-
gen consumption is disproportionately more 
effective in inducing hypoxia [35–39]. These 
variations in oxygen and nutrient delivery, as 
well as in oxygen consumption within a tumor, 
are fundamental to the pervasive metabolic het-
erogeneity exhibited by different types of can-
cers, patients with the same cancer type, and, 
most notably, a single tumor from any given 
patient.
6  Metabolic Heterogeneity 
Leads to Unpredictable 
Outcomes
Now that we have a basic understanding of how 
the various metabolic phenotypes in a given 
tumor arise and the different processes driving it, 
we can take a look at some specific examples and 
cases of intratumoral metabolic heterogeneity.
6.1  Spatial Heterogeneity 
Provides a Survival 
Advantage to Tumors
For a long time, it was believed that cancer cells’ 
major metabolic footprint was the Warburg effect, 
which dictates that cancer cells undergo glycoly-
sis to produce lactic acid even in the presence of 
oxygen, a process termed aerobic glycolysis. 
Although the Warburg effect is still relevant, it 
has recently become clear that the metabolic phe-
notypes of cancer cells are far more varied and 
intricate. In a recent study published by Le et al. 
[40], the identification of genetic variability 
within the same tumor also revealed distinct met-
abolic profiles of each cell subpopulation within 
a given tumor. In addition to the hypoxia- 
inducible factor (HIF) positive and/or cycling 
cells (Warburg effect-displaying cells), they 
found that the subpopulation that was HIF nega-
tive and non-cycling expressed a distinct set of 
genes with increased expression of mitochondrial 
genes as compared to other subpopulations. This 
subpopulation respires under hypoxia, supported 
by the fact that it has the highest oxygen con-
sumption rate and mitochondrial capacity. The 
non-cycling and HIF-negative subclone is able to 
produce a tumor when purified and injected as a 
xenograft in vivo. This points to the importance 
of understanding how cancer metabolism allows 
for tremendous metabolic variegation.
Hypoxic cells can also coexist with aerobic 
cells, those that undergo oxidative phosphoryla-
tion, in a commensal manner. Hypoxic cells pro-
vide lactate that can be converted to pyruvate in 
the aerobic cells, which use it to run the TCA 
cycle and undergo oxidative phosphorylation 
[41]. These aerobic cells are oxygenated due to 
their proximity to a nearby blood supply. 
Therefore, they can survive in this manner and 
are more suited to doing so than hypoxic cells. 
However, in addition to these two types of can-
cerous cells, Le et al. recently uncovered the exis-
tence of a non-Warburg metabolic phenotype in 
B lymphoma cells that undergo hypoxic respira-
tion by activating the TCA cycle through gluta-
mine oxidation [19]. Oxidation of glutamine 
allows it to be used as a source for running the 
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TCA cycle and enables the decrease of reliance 
on glucose as a primary fuel source for cancer 
cells [42]. This revelation once again supports the 
existence of diverse metabolic phenotypes in any 
given tumor.
The metabolic nature of cancer is muddled. 
Not only do some cancer subclones form com-
mensal relationships with each other, but cancer 
cells can also form similar relationships with 
cancer-associated fibroblasts (CAFs) [43, 44]. 
CAFs are a subpopulation of cells that reside 
within the tumor microenvironment and support 
the proliferation and growth of tumor cells. By 
providing lactate and ketone bodies, acidic com-
pounds that can form acetyl-CoA in a reversible 
manner, and by taking up reactive oxygen species 
that promote glycolytic metabolic pathways, 
CAFs establish a fundamental relationship with 
adjacent cancer cells [45]. CAFs are also involved 
in the maintenance of an acidic extracellular 
environment, providing suitable conditions for 
optimal cancer cell growth [45].
Elgogary et al. present another case of spatial 
metabolic heterogeneity. Pancreatic tumors were 
targeted by bis-2-(5-phenylacetamido-1,3,4- 
thiadiazol- 2-yl)ethyl sulfide (BPTES), a gluta-
minase 1 (GLS1) inhibitor, which was 
encapsulated in a nanoparticle to enhance drug 
delivery [46]. The drug decreased tumor sizes, 
but metabolomics analysis [47] revealed that sur-
viving tumors relied on glycolysis and glycogen 
synthesis instead. Thus, further combination 
therapy of BPTES and metformin, a drug fre-
quently used to treat diabetes by blocking glu-
cose synthesis, further reduced tumor size. These 
results support the prevailing consensus that dif-
ferent metabolic phenotypes in any given tumor 
require specific therapeutic actions based on each 
subclonal phenotype (Fig. 3).
As previously noted, hypoxia has been found 
to play an important role in the development of 
heterogeneous phenotypes in cancer cells. In a 
recent study, Fluegen et al. investigated the fate of 
disseminated tumor cells (DTCs). They revealed 
that these post-hypoxia DTCs carry an array of 
upregulated genes, such as dormancy (nuclear 
receptor subfamily 2 group F member 1 (NR2F1), 
DEC2, p27) and hypoxia (HIF-1α) genes, in addi-
tion to the GLUT-1 gene [48]. This dormant sub-
population, which evades many chemotherapies, 
as the authors of the paper noted, could explain 
relapse and the poor survival rates. As a result, 
heterogeneity in cancer metabolism comes in a 
variety of forms, and the same factor, in this case, 
hypoxia, can come into play through different 
approaches depending on each scenario.
While the different aspects of cancer metabo-
lism may seem to intertwine neatly, the relation-
ship between these parts is far more complex. For 
instance, while glutamine utilization in the TCA 
cycle is heavily linked to low oxygen consump-
tion and hypoxia, the latter can sometimes occur 
independently of the former. Thus, these path-
ways may overlap when intracellular lactate 
causes an increase in glutamine uptake and 
metabolism. However, anaplerosis (pyruvate 
conversion into oxaloacetate), an alternative use 
of pyruvate in hypoxic conditions, can sometimes 
lead to the conversion of glucose to glutamate, 
taking away glutamine’s role as the glutamate 
and α-ketoglutarate (α-KG) provider needed to 
run the TCA cycle [49].
Despite our tendency to separate different 
metabolic pathways and to assign rigid pathways 
to cancer metabolism, it must be noted that dif-
ferent pathways often cross-talk and that the cor-
relative nature of many metabolic pathways does 
not necessarily point to a causative relationship.
6.2  Temporal Heterogeneity 
Provides Cancer with Short- 
Term Adaptive Capabilities
As discussed earlier, tumors tend to evolve rapidly 
and produce dissimilar subclones through their 
interaction with the microenvironment. There exists 
a similar sort of evolution in single cancer cells: a 
form of temporal heterogeneity. Cancer cells are 
also astoundingly plastic regarding their metabo-
lism. For example, they can switch their mitochon-
drial energy source between glutamine and glucose 
through the utilization of different transcriptional 
factors that encode enzymes required for each 
respective metabolic pathway. Cancer cells achieve 
this kind of plasticity through a variety of mecha-
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nisms. Posttranslational modifications allow a quick 
and immediate response to changes in the environ-
ment, which could be useful in the sense that blood 
supply changes can be very rapid. Slower modifica-
tions do also exist, such as changes in gene expres-
sion and epigenetic modifications.
An example of such posttranslational modifi-
cations and an illustration of cancer’s remarkable 
plasticity are seen once again in hypoxic cancer 
cells. Hypoxic cancer cells increase the transcrip-
tion of pyruvate kinase muscle isoform 2 (PKM2), 
an enzyme responsible for the final nonreversible 
step in glycolysis, the conversion of phospho-
enolpyruvate to pyruvate. This is achieved as the 
first intron of the PKM2 gene contains a hypoxia 
response element that is a target for HIF-1α. 
PKM2 is produced through the alternative splic-
ing of the precursor mRNA PKM and is con-
trolled by c-MYC [50, 51]. As such, high PKM2 
levels are correlated with poor survival rates in 
gastric cancers as this upregulation of PKM2 
helps cancer cells dedicate most of their glucose 
towards lactate production quickly and efficiently 
under hypoxic conditions [52]. Therefore, this 
posttranslational modification allows cancer cells 
to switch their metabolic profiles quickly and 
efficiently when faced with varying environmen-
tal conditions.
7  Tailored Clinical Applications 
and Therapies Targeting 
Metabolic Pathways Can Lead 
to Better Clinical Outcomes
Given the different tumor microenvironments, 
the diversity of cancer cell metabolism, and their 
genetic and epigenetic composition, various tech-
niques have been developed to visualize the dif-
ferent tumor microenvironments in a given tumor. 
These imaging techniques have further propelled 
us in the search for effective cancer therapies tar-
geting different cancer cell metabolism that can 
be specialized and tailor-made for every different 
microenvironment.
The most successful methods currently used to 
identify different tumor microenvironments 














Fig. 3 Depiction of effects of combined therapy based on cancer metabolism. Depicted is an in vivo tumor containing 
different subpopulations of cancer cells (glycolytic cells presented as blue, glutamine-dependent cells presented as red, 
and other metabolic pathway-dependent cells presented as green)
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computed tomography (PET-CT) scans. 
18F-Fluorodeoxyglucose-positron-emission 
tomography (FDG-PET) images of individual 
cervical tumors have revealed varying levels of 
glucose consumption across different regions of a 
single tumor [53]. The variation of glucose con-
sumption within a tumor has been associated with 
increased expression of glucose transporters 
GLUT-1, GLUT-3, and hexokinase 2 (HK-2), the 
first key enzyme of glucose metabolism [54]. PET 
scans can also be used to identify hypoxic micro-
environments through the use of isotopically 
labeled 18F-fluoromisonidazole (FMISO), which 
is injected and taken up by cells through passive 
diffusion. In the absence of oxygen, FMISO accu-
mulates in cells to generate an image of the 
hypoxic regions within a tumor [55]. PET scans 
can also be used to measure various tumor micro-
environments based on other variables such as the 
partial pressure of oxygen [56].
Intratumoral metabolic heterogeneity in can-
cer can also serve as a useful tool for prognosis. 
In a study done by Mena et al., intratumoral met-
abolic heterogeneity was measured across 105 
patients with oropharyngeal squamous cell carci-
noma, along with either standardized uptake val-
ues of glucose (SUV) or metabolic tumor volume 
(MTV). These measurements were shown to 
have effective capacities as prognostic markers 
(p = 0.026 and 0.022, respectively), with higher 
levels indicating poorer prognoses, supporting 
the notion that the more diverse metabolic pheno-
types exist within a tumor, the more arduous a 
task it becomes to eradicate all different sub-
clones in the tumor [57].
Besides prognostication, increased knowledge 
of cancer’s heterogeneous metabolic nature, and 
specifically its intratumoral heterogeneity, can 
enable specific targeting of subclones in a single 
tumor and has resulted in a surge in specific tailor- 
made cancer therapies. One of the earliest hall-
marks of cancer is its ability to take up increased 
amounts of glucose, through the utilization of 
many GLUTs. Cancer cells are also capable of 
metabolizing glucose at much quicker rates than 
normal cells. Consequently, this has resulted in 
increased research addressing the production of 
commercial GLUT inhibitors and the transporter 
isoform specificity of inhibition [58]. Other drugs 
have been developed to target the hypoxic path-
ways of cancer cells, such as topotecan, which 
inhibits hypoxia-inducible factor 1 (HIF-1) tran-
scriptional activity and HIF-1α protein accumula-
tion in hypoxia-treated U251 human glioma cells 
[59]. This has generated increased interest in 
mRNA-regulating agents that target HIF-1α. Many 
drugs have followed with variable success that act 
by blocking mRNA transcription of the HIF-1α 
gene. Recent research has also provided many 
other pathways in cancer metabolism that can be 
targeted with effective results. For example, lactate 
dehydrogenase A (LDHA), an enzyme involved in 
the generation of lactate from glucose in Warburg 
effect-displaying cells, has also been found to be a 
suitable target for effective tumor reduction through 
small-molecule inhibition. Decreased expression 
of LDHA through small-molecule FX11 inhibition 
elevated oxidative stress levels and ultimately 
resulted in cell death and tumor volume reduction 
[60–62]. Other methods targeting HIF-1α and 
hypoxia have been formulated through the integra-
tion of different therapies to each specific tumor 
microenvironment [63], making complete cancer 
recession very promising. Again, it is vital to real-
ize the complex nature of cancer metabolism and 
the need for specific therapies to be directed at the 
individual metabolic phenotypes in order to see 
effective responses in patients (Fig. 4).
8  Conclusion
Despite the challenges, there is much hope in the 
field of cancer therapies. The recently discovered 
and understood aspects of cancer’s metabolic het-
erogeneity, including its intricate interactions with 
CAFs, the exchanges between its distinct sub-
clones, and its impressive plasticity, promise to 
greatly advance this field. The importance of 
accounting for intratumoral heterogeneity in any 
given tumor has never been as widely understood 
as it is now. The latest findings we have discussed 
in this chapter give us a more solid understanding 
of cancer complexities, which we can seek to 
translate into effective and strategic therapies in 
the near future.
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• CSCs are different from stem cells and non-
CSC tumor cells metabolically, but CSCs 
share some similarities with both stem cells 
and cancer cells in glucose, glutamine, oxida-
tive phosphorylation (OXPHOS), and lipid 
metabolism.
• The commonly shared metabolic pathways 
indicate that CSCs are a subtype of cancer 
cells that genetically evolved from normal 
stem/progenitor cells.
• The commonly shared metabolic pathways 
between CSCs, stem cells, and non-CSC 
tumor cells indicate that these metabolic path-
ways are selected due to their ability to sustain 
the catabolic and anabolic needs of highly 
proliferating cells.
• The fact that CSCs share metabolic pathways 
with stem cells and cancer cells poses a chal-
lenge for developing cancer metabolic drugs 
that do not target normal stem cells.
• Further studies are needed to shed light on 
how to develop specific metabolic drugs tar-
geting CSCs in specific cancer types.
1  Introduction
Cancer stem cells (CSCs), also known as tumor- 
initiating cells (TICs), are a group of cells found 
within cancer cells. Like normal stem cells, CSCs 
can proliferate, engage in self-renewal, and are 
often implicated in the recurrence of tumors after 
therapy [1, 2]. The existence of CSCs in various 
types of cancer has been proven, such as in acute 
myeloid leukemia (AML) [3], breast [4], pancre-
atic [5], and lung cancers [6], to name a few. 
There are two theories regarding the origin of 
CSCs. First, CSCs may have arisen from normal 
stem/progenitor cells that experienced changes in 
their environment or genetic mutations. On the 
other hand, CSCs may also have originated from 
differentiated cells that underwent genetic and/or 
heterotypic modifications [7]. Either way, CSCs 
reprogram their metabolism in order to support 
tumorigenesis.
Metabolism plays a crucial role in cellular 
function and survival, and it is no different for 
CSCs. Metabolic rewiring is necessary for CSCs 
as it enables them to adapt to different environ-
ments and survive. For example, metabolic rewir-
ing to oxidative phosphorylation (OXPHOS) 
from glycolysis makes CSCs more efficient in 
generating adenosine triphosphate (ATP) and 
more resistant to microenvironmental pressures 
such as lack of nutrients [8]. Understanding the 
metabolism of CSCs would enhance targeting 
CSCs, and in turn improve cancer therapy. In this 
chapter, we will be looking at four key metabo-
lism of CSCs—glucose metabolism, glutamine 
metabolism, mitochondrial metabolism, and lipid 
metabolism—and how they affect the state of 
CSCs (Fig. 1).
2  High Levels of Glycolytic 
Enzymes and Activities 
in CSCs (Fig. 2)
In Chap. 1, glucose metabolism and the Warburg 
effect have been described as key processes in 
cancer cells [9]. Not only are these processes 
observed in cancer cells, but they are also rele-
vant to CSCs. Stemness features of CSCs, such 
as proliferation, are shown to be reliant on the 
Warburg effect [10].
CSCs across different types of cancers are 
found to express high levels of glycolytic genes. 
Song et  al. found that CD133(+) liver CSCs 
exhibit increased expressions of glycolytic genes: 
glucose transporter 1 (GLUT1), hexokinase II 
(HK2), pyruvate dehydrogenase kinase 4 
(PDK4), and phosphoglycerate mutase 1 
(PGAM1). Furthermore, they observed a high 
extracellular acidification rate (ECAR) and 
decreased expressions of gluconeogenetic genes: 
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glucose-6-phosphatase (G6Pase) and phospho-
enolpyruvate carboxykinase (Pepck) [11]. These 
findings align with observations made in naso-
pharyngeal carcinoma (NPC) CSCs. In compari-
son to their parental cells, NPC CSCs express 
higher levels of GLUT1, HK2, and glucose- 6- 
phosphate isomerase (GPI) [12]. The high levels 
of glycolytic genes found in CSCs suggest that 
CSCs depend on glucose metabolism as a source 
of energy.
Studies have demonstrated the importance of 
glycolytic enzymes in CSCs, such as regulating 
the self-renewal and spheroid formation ability of 
CSCs. Shibuya et al. studied the role of GLUT1 in 
the CSCs of glioblastoma, pancreatic, and ovar-
ian cancers. They found that the inhibition of 
GLUT1, through either siRNA-mediated knock-
down or pharmacological inhibition by WZB117, 
a small-molecule inhibitor, resulted in a decrease 
in the uptake of glucose, a reduction in the 
expressions of stem cell markers (Sox2, Bmi1, 
Nanog), and an increase in the expressions of dif-
ferentiation markers (GFAP in glioblastoma and 
B-actin in glioblastoma, pancreatic, and ovarian 
CSCs). Furthermore, these inhibitions impaired 
the spheroid-formation ability of CSCs, and inhi-
bition by WZB117 did so without affecting their 
proliferative potential [13]. These findings sug-
gest that GLUT1 plays a crucial role in maintain-
ing the glucose metabolism and stemness 
characteristics of CSCs.
PDK4, one of the highly expressed genes in 
liver CSCs mentioned earlier, is an inhibitor of 
pyruvate dehydrogenase complex (PDHC). 
PDHC regulates the entrance of glucose-derived 
pyruvate into the mitochondria, which will subse-
quently form acetyl- CoA for the tricarboxylic 
acid (TCA) cycle. Song et al. found that low lev-
els of liver- specific miR-122, which targets 
PDK4, are expressed in CD133+ cells. This 
allows for the upregulation of PDK4 and the sub-
sequent inhibition of PDH, which in turn results 
in the failure of pyruvate to enter the mitochon-
drial matrix. Instead of going through subsequent 
Fig. 1 Cancer stem cell metabolism compared to normal cell metabolism
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oxidative phosphorylation (OXPHOS), lactate 
production in the cytosol occurs [11]. Therefore, 
this supports the idea that the Warburg effect is of 
relevance to CSCs. In fact, high levels of miR-122 
impair the spheroid-formation ability of CSCs 
[11]. Hence, suppression of miR-122  in liver 
CSCs allows the induction of glucose  metabolism 
and preference for fermentation instead of 
OXPHOS.
The conversion of pyruvate to lactate in the 
cytosol is regulated by lactate dehydrogenase A 
(LDH-A), which was found to be upregulated in 
breast CSCs compared to spheroid-derived adher-
ent cells (SDACs) [14]. The importance of LDH-A 
can be concluded from the deleterious effect of 
LDH-A suppression on CSCs. The knockdown of 
LDH-A caused liver CD133+ CSCs to produce 
fewer transcriptional factors (Sox2, Nanog, Oct4) 
that give rise to stemness characteristics, and their 
spheroid-formation ability was impaired [11]. 
Furthermore, in non- small cell lung carcinoma 
(NSCLC), the suppression of LDH-A by shRNA 
resulted in a decrease of CSCs in the A549 cell line 
and a decrease in their ability to form tumor-
spheres [15]. These findings reinforce the idea that 
glucose metabolism, which results in lactate pro-
duction, is central to the survival of CSCs and the 
maintenance of their stemness characteristics. 
LDH-A inhibitor such as FX-11 has been tested in 
Fig. 2 Glucose and glutamine metabolism in cancer stem cells. GLUT1 glucose transporter 1, HK2 hexokinase II, 
LDH-A lactate dehydrogenase A, PDHC pyruvate dehydrogenase complex, PDK4 pyruvate dehydrogenase kinase 4, 
GOT glutamic-oxaloacetic transaminase, GLS1 glutaminase 1, ASCT2 alanine, serine, cysteine transporter 2
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several types of cancers [9, 16–18] and could be a 
potential strategy in targeting CSCs.
3  Effects of Deregulation 
of Glutamine Metabolism 
on CSCs (Fig. 2)
Glutamine metabolism is also a source of energy 
for cancer cells that is an alternative to glucose 
metabolism [19, 20]. For CSCs, a lack of glucose- 
derived pyruvate for the TCA cycle would mean 
that reliance on other metabolites to drive the 
TCA cycle is needed. Compared to non-CSCs, 
metabolites from oxidative glutamine metabo-
lism contribute to the TCA cycle in CSCs [10]. 
Additionally, both glucose deprivation and treat-
ment using the glycolytic inhibitor 2-deoxy- 
glucose (2-DG) resulted in an increase in the 
uptake of glutamine into CSCs but not into non-
CSCs, further suggesting the metabolic plasticity 
of CSCs [10]. Colorectal CSCs of the SW620 
cell line were shown to be resistant to the effects 
of inhibition of mitochondrial metabolism by 
metformin because they compensated by deriv-
ing energy from glutamine metabolism [21]. 
These findings suggest the importance of gluta-
mine metabolism in CSC survival. Targeting of 
glutamine metabolism has been extensively 
 studied by many researchers [22–29]. These 
strategies could have the potential of eliminating 
CSCs.
Glutaminolysis starts with the intake of gluta-
mine into the cell via transporters such as ala-
nine, serine, and cysteine transporter 2 (ASCT2). 
Kim et al. found that the CSCs of colorectal can-
cer, both HT29 and SW260 cell lines, have a 
higher amount of ASCT2 than non-CSCs, which 
means that a higher glutamine uptake occurs in 
CSCs. After ASCT2 knockdown, the number of 
CD133+/CD44+ CSCs drastically decreased. In 
metformin-resistant cell line SW260, the siRNA- 
mediated knockdown of glutaminase 1 (GLS1) 
and ASCT2 decreased the number of CSCs, with 
a more significant decrease observed during 
ASCT2 knockdown only [21].
Another study on pancreatic CSCs has dem-
onstrated the importance of glutamine metabo-
lism to CSCs. When there is a lack of glutamine, 
pancreatic CSCs have a decreased ability to form 
both primary and secondary spheroids. 
Furthermore, the lack of glutamine also resulted 
in reduced expression of stemness-related genes 
and accumulation of intracellular reactive oxy-
gen species (ROS). Oxaloacetate (OAA), an 
intermediate of the TCA cycle, was found to alle-
viate the high ROS levels. Furthermore, the 
knockdown of cytosolic glutamic-oxaloacetic 
transaminase 1 (GOT1), which converts aspartate 
to OAA, together with the administration of low-
dose ionizing radiation (IR) resulted in impair-
ment of spheroid-formation ability, and the 
spheroids formed experienced apoptosis within 
10 days of their formation [30]. These findings 
revealed the important role that OAA plays in 
ensuring a balanced ROS level in CSCs. 
Therefore, the noncanonical pathway of gluta-
mine metabolism helps CSCs in their ability to 
resist ROS accumulation and its effects.
4  Mitochondrial Metabolism 
(Fig. 3)
The term “mitostemness” describes the crucial 
role that mitochondria play in the ability of CSCs 
to self-renew and resist differentiating and losing 
their stemness properties [31]. The ability of 
CSCs to switch across different types of metabo-
lism for better survival in different environmental 
conditions has resulted in contradictory findings 
regarding their metabolism. Some studies have 
shown that CSCs depend on glycolysis [32, 33], 
while others have described CSCs to be mostly 
dependent on OXPHOS [33–35].
In addition to their energetics contributions, 
mitochondrial metabolic pathways also epigeneti-
cally regulate CSC stemness. Mitochondrial 
metabolism is important because the TCA cycle 
and OXPHOS are involved in the production of 
metabolites such as acetyl-CoA, alpha- 
ketoglutarate, NAD+, and S-adenosyl methio-
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nine, which are substrates for chromatin-state 
modifications, whether acetylation or methylation 
[36]. In turn, these epigenetic modifications have 
been found to alter the stemness of CSCs [37].
4.1  OXPHOS
OXPHOS, which involves the mitochondrial respi-
ratory chain, is the last step of aerobic glucose 
metabolism where energy is generated as ATP, 
which is used for cell survival and growth. In a 
study done on pancreatic CSCs, it was found that in 
comparison to normal adherent cells, CSCs have a 
higher number of mitochondria and form more 
components that are required for OXPHOS. 
Furthermore, compared to non-CSCs (CD133− 
differentiated cells), CD133+ CSCs have a higher 
mitochondrial oxygen consumption rate (OCR) 
[35], suggesting the reliance of CSCs on OXPHOS 
for their growth and survival. In fact, the inhibition 
of OXPHOS resulted in CSCs experiencing an 
energy crisis. However, there is a subset of CSCs 
that are resistant to inhibition of mitochondrial 
metabolism by metformin, and they are found to 
have enhanced glycolytic capacity [35], suggesting 
the metabolic plasticity of CSCs.
Studies have shown that the inhibition of 
OXPHOS can have detrimental effects on CSCs. 
Salinomycin, a K+ ionophore, which changes the 
mitochondrial membrane potential of cells, 
inhibits OXPHOS [38] and decreases the number 
of CSCs in breast [39], gastric [40], and pancre-
atic cancers [41]. The change in mitochondrial 
Fig. 3 Mitochondrial metabolism in cancer stem cells. OXPHOS oxidative phosphorylation, ROS reactive oxygen 
species, CSCs cancer stem cells
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membrane potential caused by salinomycin 
causes mitochondrial imbalance. In turn, ATP 
depletion activates AMP-activated protein kinase 
(AMPK) and results in apoptosis of CSCs [42]. A 
balanced and well-regulated mitochondrion is, 
therefore, important to CSCs.
The mitochondrial respiratory chain is com-
prised of four enzymatic complexes for the trans-
fer of electrons to O2 and generate ATP, which is 
used for cell survival. Only complex II is com-
pletely encoded by the nuclear genome, while for 
complexes I, III, and IV, mitochondrial DNA 
(mtDNA) plays a role in encoding them [43]. The 
inhibition of these complexes is detrimental to 
the survival and growth of CSCs and, therefore, 
they serve as possible targets for eliminating 
CSCs. The inhibition of complex I in pancreatic 
cancer by metformin resulted in a cell cycle arrest 
in non-CSCs, while in CSCs, it led to apoptosis 
[34]. This observation aligns with the finding that 
metformin results in the selective killing of 
CD44+/CD24− CSCs of MCF10-A and MCF-7 
cell lines, and works well with doxorubicin in 
reducing both CSCs and non-CSCs [44]. Another 
study showed that the inhibition of complexes I 
and II by pyrvinium pamoate caused dysregu-
lated mitochondrial metabolism in the fat pad 
(FP) CSCs, but this specific mechanism was not 
Fig. 4 Lipid metabolism in cancer stem cells. SREBP sterol regulatory element-binding protein, ACC1 acetyl carbox-
ylase A, ACLY ATP citrate lyase, FA fatty acid, FASN fatty acid synthase, SCD stearoyl CoA desaturase, CPT1 carnitine 
palmitoyltransferase 1
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toxic to CSCs [45]. Treatment using atovaquone, 
a complex III inhibitor, decreased proliferation of 
CD44+/CD24− MCF7 breast CSCs, and induced 
apoptosis in dose-independent  conditions, but 
had no effect on mitochondrial respiration in nor-
mal fibroblasts [46]. Furthermore, complex V 
inhibitor bedaquiline, which causes ATP deple-
tion, was found to target MCF7 breast CSCs pref-
erentially and did not affect the viability of cancer 
cells and normal human fibroblasts [47]. These 
studies indicated the importance of OXPHOS 
across different CSCs as the inhibition of the 
complexes involved in OXPHOS negatively 
impacted the survival and growth of CSCs. 
However, it is important to keep in mind the dif-
ferent responses to mitochondrial respiratory 
chain complexes’ inhibition seen in different 
CSCs. For instance, complex I inhibition by met-
formin in pancreatic CSCs led to their apoptosis, 
but no cytotoxic effect was brought about in 
FP-CSCs when pyrvinium pamoate inhibited 
complexes I and II. Further studies regarding the 
differences in the mechanism and regulation of 
OXPHOS across different CSCs are required. 
Nevertheless, it is certain that OXPHOS is neces-
sary and important to the survival of CSCs and its 
enzymatic complexes serve as potential targets in 
the elimination of CSCs.
4.2  Resistance of CSCs Against 
ROS
ROS are reactive products generated from mito-
chondrial metabolism. Mitochondria are the 
major source of intracellular ROS, such as free 
radicals, superoxide, and peroxides [42, 48]. 
Excess ROS causes apoptosis via oxidative stress 
[49]. Radiotherapy and most of the chemothera-
pies increase ROS levels and thereby affect can-
cer cell viability and growth [50, 51]. Despite 
such therapy, tumor recurrence does occur due to 
the failure to eliminate CSCs during such treat-
ment [52, 53]. One of the mechanisms of CSC 
resistance is through increased Bcl-2 expression 
and radioresistance.
Studies have shown the resistance of CSCs 
against the effects of ROS in CD44+ CSCs of 
prostate, breast, and colorectal cancers [54–56]. 
An isoform of CD44, CD44v, was found to pro-
tect CSCs of gastric cancer from the detrimental 
effects of ROS accumulation. CD44v stabilizes 
the xCT subunit of cystine-glutamate exchange 
transporter, allowing for the uptake of cystine 
needed for glutathione (GSH) synthesis. The 
upregulation of GSH synthesis makes CSCs 
more antioxidative [57]. Other than containing 
CD44, CSCs increase the expression of antioxi-
dant enzyme genes that neutralize ROS and the 
multifunctional protein apurinic/apyrimidinic 
endonuclease/redox effector factor (Ape1/Ref- 
1). In turn, they neutralize the intracellular ROS 
and reduce DNA damage via DNA repair [58]. 
Therefore, through their antioxidative capability, 
CSCs are resistant to the effects of ROS produced 
during therapy and can, therefore, cause recur-
rence of tumors [58, 59]. The defense mechanism 
against ROS of CSCs needs to be targeted for 
improved cancer treatment.
5  Lipid Metabolism (Fig. 4)
Lipid anabolic metabolism consists of both ex 
novo incorporation of lipids and de novo synthe-
ses of lipids [60, 61]. De novo lipogenesis con-
sists of three major pathways: fatty acid synthesis 
(FAS), mevalonate biosynthesis, and cholesterol 
biosynthesis [62]. CSCs exhibit both ex novo and 
de novo lipid anabolic pathways. Interestingly, 
despite the activation of anabolic pathways, 
CSCs also activate catabolic lipid pathways, such 
as fatty acid oxidation (FAO). Classically, FAS 
and FAO are antagonistic pathways due to the 
role of FAS intermediate malonyl CoA, which 
suppresses carnitine palmitoyltransferase 1 
(CPT1), inactivating FAO in normal cellular 
metabolism [63]. However, it seems that in CSCs, 
both pathways are activated to allow them to 
adapt best to their environmental pressures and 
cellular demands for proliferation.
Lipogenesis via uptake from the environment 
has been reported in CSCs [64]. Given the com-
plexity of certain lipids such as phospholipids 
and cholesterol, which rely on the stoichiomet-
ric balancing of fatty acid with glycerol in vari-
ous combinations, it makes sense that CSCs 
have been found to incorporate these complex 
F. B. Alvina et al.
169
lipids. Mass spectrometry studies reveal that 
CSCs have abundant unsaturated lipids, choles-
terol, and triglycerides (TGs) which are impor-
tant for their stemness [61]. The combination of 
external lipid uptake and de novo lipogenesis 
seems to be the most efficient route for fulfilling 
the increasing demands of membrane produc-
tion for the proliferating CSCs.
De novo lipogenesis, however, still plays a 
major role despite CSC’s ex novo sources of lip-
ids. The FAS pathway, being the initial step of de 
novo lipogenesis, is activated in CSCs, as it is in 
some cancer cells, such as those driven by MYC 
[62, 65, 66]. The key enzymes in the FAS path-
way are ATP citrate lyase (ACLY), acetyl carbox-
ylase A (ACC1), fatty acid synthase (FASN), and 
stearoyl-CoA desaturase (SCD). ACLY is con-
nected directly to the TCA cycle via citrate syn-
thase (CS). Thus, increased TCA mitochondrial 
metabolism in CSCs would also drive the flux 
into FAS via CS into ACLY and the rest of the 
FAS pathway [62]. Though de novo lipogenesis 
may appear to be a secondary or passenger effect 
of increased glucose and glutamine metabolism 
in CSCs, inhibition of virtually any enzyme of 
the FAS pathway in CSCs leads to apoptosis. 
ACLY knockdown reduced the proliferation of 
lung cancer [67] and breast cancer CSCs [68]. 
ACC1 inhibition suppressed the stemness of 
CSCs [69]. Inhibition of FASN reduced the stem-
ness of glioma stem cells [70]. SCD inhibition 
has been correlated with the suppression of vari-
ous CSCs [71].
Like the FAS pathway, the cholesterol synthe-
sis pathways via mevalonate are regulated by 
 sterol regulatory element-binding proteins 
(SREBPs). SREBP2 actively transcribes HMG-
CoA synthase (HMGCS), HMG-CoA reductase 
(HMGCR), mevalonate kinase (MVK), and 
 phosphomevalonate kinase (PMVK) for the pro-
duction of pyrophosphate-containing intermedi-
ates, which leads to the production of cholesterol. 
The mevalonate and cholesterol synthesis path-
ways are connected to the acetyl-CoA pool from 
ACLY in FAS via acetoacetyl CoA transferase 
(ACAT), which feeds into HMGCS.  During 
epithelial- mesenchymal transition (EMT), the 
mevalonate and cholesterol pathways are acti-
vated, such that inhibition of any of the aforemen-
tioned enzymes disrupts CSCs’ stemness and the 
overall EMT [72].
In addition to the induction of the anabolic 
lipid metabolic pathways mentioned above (ex 
novo incorporation of lipids and the three de 
novo lipogenesis pathways: FAS, mevalonate, 
and cholesterol), CSCs also upregulate the cata-
bolic lipid metabolic pathway: FAO [73]. FAO 
takes place in mitochondria following the uptake 
of fatty acids via CPT1. CPT1 can be inhibited by 
malonyl CoA, which is a product of ACC1 of the 
FAS pathway, ensuring the inhibition of running 
a futile cycle between FAS and FAO. However, 
due to the highly proliferative state of FAO and 
the ex vivo uptake of lipids, FAO is also upregu-
lated in CSCs. This FAO pathway may be neces-
sary for CSCs to replenish NADH and FADH2, 
which will help facilitate the electron transport 
chain (ETC) in OXPHOS [63]. Indeed, inhibition 
of FAO has been reported to lower the number of 
CSCs [74].
6  Conclusion
From our brief overview, it is clear that CSCs 
have diverse metabolic profiles that are quite 
specific to each cancer type and tissue type, 
which is a break from convention with normal 
cell metabolism. For example, the activation of 
OXPHOS alongside the Warburg effect presents 
a complexity that demands further studies. The 
shunting of glucose-derived pyruvate to lactate 
instead of the TCA cycle by the Warburg effect 
should preclude the flow of glucose carbons to 
OXPHOS unless somehow the glutaminolysis 
carbons can compensate for all the TCA cycle to 
push forward to OXPHOS independent of glu-
cose [20]. Regardless, CSCs seem to exhibit 
both the Warburg effect and OXPHOS simulta-
neously. Another example is the activation of 
mitochondrial metabolism alongside lipogene-
sis, which also challenges conventional wisdom 
concerning cellular metabolism. Typically, the 
activation of lipogenesis would block fatty acid 
oxidation in the mitochondria due to the inhibi-
tion of CPT1 by malonyl- CoA. However, CSCs 
seem to have no problem activating both 
pathways.
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The metabolic assessment of CSCs using 
metabolomics technologies [75] reflects variation 
within the CSC population. Single-cell metabolic 
analyses would enable us to identify such diversity 
in the CSC population. Moreover, there is tissue 
and microenvironmental specificity to CSC meta-
bolic profiles. For example, breast CSCs that are 
surrounded by lipids may “prefer” to activate fatty 
acid oxidation instead of inducing de novo lipogen-
esis. This may not be the case for lymphomas that 
travel within the blood vessels, which may prefer to 
use glucose as a primary energy source instead of 
lipids. Furthermore, CSCs seem to run futile cycles 
metabolically (i.e., activating lipogenesis and fatty 
acid oxidation and OXPHOS simultaneously), 
because these processes are not absolutely effi-
cient. Thus CSCs activate both  pathways to make 
sure that all residual metabolites are processed effi-
ciently catabolically and anabolically to support 
their high demand for energy and biomass.
Despite the differences in CSC metabolic pro-
files, CSCs do share some similarities with both 
stem cells and cancer cells in glucose, glutamine, 
OXPHOS, and lipid metabolism. This makes it 
difficult to distinguish CSCs from stem cells and 
non-CSC tumor cells metabolically, and conven-
tional CSC markers are still needed (i.e., CD44 
and CD133). However, the fact that there are 
commonly activated metabolic pathways between 
CSCs, stem cells, and non-CSC tumor cells is 
consistent with three ideas pertaining to the 
nature of CSCs. First, the commonly shared met-
abolic pathways indicate that CSCs are indeed a 
subtype of cancer cells that genetically evolved 
from normal stem/progenitor cells. Second, the 
commonly shared metabolic pathways between 
the three indicate that these metabolic pathways 
are selected due to their ability to sustain the cat-
abolic and anabolic needs of highly proliferating 
cells. Third, the fact that CSCs share metabolic 
pathways with stem cells and cancer cells pres-
ents a challenge for developing cancer metabolic 
drugs that do not target normal stem cells.
Overall, this is a fascinating field in metabo-
lism, where researchers need to further delineate 
metabolic similarities and differences within the 
CSC population itself as well as with other stem 
cell and cancer cell types. These intra- and inter- 
differences will shed light on how to best develop 
specific metabolic drugs targeting CSCs in spe-
cific cancer types that would not be toxic to nor-
mal stem cells.
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Abbreviations
ASCT2 Alanine, serine, cysteine trans-
porter 2
CAFs Cancer-associated fibroblasts
CAR Chimeric antigen receptor
CTL Cytotoxic T lymphocytes
ECM Extracellular matrix
ERRα Estrogen-related receptor alpha
FAO Fatty acid oxidation
GLUT Glucose transporter
GPCRs G protein-coupled receptors
HIF1α Hypoxia-inducible factor 1 α
HPSE Heparanase
HSPG Heparan sulfate proteoglycans
IFNγ Interferon-gamma
IL Interleukin
LDHA Lactate dehydrogenase A
MCT Monocarboxylate lactate 
transporters
MDSC Myeloid-derived suppressor cells
mTOR Mammalian target of rapamycin




PDK1 Pyruvate dehydrogenase kinase
PEP Phosphoenolpyruvate




SNAT Sodium-coupled neutral amino 
acid transporter
TAM Tumor-associated macrophages
Tcm Central memory T cells
TCR T-cell receptor
Teff Effector T cells
TILs T-cell infiltrating lymphocytes
TLR Toll-like receptor
TNFα Tumor necrosis factor alpha
Treg Regulatory T cells
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TRUCKs T cells redirected for antigen- 
unrestricted cytokine-initiated 
killing
Tscm Stem memory T cells
Key Points
• Tumor cells produce numerous substances 
to create an immunosuppressive tumor 
microenvironment.
• The tumor microenvironment physically con-
stitutes a barrier against T-cell infiltration.
• Activated T cells reprogram OXPHOS and 
FAO to glycolysis and glutaminolysis.
• Tumors escape immunity via T-cell dysfunc-
tion or hyporesponsiveness by upregulation of 
several inhibitory receptors.
• Increased glucose uptake by cancer cells 
restricts T-cell function by decreasing mTOR 
activity.
• Treatments using immune checkpoint inhibitors 
increase extracellular glucose levels to improve 
T-cell infiltrating lymphocytes’ function.
1  Introduction
The tumor microenvironment (TME) is a com-
plex biological structure surrounding tumor cells 
and includes blood vessels, immune cells, fibro-
blasts, adipocytes, and extracellular matrix 
(ECM) [1, 2]. These heterogeneous surrounding 
structures provide nutrients, metabolites, and sig-
naling molecules to provide a cancer-friendly 
environment. The metabolic interplay between 
immune cells and cancer cells in the TME is a 
key feature not only for understanding tumor 
biology but also for discovering cancer cells’ vul-
nerability. As cancer immunotherapy to treat can-
cer patients and the use of metabolomics 
technologies become more and more common 
[3], the importance of the interplay between 
 cancer cells and immune cells in the TME is 
emerging with respect to not only cell-to-cell 
interactions but also metabolic pathways. This 
interaction between immune cells and cancer 
cells is a complex and dynamic process in which 
immune cells act as a determinant factor of can-
cer cells’ fate and vice versa. In this chapter, we 
provide an overview of the metabolic interplay 
between immune cells and cancer cells and dis-
cuss the therapeutic opportunities as a result of 
this interplay in order to define targets for cancer 
treatment. It is important to understand and iden-
tify therapeutic targets that interrupt this cancer- 
promoting relationship between cancer cells and 
the surrounding immune cells, allowing for max-
imum efficacy of immune checkpoint inhibitors 
as well as other genetic and cellular therapies.
2  Tumor Immunity 
and the Various Roles 
of Immune Cells
The immune system’s antitumor activity is 
mainly carried out by tumor antigen-specific 
cytotoxic T lymphocytes (CTL), T effector (Teff) 
cells, antibody-producing B cells, as well as 
antigen- presenting dendritic cells (DC), which 
lead to adaptive immunity by directly recogniz-
ing and eliminating cancer cells. Natural killer 
(NK) cells, macrophages, and NK-T cells also 
play crucial roles in suppressing tumor progres-
sion via a nonspecific immune response. Even 
though this defense system is well developed, the 
tumor often has the ability to develop an immu-
nosuppressive microenvironment favorable to its 
progression. Specifically, myeloid-derived sup-
pressor cells (MDSC), regulatory T (Treg) cells, 
and tumor-associated macrophages (TAMs) are 
well-known players. These tumor-friendly 
immune cells suppress the settlement of tumor- 
infiltrating lymphocytes (TILs) by expressing 
essential amino acid (EAA)-degrading enzymes 
including arginase 1 (Arg1) and indoleamine- 
2,3-dioxygenase (IDO) [4–7], and inhibitors tar-
geting Arg1 and IDO are being investigated in 
ongoing clinical trials [8, 9]. The TME is an envi-
ronment composed of multifaceted components 
with tumor-friendly or antitumoral characteris-
tics where there is strong competition for metab-
olites and nutrients. Studies have shown that 
T-cell-mediated adaptive response is a promising 
therapeutic strategy to strengthen the antitumor 
activity of the immune system [10–12].
J. G. Jung and A. Le
175
2.1  Metabolic Competition 
and Tumor Immunity
With strong evidence showing how T lympho-
cytes infiltrate into the tumor niche and how 
checkpoint inhibitors or chimeric antigen recep-
tor (CAR) T cells inhibit the growth of cancer 
cells, a new era of immunotherapy has just begun 
with successful clinical development [13]. 
However, cancer cells can escape immune recog-
nition via “immunoediting,” allowing cancer cell 
clones without detectable cancer antigens to 
dominate and escape from the pressure of 
immune checkpoint inhibitors [14].
Rapidly growing tumor cells require nutrients, 
oxygen, and essential metabolites to proliferate 
and, at the same time, create an immunosuppres-
sive microenvironment. How immune cells and 
cancer cells share or compete in these harsh envi-
ronmental conditions and how the TME alters 
immunometabolism are important questions to 
address. Specifically, it needs to be addressed how 
cancer cells and neighboring immune cells com-
pete to take up nutrients and metabolites, which 
consequently influences signaling cascades, met-
abolic activities, and tumor progression.
Cancer-associated adipocytes: It is well 
known that adipocytes play an important role in 
communicating with cancer cells by excreting 
inflammatory factors, adipokines, and free fatty 
acids, which help cancer growth. In addition, 
immune cell functions are heavily regulated by 
lipids, lipoproteins, and cholesterol within the 
TME.  For example, elevated levels of oxidized 
lipoproteins as a result of incorporation via scav-
enger receptors and formation of lipid droplets 
can compromise the ability of dendritic cells 
(DCs) to activate T cells by presenting tumor 
antigens [15, 16]. Also, it is well known that can-
cer cells instruct neighboring adipocytes to 
increase lipolysis [17].
Cancer-associated fibroblasts [18, 19]: It is 
reported that tryptophan catabolism by CAFs 
causes the starvation of immune cells and results 
in the production of kynurenine, an immunosup-
pressive metabolite [20]. Cancer cells also pro-
duce hydrogen peroxide (H2O2), which can lead 
to oxidative stress in CAFs. Oxidative stress is 
associated with impaired mitochondrial function, 
which results in upregulated glucose uptake and 
elevated reactive oxygen species (ROS) levels 
[21]. In addition, glucose is also a key metabolite 
for the antitumor activities of effector T (Teff) 
cells and M1 macrophages because aerobic gly-
colysis is necessary for their activation [22, 23].
Altered amino acid levels: Amino acids in the 
TME are not only a resource competed for by 
cancer and immune cells but also another meta-
bolic checkpoint regulating antitumor immunity. 
For example, glutamine is a precursor for the 
 tricarboxylic acid (TCA) cycle [24] and lipid 
synthesis in hypoxic cancer cells [25] and Teff 
cells [26]. As such, glutaminolysis, a series of 
biochemical reactions that start with the conver-
sion of glutamine carbon to glutamate and aspar-
tate, is essential for cancer cells by providing 
nutrients and metabolites through anaplerotic 
reactions, and leads to tumor cells’ and TILs’ 
competition for glutamine, the pathway’s starting 
material [27–29]. Moreover, it is known that glu-
tamine activates the mammalian target of 
rapamycin (mTOR) signaling cascades in T cells 
and macrophages and is important for protein 
O-GlcNAcylation and synthesis of S-2-
hydroxyglutarate (S-2GH), a regulator of effector 
T (Teff) cell function [30, 31]. Consequently, it 
was found that there is an upregulation of the 
major glutamine transporter alanine, serine, cys-
teine transporter 2 (ASCT2), also known as 
SLC1A5, for several types of cancer [32].
The proliferation of immune cells relies on 
growth factors for efficient nutrient utilization. 
For example, interleukin-2 (IL-2) promotes 
increased expression of glucose transporters 
(GLUT) and thus enhances glycolysis in acti-
vated T cells [33–36]. There is a question about 
how metabolites activate signaling pathways to 
induce changes in immune cell functions. A clas-
sic example is the binding of metabolites and 
energy substrates to G protein-coupled receptors 
(GPCRs) [37]. For example, succinate leads to 
increased chemotaxis and activation of dendritic 
cells after toll-like receptor (TLR) agonist treat-
ment by binding to the succinate receptor GPR91 
[38]. On the other hand, adenosine, by binding to 
A2B and A2A adenosine receptors, leads to 
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increased interleukin 4 (IL-4)-induced M2 
macrophage activation [39]. Moreover, it is 
recently reported that there is a significantly 
reduced arginine level in the TME as a result of 
inducible nitric oxide synthase (iNOS) and argi-
nase expressed by myeloid-derived suppressor 
cells, indicating that rapid dynamic changes of 
amino acids can happen in the TME [40].
2.2  Antitumor T-Cell Metabolisms 
in the TME
As T cells play a critical role in antigen-specific 
adaptive immunity against the tumor, it is funda-
mentally important to understand T-cell biology. 
T lymphocytes respond to the presence of anti-
gens and evolve rapidly. This response first 
requires T-cell growth; then their drastic expan-
sion, differentiation, and death; and lastly, the 
formation and preservation of the memory of the 
immune response.
T lymphocyte proliferation in the TME 
requires a switch in its metabolism. While naïve 
T cells utilize fatty acid β-oxidation, activated T 
cells mainly use glycolysis, pentose phosphate 
pathway, and glutaminolysis [41, 42]. 
Additionally, it is reported that distinct transcrip-
tional programs and signaling pathways are 
involved in this metabolic shift, including the 
transcription factor c-Myc [43, 44], estrogen- 
related receptor alpha (ERRα) [41, 45, 46], 
phosphatidylinositol- 3-OH kinase (PI(3)K), and 
GLUT1-dependent Akt pathways [45]. This sig-
nificant metabolic reprogramming of activated T 
cells is required for their proliferation and expan-
sion. Consistently, it is also reported that acti-
vated T cells switch from oxidative 
phosphorylation (OXPHOS) and fatty acid oxi-
dation (FAO) to glycolysis and glutaminolysis, 
which are characteristics of Teff cells, induced by 
antigenic stimulation through the T-cell receptor 
(TCR) and engagement of CD28 with a ligand on 
antigen-presenting cells (APC) [26]. Although 
glycolysis produces less ATP than OXPHOS, it is 
very efficient at producing biosynthetic precur-
sors [47], which can further support the rapid 
proliferation and pro-inflammatory functions of 
Teff. Moreover, it is consistent with the findings 
that depletion of GLUT1 impaired T-cell prolif-
eration and functions [36], while elevated expres-
sion of GLUT1 increased Teff cell functions [48]. 
In addition, demands for nutrients, such as glu-
cose, glutamine, and other amino acids, lead to 
upregulations of transporters in T cells, including 
GLUT1 [36, 45, 49], glutamine transporters and 
sodium-coupled neutral amino acid transporters 
1 and 2 (SNAT1 and SNAT2) [50], and monocar-
boxylate lactate transporters MCT1 and MCT4 to 
export lactate produced via aerobic glycolysis 
[51].
This metabolic shift from OXPHOS and FAO 
to glycolysis and glutaminolysis during T-cell 
activation is mediated by several crucial regula-
tors. It is reported that TCR directly induces 
PI3K/Akt/mTORC1 and MYC pathways, which 
not only activate effector T cells but are also cru-
cial for their proliferation and biological func-
tions [26]. Indeed, an activated mTOR pathway 
promotes glycolysis by upregulating c-MYC and 
hypoxia-inducible factor 1α (HIF1α) [41, 45, 48, 
49, 52, 53]. MYC then induces the transcriptional 
factor AP4, which further upregulates glycolytic 
enzyme gene expressions [54]. Moreover, 
increased HIF1α expression and activity upregu-
late pyruvate dehydrogenase kinase (PDK1) and 
lactate dehydrogenase A (LDHA), leading to 
increased aerobic glycolysis and decreased 
OXPHOS [55, 56], thus switching pyruvate away 
from the TCA cycle to lactate production. HIF1α 
also promotes glycolysis by upregulating GLUT1 
and MCT4 expression, in addition to glycolytic 
enzymes and regulators [57].
After fulfilling their duties, activated T cells 
undergo apoptosis during a time period called the 
contraction phase [58], while Treg cells and mem-
ory T (Tmem) cells, by using lipid oxidation for 
energy production, remain in peripheral tissues 
or secondary lymphoid organs without undergo-
ing apoptosis [48, 57, 59, 60].
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2.3  Cancer Cells’ Impacts on T-Cell 
Metabolism in the TME
It is well known that T-cell dysfunction, or hypo-
responsiveness, can result in tumors escaping 
immunity. This dysfunction or hyporesponsive-
ness is due to exhaustion and senescence of T 
cells [61]. For instance, tumor cells are shown to 
express indoleamine 2,3-dioxygenase (IDO), an 
enzyme that results in decreased tryptophan lev-
els and inhibition of T-cell proliferation [62, 63]. 
Lactate produced by tumor cells can also lead to 
reduced T-cell function by blocking their lactate 
export [64]. Intracellular lactate accumulation 
impairs their aerobic glycolysis and thus limits 
their function [65].
Moreover, increased glucose uptake and con-
sumption by cancer cells [66] impair T-cell func-
tion by decreasing their mTOR activity, glycolysis, 
and INF-γ production. These negative conse-
quences on T cells help promote tumor progres-
sion, which is also facilitated by decreased 
cytokine production due to the lack of glucose in 
the microenvironment. It is also supported by the 
fact that many types of tumors have high glycoly-
sis rates [67, 68]. Moreover, lack of glucose 
impairs IFN-γ production of T cells and pro- 
inflammatory signals in macrophages [36, 65, 69]. 
In addition, increased glycolysis rate in tumor 
cells as a result of the overexpression of the glyco-
lytic enzyme hexokinase 2 (HK2) reduced glucose 
uptake and IFN-γ production in TILs, which led to 
a more tumor-friendly microenvironment [69, 70].
2.4  Cancer Cell-Induced 
Metabolically Harsh 
Environment Impairs T-Cell 
Function
As the tumor grows larger, (1) oxygen supply 
becomes limited, thus creating a hypoxic condi-
tion; (2) nutrients become deficient; and (3) the 
microenvironment becomes acidic. Recent find-
ings suggest that these harsh metabolic states sig-
nificantly disrupt T-cell function. Therefore, the 
influence of cancer cell metabolism on the TME 
may directly control the metabolic pathways in 
surrounding T cells [71]. The tumor microenvi-
ronment physically constitutes a barrier against 
T-cell infiltration, as it is a compact structure with 
tight interactions among cancer cells, fibroblasts, 
immune cells, and ECM.  Indeed, tumor cells 
generate numerous substances to create an immu-
nosuppressive microenvironment. For example, 
hypoxic cancer cells release prostaglandin E2 
(PGE2) and adenosine, which can result in T 
lymphocyte proliferation inhibition by activating 
G protein-coupled receptors (GPCR) and protein 
kinase A [72]. Among the GPCRs, chemokine 
(C-X-C motif) receptor 3 (CXCR3) and chemo-
kine (C-C motif) receptor 5 (CCR5) are often 
expressed in active lymphocytes that have infil-
trated the tumors in melanoma, breast, and 
colorectal cancers [73] (Fig. 1).
In order to reach tumor cells and to enhance 
the efficacy of immunotherapy, T lymphocytes 
have to degrade the ECM and heparan sulfate pro-
teoglycans (HSPGs) [74]. It is reported that chi-
meric antigen receptor (CAR) T cells need to 
release heparanase (HPSE) to successfully 
degrade HSPGs, which then allows T cells to gain 
access to the solid tumor [75] (Table 1 and Fig. 1).
3  Targeting the Metabolism 
of Immune Cells for Cancer 
Treatment
Accumulating evidence from the past decade 
indicates that metabolic reprogramming greatly 
affects T cells. Indeed, when T cells recognize 
antigens, they are activated to proliferate and pro-
duce effector molecules to eliminate the foreign 
antigens. During this course of the immune 
response, immune cells respond to changes in the 
metabolic microenvironment, which serves as a 
“metabolic checkpoint” responsible for connect-
ing the metabolic states with signaling pathways 
in immune cells, which further determines their 
immune functions [47]. Accordingly, metabolic 
reprogramming of cells, such as a switch from 
OXPHOS and FAO to glycolysis and glutami-
nolysis in naïve and memory T cells, helps pro-
vide energy and other building block materials to 
generate new biomass. The manipulation of met-
abolic enzyme expressions helps T cells adapt in 
the tumor-suppressive microenvironment and 
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restore their functions. Specifically, overexpres-
sion of phosphoenolpyruvate carboxykinase 1 
(PCK1) results in a high level of the glycolytic 
metabolite phosphoenolpyruvate (PEP). High 
PEP level then enhances T-cell effector functions 
through T-cell receptor-mediated Ca2+-dependent 
nuclear factor of activated T-cell (NFAT) signal-
ing. PCK1- overexpressing T cells inhibited mel-
anoma tumor growth in  vivo [70]. Another 
example is the oxygen- sensing prolyl-hydroxy-
lase (PHD) proteins, which, as oxygen sensors in 
T cells, support cancer metastasis to the lung. 
Indeed, targeting T-cell-intrinsic PHD proteins 
resulted in increased antitumor immunity [112]. 
Also, as TILs usually have impaired mitochon-
drial function after infiltrating the tumors, reacti-
vation of PPAR-gamma coactivator 1α (PGC1α) 
by suppressing Akt signaling in these T cells can 
induce mitochondrial biogenesis. Thus, increas-
ing the expression of PGC1α in these T cells also 
activates their functions [113]. These approaches 
may improve antitumor immunity for adoptive 
T-cell therapy, which is a personalized therapy 
for cancer via T-cell manipulation [70, 112, 113].
3.1  The Metabolism of the Immune 
Checkpoint Blockades
When T cells infiltrate the TME, they gradually 
lose several abilities, including responsiveness to 
T-cell receptor (TCR) stimuli and production of 
antitumor cytokines, in a phenomenon referred to 
as T-cell exhaustion or hyporesponsiveness. This 
is the result of the upregulation of several inhibi-
tory receptors such as PD-1, LAG3, TIGIT, and 
CTLA-4 that make T cells less sensitive to tumor 
antigens [114]. In particular, the PD-1:PD-L1 
axis and CTLA-4 are critical immune check-
points for T cells, and targeting these receptors 
breaks down the cross talk between cancer cells 
and exhausted T cells. This result is supported 
by  numerous clinical successes of immune 
checkpoint inhibitors, including ipilimumab, 
nivolumab, pembrolizumab, atezolizumab, ave-
lumab, durvalumab, and cemiplimab-rwlc [115].
Interestingly, glucose deprivation caused by 
rapid uptake by actively growing cancer cells and 
glucose competition between cancer cells and 
Fig. 1 Potential immunometabolism-targeting strategy in the TME. APC antigen-presenting cells, CAR T chimeric 
antigen receptor T cell, CAF cancer-associated fibroblast, ECM extracellular matrix
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other cells in the TME further upregulates PD-1 
expression [114, 116]. In fact, PD-1 activation 
leads to suppressed T-cell receptor (TCR), PI3K, 
and mTOR signaling in T cells and reduced gly-
colysis, which may lead to increased accumula-
tion of regulatory CD4 (Treg) cells in the TME 
Table 1 Tumor microenvironment-related obstacles and possible solutions (modified from [76])
Obstacle Factor Solution References
Tumor stroma Cancer-associated fibroblast Anti-FAP CAR T cells [77]
Heparan sulfate proteoglycan Heparanase-secreting CAR T cells [75]
ECM-targeting CAR T Oncolytic virus [78]
Tumor antigen integrin Integrin αvβ6, integrin β-targeting CAR 
T
[79, 80]
MUC1 Tumor-expressing MUC1-targeting 
CAR T
[81, 82]
Cytokines and enzymes Immunosuppression of the 
TME
TRUCK T cells expressing IL-12, 
IL-15, IL-18
[83]
TGF-β TGF-β dominant-negative CAR T cells [84]
IL-4 4/7 ICR CAR T cells (IL-4 exodomain) [85]
IL-7 CCL19 CAR T cells [86]
Adenosine A2AR receptor antagonist [87, 88]
CCR CCR2/4-targeting CAR T [89]
Metabolism and hypoxia CD73 CD73 inhibitor [90]




Protein kinase A RIAD-CAR T [93]
High levels of antioxidants N-acetyl cysteine [94]
Immune inhibitory 
checkpoints
CTLA-1 CTLA-4 inhibitor [95]
CTLA-4 knockout in CAR T [96]
Anti-CTLA-1 antibody-producing CAR 
T
[95]
PD-1 PD-1 inhibitor [97]
PD-1 KO in CAR T [98]
PD1-CD28 CAR T [99]
Anti-PD-1 antibody-producing CAR T [99]
LAG-3 Blockade of LAG-3 and PD-1 [100]
TIM3 TIM3 KO in CAR T [100]
BTLA-4 BTLA-4 inhibitor [100]
Blockade of BTLA-4 and PD-1 [101]
HVEM-targeting CAR T [102]
A2AR A2AR antagonist [88]
TIGIT Blockade of TIGIT and PD-1 [103]
CD40L CD40L-CAR T [104]
Immunosuppressive cells MDSC CXC15-CXCR2 inhibitor [105]
Treg ALTRA-CAR T [106]
Genetic depletion and anti-PD-L1 
blocking Ab of Treg
[107]




TAM Induction of TAM to produce nitric 
oxide
[110]
iDC Expression of IL-18 by CAR T [110, 
111]
Metabolism of Immune Cells in the Tumor Microenvironment
180
[117–119]. If PD-L1 on the surface of tumor cells 
binds to PD-1 on T cells, referred to as the 
engagement of PD-1, T-cell proliferation, cyto-
kine production, and cytolytic function are inhib-
ited, which promotes cancer cell proliferation 
[120]. It has also been shown that the degree of 
PD-L1 expression correlates with glycolysis 
rates, as well as the expression levels of glyco-
lytic enzymes [116]. Moreover, α-PD-L1 anti-
body treatment increases extracellular glucose 
levels in  vivo, which results in improved TIL 
function and subsequently reduced tumor growth. 
Indeed, intrinsic PD-1 expression promotes 
mTOR signaling and tumor growth [121], while 
blockade of PD-1 signaling activates glycolysis 
and anabolic pathways in exhausted T cells via 
mTORC-1 [69, 122]. Thus, this metabolic shift 
provides the rationale for the clinical develop-
ment of combination therapy with immune 
checkpoint blockade and mTOR inhibitors. 
Indeed, multiple clinical trials are under investi-
gation with those drug combinations in patients 
with TNBC and renal cell carcinoma 
(NCT03805399, NCT04203901). Collectively, 
these results imply that the most promising ther-
apy should target the co-inhibitory receptor-to- 
ligand interactions and re-sensitize exhausted T 
cells in the TME.
3.2  The Metabolism of Chimeric 
Antigen Receptor (CAR) T Cells
Recent clinical progress with genetically engi-
neered chimeric antigen receptor (CAR) T cells 
for cancer therapy opens up a new era of cell/
gene therapy. However, its success is limited thus 
far to acute lymphoblastic leukemia (ALL) and 
lymphoma, whereas it shows less promising 
results for solid tumor treatment [72]. It is widely 
accepted that the major cause of the limited effi-
cacy of CAR T cells is the poor accessibility of T 
cells to the TME and the low-nutrient, hypoxic 
environment that provides suboptimal conditions 
for T-cell proliferation and cytokine production 
[123]. Thus, CAR T-cell infiltration into the 
tumor is a critical step to enhance their antitumor 
efficacy in solid tumors (Fig. 1).
The lack of therapeutic effects of CAR T cells 
in solid tumors is due, in part, to the immunosup-
pressive TME, which acts as a critical barrier. As 
such, new strategies to increase CAR T cells’ 
accessibility to TME in solid tumors have been 
proposed. For example, stabilization of HIF1α 
under hypoxic conditions regulates cellular 
metabolism, which is a critical feature in the 
hypoxic TME. A recent study found that target-
ing an oxygen-sensitive subdomain of HIF1α 
enhances the CAR-T activity in solid tumors 
[124]. Another example of new strategies for 
CAR T therapy is the targeting of heparanase 
(HPSE). Stroma and tumor cells in the TME are 
linked together through the ECM which contains 
a considerable amount of heparan sulfate proteo-
glycan (HSPG) [75]. To explore whether HSPG 
can be targeted in solid tumors, Caruana et  al. 
generated HPSE-expressing CAR T cells that 
showed ECM degradation ability in solid tumors, 
which resulted in increased infiltration and anti-
tumor activity [75]. This approach may imply the 
therapeutic benefits of the use of CAR T immu-
notherapy coupled with HPSE degradation to 
access tumor niches.
Another approach of engineering CAR T cells 
to target solid tumors is the development of the 
nuclear factor of activated T cells, which is referred 
to as T cells redirected for antigen- unrestricted 
cytokine-initiated killing (TRUCKs). For instance, 
engineered CAR T cells with several cytokines, 
including interleukin-7, -12, -15, and -18, are 
being explored for TRUCKs [125, 126]. The 
underlying physiological functions of these inter-
leukins in CAR T-cell therapies are summarized in 
the reference [126]:
• Interleukin-2: proliferation of T-cell differen-
tiation of Teff, development of Treg in thymus
• Interleukin-4: differentiation of Th2 and Th9 
cells, survial of B-cells and T-cells
• Interleukin-7: development of T-cell in thy-
mus, survival of and homeostasis in memory 
and naïve T cells
• Interleukin-9: mast cell proliferation, increased 
antitumor immunity
• Interleukin-15: development of CD8+ T-cell 
memory, survival of and homeostasis in CD8+ 
T-cells
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• Interleukin-21: suppression of Treg, survial and 
proliferation of CD4+ Th17 cells
Among them, engineered CAR T cells with 
IL-2, IL-7, IL-15, and IL-21 NFATs are being 
investigated in clinical trials [126] (Table 1 and 
Fig. 1).
In addition, it is also known that cytokines can 
be manipulated to control the metabolism of stem 
memory T cells (TSCM) and central memory (Tcm) 
T cells. Of note, T-cell activation by interleukin 
families, including IL-15 and IL-17, leads to an 
increased TSCM-like phenotype as well as 
increased interferon-gamma (IFNγ), tumor 
necrosis factor alpha (TNFα), and IL-2 produc-
tion [127]. Moreover, it has been reported that 
IL-15 activates fatty acid oxidation (FAO) and 
mitochondrial spare respiratory capacity (SRC) 
as an alternate way for energy production in T 
cells [60]. Taken together, IL-15 may provide 
therapeutic benefits in the form of T memory cell 
differentiation and mitochondrial metabolism 
[60]. In addition to mitochondrial metabolism, 
manipulation of ion and pH levels in the tumor 
microenvironment, such as decreasing the con-
centration of potassium, can also enhance T-cell 
antitumor activity [128]. As such, these metabo-
lism-targeting approaches will provide the ratio-
nales for future clinical developments and 
therapeutic use of CAR T-cell immunotherapy 
for cancer patients.
4  Conclusion
The immunosuppressive microenvironments in 
solid tumors are physically and functionally 
hostile for immune cells, including immune 
checkpoint inhibitors and CAR T cells. The rea-
sons for less promising efficacy of immunother-
apies vary and include the immune cells’ poor 
accessibility to tumor cells in the TME due to 
physical and metabolic barriers, including a 
lack of nutrients and acidosis. In order to 
improve the therapeutic efficacy of immuno-
therapies, the tightly controlled microenviron-
ment has to be modified by targeting the 
metabolic vulnerability of cancer cells. This 
includes either targeting metabolic enzymes to 
regulate the metabolism of cancer cells or dis-
rupting the tumor-friendly microenvironment. 
As metabolism is fundamental for biological 
and cellular functions, targeting the tumor 
microenvironment itself or modifying T-cell 
metabolism is a promising strategy to improve 
current treatment efficacy.
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• Cancer-associated fibroblasts undergo the 
reverse Warburg effect and provide cancer 
cells with glycolytic metabolites.
• The interaction between cancer cells and 
CAFs helps cancer cells manage the Warburg 
effect.
• Loss of stromal Cav-1 is a biomarker of poor 
prognosis in breast cancers.
• Exogenous and endogenous miRNAs are cru-
cial in the metabolic reprogramming of CAFs.
• CAF-derived exosomes (CDEs) can repro-
gram the metabolic pathway of cancer cells.
• CAF-derived lactate is crucial in prostate cancer 
metabolic transformation towards OXPHOS.
• CAFs can transfer functional mitochondria to 
prostate cancer cells.
• CAFs augment cancer’s addiction to glutamine 
and its metabolically relevant consequences.
• Alanine secreted by pancreatic stellate cells 
supports tumor metabolism.
• CAFs act as lipid synthesis factories for 
colorectal cancer cells.
1  Introduction
Cancer-associated fibroblasts (CAFs), a major 
component of the tumor microenvironment 
(TME), play an important role in cancer initia-
tion, progression, and metastasis. Recent findings 
have demonstrated that the TME not only pro-
vides physical support for cancer cells but also 
directs cell-to-cell interactions (in this case, the 
interaction between cancer cells and CAFs). As 
cancer progresses, the CAFs also coevolve, tran-
sitioning from an inactivated state to an activated 
state. The elucidation and understanding of the 
interaction between cancer cells and CAFs will 
pave the way for new cancer therapies [1–3].
The TME is a heterogeneous environment con-
sisting of fibroblasts, tumor-associated macro-
phages, adipocytes, an extracellular matrix, and 
mesenchymal stem cells [4]. The exact composi-
tion of each stroma varies depending on cancer 
and tissue type. To add to this variation, there is 
heterogeneity even within the CAF population 
itself. Different CAFs express different markers 
and influence stromal pro-tumorigenic capacity 
and cancer progression in diverse ways [5, 6].
CAFs, unlike normal fibroblasts (NF), are not 
passive bystanders. They possess similar charac-
teristics to myofibroblasts, the fibroblasts respon-
sible for wound healing and chronic inflammation, 
such as the expression of α-smooth muscle actin 
(α-SMA) [7, 8]. Regarded in a similar light, can-
cer might be considered a wound that cannot be 
healed. CAFs can originate from the activation 
and differentiation of quiescent fibroblasts, bone 
marrow-derived mesenchymal stem cells, and 
epithelial and endothelial cells [9].
The interaction of the TME, specifically 
among CAFs with cancer cells, is incontrovert-
ible. The effect of CAFs on cancer is dependent 
on cancer type and stage. The production and 
secretion of growth factors, chemokines, cyto-
kines, metabolites, and extracellular matrix com-
ponents aid in the recruitment of various cell 
types, such as pericytes and endothelial cells, 
facilitating angiogenesis and bestowing chemo-
resistant properties to the cancer cells. In this 
chapter, we discuss the properties and character-
istics of CAFs, and their importance in cancer 
progression.
As mentioned in the chapter “Different 
Tumor Microenvironments Lead to Different 
Metabolic Phenotypes” [10], Hanahan and 
Weinberg [11] have identified six hallmark 
capabilities of cancer cells: (1) self-sufficiency 
in growth signals, (2) insensitivity to  anti-growth 
signals, (3) evasion of apoptosis, (4) limitless 
replicative potential, (5) sustained angiogenesis, 
and (6) tissue invasion and metastasis. The exact 
mechanisms by which the TME can influence 
cancer and lead to the acquisition of those hall-
mark capabilities are not yet fully understood. 
However, there is growing evidence suggesting 
that the manipulation of signal transduction 
pathways in cancer cells, CAFs, and altered 
metabolic pathways may play a role in the trans-
formation process [12–17].
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2  CAFs Undergo the Reverse 
Warburg Effect and Provide 
Cancer Cells with Glycolytic 
Metabolites
As mentioned in previous chapters, cancer cells 
undergo a phenomenon known as the Warburg 
effect, an increase in aerobic glycolysis to pro-
duce ATP even in normoxic conditions (normoxia 
or normal oxygen levels) [18]. Warburg initially 
attributed this phenomenon to malfunctioning 
mitochondria forcing the cancer cells to rely on 
glycolysis for energy production. Pyruvate and 
lactate, the two end products of glycolysis, were 
believed to be secreted by the hypoxic core of the 
tumor through monocarboxylate transporters 
(MCT4) for the adjacent oxygenated cancer cells 
to take up (via MCT1) and utilize as substrates 
for the tricarboxylic acid (TCA) cycle [19–21].
Recent studies, however, have revolutionized 
the way scientists view the TME, especially the 
cross talk between CAFs and cancer cells and the 
effect of this cross talk on metabolism. The 
Warburg effect, a phenomenon initially believed 
to be limited to cancer cells, has also been 
observed in the fibroblasts surrounding the cancer 
cells. To distinguish this CAF-related phenome-
non from its cancer cell-related counterpart, 
Pavlides et al. named it the reverse Warburg effect 
[17]. Caveolin-1 (Cav-1) is a transforming growth 
factor-beta (TGF-β) type I receptor kinase inhibi-
tor, and the loss of Cav-1 expression causes a 
myofibroblastic phenotype. By using Cav-1(−/−) 
fibroblasts, Pavlides et al. induced myofibroblas-
tic differentiation to mimic CAFs. With the use of 
proteomics, they identified 25 proteins that were 
overexpressed when Cav-1 was suppressed. Eight 
of those proteins were glycolytic enzymes 
(Table  1), including M2-type pyruvate kinase 
(PKM2) and lactate dehydrogenase A (LDHA) 
[17]. These two enzymes are known to play cru-
cial roles in the Warburg effect [22, 23]. 
Additionally, two enzymes involved in oxidative 
stress, peroxiredoxin 1 and catalase, were overex-
pressed under normoxic conditions, which indi-
cates an increase of reactive oxygen species 
(ROS) in Cav-1(−/−) fibroblasts. Hypoxia- 
inducible factor-1 (HIF-1) is a transcription factor 
that responds to low oxygen concentrations. 
Under high levels of ROS, HIF-1 is stabilized. 
Subsequently, HIF-1, a regulator of all glycolytic 
enzymes, as well as glucose transporters, GLUT1 
and GLUT3, induces aerobic glycolysis [17, 23].
A similar study performed by Shan et al. pro-
vided further evidence to support the reverse 
Warburg effect hypothesis. In this study, pancre-
atic associated fibroblasts expressed elevated lev-
els of the glycolytic enzymes LDHA and PKM2, 
as well as the MCT4 transporter responsible for 
lactate secretion. Additionally, they observed that 
when pancreatic cancer cells were exposed to 
CAF-conditioned media, they underwent 
enhanced aerobic activity, causing an observable 
enlargement of the mitochondria. Furthermore, 
pancreatic cancer cells significantly increased the 
expression of MCT1, fumarate hydratase (FH), 
and succinate dehydrogenase (SDH). The over-
expression of these enzymes further indicated the 
existence of metabolic coupling between CAFs 
and cancer cells [24].
3  The Interaction Between 
Cancer Cells and CAFs Helps 
Cancer Cells Manage 
the Warburg Effect
Even though the extratumoral high lactate con-
centration produced by CAFs is crucial for the 
progression of cancer, high intracellular lactate 
concentration causes a dramatic drop in the pH, 
which, if left untreated, results in the death of the 
cell. Interestingly, experimental research revealed 
a few mechanisms by which cancer cells manage 
the elevated lactate level as a result of the Warburg 
effect [25–28]. Cancer cells overexpress a Na+/H+ 
transporter, NHE1 (sodium-hydrogen exchanger 
1), that pumps H+ out of the cell and Na+ into it, 
therefore neutralizing this decrease in pH caused 
by lactate [26]. Under hypoxic conditions, cancer 
cells overexpress carbonic anhydrase 9 (CA9), 
which is responsible for the conversion of carbon 
dioxide to bicarbonate to neutralize increased 
acidity [27]. Certain cancer cells also overex-
press MCT4, the transporter involved in secreting 
lactate out of the cell. By doing this, if intracel-
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lular lactate concentration goes too high, some of 
it can be secreted to prevent the pH from drop-
ping too low [28]. Cancer cells adjacent to 
autophagic CAFs upregulate TP53-induced gly-
colysis and the apoptosis regulator (TIGAR). 
TIGAR is capable of protecting cancer cells 
against oxidative stress by inhibiting autophagy 
and apoptosis while simultaneously shifting cells 
towards oxidative phosphorylation (OXPHOS) 
and away from aerobic glycolysis [29]. Finally, 
several antioxidant enzymes, such as peroxire-
doxin-1, have been observed to be upregulated in 
certain cancer cells [2]. It is likely that as more 
experiments are performed involving the TME 
and cancer cells, more evasion mechanisms will 
be elucidated.
4  Loss of Stromal Cav-1 Is 
an Indicator of Poor 
Prognosis in Breast Cancers
The importance of Cav-1  in transdifferentiating 
normal fibroblasts into myofibroblasts is well 
established. Recent experiments have shed light 
on the complex mechanisms by which cancer 
cells modulate their environment and manage to 
downregulate Cav-1 expression in fibroblasts. 
Cav-1 inhibits TGF-β type I receptor kinase. The 
lack of Cav-1 expression in the Cav-1(−/−) null 
skin fibroblasts can induce a myofibroblastic 
phenotype. One of the most widely known tumor- 
derived factors involved in the activation of CAFs 
is TGF-β1 [1, 30, 31]. Interestingly, in the 
absence of CAFs, TGF-β itself in cancer cells has 
no direct effect on cancer proliferation and sur-
vival [31]. It is believed that cancer-derived 
TGF-β acts in a paracrine manner and causes the 
downregulation of Cav-1α in CAFs. This event 
results in the overexpression of ROS by CAFs 
that can act both in an autocrine and a paracrine 
fashion, stimulating themselves and nearby fibro-
blasts to acquire a myofibroblastic phenotype. 
ROS inhibit prolyl hydroxylase (PHD) from tar-
geting the transcription factor HIF-1α for degra-
dation [32–34]. As a result, HIF-1α gets stabilized 
and translocated into the nucleus causing the 
overexpression of autophagy genes, BNIP3 
(BCL2/adenovirus E1B 19  kDa protein- 
interacting protein 3) and BNIP3L (BCL2/adeno-
virus E1B 19  kDa protein-interacting protein 
3-like), which compete with Beclin-1. Beclin-1 
then acts as a mitophagy/autophagy factor caus-
ing the dysfunction of mitochondria and, thus, 
the increase of ROS, acting on a positive feed-
back loop [35, 36]. HIF-1α also upregulates 
CTSB (cathepsin B) and ATG16L1 (autophagy- 
related 16 like 1), which are markers for autoph-
agy and mitophagy, respectively [29]. 
Additionally, TGF-β causes the upregulation of 
BNIP3, BNIP3L, and CTSB (cathepsin B), all of 
which can induce mitophagy/autophagy and 
therefore shift the cell away from OXPHOS and 
towards aerobic glycolysis [31]. BNIP3, BNIP3L, 
and CTSB increase lactate production, whereas 
ATG16L1 increases ketone production [37]. 
Lactate and ketone bodies can then be utilized by 
cancer cells to enhance tumor growth [37]. TGF- 
β, therefore, promotes tumorigenesis via CAF 
metabolism, and specifically TGF-β in fibroblasts 
Table 1 Glycolytic enzymes upregulated in Cav-1(−/−) mammary stromal fibroblasts
Glycolytic and metabolic enzymes Metabolic reaction involved
M2-type pyruvate kinase Phosphoenolpyruvate → pyruvate
Phosphoglycerate kinase I Glycerate-1,3P2 ↔ glycerate-3P
Lactate dehydrogenase A Lactate ↔ pyruvate
Fructose-bisphosphate aldolase A Fructose-1,6P2 ↔ glyceraldehyde-3P + dihydroxyacetone-P
Glycerol 3-phosphate dehydrogenase 2 Dihydroxyacetone-P ↔ glycerol-3P
Enolase I Glycerate-2P ↔ phosphoenolpyruvate
Triosephosphate isomerase I Glyceraldehyde-3P ↔ dihydroxyacetone-P
Phosphoglycerate mutase Glycerate-3P ↔ glycerate-2P
All eight enzymes lead to the overproduction of pyruvate and lactate, which are then secreted in the medium for adja-
cent cancer cells to take up and utilize as an energy source
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leads to the upregulated mitochondrial activity of 
cancer cells and tumor growth [31] (Fig. 1).
The rapid proliferation of cancer, without a sig-
nificant increase in vascularization, limits oxygen 
availability for normal fibroblasts, thus creating a 
hypoxic environment that forces the fibroblasts to 
undergo metabolic changes [1]. Hypoxia results in 
the stabilization of HIF-1α, which, as described 
previously, is a very important transcription factor 
for genes involved in autophagy, mitochondrial 
biogenesis, and general energy homeostasis [29]. 
Furthermore, under normoxia, NFκB (nuclear fac-
tor kappa-light-chain-enhancer of activated B 
cells), a key inducer of autophagy, is inhibited by 
the inhibitor of NFκB (IκB). IκB achieves this by 
sequestering the nuclear localization signal of 
NFκB, therefore rendering it inactive in the cyto-
plasm [38]. However, hypoxic conditions activate 
IκB kinase (IκBK), which targets IκB for degrada-
tion by phosphorylation and thus promotes the acti-
vation of NFκB [39]. Even though the exact 
mechanism by which NFκB is able to direct 
autophagy is unclear, it is believed that this tran-
scription factor upregulates the expression of cer-
tain inflammatory cytokines, such as IL-6, IL-8, 
IL-10, and TNFα [40, 41]. These inflammatory 
mediators are able to induce autophagy indepen-
dent from each other [40, 41]. Finally, NFκB also 
binds to the HIF-1α promoter and results in its 
upregulation [42] (Fig. 1). Hypoxia- and TGF-β-
Fig. 1 Conversion of normal fibroblasts (NF) to cancer-associated fibroblasts (CAF) through cancer-induced hypoxia 
and cancer-derived TGFβ
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induced autophagy cause the lysosomal degrada-
tion of Cav-1 as well as mitochondrial dysfunction 
and degradation,  leading to a highly glycolytic 
state in CAFs. Cav-1α normally inhibits nitric 
oxide synthase and prevents the accumulation of 
nitric oxide (NO). In the absence of Cav-1α, NO 
accumulates and inhibits cytochrome c oxidase, 
causing mitochondrial uncoupling and thus render-
ing mitochondria susceptible to mitophagy [43]. 
This results in high amounts of lactate, pyruvate, 
ketone bodies, glutamine, and free fatty acids [2, 
24, 44] that can be utilized by adjacent cancer cells.
The aforementioned oxidative stress and 
hypoxia derived from Cav-1 loss lead to mito-
chondrial dysfunction and degradation. 
Mitochondrial dysfunction causes the premature 
reaction of electrons with oxygen, leading to the 
generation of ROS, such as O2−, H2O2, and OH· 
[2]. ROS induce oxidative stress, stabilize HIF-1α, 
and inhibit NFκB in a positive feedback manner. 
The fact that TGF was not able to stimulate a sig-
nificant increase in angiogenesis and vasculariza-
tion suggests that the growth stimulated by CAFs 
depends on the paracrine supply of high-energy 
molecules such as lactate, pyruvate, ketone bod-
ies, amino acids, and fatty acids [45, 46].
5  miRNAs Play a Crucial Role 
in CAF Metabolic 
Reprogramming
MicroRNAs (miRNAs) are short noncoding RNAs 
that target mRNA and, therefore, can regulate 
gene transcription at the posttranscriptional level 
[47]. miRNAs have been shown to be upregulated 
in CAFs, as well as secreted by various tumors 
into the TME in microvesicles (MV) [47–51].
5.1  The Role of Endogenous 
miRNAs in the Metabolic 
Reprogramming of CAFs
Isocitrate dehydrogenase 3α (IDH3α), the 
enzyme responsible for the conversion of isoci-
trate to α-ketoglutarate, is downregulated in 
colon cancer CAFs and melanoma CAFs follow-
ing TGFβ exposure [48]. This downregulation of 
IDH3α is attributed to the increased levels of 
miR-424 which leads to the accumulation of suc-
cinate and fumarate, which in turn inhibits the 
activation of PHD2 (the predominant enzyme 
that degrades HIF-1α by hydroxylation), thus 
leading to stabilization of HIF-1α [48, 52]. It is 
this HIF-1α stabilization and activity that leads to 
the upregulation of transporters and various gly-
colytic enzymes, such as glucose transporter 1 
(GLUT1), hexokinase 2 (HK2), and 6-phospho-
fructokinase, muscle type (PKFM) [48], and 
causes an increase in glucose uptake and lactate 
production, as well as a decrease in oxygen con-
sumption by these fibroblasts [48].
Additionally, HIF-1α in colon cancer CAFs 
and melanoma CAFs is able to inhibit OXPHOS 
by downregulating mitochondria complex I 
through the overexpression of a complex I inhibi-
tor, known as NADH dehydrogenase 1 alpha sub- 
complex 4-like 2 (NDUFA4L2) [48]. It is 
noteworthy that the expression of NDUFA4L2 is 
TGFβ dose and time dependent [48].
In another set of experiments, miR-21 was 
shown to play a critical role in pancreatic cancer 
CAF development [49]. Metabolic coupling was 
evident between CAFs that had higher expression 
of miR-21 and pancreatic cancer cells. miR-21 
upregulation increases glucose uptake and lactate 
production in CAFs, while at the same time upreg-
ulating SDH and FH in pancreatic cancers [49].
5.2  The Role of Exogenous miRNA 
in the Metabolic 
Reprogramming of CAFs
Yao et al. studied the interaction between pancre-
atic cancer cells and fibroblasts in 2015 [47]. 
They identified that miR-155 was packaged in 
MVs and secreted by pancreatic cancer cells 
[47]. Once in NFs, miR-155 exerted its transfor-
mative role by targeting the TP53INP1 gene and 
transforming NFs into CAFs [47, 50]. The trans-
formative ability of miR-155 could be explained 
by the fact that TP53INP1 has pro-apoptotic 
properties and its downregulation by miR-155 
leads to decreased mitophagy and accumulation 
of dysfunctional mitochondria that produce high 
levels of ROS [47, 51].
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6  CAF-Derived Exosomes 
(CDEs) Can Reprogram 
the Metabolic Pathway 
of Cancer Cells
Much research has been focused on exosomes 
secreted by cancer cells, while little is known 
about exosomes secreted by CAFs. Zhao et al., 
with the use of isotopologue tracing [53], 
showed that CAF-derived exosomes (CDEs) are 
taken up by cancer cells in a KRAS-independent 
mechanism and are, indeed, capable of repro-
gramming the metabolic activity of pancreatic 
and prostate cancer cells [54]. They demon-
strated how CDE can sustain the rapidly divid-
ing cancer cells under hypoxic conditions or 
when the normal oxidative mitochondrial func-
tion has been disabled. Additionally, the pres-
ence of CDEs can rescue prostate and  pancreatic 
cancer cells from starvation by  providing de 
novo-synthesized metabolites, such as amino 
acids (Table 2). This suggests that there is con-
stant communication between the cancer cells 
and the adjacent fibroblasts, where both con-
stantly coevolve [54].




CAF-derived exosomes (CDEs) contain amino 
acids, fatty acids, pyruvate, lactate, miRNA, and 
many other compounds. miRNAs are essential in 
regulating gene expression [54]. Zhao et  al. 
showed that miRNAs present in CDEs are capa-
ble of downregulating all 109 OXPHOS-related 
genes in cancer cells. As shown in Table 3, the ten 
most abundant miRNAs present in these CDEs 
target one or more OXPHOS genes, leading to 
decreased OXPHOS.  Therefore, cancer cells 
must rely on alternative metabolic pathways to 
maintain their rapid proliferation [54].
6.2  Effect of CDEs on Glycolysis 
and TCA of Cancer Cells
With the use of GC-MS and 13C6-glucose, Zhao 
et al. showed that glucose from CDEs was the 
main glycolytic substrate for cancer cells. This 
was evident due to the increase in labeled gly-
colytic metabolites, lactate and pyruvate, in 
prostate cancer cells cultured with CDEs, and 
the reduced amount of non-labeled pyruvate 
and lactate (Fig. 2). Additionally, they further 




























Table 3 The ten most abundant miRNAs present in CDE 
and their respective target genes
Exosomal 
miRNA OXPHOS gene silenced
miR-302d-3p UQCRFS1





miR-29a-3p ATP5G1, ATP6V1A, ATP5G3
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showed that the labeled metabolites involved 
in the TCA cycle (citrate, α-ketoglutarate, 
fumarate, and malate) are found in signifi-
cantly lower concentrations when cultured 
with CDEs. Therefore, the increase of labeled 
glycolytic metabolites and the decrease of 
labeled TCA metabolites suggest that glucose 
provided by CDEs is primarily used in glycoly-
sis and not in mitochondrial oxidative phos-
phorylation [54].
Fig. 2 CDE-derived glucose is mainly used in cancer cell glycolysis and, to a lesser extent, the TCA cycle. Metabolites 
in red represent the metabolites found in cancer cells present in high concentrations resulting from CDE-derived glu-
cose. Metabolites in green represent the metabolites found in cancer cells present in low concentrations from CDE-
derived glucose
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6.3  Glutamine from CDEs 
Undergoes Mainly Reductive 
Metabolism that Also Results 
in Aberrant Lipogenesis 
in Adjacent Cancer Cells
Glutamine is another major carbon source for the 
TCA cycle and a nitrogen source for protein syn-
thesis [55–58]. Zhao et al. identified the contribu-
tion of CDE-derived glutamine to the TCA cycle 
in the cancer cells using U-13C5-glutamine isoto-
pologue tracing [54]. Under both normoxic and 
hypoxic conditions, glutamine can enter the oxi-
dative metabolic pathway and produce oxaloace-
tate, which then combines with acetyl-CoA to 
form citrate, a fatty acid precursor. Additionally, 
under hypoxic conditions, glutamine enters the 
reductive metabolic pathway generating 
α-ketoglutarate and then citrate [59]. As shown in 
Fig. 3, citrate is eventually converted to fumarate 
and then malate. The presence of M + 5 citrate, 
M + 3 fumarate, and M + 3 malate in high con-
centrations suggests that cancer cells mainly rely 
on the reductive glutamine metabolism when the 
normal mitochondrial function of the cell is dis-
rupted. Additional evidence to support this is the 
decreased M + 4/M + 5 citrate ratio. M + 4 citrate 
is derived from the oxidative pathway of gluta-
mine, whereas M + 5 citrate is from the reductive 
pathway, and therefore this reduced M + 4/M + 5 
citrate ratio confirms the predominance of the 
glutamine reductive pathway [54]. Furthermore, 
a major component and requirement for cell pro-
liferation is lipogenesis, the generation of fatty 
acids for cell membranes [60]. Zhao et  al. also 
showed that exposure to CDEs resulted in 
increased acetate contribution and simultane-
ously decreased pyruvate contribution to lipogen-
esis. This event suggests that the main source of 
carbon for acetyl-CoA upon exposure to CDEs is 
the glutamine reductive carboxylation pathway 
and not the oxidative glucose pathway. Finally, 
metabolic analysis of CDEs revealed significant 
amounts of stearate and palmitate that can be 
directly utilized by the cancer cells for lipid syn-
thesis [54]. It is worth mentioning that fatty acid 
synthase (FASN) expression has been found to be 
elevated in numerous types of cancer [61]. Even 
though there is still no direct link between CAFs 
and overexpression of FASN, this could be the 
result of the coevolution of stroma and cancer. 
However, more research is required before con-
clusions can be drawn.
7  CAF-Derived Lactate Is more 
Than Just a Metabolite
Sirtuins (SIRTs) are deacetylases that are acti-
vated when NADH/NAD+ ratios are unbalanced 
and act as sensors of nutrient deprivation [62–64]. 
SIRT1, specifically, targets and activates peroxi-
some proliferator- activated receptor gamma 
coactivator 1-alpha (PGC-1α), a transcription fac-
tor that promotes mitochondrial respiration and 
OXPHOS [65–68]. CAF-derived lactate is con-
verted to pyruvate by the upregulated enzyme lac-
tate dehydrogenase B (LDHB), leading to the 
accumulation of NADH. High levels of NADH 
result in the increased expression of SIRT1. 
Currently, lactate is the only metabolite capable of 
inducing SIRT1 activation and PGC-1α deacety-
lation and therefore proves the importance of lac-
tate as more than just a metabolite. NADH is then 
oxidized back to NAD+, and the unbalanced high 
levels of NAD+ cause the activation of SIRT1, 
thus help maintain the increased mitochondrial 
activity and OXPHOS in cancer cells [69].
As mentioned earlier, increased mitochondrial 
activity and oxygen consumption have been 
recorded in many tumors when co-cultured with 
CAFs. Prostate cancers are an example [69]. 
CAF-derived lactate enters the TCA cycle, lead-
ing to the accumulation of citrate, succinate, 
fumarate, and malate, but not to a significant 
increase in α-KG [69]. Additionally, in prostate 
cancer cells, mitochondrial complexes II–III are 
downregulated, and complex I is upregulated, 
leading to the accumulation of mitochondrial 
reactive oxygen species (mtROS) [69]. The 
increased complex II dysfunction leads to the 
accumulation of succinate [69].
mtROS oxidize and activate Scr, a crucial 
and mandatory step for CAF-derived lactate 
addiction of prostate cancer cells [69]. Scr is 
able to sustain the activation of SIRT1/PGC-1α. 
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In the absence of Scr activity, prostate cancer 
cells are unable to utilize CAF-derived lactate in 
this manner and show no SIRT1/PGC-1α activ-
ity [69].
Even though the increase in both mtROS and 
PGC-1α might seem controversial since PGC-1α 
is a regulator of the antioxidant response, it is 
believed that there is a fine balance between the 
two that helps aid prostate cancer survival and 
promotes OXPHOS [69]. PGC-1α could be act-
ing in a negative feedback loop, ensuring that 
mtROS remain under control [69]. Taken 
together, CAF-derived lactate is a crucial metab-
olite in prostate cancer metabolic transformation 
Fig. 3 Oxidative and reductive glutaminolysis. Green circles represent labeled carbons (13C), and black circles repre-
sent non-labeled carbons (12C). Glutamine derived from CDEs is fully labeled, and its subsequent pathways (oxidative 
or reductive) in cancer cells are analyzed. Metabolites in red represent the metabolites of the reductive metabolic path-
way of glutamine found. Metabolites in green represent the metabolites of the oxidative metabolic pathway of gluta-
mine found
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towards OXPHOS through mtROS production, 
Src activation, and SIRT1/PGC-1α activity.
8  CAFs “Surrender” Their 
Functional Mitochondria 
to Prostate Cancer Cells
In vitro experiments showed that CAFs are able to 
surrender their functional mitochondria to pros-
tate cancer cells [69]. This effect is more promi-
nent in higher grade prostate tumors [69]. 
Interestingly, after exposure to CAF-conditioned 
media, significantly more prostate tumor cells 
were able to receive CAF-derived mitochondria. 
This suggests that CAFs act in a paracrine manner 
to prime prostate cancer cells and prepare them to 
receive functional mitochondria [69]. Additionally, 
confocal microscopy and imaging techniques 
were able to show the transfer of mitochondria 
from CAFs to cancer cells through nanotubule 
formation. NFs were unable to donate their mito-
chondria, suggesting that this is a property limited 
to CAFs and not to all fibroblasts [69].
Prostate cancer cells that received CAF- 
derived mitochondria express higher levels of 
MCT1, the transporter that transports lactate into 
the cell. Those prostate cancer cells also upregu-
late SIRT-1 and PGC-1α. Interestingly, inhibition 
of MCT1 prevents the receipt of CAF-derived 
mitochondria. The exact mechanism and relation 
of MCT1 with the mitochondrial transfer are still 
unknown, but its importance in enhancing 
OXPHOS metabolism in mitochondrial recipient 
prostate cancer cells is evident [69]. An increased 
number of mitochondria and OXPHOS can aid 
higher grade tumors to meet the high energy 
demands [69].




As mentioned earlier, there exists constant coevo-
lution between cancer cells and the TME. Cancer 
cells stop directing glucose into the TCA cycle 
and, instead, use glucose for the production of 
nucleotides [70]. Consequently, cancer cells start 
relying on other carbon sources for oxidative 
phosphorylation, particularly on glutamine 
derived from CAFs [54]. However, during gluta-
minolysis, specifically during the conversion of 
glutamine to glutamate and then to α-ketoglutarate 
(which enters the TCA cycle), ammonia is 
released as a by-product [57, 71, 72]. Ammonia 
is a diffusible compound and an inducer of 
autophagy. This has detrimental effects on the 
surrounding stroma, as it causes autophagy in the 
adjacent CAFs. CAFs, subsequently, undergo 
autophagy and further release glutamine to be 
metabolized by the cancer cells. Therefore, a 
positive feedback loop exists between cancer’s 
addiction to glutamine and CAF’s conversion/
autophagy [71, 72].
10  Alanine Secreted by 
Pancreatic Stellate Cells 
Supports Pancreatic Cancer 
Metabolism
In one study, Sousa et al. discovered that myofi-
broblast-like pancreatic stellate cells (PSCs) 
secreted alanine and were able to support pancre-
atic cancer metabolism [70]. Among the 200 
metabolites analyzed, only alanine and aspartate 
met the following criteria: (1) increased amounts 
of metabolite in PSC medium, (2) decreased 
amounts of metabolite in PSC medium when 
exposed to pancreatic cancer (PDAC) cells, and 
(3) increased amounts of metabolite in PDAC 
after exposure to PSC medium. Furthermore, 
kinetic studies showed that alanine is secreted 
even more rapidly than lactate. In fact, PSC- 
derived alanine does not contribute to the produc-
tion of glycolytic intermediates or alter the NAD+/
NADH ratio, but rather, it is transaminated to 
pyruvate, providing additional substrates for the 
TCA cycle. This intermediate contribution to the 
TCA cycle subsequently increases oxygen con-
sumption [70]. Alanine-derived pyruvate enters 
the TCA cycle in the mitochondria and contrib-
utes predominantly to the generation of citrate 
(23–46% among different PDAC cell lines) and 
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isocitrate. To a lesser extent, it also contributes to 
the generation of malate, fumarate, aspartate, and 
glutamate. Alanine, therefore, fuels mitochondrial 
metabolism without affecting glycolysis. Alanine-
derived citrate is then transported from the mito-
chondria to the cytosol for lipogenesis. Metabolite 
tracing showed that alanine significantly contrib-
uted to the generation of palmitate and stearate, 
more than 20% and 10% of the total concentra-
tions, respectively [70]. In the presence of alanine, 
glucose enters the serine biosynthetic pathway in 
PDAC cells and produces serine and glycine. 
Serine and glycine can then be used in the biosyn-
thesis of nucleic acids. Under nutrient-deprived 
conditions, the entry of glucose into the serine 
biosynthetic pathway is more evident. This sug-
gests that in cases of glucose-deprived conditions, 
alanine can take over aerobic respiration by pro-
viding TCA cycle intermediate metabolites, and 
subsequently, glucose can then enter different 
metabolic pathways, such as the serine biosyn-
thetic pathway [70].
The induction of alanine secretion by PSCs 
for PDAC cells to take up is a two-way intratu-
moral cross talk. PDAC cells initially stimulate 
PSCs to undergo autophagy and thus lead to the 
release of alanine. PSC-derived alanine is then 
taken up by PDAC cells to contribute to meta-
bolic pathways. In nutrient-rich conditions, the 
PSC autophagic alanine secretion has a minimum 
effect on PDAC proliferation. However, in 
nutrient- deprived conditions, PSC autophagic 
alanine secretion can significantly rescue and 
promote the growth of PDAC cells. This effect 
mainly occurs during the early stages of cancer 
development. Interestingly, autophagy does not 
influence the proliferation rate of PSCs them-
selves [70].
11  CAFs Act as Lipid Synthesis 
Factories for Colorectal 
Cancer Cells
New research performed by Zhao et al. in 2020 
has shown that CAFs overexpress FASN and 
undergo lipidomic reprogramming to help 
colorectal cancer cells meet their high energy 
demands by providing them with newly synthe-
sized lipids [73]. Nineteen lipids were specifi-
cally identified that were produced and secreted 
by CAFs and taken up by colorectal cancer cells 
[73]. However, more research is needed to iden-
tify the exact mechanisms that stimulate this lipi-
domic reprogramming in CAFs and how the de 
novo lipids are utilized by cancer cells [74].
12  Reciprocal Communication Is 
Essential for Cancer 
Progression
The importance of KRAS in supporting heterocel-
lular communication was demonstrated by Tape 
et  al. [25]. When PDAC cells were exposed to 
homocellular conditions, mitochondrial function 
decreased, and superoxide concentrations 
increased. However, when PDAC cells were 
exposed to heterocellular conditions (i.e., co- 
cultured together with CAFs), mitochondrial 
function was restored, and superoxide concentra-
tions were well regulated. These results suggest 
that heterocellular and reciprocal communication 
between CAFs and cancer cells is essential for 
the progression of cancer. In this experiment, 
PDAC cells with KRAS mutation initially stimu-
lated the surrounding CAFs to undergo metabolic 
and cellular changes. Reciprocal stimulation 
between CAFs and PDAC cells prevents cancer 
cell mitochondrial dysfunction and superoxide 
production. The exact signals involved in this 
dialogue between CAFs and PDAC cells are still 
unclear, and further research is required to 
unravel this mechanism [25].
13  Conclusion
As cancer research progresses, the significance of 
the TME in cancer progression is better eluci-
dated [75]. Tumor cell-derived TGF-β causes the 
lysosomal targeting of fibroblastic Cav-1, induc-
ing a myofibroblastic phenotype (activated form). 
Additionally, the increased oxygen consumption 
of cancer cells with no significant increase in vas-
cularization induces hypoxia and oxidative stress, 
causing the stabilization of HIF-1α and inhibition 
of IκB in CAFs. Stabilized HIF-1α induces 
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autophagy and mitophagy. Subsequently, CAFs 
rely on glycolysis for energy, producing a high 
amount of lactate, ketone bodies, glutamine, and 
fatty acids, which are then secreted and taken up 
by the surrounding cancer cells.
In the case of PDAC, it is evident that the 
secretion of alanine by PSCs (myofibroblast-like 
pancreatic stellate cells) is sufficient to rescue 
cancer cells in low-nutrient environments. It was 
noted that alanine, not glucose, is used in the 
TCA cycle. This allows glucose to enter the 
 serine biosynthetic pathway to generate nucleic 
acids, further contributing to the rapid cancer cell 
proliferation.
Furthermore, miRNAs play a significant role 
in metabolically coupling CAFs and various can-
cers, such as pancreatic cancer. miRNAs can lead 
to increased glucose uptake and lactate produc-
tion in CAFs, while at the same time SDH and 
FH are upregulated in pancreatic cancers. CAFs 
have also been demonstrated to “surrender” their 
functional mitochondria to prostate cancer cells 
to help cancers meet their high energy demands. 
In other cases, such as with colorectal cancer, 
CAFs act as lipid synthesis factories.
CAFs’ contribution to cancer progression 
does not end here. Exosomes derived from 
CAFs (CDEs) contain a variety of miRNAs 
responsible for downregulating genes involved 
in OXPHOS and therefore contribute to the 
reprogramming of the metabolic activity of can-
cer cells. CDEs also contain de novo metabo-
lites that enable the rapidly dividing cancer cells 
to survive in low- nutrient conditions. For exam-
ple, CDE-derived glutamine undergoes reduc-
tive metabolism and generates acetyl-CoA for 
lipogenesis. However, during glutamine metab-
olism, ammonia, a diffusible autophagy factor, 
is produced as a by- product. CAFs that are stim-
ulated by ammonia undergo autophagy and, in 
turn, further release more glutamine to be 
metabolized by cancer cells in a positive feed-
back loop. It is clear that cancer should not be 
regarded as an individual entity anymore, but 
rather it should be viewed within the context of 
its microenvironment. The understanding of the 
extent of the stromal impact on cancer metabo-
lism and progression can provide new targets 
for cancer therapy [76].
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Key Points
• Metabolic cross talk between CAFs and can-
cer can be a metabolic target for cancer 
therapy.
• The reverse Warburg effects can be targeted 
via disruption of the “lactate shuttle” by 
MCT1/MCT 4 inhibitors.
• Metformin can be used to inhibit glycolysis 
and block the function of CAFs, which pro-
mote cancer cell growth.
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• Blocking the glutamine uptake of cancer cells 
from CAFs is a strategy in targeting 
glutaminolysis.
• Ketone bodies and ketosis in CAFs can be tar-
geted for cancer treatment.
• Fatty acid metabolism from cancer-associated 
adipocytes (CAAs) serves as a nutrient reser-
voir for cancer cell growth and is another tar-
get for cancer therapy.
1  Introduction
Although cancer has classically been regarded as 
a genetic disease of uncontrolled cell growth, the 
importance of the tumor microenvironment 
(TME) [1, 2] is continuously emphasized by the 
accumulating evidence that cancer growth is not 
simply dependent on the cancer cells themselves 
[3, 4] but also dependent on angiogenesis [5–8], 
inflammation [9, 10], and the supporting roles of 
cancer-associated fibroblasts (CAFs) [11–13]. 
After the discovery that CAFs are able to remodel 
the tumor matrix within the TME and provide the 
nutrients and chemicals to promote cancer cell 
growth [14], many studies have aimed to uncover 
the cross talk between cancer cells and CAFs. 
Moreover, a new paradigm in cancer metabolism 
shows how cancer cells act like “metabolic para-
sites” to take up the high-energy metabolites, 
such as lactate, ketone bodies, free fatty acids, 
and glutamine from supporting cells, including 
CAFs and cancer-associated adipocytes (CAAs) 
[15, 16]. This chapter provides an overview of 
the metabolic coupling between CAFs and can-
cer cells to further define the therapeutic options 
to disrupt the CAF-cancer cell interactions.
2  Overview of the Metabolism 
of CAFs in Solid Tumors
Pathological analysis shows that CAFs either are 
located in the tumor margin or infiltrate the tumor 
mass, indicating that CAFs and cancer cells are 
physically and functionally connected to each 
other [17, 18]. Of note, other than their locations, 
the physiological roles of CAFs depend on the 
existence of neighboring cancer cells [19], lead-
ing Madar et  al. to propose a new concept: a 
“CAF state” instead of “cell type” [20].
Studying cancer metabolism is difficult due 
to the dynamic and rapid metabolic influx/efflux 
of heterogeneous cancer cells [2]. However, it is 
clear that the reprogramming of energy metabo-
lism is one of the hallmarks of cancer [21]. 
Thus, researchers have sought to identify the 
metabolic vulnerabilities of cancer cells and 
exploit them for therapy [22, 23]. Cancer-
friendly fibroblasts are the most abundant non-
cancerous cells in solid tumors, and they 
promote cancer cell growth and induce chemo-
therapy resistance [24]. Unfortunately, the 
underlying mechanism of how CAFs help in 
tumor cell growth remains unclear. However, 
recent progress in metabolic technologies, 
including stable isotope-resolved metabolo-
mics, NMR-based metabolomics, and fluores-
cence-activated cell sorting [25–29], is 
deepening our insight into the metabolic cross 
talk between CAFs and cancer cells in the con-
text of metabolic alterations. Using these 
advanced technologies, CAF-cancer cell inter-
actions have been investigated in various types 
of cancers, including breast cancer [30], pros-
tate cancer, ovarian cancer, lymphomas [31], 
non- small cell lung cancer, and head and neck 
cancers [24]. For instance, CAF produces and 
releases lactate to the TME, while cancer cells 
simultaneously utilize this lactate for mitochon-
drial oxidative phosphorylation (OXPHOS) in 
order to produce ATP efficiently and rapidly 
(Fig.  1). Interestingly, not only do CAFs pro-
duce these metabolites to help cancer cells grow, 
but cancer cells also release epidermal growth 
factor (EGF) to enhance the production and 
secretion of leptin by CAFs, which eventually 
leads to tumor progression [32]. Additionally, 
tumor cells express pro-inflammatory genes, 
including nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and inter-
leukin-1 (IL- 1), so that normal fibroblasts can 
be guided by cancer cells to become pro-inflam-
matory CAFs [33] (Fig. 1).
Moreover, several studies have identified 
CAF gene expression profiles, including certain 
extracellular matrix (ECM) components and sev-
eral matrix metalloproteases (MMP2, MMP11, 
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and MMP14). These results suggest that ECM 
biosynthesis and remodeling is one of the critical 
features of the interplay between CAFs and can-
cer [34–36]. For instance, in ovarian and small 
cell lung cancers, many ECM genes remarkably 
elevate their expression levels in chemotherapy- 
treated cancer cells to induce chemoresistance 
[37, 38]. Additionally, CAFs bypass and help 
tumor cells resist anti-vascular endothelial 
growth factor (VEGF) treatment caused by 
angiogenesis inhibition by activating the platelet- 
derived growth factor C (PDGF-C) pathway 
[39], and stroma cells mediate RAF inhibitor 
resistance in BRAF-mutant melanoma through 
human growth hormone (HGH) secretion [40]. 
Even though gene expression profiles provide a 
method to predict the risks of metabolic cou-
pling between cancer cells and CAFs, gene 
expression levels do not always correlate with 
metabolic changes. Therefore, measuring the 
metabolite levels in a sample could be a more 
accurate method to predict the risk of the afore-
mentioned metabolic interplay.
3  Targeting the Metabolic 
Exchanges Between CAFs 
and Cancer Cells
3.1  Targeting the Reverse 
Warburg Effect via Disruption 
of the “Lactate Shuttle” by 
MCT1/MCT4 Inhibitors
Glycolysis, the process of converting glucose to 
pyruvate, is an essential metabolic pathway to pro-
duce energy in the form of ATP in cells. In the 
1920s, Otto Warburg found that cancer cells pref-
Fig. 1 Overview of CAF metabolism in solid tumors
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erably produce energy by converting glucose to 
lactic acid, even in aerobic conditions, to generate 
ATP rapidly. This is known as the Warburg effect 
[41, 42]. Interestingly, it was suggested that the 
reverse Warburg effect is the result of fibroblasts 
secreting lactate/pyruvate and epithelial cancer 
cells simultaneously taking up the energy-rich 
metabolites to utilize in the tricarboxylic acid 
(TCA) cycle and promote energy production for 
their growth [43]. In this hypothesis, cancer cells 
first guide the normal stromal cells to become 
CAFs, providing a tumor-friendly microenviron-
ment to activate tumor growth. Next, lactate from 
CAFs is directly absorbed by the cancer cells as 
fuel for OXPHOS after the conversion of lactate to 
pyruvate [44]. Accordingly, the expression levels 
of glycolytic enzymes, such as lactate dehydroge-
nase and pyruvate kinase isozymes M2, and the 
lactate transporter, monocarboxylate transporter 4 
(MCT4), are elevated in CAFs within breast and 
lung cancer tumors [24, 45]. Of note, lactate plays 
an important role in generating energy for the 
brain and the heart [46–49] and serves as an energy 
interplay shuttle between stromal cells and various 
types of cancer cells [45, 49, 50]. In this scenario, 
surrounding CAFs can communicate with cancer 
cells through direct cell-to-cell contact by releas-
ing an exosome packaged with CAF-produced 
metabolites [51]. This coincides with neovascular-
ization, inflammatory cell infiltration, and exten-
sive remodeling of extracellular matrix in the TME 
[52]. Evidence supporting the “lactate shuttle” in 
human cancers [16, 53, 54] further shows that lac-
tate can be directly transferred from CAFs to adja-
cent tumor cells under the premise that (1) CAFs 
overexpress the transmembrane monocarboxylate 
transporter 4 (MCT4) for lactate efflux from CAFs 
to cancer cells [53], (2) cancer cells overexpress 
monocarboxylate transporter 1 (MCT1) for lactate 
influx into cancer cells [45, 55], and (3) cancer 
cells finally utilize lactate as fuel for producing 
ATP via the TCA cycle [56–58]. Of note, MCT1 
and MCT4, the main transporters of lactate, are 
key modulators of lactate homeostasis [59]. The 
elevated expression levels of genes involved in the 
lactate shuttle system, including high expression 
levels of MCT4, are associated with poor progno-
sis in the prostate, pancreas, and triple-negative 
breast cancers [59–61]. Consequently, accumulat-
ing evidence suggests that MCT1 and MCT4 
transporters could be promising targets for cancer 
therapy.
Over the last decade, there has been signifi-
cant progress in understanding the roles of the 
TME in tumorigenesis and the development of 
effective strategies for cancer therapy. In order to 
disrupt the metabolic bridge in CAF-cancer cell 
interactions through glycolysis and lactate 
metabolism inhibition, three potential strategies 
have been proposed. First, elevated expression of 
the lactate transporter MCT1 in cancer cells is a 
potential target for blocking cellular uptake of 
two types of mitochondrial fuels, ketone bodies 
and lactate [62]. MCT1 and MCT2 inhibitors can 
block the influx and efflux of lactate produced by 
either CAFs or cancer cells. Thus, due to the 
rapid accumulation of lactate and protons within 
cancer cells by inhibiting lactate influx/efflux, 
rapid acidification can occur in cancer cells and 
the TME, resulting in lactic acidosis [63–65]. For 
instance, alpha-cyano-4-hydroxy-cinnamic acid 
(ACCA), an MCT inhibitor, not only inhibits lac-
tic acid efflux in glycolytic gliomas but also dis-
rupts redox hemostasis and enhances 
radiosensitivity [66, 67]. AZD3965, an MCT1 
inhibitor, is currently being tested in phase I clin-
ical trial in solid tumors, including lymphoma, 
prostate cancer, and gastric cancer 
(NCT01791595) (Fig.  2). However, there are 
concerns over the alternative effects of MCT1 
inhibitors, which include the blockage of lactate 
transport in muscles, gastrointestinal tract, and 
liver [68, 69].
3.2  Blocking the Function of CAFs 
by Metformin (Fig. 2)
Metformin, a drug that has been widely used for type 
2 diabetes treatment, has found new applications as 
an anticancer drug for its glucose- targeting effects. 
Metformin activates the AMPK pathway and simul-
taneously inhibits cancer cell growth through the 
inhibition of glycolysis by facilitating the trafficking 
of glucose transporters 1 and 4 [70, 71]. Recent stud-
ies have also shown the therapeutic potential of met-
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formin in blocking the function of CAFs [72]. In 
other words, metformin is sufficient to reverse the 
effects of CAFs on cancer cell growth [72], provid-
ing a rationale for why metformin is actively being 
tested in multiple clinical trials in solid tumors and 
lymphoma (NCTNCT00659568, NCT00881725, 
NCT00984490, and NCT00909506).
4  Targeting the Glutamine 
Uptake of Cancer Cells 
from CAFs
Glutamine addiction is a physiological phenom-
enon where cancer cells rely on the presence of 
exogenous glutamine to be used as a fuel for the 
TCA cycle and as a nitrogen donor for nucleotide 
and amino acid synthesis [73–76]. It was recently 
revealed that CAFs produce and release gluta-
mine, while cancer cells take up and utilize this 
glutamine from the TME as an alternative carbon 
and nitrogen source [51, 77]. This explains why 
glutamine transporters, alanine, serine, cysteine 
preferring transporter 2 (ASCT2), and solute car-
rier family 38 member 5 (SLC38A5) are usually 
overexpressed in breast and prostate cancers [78–
80]. Of note, ASCT2 mediates the uptake of glu-
tamine, an essential amino acid in triple-negative 
basal-like breast cancer [80]. And ASCT2 inhibi-
tors, such as benzylserine and L-γ-glutamyl-p-
nitroanilide, have been shown to inhibit glutamine 
uptake and cell growth in melanoma and endo-
metrial carcinoma [81–83] (Fig. 2). Additionally, 
FDA-approved tamoxifen and raloxifene also 
suppress estrogen receptor-negative breast cancer 
growth by inhibiting glutamine uptake [84].
5  Targeting Ketone Bodies 
and Ketosis in CAFs
Ketone bodies such as acetoacetate, 
β-hydroxybutyrate (βOHB), and acetone are 
produced through fatty acid metabolism in the 
liver [85]. Liver hepatocytes convert fatty acids 
into ketone bodies and release them into the 
bloodstream, especially under starvation con-
ditions or after excessive exercises. 
Consequently, through ketolysis, a process of 
the conversion of ketone bodies into acetyl-
CoA, they feed into the TCA cycle or OXPHOS 
to generate ATP [86]. Recent studies have 
shown that CAFs secrete ketone bodies and 
cancer cells utilize them as energy sources [77, 
85, 87]. Furthermore, Bonuccelli et al. observed 
that ketone bodies, especially βOHB, serve as a 
Fig. 2 Therapies targeting metabolic cross talk between cancer cells and cancer-associated fibroblasts
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more powerful energy source for cancer cell 
growth in comparison to lactate [88]. Genes 
associated with ketolysis and ketogenesis in 
CAFs, including 3-hydroxybutyrate dehydro-
genase 1 (BDH1) and 3-hydroxy-3-methylglu-
taryl-CoA synthase 2 (HMGCS2), were 
overexpressed [89, 90]. Specifically, BDH1 
catalyzes the conversion of acetoacetate to 
βOHB. HMGCS2, a member of the 3-hydroxy-
3-methylglutaryl-CoA (HMG- CoA) synthase 
family, generates HMG-CoA [86, 91]. In con-
trast to the gene expression profile of the sur-
rounding epithelial cells, cancer cells 
themselves have upregulated gene expressions 
associated with ketone reutilization (acetyl-
CoA acetyltransferase, ACAT1) and mitochon-
drial biogenesis (heat-shock protein 60, 
HSP60) [89]. Moreover, ketone bodies can be a 
source of lactate and pyruvate because ace-
tone—an end product of ketosis—can be 
metabolized to lactate and pyruvate [92, 93]. 
Taken together, this suggests that the ketone 
bodies produced by CAFs can serve as an 
energy fuel for tumor growth and have further 
implications as a potential therapeutic target 
for cancer therapy. Furthermore, ketone bod-
ies, including βOHB, are transported by the 
monocarboxylate transporters (MCT1 and 
MCT2), which also transport them across the 
blood-brain barrier [91, 94]. Accordingly, 
treatments targeting MCT1 and MCT2 are cur-
rently being tested in phase I clinical trials in 
solid tumor cancers (NCT01791595) [95]. 
Thus, the MCT1 and MCT2 inhibitors may 
effectively block the transport of lactate and 
ketone bodies, both generated by CAFs 
(Fig. 2).
6  Targeting Fatty Acid, 
a Nutrient Reservoir 
for Cancer Cell Growth, 
from Cancer- Associated 
Adipocytes (CAAs)
Cancer-associated adipocytes (CAAs) play an 
important tumorigenic role in fatty acid metabo-
lism in the TME.  For instance, omental adipo-
cytes promote the migration and invasion of 
ovarian cancer cells to the omentum [96, 97]. It is 
known that omental adipocytes generate free 
fatty acids (FFAs) that are further transferred to 
cancer cells to generate ATP via β-oxidation [98] 
(Fig.  1). Therefore, in order to utilize FFAs, a 
subset of cancer cells overexpress the fatty acid- 
binding protein 4 (FABP4), which plays a key 
role in fatty acid transport for ovarian and breast 
cancer metastasis [15, 96, 99] (Fig. 1). It has been 
shown that a FABP4 inhibitor, which binds long- 
chain fatty acids, reduces metastasis of prostate 
cancer and regulates fatty acid production in 
ovarian and prostate cancers [96, 100] (Fig. 2). 
Because adipocytes are a major component of the 
TME in breast and ovarian cancers, it may be a 
rationale for FABP4’s effectiveness in those can-
cers [96, 101]. Accumulation of fatty acids in the 
TME could serve as a nutrient reservoir for can-
cer cell growth during nutrient deprivation. Taken 
together, stromal catabolites, such as free fatty 
acids, promote tumor growth, and act as che-
moattractants to metastasizing cancer cells in the 
omentum.
7  Conclusion
The TME is comprised of cancer cells, CAFs, 
immune cells, adipocytes, and other supporting 
cells. Of these, CAFs are one of the key regula-
tors of tumorigenesis. Within the TME of solid 
tumors, heterogeneous cancer cells and CAFs 
interact by transferring their metabolites, 
including amino acids, fatty acids, ketone bod-
ies, cytokines, and growth factors, which recip-
rocally facilitate the growth of cancer cells. 
Moreover, CAFs provide not only a structural 
matrix for providing a tumor-friendly microen-
vironment to cancer cells but also nutrients for 
cancer cells. As such, the metabolic interplay 
between CAFs and cancer cells is considered as 
an area of vulnerability among cancer cells 
given that (1) cancer cells release HGH and 
induce pro-inflammatory gene expression in 
CAFs, (2) CAFs produce and release high-
energy metabolites to the TME, and (3) cancer 
cells take up those metabolites to produce 
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energy for cancer growth. Therefore, it is widely 
accepted that CAF-mediated metabolism plays 
a key role in tumorigenesis and that targeting 
the metabolic cross talk between cancer cells 
and CAFs can serve as a potential target for can-
cer therapy. Consequently, researchers have 
made continuous efforts to exploit areas of met-
abolic vulnerability by targeting (1) glycolysis 
and lactate metabolism, (2) glutaminolysis, (3) 
ketone bodies and ketosis, and (4) fatty acid 
metabolism.
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• Diabetes is correlated with increased risk for 
several types of cancer.
• Diabetes and cancer both exhibit abnormal 
glucose metabolism: hyperglycemia and the 
Warburg effect, respectively.
• High glucose levels can lead to increased 
O-GlcNAcylation through upregulation of the 
hexosamine biosynthetic pathway (HBP), 
which contributes to insulin resistance in dia-
betes and de novo KRAS mutations which can 
result in pancreatic cancer.
• Hyperinsulinemia, a condition commonly 
associated with diabetes, can promote cancer 
proliferation.
• Obesity can result in insulin resistance and 
increased oxidative stress contributing to dia-
betes and cancer.
• Dysregulation of leucine metabolism, which 
regulates insulin secretion and mTOR signal-
ing, can promote type 2 diabetes (T2D) patho-
genesis, insulin resistance, and cancer growth.
• Glutamine regulates insulin secretion contrib-
utes to gluconeogenesis in T2D, and can pro-
mote cancer growth.
• Different antidiabetic drugs have varied effects 
on cancer.
1  Introduction
Diabetes mellitus, commonly known as diabetes, 
and cancer are two of the most common diseases 
plaguing the world today. According to the 
Centers for Disease Control and Prevention 
(CDC), there are currently more than 20 million 
people with diabetes in the United States [1]. 
According to the International Agency for 
Research on Cancer (IARC), there were around 
18 million people diagnosed with cancer, with 
approximately ten million deaths globally in 
2018 [2]. Given the prevalence and deadliness of 
diabetes and cancer, these two diseases have long 
been the focus of many researchers with the goal 
of improving treatment outcomes. While diabetes 
and cancer may seem to be two very different dis-
eases at first glance, they share several similari-
ties, especially regarding their metabolic 
characteristics. This chapter discusses the simi-
larities and relationships between the metabolism 
of diabetes, especially type 2 diabetes (T2D), and 
cancer, including their abnormal glucose and 
amino acid metabolism, the contribution of 
hyperglycemia to oncogenic mutations, and the 
contribution of hyperinsulinemia to cancer pro-
gression. Investigating the metabolic interplay 
between diabetes and cancer in an effort to 
exploit this connection for cancer treatment has 
the potential to significantly improve clinical 
efficacy.
2  The Epidemiological 
Association: Diabetes 
Correlates with Increased 
Risk for Many Types 
of Cancer
As two of the most common diseases in the 
world, diabetes and cancer have attracted the 
attention of a great number of investigators 
since the 1950s with the intention of discover-
ing their epidemiological connections [3]. It 
was found through these studies that patients 
with diabetes have a higher risk of developing 
many different types of cancer, including liver, 
pancreatic, endometrium, breast, colon, and 
 rectum cancers [3]. Specifically, it was found 
that the risk for colorectal cancer is 30% greater 
for patients with T2D, which is caused by insu-
lin resistance, as compared to people who do not 
have diabetes [4, 5]. Among all types of cancers, 
pancreatic cancer has the most drastic associa-
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tion with diabetes. As Pannala et al. discovered, 
around 50% of the patients with pancreatic can-
cer have T2D [5, 6]. However, while the epide-
miological connections between diabetes and 
cancer have long been known, the exact mecha-
nisms behind the relationships are not well 
understood, and further studies are needed.
While it seems reasonable to speculate that 
high glucose levels in diabetes can promote can-
cer proliferation, some clinical data contradict 
this speculation. For example, it was found that 
there is a significantly decreased risk for prostate 
cancer in patients with T2D [7] and that the 
chances for developing lung [3] and ovarian can-
cers [7, 8] are not associated with T2D.  These 
exceptions call for further investigations to fully 
understand the association between diabetes, 
especially T2D, and cancer, as well as the mecha-
nisms behind it.
3  Abnormal Glucose 
Metabolism Serves as a Link 
Between Diabetes 
and Cancer
Abnormally high blood glucose levels, or hyper-
glycemia, is one of the defining characteristics of 
diabetes caused by either insulin secretion defects 
(T1D) or insulin resistance (T2D). Persistent 
hyperglycemia over a long period of time in dia-
betic patients eventually causes damage to impor-
tant organs, including the eyes, heart, and 
kidneys, thus leading to the observed symptoms 
and detrimental effects of diabetes [9]. For many 
cancers, glucose metabolism is indispensable due 
to their high need for energy and materials to sus-
tain growth and proliferation. The Warburg effect 
is one of the most well-known metabolic adapta-
tions of cancers, where the cancer cells readily 
convert glucose to pyruvate and lactate even 
under normoxic conditions in order to satisfy 
their increased need for energy [10, 11]. Diabetes 
and cancer both have abnormal glucose metabo-
lism, but with different mechanisms: one leads to 
deterioration of tissues while the other fuels 
uncontrolled cell growth.
3.1  High Glucose Levels Lead 
to Hexosamine Biosynthetic 





As mentioned previously, it has been well estab-
lished that patients with diabetes have a higher 
risk of developing many types of cancers. 
However, the mechanisms behind this associa-
tion are less well known. Only recently was one 
possible mechanism discovered, where high glu-
cose is linked to de novo mutation of the Kirsten 
rat sarcoma viral oncogene homolog (KRAS) in 
pancreatic cells, thus leading to a greater chance 
of tumorigenesis and an increased risk for cancer 
[12, 13].
From the glycolysis pathway, glucose can be 
converted to glucose-6-phosphate, which then 
alternatively enters the hexosamine biosynthetic 
pathway (HBP). The HBP utilizes around 2–3% of 
the total glucose taken up by normal cells [14]. 
The final product of the HBP is uridine diphos-
phate N-acetylglucosamine (UDP-GlcNAc). 
UDP- GlcNAc is essential for the production of 
glycans, such as O-glycans and N-glycans, which 
are important for various cellular functions that are 
involved in cancer, such as signaling pathways and 
cell proliferation regulation [15]. UDP- GlcNAc is 
also the substrate for O-GlcNAc transferase 
(OGT), an enzyme responsible for the O-linked 
N-acetylglucosaminylation (O-GlcNAcylation) of 
many proteins in the cytoplasm, the nucleus, and 
the mitochondria [16]. O-GlcNAcylation is a 
 posttranslational modification (PTM) where the 
O-linked GlcNAc moieties are attached to the 
 serine or threonine residues of the proteins.
In diabetes, increased HBP activity is caused 
by high glucose levels and overexpression of glu-
tamine: fructose-6-phosphate amidotransferase 
(GFA), the enzyme in HBP that converts fructose 
6-phosphate to glucosamine 6-phosphate, which 
can lead to increased insulin resistance [17, 18]. 
This results in a feedback loop where hyperglyce-
mia leads to an upregulation in HBP, which in 
turn leads to insulin resistance and worsens hyper-
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glycemia. In the study by Hu et al., the upregula-
tion of HBP and increased UDP-GlcNAc leads to 
increased O-GlcNAcylation of ribonucleotide 
reductase (RNR) [13]. Subsequently, this results 
in reduced activity of RNR, which coverts NDPs 
to the corresponding dNDPs, thus depleting the 
dNTP pool in the cells. Since dNTPs are indis-
pensable for DNA synthesis and repair, the 
decreased dNTP pool impairs the DNA repair 
system leading to an increased mutation rate, 
including mutations in important oncogenes such 
as KRAS. High glucose levels thus led to upregu-
lated HBP and increased O-GlcNAcylation, 
which eventually led to de novo KRAS mutation 
in pancreatic cells. Mutant KRAS is present in 
more than 95% of pancreatic ductal adenocarci-
noma (PDAC) [19, 20]. It is responsible for regu-
lating several key metabolic pathways of the cells, 
including glucose and glutamine metabolism, 
leading to PDAC’s aggressive growth and prolif-
eration. KRAS mutations caused by increased 
O-GlcNAcylation thus lead to increased risk for 
developing pancreatic cancer. Besides contribut-
ing to KRAS mutation, O-GlcNAcylation is also 
involved in regulating key oncoproteins such as 
MYC and tumor suppressors such as p53 and is 
found to be upregulated in many cancers, such as 
colon and breast cancers, along with an increase 
in OGT level [21]. Furthermore, the inhibition of 
OGT has been shown to lead to breast cancer cell 
apoptosis [22].
Taken together, the HBP plays an important 
role in both diabetes and cancer. Given the role of 
O-GlcNAcylation in pancreatic cancer tumori-
genesis, it is worth investigating its role in other 
cancer types. Downregulating the HBP by inhib-
iting enzymes such as GFA and/or inhibiting 
O-GlcNAcylation can be a potential target for 
cancer treatment. Indeed, several studies have 
shown that inhibiting GFA has tumor reduction 
Fig. 1 Associations between type 2 diabetes, cancer, and obesity. High blood glucose levels in T2D lead to upregulation 
of the hexosamine biosynthetic pathway (HBP). The upregulation of HBP, in turn, results in high UDP- GlcNAc levels 
and increased protein O-glycosylation/O- GlcNAcylation. This can lead to insulin resistance in T2D and KRAS mutation 
in pancreatic cancer. Insulin resistance can contribute to hyperinsulinemia. Hyperinsulinemia can result in increased 
insulin receptor activation, which can further activate the MAPK and PI3K pathways that promote cell growth and 
proliferation. Obesity can result in increased protein tyrosine phosphatase expression, which can impair insulin signal-
ing and contribute to insulin resistance. Obesity can also increase ROS levels which lead to DNA damages and muta-
tions and contribute to cancer. Blue circles represent glucose molecules. Green squares represent insulin molecules
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effects in both in  vitro and in  vivo models and 
cancer patients [23]. In addition, with evidence 
supporting the association between high glucose 
levels and pancreatic cancer, more attention 
should be paid to mediating these high glucose 
levels early in diabetic patients not only to pre-
vent symptoms associated with diabetes but also 
to prevent cancer development.
3.2  Hyperinsulinemia in Diabetes 
Promotes Cancer Growth 
Through Insulin Receptors 
and the Subsequent Signaling 
Pathways (Fig. 1)
Hyperinsulinemia is another common character-
istic of T2D, where there are frequently high lev-
els of insulin circulating in patients. It is usually 
caused by insulin resistance and subsequent 
treatments, such as the use of insulin secreta-
gogues, which can lead to increased insulin 
secretion. Many studies have found that high lev-
els of insulin can lead to cancer progression 
through increased activation of insulin receptors 
(IRs) and the subsequent cell signaling pathways, 
thus offering another possible explanation for the 
observed association between diabetes and can-
cer [3]. IRs are tyrosine kinases that are found in 
two isoforms: IR-A and IR-B. IR-A was found to 
activate the mitogen-activated protein kinase 
(MAPK) pathways [7]. These MAPK pathways 
are responsible for regulating many important 
cellular aspects, such as gene expression, metab-
olism, mitosis, and apoptosis through a series of 
phosphorylations [24]. IR-B, on the other hand, 
activates the phosphoinositide 3-kinase (PI3K) 
pathway [7], which promotes the synthesis of 
glycogens, lipids, and proteins [25]. Therefore, 
hyperinsulinemia can result in increased insulin 
binding to IRs, which can lead to increased acti-
vation of the MAPK pathways and the PI3K 
pathway. The activation of these pathways then 
promotes cell proliferation. Hence, diabetic treat-
ments, which have the potential to promote 
hyperinsulinemia, should be considered more 
thoroughly before being administered to patients, 
especially those with cancer, in order to prevent 
cancer growth. Inhibiting IRs or decreasing insu-
lin levels can also have potential as a cancer 
therapy.
4  Obesity Leads to Insulin 
Resistance in Diabetes 
and Oxidative Stress, Which 
Can Lead to Cancer (Fig. 1)
Obesity, another common condition associated 
with dysregulated metabolism, serves as another 
link between type 2 diabetes (T2D) and cancer. 
Obesity has been shown to increase the expres-
sion and activity of protein tyrosine phosphatases 
(PTPs), enzymes that remove the phosphate 
group from protein tyrosine residues, which can 
lead to impaired insulin signaling and thus result 
in insulin resistance [26]. Insulin resistance can 
then result in T2D and hyperinsulinemia. 
Hyperinsulinemia, as discussed in Sect. 3.2, has 
the potential to promote cancer growth. Obesity 
can also increase reactive oxygen species (ROS) 
levels in the cells through adipokine production 
by adipose tissue leading to increased oxidative 
stress [27]. Elevated ROS levels can result in 
DNA damage and mutations. The accumulation 
of mutations in cells that escape apoptosis can 
ultimately lead to cancer [28]. It has been found 
that several types of cancer, including breast can-
cer [29], pancreatic cancer [20], and liver cancer, 
are associated with obesity [3]. Therefore, more 
effort should be devoted to raising awareness of 
the connections between obesity, diabetes, and 
cancer. Inhibiting PTPs and reducing adipokine 
production as well as ROS levels can potentially 
help prevent cancer in patients with obesity.
5  Amino Acid Metabolism 
Plays Important Roles 
in Both T2D and Cancer
Aside from glucose metabolism, amino acid 
metabolism is also deeply involved in both can-
cer and T2D. Amino acids are the building blocks 
for protein synthesis and are required for almost 
all cellular functions. Dysregulation of amino 
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acid metabolism can thus contribute to the patho-
genesis and progression of many diseases, includ-
ing diabetes and cancer. Several key amino acids 
involved in diabetes and cancer include leucine, 
glutamine, methionine, and cysteine. Therefore, 
targeting dysregulated amino acid metabolism 
may serve as a promising strategy for cancer 
treatments [30, 31].
5.1  Leucine’s Regulation of Insulin 
Secretion and mTOR Signaling 
Promotes T2D Pathogenesis, 
Insulin Resistance, and Cancer 
Growth
While it is well known that glucose uptake stimu-
lates the secretion of insulin, the amino acid leu-
cine can also lead to insulin secretion. Leucine 
allosterically activates glutamate dehydrogenase 
(GDH), an enzyme that converts glutamate to 
alpha-ketoglutarate (α-KG) to enter the tricar-
boxylic acid (TCA) cycle, which leads to the sub-
sequent production of metabolic coupling factors 
which are needed for insulin secretion [32, 33]. 
Dysregulation of leucine metabolism can thus 
result in dysregulated insulin secretion contribut-
ing to diabetes. Specifically, it was found that 
constantly increased leucine levels for a long 
period of time can be detrimental to the function 
of β-cells [34], which are responsible for insulin 
synthesis and secretion. Leucine is also crucial 
for the activation of the mammalian target of 
rapamycin (mTOR) signaling pathway, specifi-
cally the mammalian target of rapamycin com-
plex 1 (mTORC1) [35]. The activation of 
mTOCR1 can lead to the activation of S6 kinases 
(S6Ks), which results in the downregulation of 
insulin signaling by phosphorylating insulin 
receptor substrate 1 (IRS-1). This downregula-
tion of insulin signaling then leads to insulin 
resistance and T2D [35]. Leucine and mTOR sig-
naling pathway also play important roles in can-
cer. Studies have shown that mTORC1 is 
responsible for signaling cell cycle progression 
and cell survival through eIF4E-binding protein 1 
(4E-BP1) and eukaryotic translation initiation 
factor 4E (eIF4E), thus promoting cancer growth 
[36]. In fact, various mTOR inhibitors are being 
tested in both preclinical and clinical studies for 
many cancer types with promising results [37]. 
Therefore, targeting leucine metabolism and 
inhibiting the mTOR signaling pathway are 
promising strategies for the treatment of cancer.




As mentioned above, GDH is regulated by leu-
cine, which can lead to insulin secretion. Thus, 
glutamate, the substrate for GDH, is indirectly 
involved in regulating insulin secretion even 
though it cannot stimulate insulin secretion on its 
own [33]. Therefore, dysregulation in glutamine 
metabolism may also lead to dysregulated insulin 
secretion and diabetes. It has also been shown 
that mutations in GDH can result in hyperinsu-
linemia [32], which has a growth-promoting 
effect on cancer cells. Aside from its influence on 
insulin secretion, a study by Miller et  al. has 
shown that glutamine’s contribution to gluconeo-
genesis is important in T2D with dysregulation of 
the glycogen signaling pathway, which can lead 
to hyperglycemia during the fasting state [38]. 
The role of glutamine in promoting cancer sur-
vival and proliferation as an important source of 
energy and building block materials is well 
known and also well described in the previous 
glutamine metabolism chapter [39, 40]. The 
important roles that glutamine and glutamate 
play in both diabetes and cancer thus serve as 
another link between the two diseases.
5.3  Increased Methionine 
and Cysteine Levels in T2D 
Can Promote Cancer Growth
Other amino acids are also implicated in 
T2D.  Specifically, studies have found that the 
levels of methionine and cysteine are elevated in 
the blood of patients with T2D [41]. Methionine 
is involved in polyamine biosynthesis and one-
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carbon metabolism, which is important for redox 
homeostasis and nucleotide synthesis [42, 43]. 
Increased methionine levels can lead to increased 
nucleotide synthesis and contribute to cancer 
growth. Methionine metabolism also leads to 
S-adenosylmethionine (SAM) production, the 
substrate for methyltransferases, which are 
responsible for the methylation of secondary 
metabolites, lipids, nucleic acids, and proteins 
[44]. SAM is involved in histone methylation, 
which can control gene expression, the dysregu-
lation of which can lead to cancer [43, 45]. In 
fact, for some cancers, methionine is indispens-
able, suggesting a condition called “methionine 
dependence” [46]. On the other hand, cysteine is 
an important component of glutathione (GSH), 
an antioxidant used by cancer cells to mediate 
oxidative stress [47]. Therefore, elevated cysteine 
levels can result in increased GSH production 
protecting cancer cells against oxidative stress. In 
short, increased methionine and cysteine levels in 
T2D can promote cancer growth, and inhibiting 
methionine and cysteine metabolism or decreas-
ing their concentrations should be investigated as 
a potential therapy for cancer.





6.1  Metformin, a Drug Developed 
for Diabetes, Can Inhibit 
Cancer Growth 
and Proliferation
As new research provides more insights into 
these similarities and relationships, it opens a 
new avenue of repurposing therapeutic strate-
gies used for one disease for the treatment of 
another. One prominent example is the use of 
metformin, which was developed decades ago 
and is a commonly used drug for the treatment 
of diabetes [48]. It has the ability to reduce the 
production of glucose in the liver, activate ade-
nosine monophosphate- activated protein kinase 
(AMPK), and improve insulin sensitivity [48]. 
Metformin administration leads to reduced pan-
creatic and breast cancer risk and prolonged sur-
vival for cancer patients even though the specific 
mechanisms behind its effects are not yet well 
understood [49]. Metformin has yielded positive 
results in in vivo studies, including in lung can-
cer xenografts [50], gastric cancer xenografts 
[51], and prostate cancer xenografts [52]. It is 
also currently under clinical trials (e.g., 
NCT01101438, NCT02122185, NCT01750567) 
for cancer treatment [53]. A study by Elgogary 
et  al. demonstrated that combination therapy 
using metformin with the glutaminase inhibitor 
bis-2-(5- phenylacetamido- 1,2,4-thiadiazol-
2-yl)ethyl sulfide (BPTES) encapsulated in 
nanoparticles resulted in a more pronounced 
reduction in pancreatic tumor growth in  vivo 
than either treatment alone since both glucose 
metabolism and glutamine metabolism of the 
cancer cells were inhibited [54]. Metformin thus 
serves as a positive example for which a drug 
developed for one disease, in this case, diabetes, 
can be repurposed for the treatment of cancer 
because of the metabolic similarities between 
the two diseases. Therefore, the strategy of 
using drugs developed for diabetes for cancer 
treatment seems promising and is worth investi-
gating further.
6.2  Polyphenols Prevent Diabetes 
and Reduce Cancer Growth
Polyphenols, such as flavonoids, are naturally 
occurring compounds found in plants that are 
being investigated for the treatment of several 
diseases, including diabetes and cancer [55]. A 
study by Rienks et  al. found that polyphenols, 
especially flavonoids, can help reduce the risk for 
T2D [56]. Polyphenols’ antihyperglycemic 
effects are associated with their ability to regu-
late glucose metabolism and enhance β-cell 
function as well as their inhibition of mTOR sig-
naling [35, 57]. In cancers, flavonoids have been 
shown to modulate several signaling pathways 
leading to reduced cell proliferation and 
increased apoptosis [58]. Specifically, Zhang 
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et  al. showed that treatment with flavonoids 
resulted in reduced levels of phospho-PI3K, 
phospho-AKT, phospho-mTOR, phospho- 
p70S6K, and phospho-ULK, thereby impairing 
the PI3K/AKT/mTOR/p70S6K/ULK signaling 
pathways, contributing to their observed effects 
[59]. Polyphenols and flavonoids thus should be 
investigated further as potential drugs for cancer 
treatment.
6.3  Thiazolidinediones and Their 
Varied Effects on Cancer
Thiazolidinediones are antidiabetic drugs that 
can help improve insulin sensitivity by activating 
peroxisome proliferator-activated receptor γ 
(PPARγ) [3, 49]. While PPARγ agonists have 
been shown to inhibit cell growth and increase 
apoptosis in vitro, in vivo studies have shown that 
Fig. 2 Antidiabetic drugs and their effects on cancer. Metformin can activate AMPK, increase insulin sensitivity, and 
decrease hepatic glucose production in T2D while it also leads to reduced pancreatic and breast cancer risk, increased 
survival, and reduced tumor growth together with glutamine metabolism inhibition by BPTES. Polyphenols such as 
flavonoids regulate glucose metabolism, increase β-cell function, and inhibit mTOR signaling in T2D while they impair 
signaling pathways such as PI3K/AKT/mTOR pathways, decrease cell proliferation, and increase apoptosis in cancer. 
Thiazolidinediones such as pioglitazone and troglitazone can activate PPARγ, leading to increased insulin sensitivity in 
T2D. However, in cancer, while they can lead to decreased cell growth and increased apoptosis in vitro, pioglitazone is 
associated with increased bladder cancer risk, and troglitazone showed no promising results in patients. Insulin secreta-
gogues can promote insulin secretion in T2D which can potentially help to explain their observed association with 
increased liver and pancreatic cancer risk through the effects of hyperinsulinemia
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they can actually lead to tumorigenesis, which is 
potentially caused by varied conditions within 
the model used that can lead to varied peroxi-
some proliferator-responsive element (PPRE) 
activation by PPARγ agonists [3, 60]. In fact, sev-
eral cohort studies with patients have indicated 
an increased risk for bladder cancer associated 
with the long-term and high-dose exposure to 
pioglitazone, a thiazolidinedione [49]. 
Troglitazone, another thiazolidinedione, has been 
tested in phase II clinical trial for the treatment of 
refractory metastatic breast cancer but did not 
exhibit promising results [61]. Therefore, 
although thiazolidinediones should theoretically 
have anticancer effects as PPARγ agonists, more 
research is required before applying them to can-
cer treatment in patients because of their observed 
association with increased cancer risk.
6.4  Insulin Secretagogues Can 
Lead to Increased Cancer 
Risks
Despite the positive effects of certain diabetes 
drugs on cancer, there are some drugs that can 
actually promote cancer, especially the drugs that 
induce insulin secretion in diabetic patients. For 
example, insulin secretagogues, such as sulfonyl-
ureas and meglitinides, which stimulate insulin 
secretion, have been found to be associated with 
increased risks for liver and pancreatic cancers 
[49]. This is likely the result of increased insulin 
binding to insulin receptors, which, as discussed 
in Sect. 4, can promote cancer growth through 
subsequent signaling pathways. Therefore, cau-
tion must be exercised, and the drug’s mechanism 
of action and effects must be thoroughly investi-
gated in preclinical models before repurposing it 
for the treatment of another disease.
7  Conclusion
Diabetes and cancer are two of the most common 
diseases around the world that have many simi-
larities and associations regarding their meta-
bolic characteristics. Diabetes is correlated with 
an increased risk for many types of cancer. 
Certain features of diabetes metabolism, such as 
upregulated HBP and hyperinsulinemia, can 
actually contribute to cancer pathogenesis and 
growth. Understanding these associations with 
the use of metabolomics technologies [62] and 
exploiting them for cancer treatment, as demon-
strated by the repurposing of metformin for can-
cer treatment, can potentially improve current 
clinical outcomes. There should also be height-
ened awareness about the connections between 
diabetes and cancer so that more efforts can be 
directed to prevent cancer in diabetic patients, 
given the metabolic similarities and associations 
between these two diseases.
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Key Points
• The elevated presence of glutamine in cancer 
and neurological diseases leads to two distinc-
tive disease progressions and compromises 
patient survival.
• Glutamate has a prognostic role in cancer, 
schizophrenia, and hyperammonemia.
• Downregulation of glutamate transporters 
causes excessive extracellular glutamate in 
cancer, hyperammonemia diseases, and neu-
rodegenerative diseases.
• NMDA receptor activation protects cancer cells 
as well as neurons in psychiatric disorders but 
results in cell deaths for neurodegenerative dis-
eases and hyperammonemia diseases.
• AMPAR expression plays a contrasting role in 
disease progression of cancer and Alzheimer’s 
disease.
• The complex relationship between glutamine 
metabolism and MYC contributes significantly 
to the pathophysiology of both cancer and 
neurodegenerative diseases.
• Elevated GAD expression is found in acute 
stress and contributes to oral squamous cell 
carcinoma invasiveness.
• GABA level is characteristic of various can-
cers and contributes to Alzheimer’s disease 
and attention-deficit/hyperactivity disorder 
(ADHD).
• GABA receptors contribute to Alzheimer’s 
disease pathogenesis, Parkinson’s disease 
severity, and cancer invasiveness.
• Autoimmune disorder’s attack on the GABA- 
ergic system correlates with neurological dis-
eases and cancers.
• NAAG affects both cancer and neurological 
disease progression via glutamate.
• Targeting GCP II is a very promising strategy 
for cancer treatment.
• NAAG inhibits GABA release and indirectly 
affects both cancer and neurological diseases 
via GABA-ergic system.
1  Introduction
Despite the many recent breakthroughs in cancer 
research, oncology has traditionally been seen as 
a distinct field from other diseases. Recently, 
more attention has been paid to repurposing 
established therapeutic strategies and targets of 
other diseases towards cancer treatment, with 
some of these attempts generating promising 
outcomes [1, 2]. Recent studies using advanced 
metabolomics technologies [3] have shown evi-
dence of close metabolic similarities between 
cancer and neurological diseases. These studies 
have unveiled several metabolic characteristics 
shared by these two categories of diseases, 
including metabolisms of glutamine, gamma-
aminobutyric acid (GABA), and N-acetyl-
aspartyl-glutamate (NAAG) [4–6]. The striking 
metabolic overlap between cancer and neuro-
logical diseases sheds light on novel therapeutic 
strategies for cancer treatment. For example, 
2-(phosphonomethyl) pentanedioic acid 
(2-PMPA), one of the glutamate carboxypepti-
dase II (GCP II) inhibitors that prevent the con-
version of NAAG to glutamate, has been shown 
to suppress cancer growth [6, 7]. These promis-
ing results have led to an increased interest in 
integrating this metabolic overlap between can-
cer and neurological diseases into the study of 
cancer metabolism. The advantages of studying 
this metabolic overlap include not only drug 
repurposing but also translating  existing knowl-
edge from neurological diseases to the field of 
cancer research. This chapter discusses the spe-
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cific overlapping metabolic features between 
cancer and neurological diseases, focusing on 
glutamine, GABA, and NAAG metabolisms. 
Understanding the interconnections between 
cancer and neurological diseases will guide 
researchers and clinicians to find more effective 
cancer treatments.
2  Glutamine Plays a Vital Role 
in Both Cancer Growth 
and Neurological Diseases
Glutamine metabolism is a vital contributor to can-
cer growth and is discussed thoroughly in Chap. 2 
[8]. The survival of some tumors depends entirely 
on the presence of exogenous glutamine, a condi-
tion known as glutamine addiction [9]. In addition, 
the severity of glutamine addiction observed in can-
cer is positively associated with the degree of tumor 
malignancies [10]. Besides its role in cancer growth, 
glutamine is also a well- established precursor of 
neurotransmitters, glutamate, and GABA [11], and 
glutamate is involved in learning and memory, 
especially long-term potentiation [12]. A growing 
body of evidence has shown that abnormalities in 
the glutamatergic neurotransmission, including 
excessive glutamate release and dysfunction of glu-
tamate receptors, play a significant role in a number 
of neurological diseases, such as Alzheimer’s dis-
ease (AD), Huntington’s disease (HD), hyperam-
monemic disease, schizophrenia, and other 
psychotic disorders [13–16]. In this section, exam-
ining the glutamine metabolism in neurological dis-
eases may provide further understanding of 
glutamine’s role in cancer and provide insights into 
glutamine-targeting cancer therapies.
2.1  The Elevated Presence 
of Glutamine in Cancer 
and Neurological Diseases 
Leads to Two Distinctive Disease 
Progressions and Compromised 
Patient Survival
Glutamine addiction and an elevated level of glu-
tamine are observed in a variety of cancers and 
promote tumor growth by serving as a major 
energy source. Similarly, the high presence of 
glutamine was also observed in hyperammone-
mia diseases, where ammonia level increases 
abnormally in blood. Hyperammonemic diseases 
are associated with many brain injuries, includ-
ing cerebral edema, and is believed to be the pri-
mary cause of hepatic encephalopathy [17]. 
Glutamine acts as an astroglial intracellular idio-
genic osmole, disturbing the delicate balance 
between water and glutamine concentrations 
inside and outside of astrocytes. The result is an 
influx of water into the cells, causing cerebral 
edema. The suppression of glutamine accumula-
tion results in reduced swelling of glial cells [13]. 
Thus, although the role of elevated levels of glu-
tamine in cancer progression and aggressiveness 
is very different from its negative effects in 
edema under hyperammonemia, both impair 
patient survival.
Glutaminase (GLS) catalyzes the conversion 
of glutamine to glutamate. Because it plays a 
central role in the glutamine/glutamate metabolic 
cycle, GLS is extremely important in cancer and 
neurological disorders. As previously discussed 
in Chap. 2, inhibition of GLS suppresses the 
growth of various tumors [8, 18–21]. Moreover, 
the upregulated conversion from glutamine to 
glutamate as a source of cellular bioenergy is a 
common characteristic observed in many cancers 
[22]. Therefore, the activity of GLS is crucial to 
cancer development.
An increase in GLS enzymatic activity, as 
well as transcription, has also been observed in 
schizophrenia, though without a detailed mecha-
nism as to how the enzyme contributes to the dis-
ease pathophysiology [16]. Nevertheless, it is fair 
to connect the increase of GLS to glutamate 
accumulation and thus to the disease symptomol-
ogy. In both cancer and schizophrenia, GLS 
upregulation is thought to be a major factor in 
disease progression.
On the other hand, glutamine-fueled tricarbox-
ylic acid cycle (TCA cycle activity) via the GLS 
pathway [23] has differing impacts on cancer and 
Alzheimer’s disease. In contrast to the increased 
GLS activation in cancer, a downregulation in 
GLS has been observed in AD pathophysiology 
[14]. Reduced GLS activation, resulting in ham-
pered oxidative glutamine metabolism, is a poten-
Bridging the Metabolic Parallels Between Neurological Diseases and Cancer
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tial early marker of AD pathogenesis, preceding 
amyloid plaque formation in mice [14]. A signifi-
cant decrease in glutamine- fueled TCA cycle 
activity, which requires GLS activity, has been 
observed in early AD [14], suggesting the impor-
tance of glutamine/glutamate-derived energy 
against disease development. It was found that a 
compromise in both ATP synthesis rate and cellu-
lar energy homeostasis caused by decreased TCA 
cycle activity likely results in amyloid plaque 
deposition [14], and thus is responsible for the 
core progression of AD.
Opposing mechanisms involving GLS, alpha- 
ketoglutarate (α-KG), and TCA cycle have been 
observed in both cancer and AD. While a decrease 
in glutamine-fueled TCA cycle activity is benefi-
cial in terms of tumor suppression, it actually 
promotes AD progression, causing plaque forma-
tion and leading to disease development, which 
may appear to be a new complication for 
glutamine- targeting cancer therapies.




In addition to the elevated presence of glutamine, 
excessive glutamate, a direct product of gluta-
mine via the glutaminase I pathway, also signifi-
cantly impacts cancer. Glutamate acts as an 
energy source for cancer cells and can be directly 
converted to α-KG, a TCA cycle intermediate. 
Glutamate concentration positively correlates 
with the severity of cancer, as measured by the 
Gleason score in prostate cancer [24]. Glutamate 
deprivation or blockage with antagonists of 
metabotropic glutamate receptor I (mGluR1) 
results in decreased cancer cell growth, migra-
tion, and invasion and eventually contributes to 
apoptotic cancer cell death [24]. With the direct 
correlation of glutamate concentration in serum 
and cancer severity, glutamate can thus serve as a 
prominent prognostic indicator of cancer 
development.
Excessive glutamate levels have also been 
observed in a wide range of neurological diseases. 
This accumulation results in neuronal cell deaths 
due to neuro-excitotoxicity, underlying the patho-
physiology of neuronal loss in multiple neurolog-
ical diseases [15, 25]. Excess glutamate amplifies 
and exacerbates excitotoxicity through the posi-
tive feedback mechanism involving Ca2+ influx 
[25, 26]. Moreover, recent research in schizophre-
nia has shown that a higher glutamate level results 
in more severe disease symptoms and lower 
remission rates after treatment [26]. Interestingly, 
as schizophrenia moves from onset to the chronic 
stage, glutamate level, especially the ratio of glu-
tamate/glutamine, increases significantly [27, 28]. 
Dysfunction of glutamate neurotransmission with 
lower glutamate levels during the disorder’s onset 
and with higher glutamate levels for the chronic 
stage suggests the facilitating role of glutamate in 
the course of schizophrenia progression. The rela-
tionship between glutamate elevation and disease 
severity is also seen in hyperammonemia diseases 
[17]. The increasing extracellular glutamate con-
centration is also observed to be in a positive feed-
back loop with nitric oxide (NO) [17], thus 
contributing to the ever-worsening progression of 
hyperammonemia and neuronal death from both 
glutamate and NO toxicity.
A higher level of glutamate contributes to 
increased disease severity in cancer, schizophre-
nia, and hyperammonemia and thus is responsi-
ble for the longitudinal development of all three 
diseases. It is clear that the negative impact of 
glutamate accumulation exacerbates a variety of 
diseases ranging from cancer to a multitude of 
neurological disorders, indicating the prognostic 
role of excessive glutamate in these diseases.
Glutamine synthetase (GS) transforms gluta-
mate into glutamine, preventing excitotoxicity 
due to glutamate accumulation. Therefore, dys-
function in GS results in an imbalance of 
 glutamate and glutamine, causing pathophysiol-
ogy in many diseases. Due to the importance of 
glutamate and glutamine in cancer, GS dysfunc-
tion and its implications are widely studied. Bode 
et al. showed that GS contributed to cancer cell 
proliferation, resistance, and aggression [4]. As 
cancer consumed glutamine to support the TCA 
cycle, GS provided an alternative influx of gluta-
mine under glutamine-depleted conditions [4]. 
An increase in GS/GLS ratio was observed at 
both mRNA and enzymatic activity levels start-
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ing at 24 h after tumor implantation in liver and 
kidney tumor models [10], suggesting an elevated 
need for glutamine production in cancer cells.
GS dysregulation is also seen in Huntington’s 
disease (HD). An increase in GS activity has been 
observed to predominate in severely affected areas 
of the brain [29], indicating the relation between 
GS upregulation and symptomology and severity 
in HD. Therefore, GS may be responsible for dis-
ease aggression through glutamatergic energy pro-
duction in cancer as well as upregulated expression 
in HD.  In hyperammonemia, a decrease in GS 
activity in non-glutamatergic areas leads to ammo-
nia and glutamate accumulation, since GS converts 
glutamate and ammonia into glutamine. This 
inability to keep the glutamate concentration from 
exceeding the normal physiological limit may be 
the root of neuronal toxicity observed in hyperam-
monemia [17] (Fig. 1).
The dysregulation of GS thus exerts divergent 
influences on different diseases. GS activity pro-
motes aggression in both cancer and HD. On the 
other hand, in hyperammonemia diseases, GS 
activity prevents excitotoxicity from elevated glu-
tamate levels. As glutamine and glutamate have 
opposite implications in diseases under certain 
conditions, the proper balance of these two, regu-
lated by GS and GLS, is a fine line to navigate.
2.3  Downregulation of Glutamate 





Given the effect of excessive glutamate, targeting 
the cause behind high glutamate concentration is 
a promising therapeutic strategy. One of the rea-
sons for the elevated concentration of glutamate 
is the downregulation of glutamate transporters, 
which are proteins embedded in the astroglial 
membrane. Impaired glutamate transporters 
often result in glutamate accumulation in the 
extracellular space, which underlies a wide range 
of diseases discussed above. As a result, the dys-
function of glutamate transporters is a contribut-
ing factor to the pathophysiology of many 
diseases, including cancers and neurological dis-
eases [30]. For example, glutamate transporters 
were found to support cancer cells’ survival, 
growth, and invasion [31]. In cancer, and espe-
cially in gliomas, the downregulation of gluta-
mate transporters resulting in a glutamate excess 
is associated with the extreme aggressiveness of 
malignant gliomas [31]. This suggests that the 
hypofunction of glutamate transporters plays a 
role in energy provision in cancer, which eventu-
Fig. 1 The effects of glutamine synthetase dysregulation on both cancer and hyperammonemic diseases
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ally results in the development of devastating 
tumors.
Downregulation of glutamate transporters is 
also observed in multiple neurological diseases 
[17]. Specifically, in hyperammonemia diseases, 
the reduced expression of astrocytic glutamate 
transporters possibly contributes to the delayed 
degeneration of a certain number of neurons as 
well as the increased extracellular concentra-
tions of glutamate [15, 17], which is thought to 
contribute to hyperammonemia severity and 
other underlying abnormalities in acute liver 
failure [17]. In addition, neurodegenerative dis-
eases, such as HD and AD, are also associated 
with excitotoxic impacts from elevated gluta-
mate due to the downregulation of glial trans-
porters [15]. Previous studies have shown that 
elicitation of glutamate transporters has neuro-
protective implications, especially in AD and 
depression [25, 32], suggesting a direct correla-
tion of reduced expression of glutamate trans-
porters to disease pathophysiology.
The downregulation of glutamate transporters 
correlates with tumor malignancy and aggres-
sion, possibly via increasing extracellular gluta-
mate levels. Downregulated glutamate 
transporters also cause neuronal deaths in hyper-
ammonemia and neurodegenerative diseases. 
Despite the different effects of glutamate trans-
porter hypofunction in cancer versus neurologi-
cal diseases, they all contribute to the progression 
of these diseases.
2.4  NMDA Receptor Leads 






Although the exact mechanisms involving gluta-
mate receptors have not yet been discovered com-
pletely in cancer, it is widely known that antagonists 
of the N-methyl-d-aspartate receptor (NMDAR), an 
ionotropic glutamate receptor, can decrease cancer 
cell viability and prevent tumor growth [33].
In schizophrenia and bipolar disorder, 
NMDAR activity has a neuroprotective advan-
tage. Hypofunction of NMDAR was observed in 
both diseases [28, 34]. In addition, the downregu-
lation of NMDAR induced and exacerbated 
schizophrenia symptoms [28]. Possible explana-
tions for downregulated NMDAR-induced abnor-
malities have been suggested for schizophrenia. 
The receptor is likely responsible for cognitive 
development, axon pruning, and neuron preser-
vation [35], which are all significantly impaired 
in schizophrenia symptomology [35].
Although NMDAR is essential for tumor sur-
vival and development as well as possible neu-
ron preservation in schizophrenia, NMDAR 
activation is, in fact, related to cell death in neu-
rodegenerative diseases. In neurodegenerative 
diseases, high Ca2+ permeability in NMDAR 
contributed to chronic neurodegeneration due to 
excitotoxicity [26]. Research has confirmed that 
neuronal survival can be maintained via 
NMDAR blockage [25, 26], indicating the direct 
causal role of NMDAR in cellular necrosis. 
Specifically, NMDAR activation, which reduces 
protein phosphatase 2A (PP-2A) activity, is a 
major contributor to the hyperphosphorylation 
of microtubule-associated protein Tau (τ) in AD 
[25]. In hyperammonemia diseases, NMDAR 
activation can result in ammonia-induced death 
of animals [17]. Moreover, excessive stimula-
tion of NMDAR is also responsible for NO for-
mation through the activation of nitric oxide 
synthase (NOS) [17]. NO accumulation through 
acute and chronic exposure is toxic to neuronal 
cells, which is observed in several neurological 
diseases, including Huntington’s disease, 
Alzheimer’s disease, and hyperammonemia 
[17].
It is safe to say that NMDAR is closely associ-
ated with the viability and growth of cancer cells 
and normal neurons in psychiatric patients’ 
brains as well as with the toxic cellular deaths 
observed in neurodegenerative diseases and 
hyperammonemia diseases. The abundant evi-
dence suggests that NMDAR activation leads to 
vastly different responses in cancer and neuro-
logical diseases. Thus, NMDAR has the potential 
as a drug target in cancer treatment.
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2.5  AMPAR Expression Played 
a Contrasting Role in Disease 
Progression of Cancer 
and Alzheimer’s Disease
α - A m i n o - 3 - h y d r o x y - 5 - m e t h y l - 4 - 
isoxazolepropionic acid receptor (AMPAR), an 
ionotropic glutamate receptor in the central ner-
vous system, is also a major contributor to disease 
development in both cancer and neurological dis-
eases. A study by Herner et al. has shown that the 
inhibition of GluR1 and GluR2 subunits of AMPAR 
significantly decreases tumor invasion [36]. 
Specifically, AMPAR activation could be a switch 
to activate the Kras/MAPK cascade, which induces 
oncogenic signaling and eventually leads to tumor 
invasion, migration, and malignant transformation 
[36]. Interestingly, though both AMPAR and 
NMDAR are involved in neuroexcitotoxicity, the 
mechanism of AMPAR works opposite to that of 
NMDAR.  In AD, a loss in GluR2 of AMPAR 
results in Ca2+-mediated neurotoxicity and severe 
neuropathology [25]. Excitotoxicity could be 
induced by a loss of GluR2 subunit alone, and 
upregulation of GluR2 subunit can confer a protec-
tive advantage under increased Ca2+ levels [25]. 
Although both NMDAR and AMPAR are activated 
by the same neurotransmitter, glutamate, their 
effects on pathophysiology in cancer and AD are 
widely different. AMPAR expression plays a con-
trasting role in the two diseases’ progression. While 
AMPAR activity in cancer is to promote tumor 
invasion and malignancy transformation, in AD, its 
role is neuroprotective against Ca2+-mediated neu-
rotoxicity and disease severity [25].








MYC is a family of regulator genes and proto- 
oncogenes that codes for transcription factors and 
plays a significant role in cancer progression [37–
39]. In addition, MYC is also closely associated 
with the glutamine metabolism in both cancers 
and neurological diseases. MYC upregulates GLS 
expression and is primarily responsible for gluta-
mine addiction in cancer [40–42]. The upregula-
tion of GLS, as discussed in Sects. 2.1 and 2.2, 
leads to enhanced glutaminolysis and glutamate 
accumulation, and in turn promotes cancer growth 
[24]. Therefore, it is not surprising that an overex-
pression of MYC is associated with tumorigenesis 
[43]. Across various cancer types, MYC suppres-
sion results in reduced cancer cell growth, impaired 
colony formation, decreased tumor progression, 
and even induced cancer cell apoptosis [44–46]. In 
a recent study, new light has been shone on what 
was originally considered to be a one-way effect 
on glutamine metabolism by MYC. There actually 
exists a reciprocal regulation between MYC and 
glutamine metabolism, meaning that suppression 
of glutamine metabolism can prevent MYC tran-
scription [47]. This mutual balance and regulation 
between the oncogene and the amino acid cause 
significant pathophysiological impacts when they 
affect each other, which can be a new research tar-
get for cancer treatment.
Interestingly, MYC, a proto-oncogene, is also 
closely involved in neurodegenerative diseases, 
especially HD and AD, via glutamine  metabolism. 
The excitotoxic pathway through NMDAR acti-
vation in HD involves the induction of MYC and 
other pro-apoptotic proteins that eventually result 
in neuronal deaths, significant underlying patho-
physiology in neurodegenerative diseases [48]. 
More specifically, MYC induces significant cog-
nitive deficits and cell cycle reentry, which is 
believed to be responsible for neuronal cell death 
through loss of trophic support during develop-
ment, thus leading to neurodegeneration in AD 
[43] (Fig. 2).
MYC and glutamine pathways are therefore 
clearly associated with each other and also with 
the pathophysiology of both cancer and neurode-
generative diseases. This is another indication of 
the close interplay between the metabolisms of 
cancer and neurological diseases, which also 
confirms glutamine as being a very promising 
drug target for cancer treatment.
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2.7  Alpha-ketoglutaramate 




Recent study revealed that alpha-ketoglutaramate 
(KGM) is a significant component in glutamine 
addiction, connecting glutamine to the TCA cycle 
via the glutaminase II pathway, in which gluta-
mine is converted to KGM by transamination 
with a suitable α-keto acid. KGM is then hydro-
lyzed to α-KG, an intermediate metabolite within 
the TCA cycle, by an enzyme known as ω-amidase 
[49]. The presence of glutamine, KGM, and 
α-KG, therefore, promotes tumor growth. In 
addition, the blockage of glutamine’s conversion 
to KGM in the glutaminase II pathway results in 
the complete inhibition of pancreatic tumorigen-
esis in vivo, suggesting the important role KGM 
plays in tumor progression [2, 22]. A recently 
publicized study correlates increasing prostate 
cancer cell aggressiveness with an upregulation 
of the glutaminase II pathway [50].
Fig. 2 MYC and its contributions in cancer and neurodegenerative diseases. NMDAR N-methyl-d-aspartate receptor
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KGM is a major contributor not only in cancer 
but also in hyperammonemia diseases. It is a bio-
marker for both primary and secondary hyperam-
monemia diseases, including hepatic 
encephalopathy [49]. KGM concentration was 
shown to be correlated with the degree of enceph-
alopathy. Although the specific mechanisms are 
still unknown, the study indicated a direct rela-
tionship between KGM and hyperammonemia 
disease progression [51].
This association of hyperammonemia and 
cancer involving KGM is a significant discovery 
in the metabolic interplay between cancer and 
neurological diseases. KGM not only promotes 
tumor growth through the glutaminase II path-
way [50], but also serves as an excellent bio-
marker for hyperammonemia diseases and an 
indicator for encephalopathy severity.
3  GABA and Its Multiple 
Functions in Neurological 
Diseases and Cancer
Gamma-aminobutyric acid (GABA) serves as an 
inhibitory neurotransmitter in the central nervous 
system, and can also be detected in peripheral tis-
sues. Dysregulation of the GABAergic system and 
related metabolisms are observed in various can-
cers and neurological diseases. In neurological dis-
eases, GABA works through the neural networks 
and mainly serves as an inhibitory neurotransmit-
ter [52], whereas in cancer, GABA is found in 
peripheral tissues, serving as an onco-metabolite 
[53] by affecting multiple cell functions, including 
cell proliferation and mobility (Fig. 3).
3.1  Elevated GAD Expression 
Is Found in Acute Stress 
and Contributes to Oral 
Squamous Cell Carcinoma 
Invasiveness
Glutamate decarboxylase (GAD) is a rate- 
limiting enzyme that catalyzes the production of 
GABA from glutamate [54]. GAD has two 
enzymes: GAD65 and GAD67. The two enzymes 
have different subcellular locations and interact 
differently with the cofactor pyridoxal 5′-phos-
phate (PLP) [55]. GAD65 and GAD67 are 
encoded by genes GAD2 and GAD1, respec-
tively. In both acute stress and oral squamous cell 
carcinoma (OSCC), the upregulation of GAD67 
is observed [56].
Acute stress primarily affects GAD67: 
increased GAD67 mRNA level is observed in 
various brain regions, including the arcuate 
nucleus, dorsomedial hypothalamic nucleus, and 
hippocampus [57]. Increased GAD67 mRNA is 
preferentially induced in acute stress, compared 
to chronic stress, possibly due to GAD67’s poten-
tiality of rapid activation as almost all GAD67 is 
bounded to its cofactor in the CNS [57].
In the case of OSCC, overexpression of GAD1 
is found to be a characteristic event. The knock-
out of GAD1  in OSCC-derived cell lines inter-
fered with the invasive ability. It is hypothesized 
that the process is completed through GAD1 
regulation of β-catenin, which leads to the activa-
tion of MMP7, a gene found to be expressed in 
many cancers, including breast cancer, lung can-
cer, and prostate cancer, that contributes to tumor 
invasiveness and metastasis [58].
Although the underlying mechanisms are dif-
ferent, the upregulation of GAD67 is observed in 
both acute stress and OSCC. Hence, GAD1 and 
GAD67 mRNA might be possible targets in the 
treatment of OSCC.







Dysregulation of GABA metabolism is observed 
in many CNS disorders and various types of can-
cers. For instance, elevated GABA levels are 
characteristic of both AD and gastric cancer [5]. 
In AD patients, astrocytes in the dentate gyrus 
exhibit increased GAD activation, leading to an 
elevated level of GABA [59]. One direct result of 
the increased GABA level is enhanced tonic neu-
ral inhibition, one of the major symptoms in AD 
[59]. In gastric cancer, evaluation of gastric neo-
plastic tissue revealed that GAD activity is sig-
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nificantly higher than in surrounding normal 
tissue and that GABA content increases above 
normal levels [5]. Similar results have also been 
obtained with other cancers, including breast 
cancer, colon cancer, and prostate cancer [5]. The 
exact underlying mechanism of the abnormal 
GABA metabolism in cancer remains unclear. It 
is still practical, however, to deem an elevated 
GABA level as a good indicator of both AD and 
various cancers.
Not all the neurological diseases and cancers 
have upregulated levels of GABA.  For exam-
ple, GABA downregulation is observed in 
ADHD and pulmonary adenocarcinoma (PAC). 
ADHD is the most diagnosed psychiatric disor-
der in children and adolescents. Recent research 
based on the spontaneous hypertensive rat 
(SHR) models suggested that a decrease in the 
extracellular concentration of GABA in the 
SHR hippocampus may be the underlying rea-
son for the ADHD-like behaviors [60]. A 
decreased GABA level was also observed in 
PAC. It was found that tobacco-specific nitrosa-
mine 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK) can significantly reduce 
GABA in the lungs and that NNK-induced PAC 
expresses particularly low levels of GABA. Data 
showed that GABA could limit PAC cell prolif-
eration and migration through the inhibition of 
cAMP signaling, suggesting that PAC cells 
downregulate GABA to promote tumor growth 
and invasion [61]. The underlying mechanism 
for how NNK suppresses GABA level remains 
unclear, however.
Fig. 3 A general view of GABA-ergic system-related metabolism with corresponding cancers and neurological dis-
eases. GAD glutamate decarboxylase, AD Alzheimer’s disease, ADHD attention-deficit/hyperactivity disorder, PD 
Parkinson’s disease, LE limbic encephalitis, SPS stiff- person syndrome, OSCC oral squamous cell carcinoma, PAC 
pulmonary adenocarcinoma, SCLC small cell lung cancer
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3.3  GABA Receptors Contribute 
to Alzheimer’s Disease 
Pathogenesis, Parkinson’s 
Disease Severity, and Cancer 
Invasiveness
GABA receptors can be divided into two classes: 
GABAA receptors and GABAB receptors. 
Downregulation of ionotropic GABAA receptor 
(GABAAR) is observed in both AD [62] and 
breast cancer [63]. A recent study of AD explored 
amyloid beta’s (Aβ) ability to weaken synaptic 
inhibition through the downregulation of 
GABAAR, indicating that such regulation is 
achieved through induced endocytosis of 
GABAAR [62]. Impaired inhibitory circuits, 
coupled with neuronal hyperexcitability [62], 
might contribute to the characteristic formation 
of amyloid plaque in AD [64].
In breast cancer, downregulation of GABAAR 
is achieved through decreased expression of 
GABAAR-related protein (GABARAP). In inva-
sive ductal and invasive lobular carcinomas, 
GABARAP mRNA and GABARAP expression 
were all found to be significantly downregulated 
[63]. GABARAP was suggested to be a tumor 
suppressor, but how GABARAP is suppressed 
and overcome by the tumor cells is yet to be 
determined. Although the underlying mecha-
nisms are different, downregulation of the 
GABAAR was observed in both breast cancer 
and AD [63]. Moreover, understanding the mech-
anism behind GABARAP suppression in cancer 
and restoring its function could be a possible 
strategy for cancer treatment. In the case of pros-
tate cancer, the GABAAR plays an important 
role in the proliferation of prostate cancer cells. 
Non-cancer prostate epithelial tissues showed no 
GABAAR expression, whereas 15% of prostate 
cancer epithelial tissue samples showed 
GABAAR expression to various extents [1]. 
Applying antagonists of various receptors, 
including GABAAR antagonist, picrotoxin, 
inhibited the proliferation of prostate cancer 
cells. Moreover, applying a GABAAR agonist 
stimulates the proliferation of several prostate 
cancer cell lines [1]. Therefore, GABAAR is 
shown to significantly promote prostate cancer 
growth, and inhibiting GABAAR becomes a 
potential strategy in prostate cancer treatment.
Just like the opposite trends of GABA concen-
tration between different neurological diseases 
and cancers, besides its downregulation, 
GABAAR upregulation is also observed in 
Parkinson’s disease (PD). PD is the second most 
common neurodegenerative disease. In patients 
with PD, the concentration of GABAAR, espe-
cially those containing the α4 subunit, is increased 
approximately 22-fold in the caudate nucleus in 
basal ganglia [65]. Increased GABAAR levels 
also strengthened the tonic inhibition by astro-
cytes, indicating a direct relationship between 
increased GABAAR and PD severity [65].
Given the malignant effect that GABAAR has 
on both PD and prostate cancer, it is worth explor-
ing whether reducing GABAAR expression or 
suppressing GABAAR function could help 
 mitigate prostate cancer. This is another excellent 
example of how the overlap between neurologi-
cal diseases and cancer sheds light on cancer 
treatment.
Besides its role in a variety of cancers, 
GABABR is also a possible target for the treat-
ment of various types of cancers and neurologi-
cal diseases. Specifically, baclofen, an agonist 
of GABABR, has been shown to be effective in 
inhibiting tumor growth in rat models, which 
further exemplifies the suppressive role of 
GABABR activation in tumor development 
[66]. Of particular note, clinical data also sug-
gest that baclofen can be used to reduce certain 
types of drug addiction, including cocaine, alco-
hol, nicotine, and heroin [52]. Positive modula-
tion of GABABR was also shown to be effective 
in treating anxiety in rat models. Rats with no 
GABABR were more anxious, whereas acute 
and chronic treatments with positive GABABR 
modulator CG39783 decreased anxiety levels 
generated in rats [67].
Research on the influence of GABA on human 
prostate cancer cells in vitro suggests that matrix 
metalloproteinase (MMP) induced by GABA 
greatly promotes the invasive ability of the cells 
[68]. Applying GABABR antagonists signifi-
cantly reduced MMP production as well as pros-
tate cancer cell invasiveness, whereas applying 
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GABABR agonists induced the opposite effect 
[68]. The overall result suggests that positive 
modulation of GABABR is implicated in the 
invasive ability of prostate cancer cells.
A blockade of GABABR using GABABR 
antagonist or GABABR knockout was found to 
produce an antidepressant-like phenotype in rat 
models. One hypothesis suggests that the antide-
pressant function is based on the interaction 
between the GABABR and the serotonergic sys-
tem and neurotrophic factors [69].
Although GABABR function is distinctly dif-
ferent in cancers and neurological diseases, sig-
nificant effects in cancers are observed with both 
the upregulation and downregulation of the 
receptors. Therefore, it is still very promising to 
develop treatments based on GABAB receptor 
modulators after taking cancer type-specific 
effects into consideration.
3.4  Autoimmune Disorders’ 




Autoimmune disorders are observed to attack the 
GABA-ergic system, and two of these disorders 
are closely intertwined with specific types of 
neurological diseases and cancers.
The first disease is limbic encephalitis (LE), 
which is frequently related to small cell lung can-
cer (SCLC). LE mainly affects the medial tempo-
ral lobes and patients exhibit symptoms including 
seizures, short-term memory impairment, and 
anxiety [70]. In a study of 20 patients who have 
GABAB receptor antibodies (GABABR-ab), 19 
(95%) patients eventually developed LE. 10 of 
these 19 patients developed SCLC [71]. The spe-
cific relationship between LE and SCLC is not 
yet clear, but the close correlation between the 
two could still provide valuable insights toward 
treatment, with GABABR-ab serving as a practi-
cal diagnostic factor.
The second disease is stiff-person syndrome 
(SPS), often seen accompanied by thymomas and 
breast cancer. SPS is a rare neurological disease 
with 1–2 cases/million [72, 73], and is character-
ized by rigidity and spasm of skeletal muscles in 
limbs and trunks. Patients showed increased sen-
sitivity to stimuli, such as noise and emotional 
perturbation [74]. The majority of SPS patients 
exhibited an increased concentration of autoanti-
bodies against both forms of GADs in cerebral 
fluids [75]. Additionally, 83% of sera from SPS 
patients with positive GAD autoantibodies 
(GAD-A) decreased GABA production in brain 
extracts of rats [75]. As a direct consequence of 
GAD malfunctioning, GABA synthesis is inter-
rupted, and magnetic resonance spectroscopy 
revealed a reduced level of GABA in the motor 
cortices of people with SPS [76]. In the case of 
paraneoplastic SPS, research showed that 53% of 
the tumors in patients with SPS are thymomas 
and breast cancer [72]. Given that GADs are 
expressed in breast cancer, and the overall GABA 
metabolism mediates breast cancer metastasis, 
the association may be caused by the cancer-
induced autoimmune disorder [53]. Thus, an 
increased GAD level might trigger an autoim-
mune response, leading to the production of 
GAD-A [72].
Although the underlying mechanisms of the 
interplay between autoimmune system disorders, 
neurological diseases, and cancers have yet to be 
identified, the altered metabolic signatures could 
serve as a prognostic indicator of cancers and 
neurological disease progression.
4  NAAG and Its Versatile Role 
in Neurological Diseases 
and Cancer
As one of the most prevalent and widely distrib-
uted neuropeptides found in the mammalian ner-
vous system, N-acetyl- aspartyl-glutamate 
(NAAG) was not initially considered a neu-
rotransmitter when it was first discovered in 
1965, due to its abundance and identity as a pep-
tide. It was not tested against neurotransmitter 
criteria until the 1980s, and only then was it for-
mally established as a new neurotransmitter. Its 
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role in the neurological system was later found to 
be more versatile than simply being the precursor 
of glutamate, since it also functions as an agonist 
of group II metabotropic glutamate receptor 
(mGluR3), synaptic GABA release inhibitor, and 
cyclic AMP inhibitor [77].
The recognition of NAAG’s role in cancer 
growth was even more delayed. Only recently a 
study by Nguyen et  al. revealed that NAAG 
plays an important role as a glutamate reservoir 
for cancer growth via GCP II [6]. Moreover, 
NAAG can also serve as an indicator of cancer 
progression as increases in NAAG concentra-
tions were observed in higher grade lymphoma, 
ovarian cancers, and gliomas compared to their 
lower grade counterparts [6, 78, 79]. Therefore, 
the direct conversion of NAAG to glutamate 
established NAAG as a juncture between the 
fields of cancer and neurological disease and 
became a shared characteristic pathway and a 
drug target for the two disease groups. Despite 
its positive correlation with cancer progression, 
the correlation between NAAG concentration 
and neurological disease progression varies 
depending on the type of neurological disease. 
In general, NAAG is established as a neuropro-
tective neurotransmitter in the neurological sys-
tem, where a decreased level of NAAG is 
correlated with neuronal loss [80]. Besides 
serving as a neurotransmitter in neurological 
diseases, NAAG can also reduce other synaptic 
neurotransmitter levels, namely GABA [81] 
and glutamate, by activating a group II G pro-
tein-coupled metabotropic glutamate (mGlu) 
receptor, mGluR3, to achieve neuroprotective 
effects and reduce neurotoxicity caused by glu-
tamate accumulation [82]. Meanwhile, mGluR3 
is also known to promote cancer growth [83–
90]. Previous studies have shown that mGluR3 
expression is associated with glioma growth 
and poor GBM survival rates [85]. In GCP 
II-negative glioblastoma, it is suspected that 
NAAG could be taking on another role to pro-
mote cell growth through an alternative path-
way by acting as an agonist to mGluR3, thereby 
precluding the role of NAAG as a glutamate 
provider.
4.1  NAAG Affects Both Cancer 
and Neurological Disease 
Progression via Glutamate
As a cancer metabolite and a neurotransmitter, 
NAAG has an effect on cancer metabolism and 
neurological diseases, which largely relies on its 
ability to regulate and be directly converted to 
another cancer metabolite/neurotransmitter, gluta-
mate. Via hydrolysis by GCP II, NAAG can be 
catabolized into N-Acetyl-aspartate (NAA) and 
glutamate. This process has proven to be a crucial 
glutamate production pathway in cancer [6], and 
the produced glutamate can serve as a source of 
carbon and nitrogen to support the elevated need 
of energy, nucleotides, and protein of the cancer 
cells [91]. Specifically, the resulting glutamate can 
be further converted to α-KG and it participates in 
the TCA cycle for energy production in cancer 
cells. Therefore, NAAG promotes cancer growth 
by playing the role of a glutamate reservoir [6].
The conversion of NAAG to glutamate also 
plays an important role in neurological diseases. 
Glutamate has long been recognized as a neuro-
degenerative neurotransmitter, and its excessive 
release leads to neuronal loss and neural excito-
toxicity. The excitotoxicity caused by glutamate 
is very complicated, and is promoted by extracel-
lular Ca2+, mediated by NO, and involves synap-
tic free radicals and zinc accumulation [92]. In 
the neurodegenerative disorder, amyotrophic lat-
eral sclerosis (ALS), increased GCP II activity is 
observed, which further supports NAAG’s role as 
a major source of extracellular glutamate [93]. 
Thus, this conversion of NAAG to glutamate 
contributes not only to cancer growth but also to 
a wide range of neurological diseases. This points 
to the significance of the NAAG-glutamate path-
way as a very promising potential target in cancer 
therapy. Inhibition of the conversion of NAAG to 
NAA and glutamate has been the focus of 
researchers working with neurological diseases 
for years [94]. As we begin to uncover the valu-
able interplay between cancer and neurological 
disease, previous and ongoing research may 
serve to catalyze potential developments for can-
cer therapies.
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Due to the diverse nature of different neuro-
logical diseases, the direct relationships between 
NAAG and these diseases are not consistent. As 
an established neuroprotective neurotransmitter, 
NAAG typically reduces neurotoxicity caused by 
excitatory neuroactivity, and suppresses and 
reverses the effect of neurodegenerative neu-
rotransmitters like glutamate [77]. The decrease 
of NAAG levels in most cases is related to neuro-
nal loss and consequent neurodegenerative disor-
ders. In a study of HD and AD, researchers 
observed a decrease in NAAG level and GCP II 
activity and its correlation with the neuronal loss 
[80]. A similar trend was also observed in another 
neurodegenerative disease, ALS, where decreased 
NAAG levels in all regions of the spinal cord, 
except for the posterior column, were observed in 
ALS patients. However, in this case, GCP II 
activity was found to be increased, which led to 
excessive hydrolysis of GCP II and to a subse-
quent decrease in the NAAG levels [93]. 
Therefore, decreased NAAG level reflects the 
pathogenesis and progression of neurodegenera-
tive diseases.
A reverse relationship between NAAG and 
disease progression, however, was observed in 
cancer. A recent study showed that NAAG has 
great potential as a noninvasive cancer- 
monitoring biomarker. Moreover, the NAAG 
concentration in plasma reflects its concentration 
in tumors, which indicates a higher translational 
value of NAAG as a cancer biomarker [6]. 
Another translational aspect of NAAG concen-
tration is in monitoring cancer growth as a NAAG 
concentration spike could be detected prior to 
tumor growth surge and thus allow for the moni-
toring of tumor growth in a timely fashion [6, 
95]. Therefore, considering the ability of NAAG 
concentration to reflect cancer grade, the mirror 
relationship between plasma NAAG concentra-
tion and tumor NAAG concentration, and its pre-
dictive time point of occurrence, NAAG shows 
great potential as a real-time tumor growth 
monitor.
Few studies have been conducted on the role 
of NAAG in another major neurological disease 
category, psychiatric disorders, and the results 
are more controversial. In one study of the effect 
of NAAG on schizophrenia, an increase in brain 
NAAG level and decreases in GCP II and gluta-
mate levels were observed, which indicates a 
completely reverse relationship between NAAG 
and psychiatric disorders compared with its rela-
tionship with neurodegenerative disorders [96]. 
However, in another study, brain NAAG was 
found to be higher in younger schizophrenia sub-
jects compared to control counterparts, while a 
reverse relationship was observed in the older 
groups [97]. Therefore, possibly due to the com-
plex nature and disease dynamics of psychiatric 
disorders and their reduced reliance on neuron 
loss, NAAG does not completely reflect the dis-
ease progression in this category of neurological 
disorders compared to cancer and neurodegener-
ative disorders.
4.2  Targeting GCP II Is a Promising 
Strategy for Cancer Treatment
After recognizing the crucial role of NAAG in 
both cancer growth and neurological disease pro-
gression via its catabolism to NAA and  glutamate, 
we can shift our attention from NAAG itself to its 
conversion process. As mentioned in Sect. 4.1, a 
very promising strategy for both neurological 
disease and cancer treatment would be shutting 
down the hydrolysis of NAAG to glutamate. GCP 
II, also known as N-acetyl-l-aspartyl-l- glutamate 
peptidase (NAALADase), is the key enzyme in 
NAAG’s hydrolysis to glutamate and NAA [98]. 
Due to its dominant role in this process, GCP II 
has long been in consideration as a drug target. 
Generations of GCP II inhibitors have been 
developed to treat cancer and neurological dis-
eases, including 2-(phosphonomethyl) pentane-
dioic acid (2-PMPA), thiol and indole thiol 
derivatives, and NAAG analogs. Among these, 
2-(3-mercaptopropyl) pentanedioic acid 
(2-MPPA) showed great tolerance in a Phase I 
clinical trial, and a Phase II clinical trial has been 
initiated [94].
The use of GCP II inhibitors on a variety of 
neurological diseases has been proven to be 
effective. The GCP II inhibitors (2-PMPA, thiol- 
based 2-MPPA, and urea-based ZJ43) reduce 
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inflammatory pain and neuronal loss in rat mod-
els, and another GCP II inhibitor, GPI5232, 
greatly reduces the number of seizures in a rat 
stroke model compared to vehicle control [94]. 
Besides these acute neurological diseases, the 
effect of GCP II inhibitors was also shown in 
chronic neurological disorders. ZJ43 was shown 
to reduce dissociative anesthetic phencyclidine 
(PCP)-induced motor activation, falling, stereo-
typic circling behavior, and head movements in 
schizophrenia patients. In addition, GPI5332 
reduces diabetic neuropathy, and 2-PMPA and 
2-MPPA delay mortality and pathological abnor-
malities of ALS in vitro and in vivo, respectively 
[94]. All the above positive effects of GCP II 
inhibitors over neurological diseases are driven 
by a two-faceted mechanism. Firstly, GCP II 
inhibition cuts off the supply of glutamate from 
NAAG hydrolysis and results in a direct decrease 
of glutamate level. Secondly, although GCP II 
inhibition reduces extracellular glutamate 
directly, its therapeutic effects seem to primarily 
rely on inhibition of the synaptic release of gluta-
mate [94]. An observation in a rat stroke model 
showed that after GCP II inhibition, the decrease 
in extracellular glutamate level exceeded extra-
cellular NAAG levels. Via this two-faceted mech-
anism, GCP II exhibits great potential and 
effectiveness as a treatment for neurological dis-
eases (Fig. 4). The success of the use of GCP II 
inhibitors in neurological diseases and the devel-
opment of reliable GCP II inhibitors provides 
further evidence for this strategy’s potential in 
cancer treatment and it exhibits great transla-
tional value due to the shared metabolic pathway. 
Likewise, GCP II inhibitors have gained interest 
in cancer treatment. A study by Nguyen et  al. 
showed that the use of 2-PMPA reduces both 
tumor growth and glutamate concentration 
in  vivo [6]. This was further supported by the 
finding that the combination use of 2-PMPA and 
glutaminase inhibition accentuated the effects by 
further cutting off glutamate supply [95]. 
Therefore, inhibiting GCP II and in turn shutting 
down the hydrolysis of NAAG to glutamate have 
proven to be effective in cancer treatment, and 
thus GCP II has become a very promising drug 
target.
Besides its function in hydrolyzing NAAG, 
GCP II is also connected with cancer from other 
aspects. In prostate cancer, GCP II is also 
known as prostate-specific membrane antigen 
(PSMA), which serves as a biomarker that 
serves to cleave terminal carboxyl glutamate 
from NAAG [99]. In prostate cancer, its con-
centration greatly increases. A study by Evans 
et  al. has shown that reducing GCP II expres-
sion led to cell cycle arrest, decreased cell pro-
liferation, and diminished invasiveness in 
prostate cancer. This trait makes GCP II a tool 
for prostate cancer imaging and treatment 
[100]. The strategy of targeting GCP II in can-
cer treatment, therefore, becomes more promis-
ing by the addition of this connection between 
GCP II and prostate cancer.
4.3  NAAG Inhibits GABA Release 
and Indirectly Affects Both 
Cancer and Neurological 
Diseases via the GABA-ergic 
System
Besides its direct effect on cancer and neurologi-
cal diseases, NAAG also interacts with other 
molecules to indirectly influence the two disease 
groups. The activation of mGluR3 and the 
decrease of the cAMP level induced by NAAG 
inhibit the calcium-dependent, KCl-induced 
GABA release [81]. As discussed in Sect. 3, 
GABA is found to contribute to the TCA cycle 
and cancer energy supply by its conversion to 
succinate. The inhibition of GABA release is 
observed when either NAAG or DCG-IV, another 
mGluR3 agonist, is applied. The addition of for-
skolin, which leads to forskolin-induced cAMP 
synthesis, reverses the inhibition of GABA 
release caused by NAAG [81]. Therefore, NAAG 
potentially inhibits GABA release by mGluR3 
activation and consequent cAMP decrease, and 
in turn downregulates the GABA-ergic system. 
As discussed in Sect. 3 of this chapter, this down-
regulation could have multifaceted effects on 
cancer and neurological diseases, including 
relieving AD and deducing the invasiveness of 
prostate cancer.
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5  Conclusion
Glutamine/glutamate, GABA, and NAAG metab-
olism are closely involved in both cancer and 
neurological diseases. As important factors in 
neurotransmission in neurological diseases and 
as significant components in cancer metabolism 
and energy supply, glutamine/glutamate, GABA, 
and NAAG introduce considerable overlaps 
between the two categories of diseases. Possibly 
due to the complex nature of the neurological 
system and the divergent causes of different neu-
rological disorders, the effect and correlation of 
one neurotransmitter are very specific to that dis-
ease type, sometimes even opposite to its effect 
on other diseases. However, these neurotransmit-
ters, as cancer metabolites and signaling mole-
cules, affect cancer development in unique ways. 
Glutamine and glutamate, in general, serve as 
cancer cell energy sources, while GABA and 
NAAG both have more versatile roles serving as 
signaling factors, metabolic reservoirs, and prog-
nostic indicators for cancer. Therefore, taking 
insights gleaned from the metabolic interplay 
between neurological diseases and cancer and 
applying them to the field of oncology may not 
only provide further understanding of the mecha-
nisms by which these metabolites affect cancer 
growth but also allow established therapeutic 
strategies in neurological diseases to be repur-
Fig. 4 Regulation of 
NAAG metabolism and 
its contribution to 
cancer. AD Alzheimer’s 
disease, HD 
Huntington’s disease, 
ALS amyotrophic lateral 
sclerosis, GCP II 
glutamate 
carboxypeptidase II
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posed for cancer treatment and even shed light on 
novel drug targets. As discussed in this chapter, 
the regulation of these four metabolites/neu-
rotransmitters and their related enzymes and 
receptors greatly impacts diagnosis, monitoring, 
and treatments for cancer, with some already in 
the process of being translated into cancer clini-
cal trials. The future direction includes investi-
gating potential therapeutic methods involving 
intertwining glutamine metabolism, GABA regu-
lation, and GCP II/GLS/GS inhibition, which can 
eventually be utilized for cancer and neurological 
disease treatment.
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targets.
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• Alteration in circulating glutamine and gluta-
mate levels is indicative of both cancer prolif-
eration and cardiometabolic diseases.
• Glutaminolysis is upregulated in cancer and 
pulmonary arterial hypertension.
• Glutaminase is a treatment target for cancer, 
hypertension, and hyperglycemia.
• Glutamine supplementation is implemented in 
the treatment of cancer to support immuno-
regulation and the treatment of many cardio-
vascular diseases.
• Pharmacological inhibition of fatty acid oxi-
dation is proven effective in slowing cancer 
progression and treating some cardiovascular 
diseases.
• Inhibition of fatty acid synthesis is proven 
both effective in cancer treatment and protec-
tive against pulmonary hypertension.
• Upregulated tryptophan catabolism has been 
linked to the progression of cardiovascular 
diseases and enhanced immune system eva-
sion in cancer.
• Pyruvate dehydrogenase complex downregu-
lation is associated with many cardiovascular 
diseases and chemoresistance in cancer.
1  Introduction
According to data from the World Health 
Organization, cardiovascular diseases and can-
cer are the two leading causes of mortality in the 
world [1]. Despite the immense effort to study 
these diseases and the constant innovation in 
treatment modalities, the number of deaths asso-
ciated with cardiovascular diseases and cancer is 
predicted to increase in the coming decades [1]. 
From 2008 to 2030, due to population growth 
and population aging in many parts of the world, 
the number of deaths caused by cancer globally 
is projected to increase by 45%, corresponding 
to an annual increase of around four million peo-
ple [1]. For cardiovascular diseases, this number 
is six million people [1]. In the United States, 
treatments for these two diseases are among the 
most costly and result in a disproportionate 
impact on low- and middle- income people. As 
the fight against these fatal diseases continues, it 
is crucial that we continue our investigation and 
broaden our understanding of cancer and cardio-
vascular diseases to innovate our prognostic and 
treatment approaches. Even though cardiovascu-
lar diseases and cancer are usually studied inde-
pendently [2–12], there are some striking 
overlaps between their metabolic behaviors and 
therapeutic targets, suggesting the potential 
application of cardiovascular disease treatments 
for cancer therapy. More specifically, both can-
cer and many cardiovascular diseases have an 
upregulated glutaminolysis pathway, resulting in 
low glutamine and high glutamate circulating 
levels. Similar treatment modalities, such as glu-
taminase (GLS) inhibition and glutamine sup-
plementation, have been identified to target 
glutamine metabolism in both cancer and some 
cardiovascular diseases. Studies have also found 
similarities in lipid metabolism, specifically 
fatty acid oxidation (FAO) and synthesis. 
Pharmacological inhibition of FAO and fatty 
acid synthesis have proven effective against 
many cancer types as well as specific cardiovas-
cular conditions. Many of these treatments have 
been tested in clinical trials, and some have been 
medically prescribed to patients to treat certain 
diseases, such as angina pectoris [13, 14]. Other 
metabolic pathways, such as tryptophan catabo-
lism and pyruvate metabolism, were also dys-
regulated in both diseases, making them 
promising treatment targets. Understanding the 
overlapping traits exhibited by both cancer 
metabolism and cardiovascular disease metabo-
lism can give us a more holistic view of how 
important metabolic dysregulation is in the pro-
gression of diseases. Using established links 
between these illnesses, researchers can take 
advantage of the discoveries from one field and 
potentially apply them to the other. In this chap-
ter, we highlight some promising therapeutic 
discoveries that can support our fight against 
cancer, based on common metabolic traits dis-
played in both cancer and cardiovascular 
diseases.
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2.1  Alterations in Circulating 
Glutamine and Glutamate 
Levels Are Indicative of Both 
Cancer Proliferation 
and Cardiometabolic Diseases
Glutamine metabolism in cancer has been exten-
sively studied [15, 16], in which glutamine 
addiction has been highlighted as a signature 
cancer behavior. This rapid consumption of glu-
tamine by tumors eventually results in glutamine 
depletion in the patient’s body and can serve as 
an indicator of cancer proliferation [17]. 
However, glutamine depletion is not always an 
immediate result of cancer onset. The presence 
of a tumor alters the host’s glutamine metabo-
lism and creates a net flux of glutamine from 
other tissues and organs towards the tumor [12]. 
Specifically, as described in a review paper by 
Medina et al., glutamine synthesis is upregulated 
in the liver and skeletal muscles of carcinoma-
bearing animals, reflected by an increase in the 
glutamine synthetase (GS)/glutaminase (GLS) 
ratio [18]. The synthesized glutamine is then 
secreted into the circulatory system and results 
in an initial elevated glutamine plasma level 
within the first 24 hours of tumor transplantation 
[18]. However, this initial increase is later over-
shadowed by the rapid glutamine consumption 
by the tumor which eventually leads to gluta-
mine depletion in the body. The active absorp-
tion of glutamine by cancer is shown by the 
upregulated glutamine transportation through 
the plasma membrane in malignant cells [19, 
20]. For cardiovascular diseases, many clinical 
and experimental studies have shown that the 
low presence of circulating glutamine is indica-
tive of cardiometabolic diseases and hemolytic 
disorders [11, 21, 22]. Specifically, the low 
 glutamine/glutamate ratio in the plasma is asso-
Fig. 1 Glutamine metabolism dysregulation and corresponding therapeutic targets in cancer and cardiovascular dis-
eases. The upregulation of glutaminolysis pathway, resulting in low glutamine and high glutamate concentrations, is 
observed in many cancers and cardiovascular diseases. Pharmacological inhibition of glutaminase (GLS) with BPTES 
and CB-839, as well as dietary glutamine supplementation, has been incorporated into the treatment of both conditions 
and has shown promising results
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ciated with higher blood pressure, higher circu-
lating triglycerides, obesity, and insulin-resistant 
traits [11]. In contrast, a high glutamine/gluta-
mate ratio is connected to lower risks of stroke 
and diabetes mellitus and is generally related to 
better cardiovascular health [23]. In patients 
with sickle cell diseases, glutamine concentra-
tion in plasma and endothelial cells has been 
reported to decrease significantly [24].
On the other hand, circulating glutamate lev-
els have been shown to increase in breast and 
prostate cancer patients and reflect tumor pro-
gression to some extent [25–27]. The increase in 
glutamate levels is also associated with increased 
risks of cardiovascular events and decreased 
insulin production and sensitivity, and is posi-
tively correlated with diabetes [11, 28]. In other 
words, a decrease in glutamine levels and an 
increase in glutamate levels are generally associ-
ated with adverse health outcomes in both cancer 
and cardiovascular diseases. There are, however, 
exceptions to this trend: elevated serum gluta-
mine levels are observed in acute myocardial 
ischemia patients [29].
Even though there has not been clear evidence 
suggesting that circulating glutamine and gluta-
mate levels could be used for prognosis, their 
abnormalities have been consistently demon-
strated as consequences of cancer and a variety of 
cardiovascular disorders. This imbalance in glu-
tamine and glutamate levels further highlights the 
upregulated conversion from glutamine to gluta-
mate, and more generally, the glutaminolysis 
pathway in both diseases.




The role of glutaminolysis in cancer prolifera-
tion has been well established as it contributes to 
tumor growth by both promoting cell prolifera-
tion and inhibiting cell death. Glutaminolysis 
fuels energy metabolism via the tricarboxylic 
acid (TCA) cycle and serves as a source of mate-
rials for biosynthesis, especially for purine and 
pyrimidine metabolism [15, 16]. Glutaminolysis 
upregulation is also associated with cancer 
aggressiveness, invasiveness, and metastasis [25, 
30]. The upregulation of glutaminolysis has been 
extensively studied in many cancer types and has 
proven crucial for cancer development, making 
it a well-known target for cancer therapy. 
However, it is important to note that the upregu-
lation of glutaminolysis is a trait exhibited by 
cancer cells, localized to the tumor, and not a 
signature trait exhibited by normal cells in the 
patient body [15, 18].
For cardiovascular diseases, glutaminolysis 
has been shown to increase in pulmonary endo-
thelial cells of patients with pulmonary arterial 
hypertension (PAH) [11]. PAH is a potentially 
fatal condition caused by the abnormal prolifera-
tion of vascular cells, forming lesions that 
obstruct blood flow [31]. Vascular transforma-
tion, coupled with fibrosis and vasoconstriction, 
can lead to an increase in blood pressure and, if 
left untreated, can cause right ventricular failure 
and death [11]. Studies have shown an increased 
GLS1 expression and decreased glutamine levels 
in pulmonary endothelial cells and in myocardio-
cytes of the right ventricle in PAH in  vivo rat 
model [32]. An upregulation in glutaminolysis is 
found in PAH patients’ right ventricular samples, 
suggesting that upregulated glutaminolysis is 
associated with PAH [32]. Furthermore, increas-
ing glutaminolysis can result in an increased 
alpha-ketoglutarate level, a direct product of glu-
tamate that helps promote the translation and sta-
bilization of collagens, which stimulates fibrosis 
and worsens PAH [33]. As a result, glutaminoly-
sis has also become a promising treatment target 
for PAH.
Thus, as an important energetic pathway fre-
quently dysregulated in both cancer and cardio-
vascular disease metabolism, glutaminolysis has 
been widely investigated as a treatment target, 
resulting in the development of several pharma-
cological innovations and dietary implementa-
tions, discussed in detail in the next sections.
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GLS is an aminohydrolase enzyme that catalyzes 
the hydrolysis of glutamine to glutamate, which 
marks the initiation of glutaminolysis. There are 
two main types of GLS expressed in humans: 
GLS1, the kidney-type glutaminase, and GLS2, 
the liver-type glutaminase [34]. In cancer, GLS1 
is expressed more often than GLS2, and thus, 
more frequently targeted for therapy. The most 
common GLS1 pharmacological inhibitors are 
bis-2-(5-phenylacetamido-1,2,4-thiadiazol- 2-yl)
ethyl sulfide (BPTES) and CB-839, discussed in 
depth in Chap. 2, which have shown tumor sup-
pression ability in breast cancer, leukemia, and 
lymphoma cells [35–39]. The inhibition of GLS1 
expression has been extensively studied in cancer 
researches for cancer treatment [40–43]. As dis-
cussed in the previous section, GLS1 expression 
is also upregulated in PAH and has been targeted 
for PAH treatment. Specifically, pharmacological 
inhibition of GLS1 using C968 or CB-839 in rats 
exposed to monocrotaline, a pneumotoxic liver-
activated compound commonly used to induce 
pulmonary hypertension, significantly decreased 
pulmonary arteriolar and right ventricular remod-
eling and ameliorated pulmonary hypertension 
[44]. Thus, the use of GLS1- inhibiting drugs can 
target both cancer and PAH.
On the other hand, the role of GLS2 in cancer 
has been quite controversial and needs further 
studies to gain a comprehensive understanding 
[10]. A study by Martin-Rufian et  al. suggests 
that GLS2 overexpression in cancer cells inhib-
its c-MYC expression [45, 46] and prevents the 
proliferation of several types of glioma cells 
[47]. In contrast, a study by Xiang et al. showed 
that knocking down GLS2 increases the sensi-
tivity of cervical tumors to radiotherapy [48]. In 
hyperglycemia, GLS2 has been identified as a 
treatment target [49]. Specifically, in type 2 dia-
betic patients, dysregulation of glucagon causes 
an increase in gluconeogenesis in the liver and 
skeletal muscles, resulting in hyperglycemia. 
Inhibition of GLS2 can block glutaminolysis, 
decrease the hepatic metabolic flux from gluta-
mine to glucose, decrease the initial blood glu-
cose level, and increase insulin sensitivity [49]. 
Despite some attempts to study the selective 
inhibition of GLS1 and GLS2 [35, 49, 50], there 
has not been a defined pharmacological inhibi-
tion of GLS2 that is qualified for general use in 
research. As a promising therapeutic target, 
research on the role of GLS2 in cancer and car-
diovascular diseases should be further expanded.
2.4  Glutamine Supplementation 
Is Implemented for Treatment 
of Cancer and a Variety 
of Cardiovascular Diseases
In addition to blocking glutamate production 
from glutamine, glutamine supplementation has 
also been proven effective in cardiovascular dis-
ease prevention and sickle cell disease treatment 
and is used in combination with chemotherapy 
for cancer treatment.
In cancer treatment, the use of dietary gluta-
mine supplementation is to make up for the 
tumor’s “nitrogen trap” behavior that aggressively 
consumes dietary amino acids as well as the amino 
acids synthesized by the host [12]. Despite the sus-
picion that increasing glutamine availability may 
support tumor growth, a study by Austgen et  al. 
shows that dietary supplementation of glutamine 
leads to no significant change in tumor growth 
in vivo [51]. The additional source of glutamine 
helps replenish glutathione (GSH) level, a crucial 
intracellular antioxidant, and hepatic detoxifier, in 
natural killer cells. Experimental data supports 
that glutamine supplementation impedes tumor 
growth by restoring the function of natural killer 
cells and increasing immunoregulation [52, 53]. 
The restored GSH level also protects patients from 
oxidative damages as well as increases the selec-
tivity and decreases the cardiotoxicity and neuro-
toxicity effects of chemotherapeutic drugs, such as 
doxorubicin, methotrexate, cyclophosphamide, 
Eloxatin, and 5-fluorouracil, to name a few [54]. In 
combination with chemotherapy, supplemented 
glutamine can potentially help increase treatment 
efficacy and improve patient outcomes [55]. 
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However, despite the promising experimental data, 
we still do not have enough evidence to recom-
mend its regular use in cancer treatment. More 
experimental and clinical studies should be done 
to investigate the use of glutamine supplementa-
tion in cancer treatment.
On the other hand, the use of glutamine sup-
plementation to protect against cardiometabolic 
diseases and its benefits have been widely estab-
lished [11]. In diabetic patients, chronic oral 
administration of glutamine decreases blood glu-
cose concentration for patients with type 1 and 2 
diabetes, increases circulating insulin levels, and 
reduces systolic blood pressure in type 2 diabetic 
patients [56]. In mice, glutamine supplementa-
tions increase glucose tolerance and decrease 
mean arterial blood pressure [11]. For mice on a 
high-fat diet, studies show that glutamine intake 
helps lower body weight, decreases hyperglyce-
mia, and improves insulin sensitivity [57]. In 
patients with coronary artery diseases, glutamine 
supplementation enhances myocardial repair and 
prevents damage to the cardiovascular system 
during surgical interventions or cardiac injuries 
[9, 58, 59]. The protective role of glutamine in 
ischemia-reperfusion injury is especially well 
investigated [60–64]. Glutamine reduces oxida-
tive stress, ameliorates inflammation, and inhib-
its apoptosis, necrosis, and lipid peroxidation 
following ischemia-reperfusion. Its tissue protec-
tion effects reach a variety of organs throughout 
the body, including skeletal muscles, intestine, 
liver, kidney, brain, and heart [11]. Especially, 
dietary glutamine supplementation has been 
approved by the United States Food and Drug 
Administration as a treatment for sickle cell dis-
ease and is now being prescribed for patients to 
reduce the rate of complications [11, 65, 66]. 
This is a result of a successful phase 3 clinical 
trial, which demonstrated a significantly lower 
number of pain crises in patients with sickle cell 
disease when taking oral pharmaceutical grade 
glutamine. The precise mechanism of the gluta-
mine treatment for sickle cell disease is unknown. 
Nevertheless, glutamine may serve as an energy 
source for endothelial cells and early stage retic-
ulocytes, or premature red blood cells (RBCs) 
that still contain mitochondria. The established 
role of glutamine as a protective treatment against 
cardiovascular diseases reinforces the need for 
more clinical trials to determine its pharmaco-
logical efficacy.
Compared to cardiovascular diseases, the 
implementation of glutamine supplements in 
cancer treatment is still in its early stages of the 
investigation. Researchers should take advantage 
of the established work done on cardiovascular 
diseases and explore their potential integration 
into cancer therapy. Building upon previous 
knowledge can pave the way towards many 
groundbreaking discoveries.
3  Lipid Metabolism Plays 




3.1  Fatty Acid Oxidation in Cancer 
and Cardiovascular Diseases
Mitochondria fatty acid β-oxidation (FAO) 
involves the breakdown of energy-rich lipid mol-
ecules and plays a crucial role in the bioenergy 
metabolism exploited by cancer cells. The upreg-
ulation of FAO in cancer is relatively less thor-
oughly examined than glucose or glutamine 
metabolism and has been discussed in detail in 
Chap. 3 [67]. A variety of FAO enzymes has been 
shown to be overexpressed in many cancers [68]. 
For example, in chronic lymphocytic leukemia 
(CLL) cells, Liu et al. recorded a drastic increase 
in carnitine palmitoyltransferase 1A (CPT1A), 
CPT1B, and CPT2 expression [69]. High expres-
sion of CPT1A has also been shown to be indica-
tive of poor patient outcomes in both ovarian 
cancer and acute myeloid leukemia (AML) [70, 
71]. In prostate cancer, FAO has been identified 
as a dominant bioenergetics pathway and can 
potentially serve as a biomarker for prostate can-
cer diagnosis [72]. The association between FAO 
upregulation and metastasis has also been estab-
lished in breast cancer [73, 74], colorectal cancer 
[75], and glioblastoma [76, 77], in which an 
increased FAO helps cancer cells overcome anoi-
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kis, a type of programmed cell death that occurs 
when anchorage-dependent cells detach from the 
extracellular matrix (ECM) [68]. Other studies 
suggest that FAO affects metastasis via cancer 
stem cell regulation [8, 78]. Despite the differ-
ence in its underlying mechanistic benefits 
towards cancer proliferation, there is an upregu-
lation of FAO for most cancer types.
However, the alterations in FAO vary depend-
ing on the specific cardiovascular disease and the 
stage of the disease. The role of FAO in cardio-
vascular diseases is especially important, consid-
ering that it is the predominant pathway utilized 
by myocardiocytes for energy production [79]. In 
heart failure patients, many independent studies 
have shown an increase in the level of circulating 
free fatty acids and a significant decrease in the 
rate of FAO in the heart [80]. This downregula-
tion of FAO is primarily due to mitochondria dys-
function and leads to an upregulated glycolysis 
pathway, signifying the shift back to what is 
known as “the fetal energy metabolism” of the 
failing heart. On the other hand, during ischemia-
reperfusion injury, an elevated circulating level 
of free fatty acids increases FAO in the heart [7]. 
For diabetic cardiomyopathy and obese-related 
cardiomyopathy, there are consistent reports stat-
ing that cardiac FAO is upregulated in these con-
ditions, along with an increase in circulating free 
FA and FA uptake [80]. Despite FAO upregula-
tion, the high influx of FA overwhelms the con-
sumption capacity, resulting in myocellular lipid 
accumulation and lipid toxicity in the heart, an 
extremely common phenomenon in these cardio-
myopathy conditions [81]. The changes in FAO 
in these cardiovascular diseases all resulted in 
higher oxygen consumption per ATP molecule 
and an overall lower cardiac efficiency [80].
Fig. 2 Lipid metabolism dysregulation and corresponding therapeutic targets in cancer and cardiovascular diseases. 
Similar metabolic dysregulations in fatty acid uptake, synthesis, and oxidation have been observed in both cancer and 
cardiovascular diseases, thus highlighting several common treatment targets. The “repurposing” of pharmacological 
inhibitors used in cardiovascular diseases to cancer therapy has shown promising experimental results. CD36 cluster of 
differentiation 36, FASN fatty acid synthase, CPT carnitine palmitoyltransferase, 3-KAT 3-ketoacyl-CoA thiolase
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3.2  Pharmacological Inhibition 
of Fatty Acid Oxidation Has 




The importance of FAO on cardiovascular dis-
eases and cancer progression has made FAO a 
promising target for treatment. CPT1 is one of the 
most common and well-investigated targets for 
FAO inhibition in cancer therapy. Pharmacological 
inhibition of CPT1 using etomoxir has shown 
promising anticancer results in breast cancer, leu-
kemia, and prostate cancer [68]. In cardiovascular 
diseases, etomoxir was used to treat diabetes and 
heart failure and showed great results in  vivo. 
However, due to toxicity effects in the liver and 
the heart, phase II clinical trials with etomoxir 
were terminated [68]. A revision of etomoxir dos-
age might be able to improve the clinical outcome 
and pave the way for effective cancer and cardio-
vascular disease treatment. Other CPT1 and CPT2 
inhibitors such as oxfenicine, aminocarnitine, 
ST1326, and avocatin B, all show anticancer 
effects in vitro and in vivo [68].
Perhexiline is another pharmacological inhibi-
tor of CPT1 and CPT2, currently being pre-
scribed in Asia, Australia, and New Zealand as 
medicine to treat angina pectoris [13, 14], a 
symptom of coronary artery disease character-
ized by chest pain or discomfort. Studies done on 
chronic lymphocytic leukemia and prostate can-
cer cells have shown that perhexiline has a 
growth-inhibiting effect against cancer cells [6, 
69]. Similarly used in the treatment of angina 
pectoris in Europe and Asia, trimetazidine is a 
competitive inhibitor of 3-ketoacyl-CoA thiolase 
(3-KAT), a component of the trifunctional pro-
tein (TFP) in FAO [68, 82]. In many studies, 
trimetazidine has shown positive effects in restor-
ing heart function in hypertrophied hearts in vivo 
or heart failure patients [80]. In cancer, trimetazi-
dine was also found to inhibit cell proliferation 
and induce apoptosis in breast cancer and glio-
blastoma cells in  vitro [83, 84]. With the safe 
usage of perhexiline and trimetazidine estab-
lished in cardiovascular disease, the potential 
clinical application of these drugs in cancer treat-
ment should be carefully examined.
Despite the positive effect of FAO inhibition 
in many cardiovascular conditions, adverse car-
diac consequences can arise when FAO is down-
regulated. Specifically, inhibited FAO can cause a 
buildup of lipids in cardiovascular tissues and 
increase lipid toxicity in the already damaged tis-
sues. Drugs targeting FAO that lack specificity 
can cause damage to neighboring organs and may 
worsen the condition. Thus, it is crucial to take 
this into account when using these drugs for can-
cer treatment, as they might cause negative 
impacts on the cardiovascular system.
3.3  Inhibition of Fatty Acid 
Synthesis Has Proven Both 
Effective in Cancer Treatment 
and Protective Against 
Pulmonary Hypertension
As discussed in Chap. 3, fatty acid synthesis and 
fatty acid elongation are upregulated in many 
cancer types, including lung, breast, and bladder 
cancer. Its upregulation is also associated with 
cancer metastasis [85–87]. Antibody treatments 
targeting CD36, a fatty acid receptor, in the 
mouse model of human oral cancer have shown 
strong evidence in preventing metastasis initia-
tion [88]. Another promising treatment targeting 
fatty acid synthesis for cancer therapy is TVB- 
2640, a fatty acid synthase (FASN) inhibitor that 
is currently involved in a variety of clinical trials 
in combination with chemotherapy [89]. FASN 
activity is also shown to increase in pulmonary 
hypertension. A study by Singh et al. shows that 
inhibition of FAS using siRNA in pulmonary 
hypertension-induced mice helps restore mito-
chondria function, and decrease hypertrophy, 
ventricular pressure, and vascular remodeling 
[5]. These promising results show potential for 
FAS inhibition to be applied to both cancer and 
pulmonary hypertension therapy.
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4  Upregulated Tryptophan 




System Evasion in Cancer 
(Fig. 3)
Tryptophan is one of the nine essential amino 
acids that play key roles in protein synthesis and 
participate in the synthesis of a spectrum of cru-
cial molecules. In mammals, the kynurenine met-
abolic pathway is tryptophan’s main catabolic 
route, resulting in 95% of peripheral tryptophan 
catabolism in mammals [90]. The kynurenine 
pathway is a complex metabolic route that is 
driven by the enzymes indoleamine 
2,3- dioxygenase (IDO) and, to a lesser extent, 
tryptophan 2,3-dioxygenase (TDO). IDO has two 
isoenzymes, IDO1 and IDO2, with IDO1 being 
the primary one controlling tryptophan degrada-
tion [91]. In this pathway, tryptophan is converted 
to kynurenine, and the regulation is primarily 
associated with IDO1, the rate-limiting enzyme.
In the cardiovascular system, IDO and kyn-
urenine are known as cardiovascular relaxing 
factors, which bring down pressure during sys-
temic inflammation [92]. Thus, the expression of 
IDO and kynurenine levels is upregulated post- 
inflammation and correlated with onsets of stroke 
events [93]. The increase in tryptophan degrada-
tion accompanied by an increased kynurenine/
Fig. 3 The upregulation of tryptophan catabolism is linked to the progression of cardiovascular diseases and enhanced 
immune system evasion in cancer. The upregulation of tryptophan 2,3-dioxygenase (TDO) and indolamine 2,3-dioxy-
genase (IDO) and increase in kynurenine-to-tryptophan ratio (KTR) are positively associated with risks of severe coro-
nary events and systemic low-grade inflammation. In tumors, kynurenine binds to aryl hydrocarbon receptor (AHR), 
which causes the receptors to translocate into the cell’s nucleus, activating genes that help cell migration. In addition, 
kynurenine acts as an endogenous ligand that inhibits T cells via a variety of mechanisms to enhance immune evasion 
in tumors. Pharmacological inhibition of the kynurenine pathway could be applied to the treatment of cancer and car-
diovascular diseases. LDL low-density lipoproteins, HDL high-density lipoproteins
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tryptophan ratio (KTR) in the blood plasma is 
indicative of the body’s counteraction to an 
inflammation response, and can thus be predic-
tive of cardiovascular events [93]. Increased KTR 
is also positively associated with low-density 
lipoproteins (LDL) and body mass index (BMI) 
and is negatively associated with HDL and tri-
glycerides [94]. In individuals suffering from 
coronary heart disease, low tryptophan plasma 
concentration in combination with high KTR is 
prevalent [4]. The upregulation of IDO is also 
identified in the core of atherosclerotic plaques in 
humans [95].
For cancer, an elevated level of IDO expres-
sion is correlated with advanced-stage breast 
cancer [96]. Moreover, tryptophan degradation 
via the kynurenine metabolic pathway has also 
been linked to tumoral immune resistance [97]. 
Opitz et al. shows that many cancers upregulate 
TDO to boost tryptophan consumption [98]. 
When IDO and TDO are upregulated, a high 
level of kynurenine is synthesized, which binds 
to the aryl hydrocarbon receptor (AHR), induc-
ing gene expressions that help tumor cells prolif-
erate and metastasize. High kynurenine 
concentration also suppresses effector T cells, 
thus aiding cancer cells to evade immune 
responses [98]. Overexpression of IDO also 
occurs in different classes of immune cells, spe-
cifically antigen- presenting cells, which 
increases immune suppression and impedes the 
immune system’s ability to recognize and attack 
malignant cells [99].
In general, IDO upregulation in tryptophan 
catabolism is associated with both cardiovascular 
diseases and cancer and supports tumor progres-
sion via immune suppression and inflammatory 
tumor carcinogenesis [98]. The pharmacological 
administering of 1-methyl tryptophan, an IDO 
inhibitor, could prove to be a novel therapeutic 
solution for future investigation [93]. The con-
certed use of IDO and TDO pharmacological 
inhibitors could also be a potential treatment can-
didate for cancer therapy.
5  Pyruvate Metabolism 




The dysregulation of pyruvate metabolism is 
observed in myocardial ischemia, hypertrophy, 
and heart failure [3], and contributes to cancer 
chemoresistance [2, 100]. Pyruvate dehydroge-
nase complex (PDHC) is responsible for the con-
version of pyruvate to acetyl-CoA, a key enzyme 
of aerobic cellular oxidation, and the connector 
between glycolysis and the TCA cycle [101, 102]. 
Previous studies on ischemia and reperfusion 
reveals a decreased flux of pyruvate through the 
PDHC, leading to a metabolic shift towards myo-
cardial lactate production and a large rate of gly-
colysis despite high oxygen consumption [3]. 
PDHC activity has also been shown to decrease in 
hypertrophied and diabetic hearts [3]. Moreover, 
the upregulation of pyruvate dehydrogenase 
kinase (PDK), an enzyme that inactivates pyru-
vate dehydrogenase (the first enzyme in the 
PDHC), has been linked to cardiomyopathy as 
well as poor prognosis in patients after major car-
diovascular accidents [3]. Consequentially, PDHC 
and PDK have become treatment targets for many 
cardiovascular diseases. Studies have shown that 
infusing pyruvate or stimulating PDHC can help 
recover the contractile function of the damaged 
heart [3]. Especially, activating PDC using the 
PDK inhibitor, dichloroacetate (DCA), has shown 
protective effects against heart failure, ischemia, 
and reperfusion [103] (Fig. 4).
The upregulation of PDK is also seen in many 
cancers and is consistently associated with inva-
sion, metastasis, and drug resistance [104]. In 
bladder cancer, PDK upregulation is connected to 
aerobic glycolysis and chemotherapy resistance 
[2, 105]. A study by Woolbright et al. showed that 
by using DCA to inhibit PDK, bladder cancer 
cells showed a decrease in growth and a G0–G1 
cell cycle arrest [2]. Other studies also reveal the 
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significant role of PDK overexpression in con-
tributing to drug resistance and the resistance to 
chemotherapy [105, 106]. However, despite the 
promising anticancer and cardioprotective 
effects, the use of DCA has shown many draw-
backs due to its short half-life, low potency, and 
many toxic side effects, preventing it from being 
successfully incorporated into a clinical setting 
[107].
The shortcomings regarding DCA should not 
discourage researchers from identifying pyruvate 
metabolism as a potential treatment target for 
cancer and cardiovascular diseases. Promisingly, 
a list of small PDK-inhibitor molecules has been 
recently proposed, which can serve as the starting 
point for many investigations targeting this path-
way [104]. Aside from PDK, pharmacological 
inhibitors of other key regulators of pyruvate 
metabolism and glucose oxidation should also be 
explored.
6  Conclusion
Altogether, many studies have pointed out simi-
lar trends in metabolic abnormalities in cancer 
and various cardiovascular diseases. The com-
mon metabolic dysregulations have served as 
overlapping treatment targets, allowing research-
ers and clinicians to expand their studies and 
treatment options. Some pharmacological inhib-
itors used to treat cardiovascular conditions have 
gone through different phases of clinical trials. 
However, despite also targeting problems exhib-
ited in cancer, these drugs have not yet reached 
similar phases in cancer treatment. With the use 
of metabolomics technologies [108], researchers 
have continued to identify the metabolic simi-
larities of these two diseases, paving the way for 
the next steps in the investigation to improve 
cancer therapy.
Fig. 4 The effects of dichloroacetate (DCA) on cancer and cardiovascular diseases. DCA inhibits pyruvate dehydroge-
nase kinase (PDK) resulting in the upregulation of the pyruvate dehydrogenase complex (PDC)
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